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ABSTRACT	
The	objective	was	to	examine	how	diabetes	mellitus	(DM)	impacts	the	arterial	system	of	
the	lower	limbs	by	assessing	both	macrovascular	disease	and	the	microvascular	function.		
A	 retrospective	 cohort	 study	 assessed	 the	 distribution	 of	 disease	 on	 digital	 subtraction	
angiography	 in	 306	 patients,	 half	 with	 DM.	 The	 Bollinger	 score	 was	 applied	 to	 all	 infra-
inguinal	vessels	seen.	There	was	a	trend	towards	patients	with	DM	having	a	higher	burden	of	
disease	throughout	the	infra-inguinal	arterial	tree.	When	divided	by	indication	for	procedure	
patients	without	DM	had	more	disease	in	the	pedal	vessels.	
Secondly,	 in	a	prospective	 study,	24	patients	with	active	 foot	ulceration	were	 recruited	
and	 grouped	 as	 having	 no	 significant	 arterial	 disease	 (n=14)	 and	 those	 requiring	
percutaneous	 angioplasty	 (PCA,	 n=10).	 Laser	 Doppler	 fluxmetry	 (LDF)	 assessed	 the	
microcirculation	 at	 regular	 intervals	 until	 healing.	 Using	 LDF,	 the	 time	 to	 maximum	 flux	
significantly	 reduced	 following	 PCA,	 in	 those	 that	 healed	 (210.5s	 (72.18-231)	 to	 50.71s	
(27.38-105.18)	p=0.046).	
The	microcirculation	is	suggested	to	improve	following	PCA;	further	research	is	required	
to	explore	how	changes	in	the	macrocirculation	relate	to	the	microcirculation	particularly	in	
patients	with	DM.	
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CHAPTER	1: INTRODUCTION	
1.1. DIABETES	MELLITUS	
The	World	Health	Organisation	(WHO)	describes	diabetes	mellitus	(DM)	as	“a	condition	
primarily	 defined	 by	 the	 level	 of	 hyperglycaemia	 giving	 rise	 to	 risk	 of	 microvascular	
damage.1”	 As	 well	 as	 being	 characterised	 by	 chronic	 hyperglycaemia	 DM	 also	 involves	
disturbances	of	carbohydrate,	fat	and	protein	metabolism.	These	are	the	results	of	defects	
in	 insulin	 secretion,	 insulin	 action	 or	 both2.	 Long	 term	 the	 effects	 of	 DM	 include	 both	
macrovascular	 and	 microvascular	 complication,	 namely	 retinopathy,	 nephropathy,	
neuropathy,	 ischaemic	 heart	 disease,	 cerebrovascular	 disease	 and	 peripheral	 vascular	
disease1,2.		
The	current	diagnostic	criteria	for	DM	based	on	WHO	recommendations	are	as	follows	
• Diabetes	symptoms	plus	
o A	random	venous	plasma	glucose	concentration	³11.1	mmol/l	or	
o A	fasting	plasma	glucose	concentration	³7.0	mmol/l	(whole	blood	³6.1	
mmol/l)	or	
o Two	hour	plasma	glucose	concentration	³11.1	mmol/l	two	hours	after	75g	
anhydrous	glucose	in	an	oral	glucose	tolerance	test.	
o With	no	symptoms	diagnosis	should	not	be	based	on	a	single	glucose	
determination	but	requires	confirmatory	plasma	venous	determination.	At	
least	one	additional	glucose	test	result	on	another	day	with	a	value	in	the	
diabetic	range	is	essential,	either	fasting,	from	a	random	sample	or	from	
the	two	hour	post	glucose	load.	If	the	fasting	random	values	are	not	
diagnostic	the	two	hour	value	should	be	used.	
• A	laboratory	glycated	haemoglobin	(HbA1c)	³48	mmol/l	(6.5%)	
o A	value	of	less	than	48	mmol/l	(6.5%)	does	not	exclude	diabetes	diagnosed	
using	glucose	tests.	
o In	patients	without	symptoms	of	DM	the	laboratory	venous	HbA1c	should	
be	repeated.	If	the	second	sample	is	<48	mmol/l	(6.5%)the	person	should	
be	treated	as	at	high	risk	of	DM	and	the	test	should	be	repeated	in	six	
months	or	sooner	if	symptoms	develop.1,2	
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1.2. EPIDEMIOLOGY	OF	DIABETES	MELLITUS	
DM	 is	 an	 increasing	problem	worldwide.	Between	1980	and	2014	 the	prevalence	of	DM	
increased	from	4.3%	to	9.0%	in	men	and	from	5.0%	to	7.9%	in	women3.	This	is	based	on	a	
sophisticated	 statistical	 analysis,	 performed	 by	 the	 NCD	 Risk	 Factor	 Collaborative,	 that	
pooled	 the	population-based	data	 for	 751	 studies,	 4.4	million	 adults,	 from	146	 countries.	
The	definition	the	NCD	Risk	Factor	Collaborative	used	for	DM	was	fasting	plasma	glucose	of	
7.0	 mmol/l	 or	 higher	 or	 history	 of	 diagnosis	 with	 diabetes,	 or	 use	 of	 insulin	 or	 oral	
hypoglycaemic	 drugs.	 Their	methods	 accounted	 for	 different	 definitions	 of	 DM	over	 time	
and	was	able	to	demonstrate	that	while	some	of	the	increase	in	prevalence	is	due	to	change	
in	population	size	and	age	structure	and	an	interaction	between	change	in	prevalence	and	
change	in	population	size	and	age	structure	there	is	a	significant	element	of	the	increase	in	
prevalence	that	is	due	to	a	change	in	prevalence	alone3.		
As	 of	 2014,	 422	million	 adults	were	 living	with	DM	worldwide3.	 In	 the	United	 Kingdom,	
there	 are	 almost	 3.7	 million	 people	 currently	 living	 with	 DM,	 with	 an	 estimated	 million	
people	who	are	as	yet	undiagnosed4.	The	increase	in	prevalence	includes	patients	with	both	
type	1	and	type	2	DM	although	90%	of	affected	patients	suffer	from	type	24.	The	accepted	
causes	 for	 type	 1	 DM	 include	 genetic	 factors5,	 viral	 infections	 and	 other	 environmental	
factors6,7.	With	type	2	DM	there	are	also	factors	related	to	genetics	and	ethnicity8,9	however	
the	main	 driving	 factors	 for	 the	 continued	 increase	 in	 prevalence	 are	 thought	 to	 be	 the	
obesity	 epidemic,	 lack	of	 physical	 activity	 and	 increasing	 age	of	 the	population9,10.	As	 the	
prevalence	 of	 DM	 has	 increased	 so	 have	 the	 complications	 related	 to	 persistent	
hyperglycaemia.	 These	 complications	 include	 diabetic	 retinopathy,	 nephropathy	 and	
diabetic	 peripheral	 neuropathy	 (DPN)	 as	 well	 as	 increased	 cardiovascular	 risk	 and	 risk	 of	
	3	
amputation11-15.	 DM	 is	 now	 a	 leading	 cause	 of	 blindness,	 renal	 failure	 and	 lower	 limb	
amputation16.	
1.3. VASCULAR	PATHOPHYSIOLOGY	IN	DIABETES	MELLITUS	
The	global	odds	ratio	for	peripheral	arterial	disease	(PAD)	in	the	presence	of	DM	is	1.68	
(95%	CI	1.53	–	1.84,	p	=	0.009)17.	 In	 the	population	of	 the	United	States	of	America,	aged	
over	 40	 years,	 the	 prevalence	 of	 PAD	 has	 been	 found	 to	 be	 double	 in	 those	 with	 DM	
compared	to	those	without	(4%	[95%	CI	2.9	–	5.2]	vs	9.5%	[5.5	–	13.4])18.	There	is	overlap	
between	 the	 risk	 factors	 for	 coronary	 artery	 disease	 (CAD)	 and	 PAD,	 however	 some	 risk	
factors	seem	to	play	a	larger	role	in	the	development	of	atherosclerosis	in	one	vascular	bed	
over	 the	 other.	 A	 large	 prospective	 cohort	 study	 based	 in	 Scotland	 found	 the	 strongest	
predictors	 for	development	of	PAD	were	DM	(hazard	ratio	3.38)	and	smoking	(2.15)19.	For	
CAD	the	largest	hazard	ratio	was	still	for	DM	(2.21)	followed	by	gender	(1.99)	however	the	
spread	 of	 risk	 across	 the	 other	 risk	 factors	 considered	 was	 much	 more	 evenly	 spread	
compared	to	PAD19.	While	there	is	overlap	between	the	risk	factors	for	PAD	and	CAD	it	has	
been	 proposed	 that	 there	 are	 significant	 differences	 in	 how	 the	 peripheral	 vasculature	
responds	to	pathological	insults	in	particular	in	the	expression	of	cell	surface	receptors	and	
signalling	pathways20,21.	
The	basic	process	of	development	of	atherosclerotic	plaques	involves	deposition	of	low-
density-lipoproteins	 (LDLs)	 in	 the	 vascular	 sub-endothelial	 space,	 increased	 expression	 of	
cell	 adhesion	 molecules	 leading	 to	 macrophage	 migration,	 increased	 tissue	 factor	 and	
matrix	 metalloproteinase	 expression	 and	 smooth	 muscle	 cell	 proliferation	 with	
vasovasorium	 neovascularisation	 (Figure	 1.3-1)22.	 DM	 predisposes	 to	 accelerated	
atherosclerosis	 through	 a	 combination	 of	 insulin	 resistance,	 hyperglycaemia	 and	
	4	
dyslipidaemia.	 Through	 different	 and	 interconnected	 processes	 these	 lead	 to	
vasoconstriction,	 inflammation	 and	 thrombosis	 which	 in	 turn	 contribute	 to	
atherogenesis23,24.		
Dysfunction	of	the	endothelium	may	well	precede	the	development	of	insulin	resistance	
or	 promote	 the	 conversion	 from	 a	 pre-diabetes	 state	 to	 overt	 DM25.	 The	 endothelium	
consists	of	a	single	layer	of	cells	that	coat	the	inner	surface	of	all	blood	vessels.	These	cells	
are	 dynamic	 and	 as	 well	 as	 providing	 semi-permeable	 barriers	 have	 both	 metabolic	 and	
synthetic	functions26.	The	autocrine,	paracrine	and	endocrine	functions	of	the	endothelium	
combine	to	regulate	vascular	tone,	mediate	thrombogenicity	and	reduce	inflammation23,27.		
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Figure	1.3-1:	Development	of	atherosclerotic	plaque	in	diabetes	mellitus	
The	 inter-related	 combination	 of	 hyperglycaemia,	 dyslipidaemia,	 hypertension	 and	
inflammation	 lead	 to	 endothelial	 dysfunction.	 There	 is	 reduced	 production	 of	 nitric	 oxide	
(NO)	and	subsequent	non-laminar	flow.	Low-density-lipoproteins	(LDLs)	are	deposited	in	the	
sub-endothelial	space	and	interact	with	reactive	oxygen	species	(ROS)	to	form	oxidised-LDLs	
(ox-LDL).	The	combination	of	down	regulation	of	the	insulin	regulated	phosphatidylinositol	
3-kinase	 (PI-3	 kinase)	 pathway	 and	 up	 regulation	 of	 the	mitogen-activated	 protein	 kinase	
(MAP-kinase)	pathway	leads	to	increased	expression	of	endothelin-1	(ET-1).	ET-1	promotes	
vascular	smooth	muscle	cell	 (VSMC)	proliferation	and	stimulates	the	expression	of	the	ETB	
receptor	on	endothelial	cells	and	subsequent	increased	expression	of	inter-cellular	adhesion	
molecule	 and	 vascular	 cellular	 adhesion	 molecule.	 Monocytes	 couple	 with	 the	 adhesion	
molecules	 and	migrate	 into	 the	 sub-endothelial	 space.	 In	 the	 sub-endothelial	 space,	 they	
differentiate	 into	macrophages	 and	 scavenge	 the	 ox-LDL,	 forming	 foam	 cells.	 The	 lesions	
progress	sequentially	from	isolated	foam	cells	to	fatty	streaks	with	mainly	intracellular	lipid	
accumulation.	 Extracellular	 lipids	 then	 also	 start	 to	 accumulate	 and	 form	 an	 extracellular	
lipid	core.	Fibroatheromatous	lesions	subsequently	form,	containing	a	combination	of	lipid,	
foam	 cells,	 VSMC.	 Cellular	 apoptosis	 leads	 to	 the	 formation	 of	 a	 lipid-rich	 necrotic	 core.	
Fibrous	 tissue	 forms	 over	 the	 core	 and	 may	 eventually	 rupture	 activating	 platelet	
aggregation	and	thrombosis.	
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In	 the	physiological	 state	 insulin	binds	with	 insulin	 receptors	on	endothelial	cells	which	
induce	the	production	of	nitric	oxide	(NO).	NO	causes	vasodilatation,	increasing	blood	flow,	
which	 augments	 the	 disposal	 of	 glucose	 in	 skeletal	muscle28.	 In	more	 detail	when	 insulin	
binds	to	the	insulin	receptor	the	transmural	ß	subunit	undergoes	auto-phosphorylation	with	
adenosine	 triphosphate	 at	 specific	 tyrosine	 sites29.	 The	 activated	 receptor	 itself	 becomes	
tyrosine	 kinase	which	 in	 turn	 phosphorylates	 intracellular	 substrates	 like	 insulin	 receptor	
substrate-1	 (IRS-1)	 and	 Shc	 proteins28,29.	 There	 are	 two	 main	 insulin	 signal	 transduction	
pathways	(Figure	1.3-2)	The	phosphatidylinositol	3-kinase	(PI-3	kinase)	pathway,	in	vascular	
endothelium,	 leads	 to	 increased	 activity	 in	 endothelial	 nitric	 oxide	 synthase	 (eNOS),	
increased	 production	 of	 NO	 and	 vasodilatation22,28.	 The	 growth	 factor	 like	 pathway	 is	
mediated	 by	 mitogen-activated	 protein	 kinase	 (MAP-kinase).	 It	 initiates	 a	 cascade	 of	
signalling	 events	 that	 lead	 to	 the	 induction	 of	 genes	 involved	 in	 cell	 proliferation	 and	
differentiation22,28.	In	DM	the	anti-atherogenic	PI-3	kinase	pathway	is	down	regulated	so	the	
protective	 factors	of	 decreased	expression	 and	 secretion	of	 vascular	 adhesion	molecule-1	
and	 E-selectin,	 pro-inflammatory	 cytokines,	 tumour	 necrosis	 factor-⍺,	 monocyte	
chemoattractant	 protein-1	 and	 subsequent	 reduced	 platelet	 adhesion	 and	 prostacyclin	
production	 are	 lost.	 This	 leads	 to	 increased	 platelet	 aggregation22.	 Conversely	 the	 pro-
atherogenic	MAP-kinase	pathway	becomes	dominant	leading	to	vasoconstriction,	increased	
vascular	permeability,	vascular	smooth	muscle	cell	proliferation	and	increased	production	of	
interleukin-622.	
Hyperglycaemia	 in	 DM	 contributes	 to	 oxidative	 stress	 and	 formation	 of	 advanced	
glycation	end-products	(AGEs)25.	Oxidative	stress	is	a	condition	in	which	the	overproduction	
of	 reactive	 oxygen	 species	 (ROS)	 overwhelms	 endogenous	 antioxidant	 defence	
mechanisms30.	AGEs	occur	as	a	result	of	non-enzymatic	glycation	of	proteins	and	lipids.	They	
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are	 found	 deposited	 in	 macrophages	 and	 vascular	 smooth	 muscle	 cells	 and	 cause	
mechanical	 dysfunction	 in	 vessel	 walls	 among	 other	 actions22.	 By	 interacting	 with	 the	
receptor	 for	AGEs	 (RAGE)	AGEs	 cause	a	 variety	of	 adverse	effects	 including	uncoupling	of	
eNOS	and	its	inactivation,	increased	nicotinamide	adenine	dinucleotide	phosphate	(NADPH)	
oxidase	expression,	increased	protein	kinase	C	(PKC)	activity,	increased	MAP-kinase	activity	
and	 increased	 nuclear	 factor-	"B	 (NF-	 "B)	 expression25.	 NADPH	 oxidase	 is	 an	 enzyme,	 or	
family	of	enzymes,	that	are	the	predominant	source	of	the	superoxide	anion	(O2•–),	a	ROS,	
in	the	vasculature.	As	well	as	being	activated	by	RAGE,	NADPH	oxidase	is	also	activated	by	
angiotensin	 II,	 endothelin-1,	 growth	 factors,	 cytokines	 and	 mechanical	 shear	 stress	 and	
stretch30.	 Increased	PKC	activity	and	other	kinases	 lead	 to	serine	phosphorylation	of	 IRS-1	
which	means	that	PI-3	kinase	is	not	activated	leading	to	reduced	eNOS	activity.	PKC	activity	
also	leads	to	increase	NF-	"B	expression	which	lead	to	expression	of	pro-inflammatory	and	
pro-fibrotic	genes22,28.	Increased	MAP-kinase	activity	stimulates	the	MAP-kinase	dependent	
insulin	 pathway	 and	 promotes	 secretion	 of	 endothelin-1	 leading	 to	 vasoconstriction	 and	
vascular	smooth	muscle	cells	(VSMC)	proliferation22,25,28.	
Insulin	resistance	and	type	2	diabetes	are	associated	with	hypercholesterolaemia	there	is	
a	relative	reduction	in	high	density	lipoproteins,	which	protect	against	atherosclerosis,	and	
an	increase	in	LDLs	and	free	fatty	acids(FFAs)23.	FFAs	impair	eNOS	and	subsequently	reduce	
the	 production	 of	 NO24,25.	 They	 are	 also	 associated	 with	 mitochondrial	 uncoupling	 and	
increased	expression	of	NADPH	oxidase	leading	to	increased	ROS24,25,30.	The	combination	of	
oxidative	 stress	 and	 hyperglycaemia	 leads	 to	 an	 oxidative	 modification	 of	 LDLs	 (oxLDL).	
OxLDLs	 contribute	 to	 eNOS	 uncoupling	 are	 associated	 with	 endothelial	 cell	 apoptosis25.	
OxLDLs	also	promote	pro-inflammatory	cytokines	and	upregulation	of	angiotensin-II	type	1	
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receptors	leading	to	vasoconstriction	and	are	easily	ingested	by	macrophages	to	form	foam	
cells	and	contribute	to	atherosclerotic	plaque	formation25.	
Adipose	tissue	is	itself	an	active	endocrine-paracrine	organ22	and	its	function	is	altered	in	
obesity	 and	 DM22,25.	 As	 well	 as	 producing	 inflammatory	 molecules	 like	 tumour	 necrosis	
factor-a,	interleukins-6,8	and	10,	and	plasminogen	activator	inhibitor-1,	adipocytes	produce	
adipokines	 like	 adiponectin,	 leptin	 and	 angiotensinogen22.	 Adiponectin,	 unlike	 the	 other	
adipokines,	 increases	sensitivity	 to	 insulin	and	 is	downregulated	 in	obesity	and	type	 II	DM	
and	 so	 its	 anti-inflammatory	 and	 anti-thrombotic	 properties	 are	 reduced.	 It	 has	 these	
effects	by	decreasing	the	expression	of	adhesion	molecule,	reducing	oxLDL	uptake,	reducing	
foam	 cell	 formation	 and	 reducing	 proliferation	 of	 VSMCs22,25,28,31.	 Leptin	 conversely	 is	
upregulated	in	DM	and	reduces	sensitivity	to	insulin,	stimulates	cholesterol	accumulation	by	
macropahges	and	encourages	VSMC	proliferation22,25.	There	is	also	increased	production	of	
angiotensinogen	 which	 is	 a	 precursor	 to	 angiotensin	 II.	 Angiotensin	 II	 is	 a	 major	
vasoconstrictor	 which	 also	 enhances	 foam	 cell	 formation,	 stimulates	 adhesion	molecules	
and	 enhances	 the	 conversion	 of	 NO	 to	 ROS	 via	 the	 NADPH	 oxidase	 pathway22.	
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Figure	1.3-2:	Endothelial	insulin	signalling	pathways	including	pathological	pathways	leading	to	dysfunction.	
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Physiologically	the	dominant	pathway	is	the	phosphatidylinositol	3-kinase	(PI-3	kinase)	pathway	(Dark	blue)	which	has	vasoprotective	effects.	
In	DM	the	PI-3	kinase	pathway	is	down	regulated	by	the	combined	results	of	hyperglycaemia	and	dyslipidaemia	(Orange)	making	the	mitogen-
activated	protein	kinase	(MAP-kinase)	pathway	dominant	(Light	blue)	and	up	regulating	outcomes	that	lead	to	endothelial	dysfunction.		
AGEs,	advanced	glycation	end	products;	AKT,	serine/threonine-specific	protein	kinase	B;	CRP,	C-reactive	protein;	eNOS,	endothelial	nitric	oxide	
synthase;	ERK1/2,	extracellular	signal	regulated	kinase	1	or	2;	ET-1,	endothelin–1;	FFA,	free	fatty	acids;	Grb-2,	growth	factor	receptor-bound	
protein	 2;	 IL-1,	 interleukin-1;	 IRS,	 insulin	 receptor	 substrates;	MCP-1,	monocyte	 chemoattractant	 protein-1;	 NADPH,	 reduced	 nicotinamide	
adenine	 dinucleotide	 phosphate;	 NF-κB,	 nuclear	 factor-κB;	 NO,	 nitric	 oxide;	 PDK-1,	 phosphoinositide-dependent	 protein	 kinase-1;	 PGI2,	
prostacyclin;	RAGE,	receptor	for	advance	glycation	end	products;	ROS,	reactive	oxygen	species;	Ser,	serine;	PKC,	protein	kinase	C;	SOS,	son	of	
sevenless;	Thr,	threonine;	TNF-a,	tumour	necrosis	factor-a;	VSMC,	vascular	smooth	muscle	cells;	
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1.4. SKIN	CIRCULATION	IN	DIABETES	MELLITUS	
The	 skin	 is	 the	 largest	 organ	 of	 the	 body,	 covering	 the	 body	with	 a	 thickness	 between	
0.5mm	on	the	eyelids	to	4.0mm	on	the	heels32.	Two	layers	form	the	skin,	the	epidermis	and	
the	dermis.	The	epidermis	is	a	thin	avascular	layer	of	cells.	The	dermis	consists	of	connective	
tissue	and	contains	hair	follicles,	sweat	and	sebaceous	glands	and	blood	vessels33.	The	blood	
supply	 for	 the	 skin	 is	 derived	 from	 a	 combination	 of,	 tributaries	 of	 the	 major	 vessels,	
musculocutaneous	 perforators	 and	 fasciocutaneous	 perforators.	 These	 tributaries	 are	
organised	into	anastomotic	plexi	that	give	off	capillary	loops	into	the	dermal	papillae.	Within	
the	 deep	 layers	 of	 the	 dermis,	 there	 are	 arterio-venous	 anastomoses	 which	 can	 rapidly	
increase	and	decrease	 the	blood	 flow	 to	 the	 skin34.	 In	normothermic	 conditions	 the	blood	
flow	to	the	skin	 is	approximately	250ml/min,	however,	 this	can	range	 from	almost	zero	to	
8l/min	 in	 extreme	 conditions35.	 There	 are	many	more	 anastomoses	 in	 glabrous	 skin	 (non-
hairy	skin,	i.e.	palms,	soles	and	lips)	than	non-glabrous	(hairy)	skin36.	Two	sets	of	sympathetic	
nerves	 control	 the	 cutaneous	 circulation;	 sympathetic	 adrenergic	 vasoconstrictors	 and	
sympathetic	 cholinergic	 vasodilators.	 Within	 non-glabrous	 skin,	 both	 these	 systems	 are	
active	 whereas	 in	 glabrous	 skin	 only	 sympathetic	 vasoconstrictors	 are	 found.	 The	
vasoconstrictors	 have	 tonic	 activity	 during	 normothermic	 conditions	 and	 increase	 their	
activity	during	cooling	to	reduce	blood	flow	to	the	skin.	However,	the	vasodilators	are	only	
active	when	the	body	temperature	rises,	i.e.	during	exercise35.		
The	 historical	 concept	 was	 that	 patients	 with	 DM	 suffered	 from	 occlusion	 of	 the	
microcirculation	 meaning	 that	 macrovascular	 revascularisation	 was	 often	 considered	
hopeless.	 However	 further	 investigation	 using	 various	 techniques	 has	 not	 found	 occlusive	
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microvascular	 disease37	 in	 these	 patients.	 Histological	 examination	 of	 the	 capillaries	
supplying	 the	 skin,	muscle	 and	 nerves	 has	 shown	 thickening	 of	 the	 basement	membrane	
compared	to	non-diabetic	patients	and	an	increase	in	porosity37-42.	The	basement	membrane	
is	a	specialised	form	of	the	extracellular	matrix.	It	provides	mechanical	stability	for	cells	and	
can	also	act	as	a	substrate	for	cellular	interactions43.	The	layer	contains	a	combination	of	the	
glycoproteins	entactins	and	laminins,	heparin	sulphate	proteoglycans	and	type	IV	collagen43.	
Chronic	hyperglycaemia	leads	to	the	stimulation	of	the	hexosamine	and	PKC	pathways,	both	
of	which	lead	to	the	overexpression	of	transforming	growth	factor-ß	(TGF-	ß),	plasminogen	
activator-1	 and	 vascular	 endothelial	 growth	 factor	 (VEGF)44-46.	 These	 induce	 the	 increased	
synthesis	of	collagen	IV,	the	degradation	of	proteoglycans	and	the	unbalanced	synthesis	of	
other	 basement	 membrane	 constituents38,42,44,46.	 Changes	 to	 the	 basement	 membrane	
appear	 early	 in	 the	 diabetic	 disease	 process,	 before	 the	 development	 of	 overt	
complications47.	 It	 is	 thought	 that	 thickening	 of	 the	 basement	 membrane	 reduces	 the	
distensibility	of	the	vessels	and	provides	a	barrier	to	the	diffusion	of	NO48,49.	These	changes	
contribute	 to	 a	 reduction	 in	 the	 hyperaemic	 response	 to	 trauma	 (thermal	 or	 occlusive)	
41,47,49,50	and	it	is	this	inability	to	vasodilate	and	achieve	maximal	blood	flow	that	is	thought	
to	be	a	major	contributory	factor	to	diabetic	foot	problems51.		
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1.5. THE	 IMPACT	 OF	 DIABETES	MELLITUS	 ON	 FOOT	 ULCER	 DEVELOPMENT	
AND	WOUND	HEALING		
Foot	ulcers	in	DM	can	be	classified	as	neuropathic,	neuro-ischaemic	or	ischaemia15.	It	has	
been	 suggested	 that	 there	 is	 a	 stepwise	 progression	 from	 the	 development	 of	 DM	 to	
neuropathy	to	development	of	an	ulcer	which	is	complicated	by	ischaemia	and/or	infection	
leading	to	amputation52.		
For	a	wound	to	heal	there	has	to	be	coordination	between	a	complex	array	of	biological	
and	physiological	functions.	As	already	discussed	in	sections	1.3	and	1.4	DM	has	a	significant	
impact	on	the	function	of	the	macro	and	microcirculation	leading	to	ischaemia.		
Diabetic	neuropathies	are	a	group	of	conditions	that	affect	different	parts	of	the	nervous	
system.	As	such	the	symptoms	that	patients	experience	can	vary	significantly53,	they	can	be	
focal	or	diffuse,	proximal	or	distal54.	The	most	common	types	of	diabetic	neuropathies	are	
chronic	 sensorimotor	 distal	 symmetric	 polyneuropathy	 (DSPN)	 and	 autonomic	
neuropathies53.	 Other	 types	 of	 neuropathies	 include	 acute	 sensory	 neuropathy,	 focal	 and	
multifocal	 neuropathies	 including	 cranial	 nerve	 neuropathies	 and	 diabetic	 amyotrophy53.	 I	
am	 not	 going	 to	 concentrate	 on	 these	 rarer	 forms	 any	 further	 here	 as	 they	 have	 less	
relevance	to	the	development	of	foot	ulceration.		
Like	 PAD	 the	 causes	 of	 DPN	 are	 multifactorial,	 glycaemic	 control,	 cardiovascular	 risk	
factors	including	dyslipidaemia,	inflammation	and	activation	of	multiple	molecular	pathways	
all	contribute54-57.	Duration	of	DM	is	a	risk	factor	for	DPN56	but	tight	glycaemic	control	has	
been	shown	to	slow	the	progression	of	DPN58-60.	Pathways	for	the	effect	of	hyperglycaemia	
on	 peripheral	 nerves	 include	 oxidative	 stress,	 polyol	 shunting,	 accumulation	 of	 AGEs,	 and	
activation	of	PKC54,55,61.	Persistent	hyperglycaemia,	as	mentioned	above	(Section	1.3),	causes	
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oxidative	 stress	 in	many	 tissues	 including	 peripheral	 nerves54.	Multiple	 free	 radicals	 have	
been	 shown	 to	 be	 associated	 with	 DPN	 and	 they	 have	 been	 shown	 to	 both	 activate	
pathological	pathways	 (i.e.	polyol	pathway)	and	occur	as	 the	result	of	 these	pathways54-56.	
The	free	radicals	cause	damage	to	the	lipids	in	myelinated	structures	and	there	is	associated	
apoptosis	 of	 neurons	 and	 Schwann	 cells57.	 The	 damage	 also	 results	 in	 hyperexcitability	 in	
afferent	nociceptors	and	central	neurons	resulting	in	neuropathic	pain57.	In	addition,	there	is	
damage	 to	 the	 microvasculature	 of	 the	 neurons	 leading	 to	 endogenous	 hypoxia	 and	
decreased	neurological	function57.		
Polyol	shunting	occurs	in	the	presence	of	hyperglycaemia	and	associated	ROS	leading	to	
inhibition	 of	 glyceraldehyde	 3-phosphate	 dehydrogenase	 and	 subsequent	 upregulation	 of	
the	polyol	pathway55.	In	normoglycaemic	conditions	the	glycolytic	pathway	is	dominant	but	
becomes	saturated	in	hypergylcaemia57.	In	the	polyol	pathway	aldose	reductase	uses	NADPH	
to	 reduce	 glucose	 to	 sorbitol.	 Sorbitol	 dehydrogenase	 then	 uses	 oxidised	 nicotinamide	
adenine	dinucleotide	to	reduce	sorbitol	to	fructose55,57.	Sorbitol	and	fructose	are	too	large	to	
cross	 cell	membranes	 and	 so	 accumulate	 in	 nerve	 cells55.	 This	 leads	 to	 change	 in	 osmotic	
pressure	within	the	cells,	efflux	of	other	electrolytes	and	swelling	of	the	axons57.	In	addition,	
there	 is	 reduction	 in	 the	 osmolytes	 myoinositol	 and	 turin,	 and	 inhibition	 of	 the	 Na+/K+	
ATPase	 pump	 with	 accumulation	 of	 intracellular	 sodium55,57.	 As	 well	 as	 damage	 to	 the	
Schwann	 cells	 and	 a	 reduction	 in	 nerve	 conduction	 velocity,	 these	 changes	 cause	
consumption	 of	 NADPH	 leading	 to	 endothelial	 damage	 and	 reduced	 NO-dependant	
vasodilatation	 and	 increases	 in	 MAP-kinase	 and	 NF-!B	 activity55,57.	 AGEs	 accumulate	 in	
peripheral	 nerves	 and	 there	 is	 an	 associated	 upregulation	 in	 RAGE.	 The	 AGEs	 themselves	
induce	 tissue	 damage,	 including	 endothelial	 damage,	 by	 causing	 protein	 cross	 linking,	
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apoptosis	of	Schwann	cells	and	driving	oxidative	stress55,57.	Associated	upregulation	of	RAGE	
leads	 to	 increased	NF-!B,	 ROS	 and	 nuclear	 DNA	 degradation	 leading	 to	 apoptosis,	 axonal	
degradation	 and	 nerve	 atrophy55,57.	 As	 well	 as	 stimulation	 of	 the	 hexosamine	 and	 PKC	
pathways	 (Sections	 1.3	 and	 1.4),	 which	 are	 also	 active	 in	 peripheral	 nerves,	 leading	 to	
upregulation	 of	 TGF-ß	 and	 VEGF	 and	 subsequent	 endothelial	 fibrosis,	 there	 is	 down	
regulation	of	nerve	growth	factor	(NGF)54-57.	Physiologically	NGF	stimulates	neuronal	growth	
and	differentiation	and	protects	nerve	 cells	 from	apoptosis,	 particularly	 small	 sensory	and	
sympathetic	 neurons56,57.	 Hyperglycaemia	 downregulates	 the	 production	 of	 NGF	 and	
prevents	it	from	binding	with	the	tropomyosin	receptor	kinase	A	and	so	there	is	decreased	
availability	within	neuronal	cells57.	Subsequently	there	is	reduction	in	the	p75	neurotrophin	
receptor	and	impaired	PI-3	kinase	and	extracellular	signal	regulated	kinase	1	or	2	signalling	
leading	to	decreased	survival,	growth,	proliferation	and	increased	apoptosis	in	small	sensory	
and	autonomic	nerve	fibres57.	
The	above	pathways	combine	to	contribute	to	the	clinical	presentation	of	DPN.	A	simple	
definition	of	DPN	is	“the	presence	of	symptoms	and/or	signs	of	peripheral	nerve	dysfunction	
in	people	with	DM	after	exclusion	of	other	causes”62.	Many	patients	are	asymptomatic	but	
careful	 examination	may	 elicit	 signs	 of	 neuropathy53.	 Symptoms	 of	 DSPN	 include	 burning,	
tingling	or	shooting	pains	and/or	hyperaesthia	that	affect	the	feet	or	hands	in	a	symmetrical	
way.	 Over	 time	 the	 symptoms	 spread	 proximally	 in	 a	 length	 dependant	 fashion53,63.	 On	
examination	there	may	be	 loss	of	vibration,	pressure,	pain	and/or	temperature	perception	
and	ankle	reflexes	may	be	absent53.	In	patients	who	have	associated	autonomic	dysfunction	
a	clinician	may	find	that	the	skin	of	the	foot	is	dry	or	cracked	with	distended	dorsal	veins	and	
that	it	is	a	different	temperature	compared	to	proximal	skin53.	
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Loss	of	sensation	leads	to	loss	of	protective	symptoms	in	response	to	trauma	of	the	foot,	
so	 a	 minor	 injury	 can	 easily	 be	 neglected64,65.	 Motor	 and	 autonomic	 dysfunction	 lead	 to	
wasting	of	the	intrinsic	muscles	of	the	foot	causing	the	characteristic	deformities	of	a	high-
arched	foot	with	clawing	of	the	toes65,66.	These	deformities	alter	the	biodynamics	of	the	foot	
resulting	in	abnormal	foot	pressures	that	lead	to	callus	formation.	Further	repetitive	injury	in	
the	presence	of	callus	eventually	leads	to	tissue	injury	and	ulceration67.	
Once	 ulceration	 has	 occurred,	 healing	may	 be	 interrupted	by	 a	 combination	 of	 chronic	
inflammation,	 hyperglycaemia,	 disruption	 of	 collagen	 synthesis	 and	 abnormal	 action	 of	
growth	 factors68,69.	 Normal	 healing	 involves	 four	 phases,	 haemostasis,	 inflammation,	
proliferation	and	remodelling.	Patients	with	DM	suffer	from	chronic	low-grade	inflammation	
and	may	experience	a	prolonged	inflammatory	phase	following	injury;	they	can	also	stall	in	
any	of	the	other	phases68,69.	All	of	the	above	factors	combine	to	make	a	diabetic	wound	very	
vulnerable	 to	 chronic	 infection.	 Hypoxia	 and	 hyperglycaemia	 and	 biomechanical	
disturbances	combine	to	encourage	overgrowth	of	bacteria	and	adversely	affect	the	function	
of	neutrophils	and	macrophages66.	In	any	open	wound	there	is	the	risk	of	invasion	of	micro-
organisms,	 if	 the	 organisms	 multiply,	 within	 the	 tissues,	 at	 a	 rate	 sufficient	 to	 cause	
inflammation	 then	 this	 is	 defined	 as	 infection70.	 These	 infections	 can	 be	 graded	 as	 mild,	
moderate	or	 severe.	The	 International	Working	Group	on	 the	Diabetic	Foot	and	 Infectious	
Diseases	Society	of	America	definitions	are	shown	in	Table	1.5-1.	Samples	taken	from	mildly	
infected	wounds	are	more	likely	to	have	a	single	organism	isolated	whilst	severe	infections	in	
chronic	 wounds	 are	 more	 likely	 to	 be	 polymicrobial70,71.	 Potential	 organisms	 that	 cause	
infection	 are	 Staphylococci,	 Streptococci,	 Proteobacters,	 Pseudomonas	 aeruginosa	 and	
Coliforms65,70-72.	The	most	common	growths	are	Staphylococcus	aureus	and	Escherichia	coli,	
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chronic	and	 ischaemic	wounds	are	more	likely	to	grow	anaerobic	organisms65,71.	In	a	study,	
that	examined	the	isolates	from	the	same	patient	population	as	the	studies	presented	over	
the	next	chapters,	mixed	anaerobes,	Staphylococcus	aureus,	Escherichia	coli	and	coagulase	
negative	Staphylococcus	where	the	most	common	organisms	 identified.	Twenty	percent	of	
patients	(n=71)	grew	both	gram	negative	and	positive	organisms72.	Most	mild	to	moderate	
infections	will	 settle	with	one	 to	 two	weeks	of	oral	 antibiotics.	Whereas	 severe	and	 some	
moderate	 infections	 with	 require	 intravenous	 antibiotics	 with	 an	 appropriate	 oral	 switch	
once	there	has	been	a	satisfactory	response.	 In	cases	of	osteomyelitis	where	the	bone	has	
not	been	resected	at	least	6	weeks	of	treatment	will	be	required15.	
To	 optimise	 the	 chances	 of	 a	 diabetic	 foot	 ulcer	 healing,	 all	 elements	 contributing	 to	 the	
initiation	of	the	ulcer	must	be	tackled.	Glycaemic	control	should	be	tightened,	blood	supply	
enhanced,	infection	treated,	wounds	dressed	and	pressure	areas	offloaded73,74.	For	each	of	
these	 areas	 there	 are	 clinicians	 with	 specialist	 knowledge	 and	 skills,	 e.g.	 diabetologists,	
vascular	 surgeons,	 microbiologists	 and	 podiatrists.	 By	 working	 together	 as	 a	 multi-
disciplinary	 team,	 in	 conjunction	 with	 the	 patient,	 it	 has	 been	 shown	 to	 be	 possible	 to	
improve	 outcomes	 and	 reduce	 rates	 of	 major	 amputation15,73,75.	 Unfortunately	 despite	
improvements	 being	 made,	 as	 mentioned	 above,	 amputation	 rates	 in	 patients	 with	 DM	
remain	high.	This	is	in	part	due	to	the	difficulties	faced	when	revascularisation	of	the	lower	
limb	is	attempted.	
	
	
	
	
	18	
	
Table	 1.5-1:	 International	 Working	 Group	 on	 the	 Diabetic	 Foot	 (IWGDF)	 and	 Infectious	
Diseases	 Society	 of	 America	 (IDSA)	 classification	 system	 for	 defining	 the	 presence	 and	
severity	of	an	infection	of	the	foot	in	a	person	with	diabetes.	Adapted	from	Lipsky	et	al15	
IWGDF/IDSA	
Classification	
Definition	
1	(Uninfected)	 No	systemic	or	local	symptoms	or	signs	of	infection	
Infection	
At	least	two	of	the	following	items	are	present:	
•	Local	swelling	or	induration	
•	Erythema	>0.5	cm*	around	the	wound	
•	Local	tenderness	or	pain	
•	Local	warmth	
•	Purulent	discharge	
-	 Other	 causes	 of	 an	 inflammatory	 response	 of	 the	 skin	 should	 be	 excluded	 (e.g.	
trauma,	 gout,	 acute	 Charcot	 neuro-osteoarthropathy,	 fracture,	 thrombosis	 and	
venous	stasis)	
2	(Mild	infection)	 -	 Infection	 involving	 only	 the	 skin	 or	 subcutaneous	 tissue	
(without	 involvement	 of	 deeper	 tissues	 and	 without	
systemic	manifestations	as	described	next)	
-	Any	erythema	present	extends	<2	cm*	around	the	wound	
-	 No	 systemic	 signs	 or	 symptoms	 of	 infection	 (see	 the	
following	discussions)	
3	(Moderate	infection)	 -	 Infection	 involving	 structures	 deeper	 than	 skin	 and	
subcutaneous	tissues	(e.g.	bone,	joint,	tendon	or	muscle)	
or	erythema	extending	≥2	cm*	from	the	wound	margin	
-	 No	 systemic	 signs	 or	 symptoms	 of	 infection	 (see	 the	
following	details)	
4	(Severe	infection)	 Any	 foot	 infection	 with	 the	 systemic	 inflammatory	 response	
syndrome,	as	manifested	by	≥2	of	the	following:	
-	Temperature	>38	°C	or	<36	°C	
-	Heart	rate	>90	beats/min	
-	Respiratory	rate	>20	breaths/min	or	PaCO2	<4.3	kPa	
(32mmHg)	
-	White	blood	cell	count	>12	000/mm3	or	<4000/mm3,	or	
>10%	immature	(band)	forms	
*In	 any	 direction,	 from	 the	 rim	 of	 the	 wound.	 The	 presence	 of	 clinically	 significant	 foot	
ischaemia	makes	both	diagnosis	and	treatment	of	infection	considerably	more	difficult.	
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1.6. VASCULAR	SURGERY	IN	DIABETES	MELLITUS	
Patients	 with	 DM	 have	 been	 found	 to	 have	 higher	 rates	 of	 failed	 revascularisation	
compared	to	patients	without	DM.	This	is	true	of	both	peripheral	bypass	surgery	(PBS)	and	
percutaneous	angioplasty	(PCA).	 In	2008	Söderström	et	al.	performed	infra-inguinal	bypass	
surgery	 on	 150	 limbs	 with	 tissue	 loss.	 Fifty	 percent	 of	 the	 participants	 had	 DM.	 Wound	
healing	had	occurred	in	63%	of	the	patients	with	DM	and	87%	of	patients	without	DM	at	12	
months	 follow-up76.	 Lee	et	 al.	 compared	 the	 restenosis,	 occlusion	 and	 amputation	 rate	 in	
239	(176	with	DM,	63	without)	patients	undergoing	PCA	for	symptomatic	PAD.	They	found	
that	those	with	DM	had	a	higher	rate	of	restenosis	after	2	years	follow-up	(54.4%	vs	31.5%,	
p=0.02)	 and	 a	 trend	 towards	 occlusion	 (38.2%	 vs	 26.3%,	 p=0.21)	 and	 major	 amputation	
(5.1%	vs	1.5%,	p=0.46)77.	The	reasons	for	these	high	failure	rates	are	poorly	understood	and	
the	following	work	aims	to	investigate	this	further.	
1.6.1. Changes	 in	 neuropathy	 and	 the	 microcirculation	 following	
revascularisation	
Akbari	et	al.78	assessed	55	patients	with	type	I	and	type	II	DM	who	required	distal	arterial	
bypass.	The	proportion	of	patients	whose	indication	was	ulceration	was	not	stated,	and	only	
54%	made	it	to	the	follow-up	appointment	due	to	a	combination	of	unsuccessful	procedure,	
death	 or	 not	 attending	 the	 appointment.	 Neuropathy	was	 assessed	 using	 peroneal	 nerve	
conduction	velocity	(NCV)	and	Neuropathy	Symptom	Score	(NSS)	and	microcirculation	using	
transcutaneous	oxygen	pressure	 (TcPO2).	A	significant	 improvement	 in	TcPO2	was	 found	 in	
the	revascularised	leg	but	not	in	the	non-operated	leg.	When	comparing	patients	operated	
on	legs	to	non-operated	legs	at	follow-up	(mean	19	months),	they	found	that	the	operated	
	20	
leg	 experienced	 stabilisation	 in	 NCV	 while	 the	 non-operated	 experienced	 a	 significant	
decrease	during	the	follow-up	period.		
Arora	et	al.51	compared	13	patients	with	diabetic	peripheral	neuropathy	(DPN)	and	PAD	
(DI	group)	requiring	distal	arterial	bypass	to	patients	with	DPN	but	no	PAD	(DN	group)	and	
patients	with	DM	in	the	absence	of	DPN	or	PAD	(D	group).	Neuropathy	was	assessed	using	
NSS,	Neuropathy	Disability	 Score,	 vibration	perception	 threshold	 (VPT)	 and	monofilament.	
Laser	 Doppler	 fluxmetry	 (LDF)	 was	 used	 to	 measure	 hyperaemic	 response	 to	 heat,	
acetylcholine	and	sodium	nitroprusside	and	the	neurovascular	response.	Follow-up	occurred	
at	 4	 to	 6	 weeks.	 Following	 bypass,	 there	 was	 a	 statistically	 significant	 improvement	 in	
cutaneous	vasodilatory	response	that	brought	 the	DI	group	up	to	a	similar	 level	 to	the	DN	
group.	 The	 eight	 patients	 with	 tissue	 loss	 showed	 full	 healing	 in	 four	 patients,	 signs	 of	
healing	in	two	and	healing	digital	amputation	sites	in	the	two	patients	who	required	minor	
amputation.	There	was	no	significant	change	in	the	neurovascular	response.		
Toursarkissian	 et	 al.79	 considered	 113	 patients	 with	 PAD	 who	 required	 distal	 arterial	
bypass.	Ninety-five	of	these	patients	had	tissue	 loss	and	88	suffered	from	DM.	There	 is	no	
report	of	the	healing	status	post-operatively.	Neuropathy	was	assessed	using	VPT.	After	six-
months	of	follow-up	no	significant	difference	was	found	between	the	pre	and	post-operative	
VPTs.		
Hinchcliffe	et	al.80	conducted	a	systemic	review	of	the	role	of	revascularisation	in	diabetic	
foot	ulcers.	 In	7	 studies	a	healing	 rate	of	60%	or	more	was	 reported.	They	suggested	 that	
future	research	should	be	focused	on	the	indications	for	and	timing	of	intervention	for	these	
patients.	
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1.7. HYPOTHESIS	
Patients	with	DM	have	a	different	distribution	of	 arterial	 disease	 compared	 to	patients	
without	DM	and	this	impacts	the	healing	of	foot	ulcers.	
1.8. AIMS		
This	 research	project	aims	 to	examine	both	 the	macrovascular	and	microvascular	blood	
supply	to	the	leg	and	foot	in	patients	with	DM.	
1.9. STUDY	DESIGN	
Two	 reviews	 of	 the	 literature	 and	 two	 studies	 were	 planned	 to	 address	 this.	 The	 first	
review	gathered	 the	 current	evidence	 regarding	how	 the	distribution	disease	 in	 the	 lower	
limbs	differs	 in	those	with	DM.	This	was	followed	by	a	retrospective	cohort	study	with	the	
aim	 of	 adding	 to	 the	 literature	 in	 this	 area.	 The	 study	 compared	 the	 digital	 subtraction	
angiograms	(DSA)	of	patients	with	DM	to	those	without	using	the	Bollinger	scoring	system.	
For	full	details	see	Chapter	2	and	Chapter	3.	
The	second	review	gathered	evidence	on	how	the	function	of	the	microcirculation	differs	
between	 diabetic	 foot	 ulcers	 that	 heal	 and	 those	 that	 do	 not.	 The	 research	 project	
undertaken	 following	 this,	 recruited	 patients	 with	 active	 ulceration,	 with	 the	 aim	 of	
measuring	how	the	function	of	the	microcirculation	changed	during	the	process	of	healing,	
see	Chapter	4	and	Chapter	5.	
The	final	sections	of	this	introductory	chapter	present	the	methods	of	examining	for	PAD	
and	PND	considered	for	use	in	the	following	body	of	work.	
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1.10. METHODS	OF	EXAMINING	THE	VASCULAR	TREE	
1.10.1. Macrovascular	
Angiography	 is	 the	gold	 standard	 for	 assessing	 the	patency	of	 the	 lower	 limb	arteries81	
and	 various	 methods	 of	 quantifying	 the	 degree	 of	 disease	 in	 each	 arterial	 segment	 have	
been	described.	The	most	commonly	used	scoring	system	is	the	one	described	by	Bollinger	
in	198182-90.	The	system	semi-quantitatively	assesses	ten	arterial	segments	(per	leg)	from	the	
infra-renal	 aorta	 down	 to	 the	 proximal	 3cm	 of	 the	 anterior	 tibial	 artery	 (ATA)	 and	 the	
proximal	5cm	of	the	posterior	tibial	artery	(PTA)	and	peroneal	artery	(PEA)	(Figure	1.10-1).	
Each	segment	 is	scored	individually	using	the	scoring	matrix	shown	in	Table	1.10-1.	One	of	
the	 limitations	of	 the	 scoring	 system	 is	 that	 it	does	not	extend	beyond	 the	proximal	 tibial	
arteries	 which	 means	 the	 arterial	 runoff	 is	 not	 adequately	 assessed.	 Three	 studies	 have	
extended	 the	 Bollinger	 score	 to	 include	 the	 distal	 vessels.	 Willenberg	 et	 al.	 in	 their	
assessment	 of	 progression	of	 disease	 in	 patients	with	 intermittent	 claudication	 imply	 that	
they	are	assessing	the	whole	of	the	tibial	arteries	although	this,	and	the	boundaries	used,	is	
not	 explicitly	 stated.	 They	 found	 a	 higher	 proportion	 of	 disease	 in	 the	 ATA	 and	 PTA	
compared	to	the	PEA	and	that	DM	was	an	independent	predictor	of	progression	of	disease	
at	2-5	years	 follow-up89.	For	 the	Bypass	versus	Angioplasty	 in	Severe	 Ischaemia	of	 the	Leg	
(BASIL)	trial	Bradbury	et	al.	defined	different	arterial	segments	to	those	originally	described	
by	 Bollinger.	 This	 included	 dividing	 the	 popliteal	 artery	 (PA)	 into	 proximal	 and	 distal	
segments	 (above	 knee	 and	 below	 knee),	 counting	 the	 tibial-peroneal	 trunk	 (TPT)	 as	 a	
discrete	segment,	assessing	the	whole	length	of	the	ATA,	PTA	and	PEA	(divided	into	proximal	
and	distal	segments)	and	assessing	the	plantar	arch.	 Inter-observer	reliability	between	two	
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observers	was	evaluated	after	the	Bollinger	scores	had	been	combined	into	three	segments	
(whole	leg,	above	knee	and	below	knee)	and	divided	into	four	scoring	groups	(<3,	3-5,	6-8,	
≥9).	 The	 plantar	 arch	 was	 excluded	 from	 this	 assessment	 due	 to	 the	 high	 proportion	 of	
missing	 data.	 They	 found	 that	 in	 approximately	 75%	 of	 patients	 the	 observers	 agreed	 on	
their	Bollinger	score	group	and	in	less	than	1%	of	patients	the	discrepancy	was	greater	than	
one	Bollinger	score	group	91.	When	the	arterial	segments	were	assessed	individually	 in	this	
cohort	 of	 418	 patients	with	 critical	 limb	 ischaemia,	 in	whom	 approximately	 40%	 suffered	
from	DM91,	 they	 found	 the	highest	burden	of	disease	was	 in	 the	distal	 superficial	 femoral	
artery	(SFA)	and	proximal	popliteal	artery.	Below	the	knee	the	PTA	was	most	diseased	with	
relative	 sparing	of	 the	PEA84.	Diehm	et	al.	 (2008)	extended	 the	 score	down	 to	 include	 the	
pedal	arch	to	enable	comparison	of	patients	with	DM	and	renal	failure	and	included	the	TPT,	
ATA,	PTA	and	PEA	 in	between.	They	found	a	high	atherosclerotic	burden	 in	the	pedal	arch	
compared	to	controls	in	both	the	DM	group	and	renal	failure.	The	presence	of	renal	failure	
predisposed	to	worse	disease	compared	to	DM90.	
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Figure	1.10-1:	Arterial	segments	as	described	by	Bollinger.	
A;	 infrarenal	 aorta,	 CIA;	 common	 iliac	 artery,	 IIA;	 internal	 iliac	 artery,	 EIA;	 external	 iliac	
artery,	 PFA;	 profunda	 femoris	 artery,	 SFA;	 superficial	 femoral	 artery,	 PA;	 popliteal	 artery,	
ATA;	 proximal	 3cm	 of	 anterior	 tibial	 artery,	 PEA;	 proximal	 5cm	 of	 peroneal	 artery,	 PTA;	
proximal	5cm	of	posterior	tibial	artery.	
	
Table	1.10-1:	Bollinger	scoring	system	
Location	 Occlusion	 Stenosis	>50%	 Stenosis	≤	50%	 Plaques	≤	25%	
Single	 -	 4	 2	 1	
Multiple	≤	half	 13	 5	 3	 2	
Multiple	>	half	 15	 6	 4	 3	
Adapted	from	Bollinger	et	al.	1981.	Each	arterial	segment	will	have	an	additive	score	based	
on	 the	 above	 scoring	 matrix.	 To	 avoid	 inadequate	 scoring	 the	 following	 rules	 should	 be	
obeyed.	1)	 In	 the	presence	of	occlusions,	plaques	or	stenosis	are	not	considered.	2)	When	
both	categories	of	stenosis	(>50%	and	≤50%)	are	present	plaques	are	not	scored.	3)	For	each	
type	of	occlusive	lesion	only	one	length	category	is	indicated	
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1.10.2. Microvascular	
The	 screening	 tests	 above	 and	 further	 investigative	 tests	 such	 as	 duplex	 ultrasound,	
computed	 tomography	 angiography	 and	 magnetic	 resonance	 angiography	 all	 assess	 the	
macrovascular	disease	burden.	The	microcirculation	(arterioles,	capillaries	and	venules)	also	
has	a	significant	impact	on	the	disease	process	in	patients	with	DM.	The	relationship	of	the	
microvascular	impairment	with	macrovascular	disease	is	less	clear	but	may	be	related	to	the	
inhibition	of	rapid	refilling	of	the	arterial	segments	 in	the	presence	of	arterial	stenosis	and	
that	 in	 critical	 ischaemia	maximum	vasodilatation	has	already	been	 reached	 in	 the	 resting	
period92.	 One	 study	 has	 found	 no	 difference	 in	microvascular	 impairment	 between	 those	
with	 and	without	 PAD47	 but	Arora51	 found	 an	 improvement	 in	 the	 cutaneous	 vasodilatory	
response	following	peripheral	vascular	bypass.		
1.10.2.1. Capillary	microscopy	
The	skin	receives	its	blood	supply	from	deep	and	superficial	dermal	plexi,	which	are	made	
up	of	multiple	arteriovenous	anastomoses.	The	superficial	plexus	has	capillaries	arising	from	
it	 that	 provide	 the	 nutritional	 supply	 to	 the	 skin.	 The	 deep	 plexus	 is	 predominantly	
concerned	with	thermo-regulation93.	Light	microscopy	can	be	used	to	assess	the	number	and	
morphology	of	capillaries	 in	 the	superficial	plexus.	Most	commonly	the	nailfold	 is	used.	By	
use	 of	 videophotometric	 capillaroscopy	 it	 is	 possible	 to	 non-invasively	 visualise	 the	 size,	
shape,	 and	 the	 number	 of	 nutritional	 skin	 capillaries,	 in	 addition	 to	 this	 it	 is	 possible	 to	
measure	the	velocity	of	the	blood	in	the	capillaries93-95.	
Capillary	 microscopy	 (CM)	 has	 the	 advantage	 over	 the	 other	 non-invasive	 methods	 of	
being	 the	only	method	 that	assesses	only	 the	nutritional	 vessels.	 It	has	been	shown	 to	be	
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highly	 reproducible	when	performed	by	one	observer	and	when	 the	 findings	are	classified	
using	a	 staging	 system	 it	has	 the	ability	 to	discriminate	between	 the	 severity	of	 ischaemic	
disease93.	However,	the	method	can	be	time-consuming,	and	as	capillary	morphology	varies	
between	the	toes	on	one	foot	in	a	single	patient,	it	is	important	that	there	is	consistency	in	
the	 area	 being	 measured.	 Velocity	 measurements	 are	 also	 heavily	 influenced	 by	
movement95.	
1.10.2.2. Laser	Doppler	fluxmetry	
LDF	uses	a	helium-neon	laser	to	penetrate	the	superficial	layers	of	the	skin96-98.	The	light	
is	scattered	by	the	tissue	it	encounters,	any	moving	blood	cells	cause	the	light	to	be	Doppler	
shifted.	 This	 results	 in	 an	 arbitrary	 unit,	 flux,	 that	 reflects	 the	 concentration	 and	 average	
speed	of	the	cells97,99.	The	laser	penetrates	the	skin	to	approximately	1.5mm	93	and	as	such	
provides	 information	 on	 both	 the	 superficial	 and	 deep	 dermal	 capillary	 beds	 with	 the	
possibility	 of	 also	 detecting	 flow	 in	 small	 arterioles	 and	 arterio-venous	 anastomoses.	 This	
means	unlike	CM	it	does	not	assess	nutritional	blood	flow	only	and	should	be	regarded	as	a	
total	measure	of	blood	 flow	 in	 the	skin	 94,95.	Resting	 flux	of	 the	skin	can	be	measured	and	
provocation	 tests	 like	 post	 occlusive	 reactive	 hyperaemia	 (PORH),	 skin	 perfusion	 pressure	
(SPP)	 and	 thermal	 challenge	 can	 be	 performed100-102.	 LDF	 has	 been	 used	 in	 research	 to	
diagnose	PAD103,	predict	wound	healing104,	assess	outcomes	following	revascularisation105,106	
and	examine	patients	with	DM107,108.		
1.10.2.3. Transcutaneous	measurement	of	oxygen	pressure	
TcPO2	looks	at	the	end	product	of	perfusion.	A	heated	probe	is	attached	to	the	skin	and	
induces	 localised	 hyperaemia	 allowing	 excess	 oxygen	 to	 diffuse	 across	 the	 skin	 and	 be	
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measured	by	the	probe	95.	TcPO2	has	been	shown	to	be	able	to	predict	clinical	response	to	
revascularisation,	the	risk	of	amputation	and	has	the	ability	to	discriminate	between	severity	
of	disease	109-112.	Various	factors	affect	the	accuracy	of	TcPO2	including	arterial	and	venous	
blood	 pressure,	 epidermal	 thickness,	 capillary	 density,	 inflammation	 and	 oedema	 95	 and	
when	compared	to	LDF	it	has	less	accuracy	110,112.	
1.11. METHODS	 FOR	 EXAMINING	 FOR	 PERIPHERAL	 NEUROPATHY	 IN	
DIABETES	MELLITUS	
The	American	Diabetes	Association	advises	that	screening	for	DPN	should	be	carried	out	
using	more	than	one	of	pinprick	testing,	VPT,	10g	monofilament	and	ankle	reflexes53,113.	
1.11.1. Pinprick	
Pinprick	testing	assesses	the	small	fibres	of	the	somatic	nervous	system114.	A	proximal	site	
is	compared	to	a	distal	site	and	the	result	recorded	as	normal	or	abnormal62.	Pinprick	testing	
has	been	found	to	be	less	objective	than	VPT	or	monofilament	testing114.	
1.11.2. Vibration	perception	threshold	
The	ability	of	a	patient	to	detect	vibration	is	a	test	of	somatic	nerve	function,	specifically	
large	fibre	activity114.	While	a	tuning	fork	can	be	used	as	a	crude	screening	tool	the	use	of	a	
neurothesiometer	or	vibratron	allows	a	quantitative	assessment	of	the	degree	of	sensation	
loss	 115.	 The	 neurothesiometer	 has	 better	 accuracy	 than	 the	 vibratron	 and	 comparable	
variability	to	NCV116.	VPT	is	usually	measured	on	the	pulp	of	the	great	toe,	and	a	value	of	>25	
is	associated	with	a	seven-fold	increase	in	the	risk	of	ulceration	when	compared	to	patients	
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with	a	VPT	of	<15117,118.	VPT	has	a	significant	correlation	with	NCV	and	when	diagnosing	DPN	
has	a	sensitivity	of	87%116,119.	
1.11.3. 10g	Monofilament	
	Like	VPT	monofilament	tests	the	large	fibres	of	the	somatic	nervous	system114.	The	test	
involves	the	placement	of	a	monofilament	on	the	skin	area	to	be	tested.	A	negative	test	 is	
when	the	patient	is	unable	to	detect	the	presence	of	the	monofilament	when	the	pressure	
applied	 is	 sufficient	 to	 cause	 the	monofilament	 to	 buckle.	 The	most	 sensitive	 and	 specific	
areas	 to	 test	 are	 the	 plantar	 aspect	 of	 the	 hallux	 and	 the	 bases	 of	 the	 third	 and	 fifth	
metatarsal	 heads120.	 A	 positive	 result	 (patient	 unable	 to	 detect	 the	 monofilament)	 is	 a	
significant	and	independent	predictor	of	foot	ulceration121,122.	
1.11.4. Ipswich	touch	test	
The	 Ipswich	 touch	 test	 (ITT)	 is	 an	 alternative	 to	 monofilament	 testing	 that	 has	 the	
advantage	of	not	 requiring	any	 specialist	 equipment.	 The	 test	 involves	 touching	 the	 tip	of	
the	1st,	3rd	and	5th	toes	lightly	for	1	to	2	seconds.	The	patient’s	eyes	are	closed	and	are	asked	
to	respond	yes	whenever	they	feel	the	touch.	Two	or	more	insensate	areas	are	classified	as	
neuropathy123.	The	test	has	been	shown	to	have	similar	sensitivity	and	specificity	(76%	and	
90%	respectively)	to	monofilament	(81%	and	90%)	and	high	reproducibility123.	
1.11.5. Ankle	reflex	
A	 reduced	 or	 absent	 ankle	 reflex	 is	 an	 independent	 predictor	 of	 ulceration122.	 When	
compared	to	VPT	ankle	reflex	has	been	found	to	have	a	high	sensitivity	of	more	than	90%,	
but	a	low	specificity	of	less	than	40%124	and	when	compared	to	NCV	has	a	sensitivity	of	91%	
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and	specificity	of	67%125.	Ankle	reflex	 is	seldom	used	alone	and	generally	 forms	part	of	an	
assessment	that	encompasses	the	signs	and	symptoms	of	neuropathy.	
1.11.6. Nerve	conduction	studies	
Nerve	 conduction	 studies	 (NCS)	 are	 the	 gold	 standard	 for	 the	 diagnosis	 of	 peripheral	
neuropathy114,126.	 In	the	diagnosis	of	peripheral	neuropathy	of	the	lower	limb	the	peroneal	
and	 sural	 nerves	 are	 commonly	 used.	 This	 provides	 a	 measure	 of	 both	 the	 motor	 and	
sensory	deficit.	Recording	and	stimulating	electrodes	are	placed	at	either	end	of	the	nerve	
and	electrical	 stimulation	 is	 passed	between	 them.	 The	 velocity,	 amplitude	and	 latency	of	
the	 nerve	 are	 recorded126.	 In	 experienced	 hands	 NCS	 have	 been	 found	 to	 have	 low	
variability,	good	reproducibility	and	high	sensitivity.	In	combination	with	symptoms	and	signs	
of	DPN	NCS	have	been	recommended	as	the	investigation	of	choice	in	research	of	DPN126-129.	
The	limitations	of	NCS	are	the	expensive	equipment	and	technical	expertise	required.	
1.11.7. Neurological	symptom	scores	
There	are	multiple	different	scores	for	the	symptoms	of	neuropathy.	Many	of	the	scores,	
for	 example	 the	 Neuropathy	 Symptom	 and	 Change	 score	 (also	 known	 as	 the	 Number	
Severity	and	Change	score)	(NSC),	McGill	Pain	Questionnaire,	Neuropathy	Impairment	Score	
and	 Lower	 Limb	 Function	 Test	 include	 assessment	 of	 sensory,	 motor	 and	 autonomic	
symptoms	 and	 include	 an	 element	 of	 examination130.	 Due	 to	 this	 they	 are	 lengthy	
questionnaires	 and	 time	 consuming	 to	 administer,	 such	 as	 the	 NSC	 which	 has	 38	
questions131.	 The	 NSS	 has	 been	 extensively	 used	 in	 clinical	 trials	 and	 has	 been	 found	 to	
correlate	well	with	NCS	and	have	reasonable	sensitivity132,133	but	like	those	above	is	lengthy	
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and	was	not	 explicitly	 developed	 for	 evaluating	 changes	 in	neuropathy	after	 treatment130.	
The	Neuropathy	Total	Symptom	Score	–	6	(NTSS-6)	overcomes	some	of	these	shortcomings.	
It	 consists	 of	 six	 questions	 focusing	 solely	 on	 sensory	 symptoms	 in	 the	 lower	 limbs.	 The	
patient	 is	 asked	 to	 consider	 the	 frequency	 and	 intensity	 of	 the	 symptoms	 they	 have	
experienced	 over	 the	 last	 twenty-four	 hours.	 The	maximum	 score	 is	 21.96	 and	 a	 score	 of	
more	 than	 six	 indicates	 clinically	 significant	 symptoms.	On	 testing	 the	 score	was	 found	 to	
have	good	internal	consistency	and	results	that	correlate	with	NCS	130.	NTSS-6	has	been	used	
in	clinical	trials	testing	changes	in	DPN	symptoms	and	been	able	to	demonstrate	a	difference	
between	treatment	groups134-136.	
1.11.8. Intra-epidermal	nerve	fibre	density	
Full-thickness	 punch	 biopsy	 of	 the	 skin	 allows	 for	 staining	 with	 protein	 gene	 product	
(PGP)	 9.5	 and	 subsequent	 immunofluorescence.	 PGP	 9.5	 is	 a	 pan-axonal	 and	 pan-
neuroendocrine	marker	and	means	the	density	of	nerve	fibres	per	millimetre	squared	can	be	
measured137.	 A	 reduction	 in	 intra-epidermal	 nerve	 fibre	density	 (IENFD)	 is	 associated	with	
severity	 of	 diabetic	 neuropathy138,139.	 It	 has	 also	 been	 shown	 to	 be	 possible	 to	 observe	
axonal	regeneration	over	a	period	of	months	using	this	method140.	As	such	IENFD	represents	
an	 interesting	 area	 of	 current	 research	 that	 would	 be	 relevant	 in	 our	 cohort	 of	 patients.	
However,	the	consensus	among	the	project	designers	was	that	it	would	be	ethically	unviable	
to	create	a	new	area	of	skin	loss	in	patients	already	suffering	from	the	complications	of	skin	
loss	on	a	background	of	DM	and	or	PAD.	
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CHAPTER	2: THE	DISTRIBUTION	OF	ATHEROSCLEROSIS	IN	THE	LOWER	LIMB	
ARTERIES:	A	REVIEW	OF	HOW	THE	DISTRIBUTION	OF	DISEASE	IS	
AFFECTED	BY	DIABETES	MELLITUS	
2.1. INTRODUCTION	
Infra-popliteal	disease	is	associated	with	critical	limb	ischaemia	which	is	the	final	stage	in	
the	 disease	 course	 of	 peripheral	 arterial	 disease	 (PAD)141.	 The	 pattern	 of	 vascular	 disease	
influences	the	options	that	are	available	for	revascularisation.	Management	of	distal	disease	
is	more	challenging	than	proximal	disease,	although	advances	in	this	area	are	being	made142-
145.	Despite	these	advances	patients	with	distal	disease	have	a	higher	risk	of	amputation	and	
shorter	amputation-free	survival146.	
The	prevalence	of	diabetes	mellitus	(DM)	is	increasing	worldwide	and	is	a	significant	risk	
factor	 for	 PAD3,16.	 Patients	 with	 DM	 have	 a	 predisposition	 towards	 a	 higher	 burden	 of	
atherosclerotic	 disease	 below	 the	 knee	 compared	 to	 patients	 without	 DM	 (NDM).	 This	 is	
considered	 to	 have	 an	 impact	 on	 both	 the	 treatment	 options	 available	 and	 prognosis	
following	revascularisation	in	patients	with	DM147,148.	
This	hypothesis	of	a	higher	burden	of	disease	in	the	tibial	arteries	is	widely	accepted	on	
an	 anecdotal	 level	 within	 the	 medical	 community.	 Many	 medical	 students	 and	 surgical	
trainees	will	have	heard	this	stated	as	 fact	as	part	of	bedside	teaching	 in	vascular	surgery.	
This	review	aimed	to	summarise	the	quality	of	the	evidence	supporting	this	hypothesis.	
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2.2. METHODS	
A	literature	search	was	performed	using	the	search	terms	“diabetes	mellitus”,	“peripheral	
vascular	 disease”,	 ‘distribution	 of	 disease”,	 “angiography”,	 “computed	 tomography	
angiography”	and	“magnetic	resonance	angiography”.	Synonyms	and	various	combinations	
were	used	in	the	search	strategy	which	involved	both	Medical	Subject	Headings	(MESH)	and	
keyword	 searches.	 Embase	 and	 MEDLINE	 databases	 were	 searched	 including	 papers	
published	 from	1946	 to	present	day	and	 in-process	 citations	 (Search	 terms	 in	Appendix	 I).	
References	from	relevant	studies	were	also	scrutinised	for	potential	studies.	
Papers	were	 included	 if	 arterial	 imaging	of	 the	 lower	 limb	was	undertaken	using	digital	
subtraction	 angiography	 (DSA),	 Computed	 Tomography	 Angiography	 (CTA),	 or	 Magnetic	
Resonance	 Angiography	 (MRA).	 They	were	 excluded	 if	 the	 indication	 for	 imaging	was	 not	
PAD,	if	there	was	no	separation	of	patients	with	and	without	DM	or	only	patients	with	DM	
were	included.	The	final	requirement	was	an	anatomical	description	of	the	arteries	affected	
by	 atherosclerotic	 disease.	 This	 description	 could	 be	 given	 using	 a	 scoring	 system	 or	
proportions	of	arterial	segments	affected.	
2.2.1. Statistical	analysis	
For	 papers	 that	 included	 proportions	 of	 patients	 with	 PAD	 by	 arterial	 segment	 the	
number	of	patients	who	had	disease	in	each	arterial	segment	was	extracted	by	one	author	
(DL).	 These	 papers	 were	 included	 in	 a	 forest	 plot	 that	 was	 produced	 using	 Revman	 5.3	
(Review	 Manager	 (RevMan)	 [Computer	 program].	 Version	 5.3.	 Copenhagen:	 The	 Nordic	
Cochrane	Centre,	The	Cochrane	Collaboration,	2014.).	Data	were	summarised	as	odds	ratio	
(OR)	with	95%	confidence	intervals.	
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2.3. RESULTS	
From	the	literature	search,	151	potential	papers	were	identified	and	following	review	of	
titles,	 abstracts,	 full	 text	 and	 references	 14	 studies	 were	 included	 in	 the	 review	 (Figure	
2.3-1).	The	papers	dated	from	1964	to	2009	and	were	all	cross-sectional	studies	apart	from	
one	 cohort	 study90	 and	 two	 case-control	 studies149,150	 (Table	 2.3-1	 and	 Table	 2.3.2).	 The	
majority	 of	 papers	 did	 not	 state	 if	 their	 analysis	 was	 by	 patient	 or	 by	 limb,	 in	 most,	 it	
appeared	that	a	single	treated	 limb	was	 included	per	patient90,150-155.	Four	papers	 included	
all	treated	limbs156-159,	one	paper	 included	both	 legs	for	all	patients149,	one	paper	analysed	
by	lesion160	and	one	paper	only	used	the	data	from	the	left	leg	if	there	was	bilateral	imaging	
as	 they	 found	 the	 legs	 to	 be	 comparable83.	 How	 risk	 factors	 for	 PAD	were	 treated	 varied	
between	papers.	 Four	papers	performed	 some	 form	of	multivariate	analysis	 to	 stratify	 for	
risk	factors149,155,159,160,	the	majority	of	remaining	papers	reported	proportions	of	risk	factors	
and	 comparability	 between	 groups	 however	 two	 papers	 made	 no	 mention	 of	 risk	
factors151,156.	 No	 studies	 considered	 type	 I	 and	 type	 II	 DM	 separately.	 One	 paper	 found	 a	
significant	difference	in	the	proportion	of	men	and	women	in	their	cohorts149	and	one	paper	
found	significant	differences	in	the	proportions	of	smokers157.	Most	papers	had	cohorts	with	
a	mean	age	in	the	mid-sixties	although	two	papers	deliberately	selected	young	cohorts151,152	
and	two	papers	had	older	cohorts90,158.	The	majority	of	cohorts	consisted	of	approximately	
60%	men	apart	from	Ozkan	et	al.	who	had	85.9%	men155.	The	proportion	of	smokers	in	each	
group	ranged	from	13.5%	to	83.2%	(Table	2.3-3).	
All	 the	 studies	 used	 angiography	 to	 visualise	 the	 arterial	 tree	 and	 in	 total	 15	 different	
arterial	 segments	were	described	 (Table	2.3-1	 and	Table	2.3.2).	 The	most	 commonly	used	
segments	 that	 differentiated	 between	 proximal	 and	 distal	 disease	 were	 aorto-iliac	 (A-I),	
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femoro-popliteal	 (F-P),	 and	 tibial.	 Seven	 studies	 also	 included	a	 category	 that	 represented	
disease	 at	 multiple	 levels.	 These	 segments	 were	 included	 in	 the	 forest	 plot	 along	 with	
smaller	 segments	 that	 fitted	 in	 the	 same	 group.	 I.e.	 patients	with	 disease	 in	 the	 popliteal	
artery	could	be	included	in	the	F-P	group	but	those	in	a	popliteal/tibial	group	could	not	be	
included.	The	description	of	what	constituted	significant	disease	varied	between	papers.	Of	
the	 papers	 that	 described	 proportions	 of	 arterial	 segment	 involved	 five	 only	 included	
occlusions151,154,156-158,	two	defined	a	significant	stenosis	as	 involving	more	than	20%	of	the	
lumen152,153,	two	defined	it	as	more	than	50%149,155	and	in	one	paper	the	definition	was	not	
stated160.		
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Figure	2.3-1:	Distribution	of	disease	review	inclusion	flow	chart	
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Table	2.3-1:	Characteristics	of	included	studies.	Studies	which	presented	proportions	
Author	 Year	 Country	 Study	design	 Patients	 Groups	 Method	of	describing	pattern	
De	Bakey	ME151	 1964	 USA	 Cross-sectional	study	
Patients	with	occlusive	disease	
of	the	lower	extremities	
DM=6	
NDM	=	41	
A-I,	F-P,	A-I/F-P,	PEA/tib,	F-
P/PEA/tib,	A-I/F-P/PEA/tib,	
ML	
Haimovici	H156	 1967	 USA	 Cross-sectional	study	
Patients	with	arteriosclerosis	
obliterans	
DM=91	
NDM=98	
A-I,	F-P,	F-P/tib,	P-tib,	P,	tib,	
ML	
Ciavarella	A157	 1993	 Italy	 Cross-sectional	study	
Patients	with	symptomatic	
PAD	
DM=89	
NDM=61	
A-I,	F-P,	tib,	F-P/tib,	ATA,	
PTA,	PEA,	DP,	Plant,	ML	
Hansen	ME152	 1995	 USA	 Cross-sectional	study	
Patients	with	symptomatic	
PAD	
DM=22	
NDM=37	 A-I,	F-P/tib,	ML	
Kroger	K153	 2000	 Germany	 Cross-sectional	study	 Patients	with	PAD	
DM=46	
NDM=86	 A-I,	F-P,	tib,	ML	
Haltmayer	M149	 2001	 Austria	 Case-control	study	
Patients	with	symptomatic	
PAD	
DM=41	
NDM=65	 A-I,	F-P,	tib,	
Lazaris	AM158	 2004	 UK	 Cross-sectional	study	
Patients	undergoing	sub-
intimal	angioplasty	
DM=33	
NDM=66	 F,	F-P,	F-P-tib,	P-tib,	tib,	ML	
Rueda	CA154	 2008	 USA	 Cross-sectional	study	
Patients	undergoing	
infrainguinal	revascularisation	
DM=262	
NDM=168	 A-I,	F,	P-tib,	ML	
Diehm	N160,a	 2006	 Switzerland	 Cross-sectional	study	
Patients	undergoing	
endovascular	therapy	of	lower	
limb	
DM=891	
NDM=1768	 I,	F-P,	tib	
Ozkan	U155,a	 2009	 Turkey	 Cross-sectional	study	 Patients	with	PAD	
DM=261	
NDM=365	 A-I,	F-P,	tib,	ML	
aNot	included	in	meta-analysis.	A=Aorta,	I-Iliacs,	F=Femoral,	P=Popliteal,	tib=Tibials,	PEA=Peroneal,	ATA=Anterior	tibial	artery,	PTA=Posterior	
tibial	artery,	Plant=Plantar	vessels,	TPT=	Tibial-	peroneal	trunk,	ML=Multi-level	disease,	USA=United	States	of	America	
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Table	2.3-2:	Characteristics	of	included	studies.	Studies	which	presented	scores	
Author	 Year	 Country	 Study	design	 Patients	 Groups	 Method	of	describing	pattern	
Menzoian	JO159	 1989	 USA	 Cross-sectional	study	 Patients	with	PAD	
DM=115		
NDM=119	 ATA,	PTA,	PEA,	Plant	
Jude	EB83	 2001	 UK	 Cross-sectional	study	
Patients	undergoing	
infrainguinal	
revascularisation	
DM=58	
NDM=78	 Individual	vessels	I	to	tib	
van	der	Feen	C150	 2002	 Netherlands	 Case-control	study	
Patients	with	symptomatic	
PAD	
DM=37	
NDM=37	 I-F,	P-tib	
Diehm	N90	 2008	 Switzerland	 Cohort	study	
Patients	undergoing	
angiography	for	chronic	
lower	limb	ischaemia	
DM=	25	
NDM=25	
Individual	vessels	TPT	to	tib,	
TPT-tib	average	score,	Plant	
A=Aorta,	I-Iliacs,	F=Femoral,	P=Popliteal,	tib=Tibials,	PEA=Peroneal,	ATA=Anterior	tibial	artery,	PTA=Posterior	tibial	artery,	Plant=Plantar	
vessels,	TPT=	Tibial-	peroneal	trunk,	ML=Multi-level	disease	
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Table	2.3-3:	Demographics	of	studies	included	in	the	review.	
Author	
Age	
(Mean	±	SD)	
Gender	
(/)	
Smoking	status	
(smokers/non-smokers)	
DM	 NDM	 DM	 NDM	 DM	 NDM	
De	Bakey	ME151,a	 16-37b	 4/2	 25/16	 2/4	 29/12	
Haimovici	H156	 -	 -	 -	 -	 -	 -	
Ciavarella	A157	 65	±	9	 64	±	10	 62/27	 44/17	 45/44	 52/9	
Hansen	ME152,a	 43.4	±	5.8	 29/30	 45/14	
Kroger	K153	 61	±	13	 85/47	 -	 -	
Haltmayer	M149	 66.4	(57.9-74.4)c	 63.9	(59.5-68.7)c	 80/26	 32/21	 48/58	 7/45	
Lazaris	AM158	 78.5	(42-92b)	 53/46	 21/19	 47/25	
Rueda	CA154	 66	±	12	 302/148	 -	 -	
Diehm	N160	 70	±	11	 1583/1076	 1144/1515	
Ozkan	U155	 62	±	11	 538/88	 494/132	
Menzoian	JO159	 67	±	1.2/69.8	±	1.6d	 64	±	1/75.4	±	1.3d	 -	 -	 73/42	 98/21	
Jude	EB83	 63.83	±	10.4	 65.3	±	11.11	 34/24	 47/31	 47/11	 60/18	
van	der	Feen	C150	 65.5	±	13.6	 65.7	±	12.7	 20/17	 20/17	 12/25	 12/25	
Diehm	N90	 74.2	±	10.3	 77.4	±	9.6	 10/15	 12/13	 11/14	 9/16	
aDeliberately	selected	young	age	group,	bage	range,	cMedian	(IQR),	dSmokers/non-smokers,	SD=	standard	deviation	
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2.3.1. Proportions	of	arterial	segments	affected	
Ten	studies	described	the	proportions	of	arterial	segments	affected	by	PAD	and	included	
1682	patients	with	DM	and	2775	without	DM149,151-158,160.	For	two	papers,	it	was	not	possible	
to	extract	sufficient	data155,160	they	were	not	included	in	the	analysis	but	their	results	will	be	
discussed.		
The	 resulting	 forest	 plot	 (Figure	 2.3-2)	 demonstrates	 that	 those	 with	 DM	 were	
significantly	less	likely	to	have	disease	in	the	aorto-iliac	segment	(OR	0.25	(0.15-0.42),	n=DM	
466/NDM	458)	and	significantly	more	 likely	 to	have	disease	 in	 the	tibial	 segment	 (OR	1.94	
(1.27-2.96),	n=DM	306/NDM	417).	In	the	DM	group,	there	is	a	trend	towards	relative	sparing	
in	the	femoro-popliteal	segment	but	this	does	not	reach	significance	(0.66	(0.33-1.31),	n=DM	
568/NDM	 585).	 There	 is	 also	 a	 suggestion	 that	 those	 with	 DM	were	more	 likely	 to	 have	
multilevel	disease,	again	this	does	not	reach	significance	(1.26	(0.93-1.70),	n=DM	549/NDM	
557).		
The	 two	 papers	 not	 included	 in	 the	meta-analysis	 showed	 a	 similar	 pattern.	 Diehm	 et	
al.160,	 in	 a	 retrospective	 cohort	 that	 examined	 the	 risk	 factors	 for	 distribution	 pattern	 of	
lower	limb	atherosclerosis	in	2659	patients	(891	with	DM),	on	multivariate	logistic	regression	
found	 that	 DM	 had	 a	 relative	 risk	 ratio	 of	 0.59	 (0.49-0.72,	 p<0.001)	 for	 iliac	 disease	
compared	to	1.68	(1.47-1.92,	p<0.001)	for	tibial	disease.	Ozkan	et	al.155	performed	a	similar	
analysis	 in	 626	 patients	 with	 symptomatic	 PAD	 261	 of	 whom	 had	 DM.	 They	 found,	 on	
univariate	 analysis,	 the	 presence	 of	 DM	was	 related	 to	 odds	 ratios	 of	 0.56	 (p=0.001)	 for	
aorto-iliac	disease,	1.16	 (p=0.39)	 for	 femoro-popliteal	disease	and	2.44	 (p=0.001)	 for	 tibial	
disease.	
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Figure	2.3-2:	Forest	plot	comparing	the	presence	of	arterial	disease	by	arterial	segment	in	
patients	with	diabetes	compared	to	patients	without.	
2.3.2. Scores	to	describe	the	distribution	of	disease	
Four	 papers	 reported	 scores	 by	 arterial	 segment83,90,150,159.	 Three	 of	 these	 used	 the	
Bollinger	score82	and	one159	a	score	described	by	LaMorte	et	al.	in	1985161.	Briefly,	Bollinger’s	
score	 is	 a	 semi-quantitative	 score	 that	 considers	 each	 arterial	 segment	 separately.	 Each	
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arterial	 segment	 is	 assessed	 for	 the	 presence	 of	 plaques	 less	 than	 25%	 of	 the	 lumen,	
stenoses	less	than	50%	of	the	lumen,	stenoses	more	than	50%	of	the	lumen	and	occlusions.	
A	higher	score	is	achieved	if	these	lesions	are	multiple	and	involve	more	than	half	the	length	
of	the	segment.	The	minimum	score	is	zero	and	maximum	fifteen	(occlusion	for	more	than	
half	the	length).	The	segments	and	the	scoring	matrix	used	for	each	segment	individually	are	
shown	in	Figure	1.10-1	and	Table	1.10-1.	LaMorte	et	al.’s	score	assigns	a	score	of	zero	to	a	
non-visualised	vessel,	one	to	a	partially	compromised	vessel	and	two	to	an	intact	vessel.	By	
applying	 this	 score	 to	 227	 patients	 with	 PAD,	Menzoian	 et	 al.	 demonstrated	 significantly	
lower	scores	(i.e.	more	disease)	in	the	posterior	tibial	artery	(PTA)	(0.51	vs	1.02,	p<0.05)	and	
peroneal	artery	 (PEA)	 (0.9	vs	1.28,	p<0.05)	as	well	as	 the	sum	of	 the	tibial	vessels	 (2.17	vs	
3.13,	p<0.05)	in	the	DM	group159.		
Despite	all	using	the	Bollinger	score	it	 is	hard	to	compare	the	results	for	Jude	et	al.,	van	
der	Feen	et	al.	and	Diehm	et	al.	due	to	the	different	vessels	reported.	Jude	et	al.	used	the	
segments	 originally	 described	 by	 Bollinger	 (ten	 arterial	 segments	 (per	 leg)	 from	 the	 infra-
renal	aorta	down	 to	 the	proximal	3cm	of	 the	anterior	 tibial	artery	 (ATA)	and	 the	proximal	
5cm	of	the	PTA	and	PEA82)	and	reported	the	median	score	for	each	segment.	In	136	patients	
they	 found	 those	 in	 the	DM	group	 (n=58)	had	a	 significantly	higher	 score	 in	 the	profunda	
femoris	(mean	score	3	(Inter-quartile	range	(IQR)	0-5)	vs	0	(0-2)),	popliteal	(7	(3-10)	vs	3	(0-
4)),	ATA	(13	(4-15)	vs	3	(0-4)),	PTA	(15	(0-15)	vs	4	(0-14))	and	PEA	(5	(0-5)	vs	0	(0-6))83.	Van	
der	 Feen	 et	 al.	 also	 used	 the	 original	 description	 of	 the	 segments	 but	 did	 not	 report	 the	
individual	scores	for	each	segment.	 Instead,	the	scores	were	combined	to	form	the	"upper	
leg"	(aorta,	iliacs,	profunda	femoris	and	superficial	femoral	artery)	and	"lower	leg"	(popliteal,	
ATA,	 PEA,	 and	 PTA).	 In	 37	 patients	 with	 DM	matched	 for	 age	 gender	 and	 smoking	 to	 37	
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patients	without	DM,	there	was	a	higher	mean	score	for	the	lower	leg	in	the	DM	group	but	
this	was	not	significant	(47.4	vs	37.6,	p=0.22).	While	the	scores	for	the	individual	segments	
were	not	 reported,	 the	 included	bar	graphs	 show	that	 the	only	 segment	with	a	 significant	
difference	 was	 the	 PEA	 in	 the	 right	 legs	 (p<0.05),	 those	 in	 the	 DM	 group	 had	 a	 higher	
score150.	Diehm	et	al.	only	scored	the	below	the	knee	segments	including	the	plantar	vessels	
and	so	extended	Bollinger's	original	description.	Their	patient	groups	were	patients	with	DM	
(n=25),	 patients	 with	 renal	 insufficiency	 (n=15),	 patients	 with	 both	 DM	 and	 renal	
insufficiency	 (n=25)	and	25	controls	with	neither	DM	or	 renal	 insufficiency.	They	 found	no	
significant	 difference	 between	 the	 groups	 although	 those	 in	 the	 DM	 group	 and	 the	 renal	
insufficiency	group	tended	towards	higher	scores.	
2.4. DISCUSSION	
These	results	demonstrate	that	there	is	a	difference	in	the	distribution	of	atherosclerotic	
disease	in	patients	with	DM	compared	to	those	without.	The	hypothesis	that	patients	with	
DM	have	more	disease	below	the	knee	is	supported.	Patients	with	DM	are	less	likely	to	have	
disease	in	the	aorto-iliac	segment	and	more	likely	to	have	disease	in	the	tibial	segment.	This	
is	demonstrated	in	the	forest	plot,	the	papers	that	applied	scores,	and	also	the	papers	that	it	
was	not	possible	to	include	in	the	forest	plot.	In	the	femoro-popliteal	segment,	the	trend	is	
towards	those	without	DM	having	more	disease,	although	this	does	not	reach	significance.	
There	was	 a	 trend	 towards	multi-level	 disease	 being	more	 common	 in	 patients	with	 DM.	
Four	 papers	 assessed	 the	 severity	 of	 disease	 in	 individual	 vessels	 rather	 than	
segments83,90,159	although	only	Jude	et	al.	did	for	both	above	and	below	knee	vessels	83.	 In	
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patients	with	and	without	DM,	 the	 least	affected	of	 the	 tibial	 vessels	was	consistently	 the	
PEA.	
The	PEA	as	a	target	vessel	 for	revascularisation	has	been	considered	to	have	 limitations	
due	to	success	relying	on	indirect	collateralisation	to	supply	the	forefoot162.	The	patency	of	
the	 PEA	 has	 also	 been	 demonstrated	 to	 be	 less	 critical	 in	 preventing	 amputation163.	 The	
angiosome	model	holds	that	the	areas	supplied	by	the	PEA	are	the	anterior	and	lateral	ankle	
and	 plantar	 heel164.	 However	 increasingly	 the	 PEA	 has	 been	 shown	 to	 have	 multiple	
collaterals	and	to	commonly	supply	the	pedal	arteries	and	as	such	has	comparable	outcomes	
for	 both	 surgical	 and	 endovascular	 revascularisation	 compared	 to	 other	 distal	 target	
vessels165-168.	 Only	 three	 papers	 included	 in	 the	 review	 considered	 pedal	 vessels90,157,159.	
Ciavarella	et	al	found	that	a	higher	proportion	of	patients	with	DM	had	complete	obstruction	
of	the	plantar	vessels	(53%	vs	29%	p<0.001).	There	was	however	no	significant	difference	in	
the	 rate	 of	 occlusions	 in	 the	 dorsalis	 pedis	 artery	 (43%	 vs	 40%)157.	 Diehm	et	 al,	 using	 the	
Bollinger	score	found	that	both	DM	and	renal	failure	were	associated	with	more	disease	in	
the	pedal	vessels	when	compared	to	the	calf	vessels.	However,	when	patency	of	at	least	one	
pedal	 vessel	 suitable	 for	 bypass	 was	 considered,	 patients	 with	 DM	where	 comparable	 to	
controls	without	DM90.	Menzoian	et	al	found	that	there	was	less	disease	of	the	pedal	arch	in	
patients	with	DM,	the	difference	was	not	significant159.	Whether	 there	 is	sparing	or	not	of	
the	pedal	vessels	 in	DM	is	an	inconsistent	finding	in	the	literature169-171,	but	there	are	case	
series	that	suggest	that	revascularisation	with	bypass	to	pedal	vessels	 is	a	viable	option	on	
patients	with	DM172.		
DM	is	known	to	have	an	impact	on	both	the	presentation	of	PAD	and	outcomes	following	
revascularisation173,174.	The	distribution	of	atherosclerotic	disease	has	also	been	shown	to	be	
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related	 to	 outcomes	 following	 revascularisation	 procedures	 in	 patients	 both	 with	 and	
without	 DM84.	 The	 pathophysiology	 behind	 why	 patients	 with	 DM	 have	 increased	 PAD	 is	
complex	but	thought	to	be	related	to	a	combination	of	down-regulation	of	nitric	oxide	and	
prostacyclin,	 upregulation	 of	 vasoconstrictors,	 apoptosis	 of	 endothelial	 cells,	 activated	
coagulation,	 abnormal	 platelet	 activation	 and	 propensity	 towards	 plaque	 rupture	 (Section	
1.3	 for	 more	 detail)175.	 There	 is	 not	 any	 clear	 evidence	 why	 the	 distal	 vessels	 are	
predominantly	 affected	 and	while	 these	 results	 support	 the	 hypothesis	 that	 patients	with	
DM	 have	 a	more	 significant	 disease	 burden	 below	 the	 knee	 they	 provide	 us	with	 limited	
information	on	the	degree	to	which	individual	vessels	or	areas	of	vessels	are	affected.	
A	 strength	 of	 the	 review	 is	 that	 all	 the	 papers	 used	DSA	 as	 the	 imaging	modality.	 DSA	
remains	 the	 gold	 standard	 for	 imaging	 of	 the	 lower	 limbs	 and	 describing	 the	 anatomic	
distribution	of	stenotic	disease176.	The	literature	search	did	include	CTA	and	MRA	as	imaging	
modalities	 but	 no	 papers	 that	 used	 these	 modalities	 and	 met	 the	 inclusion	 criteria	 were	
found.	These	modalities	could	be	used	to	assess	distribution	of	disease	keeping	in	mind	their	
limitations	 compared	 to	 DSA81,176,	 however	 the	 studies	 have	 not	 been	 done.	 In	 terms	 of	
scoring	 systems	 very	 few	 papers	 have	 described	 systems	 that	 employ	 imaging	modalities	
other	than	DSA	and	those	that	have,	have	not	been	validated177-179.	In	the	forest	plot,	there	
was	 low	 heterogeneity	 between	 the	 papers	 apart	 from	 those	 considering	 the	 femoro-
popliteal	 segment	 (I2=68%).	 A	 significant	weakness	 of	 the	 review	 is	 the	 low	quality	 of	 the	
papers	included.	They	are	all	observational	studies,	predominantly	retrospective	and	so	the	
body	 of	 evidence	 is	 low	 to	 very	 low	 quality180.	 An	 attempt	 to	 assess	 the	 methodological	
quality	of	the	papers	using	the	Newcastle-Ottawa	scale181	was	made.	However,	all	but	three	
papers	 were	 cross-sectional	 studies	 making	 it	 not	 possible	 to	 apply	 the	 scale.	 There	 was	
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consistency	 in	 the	 type	of	patients	 selected	with	 the	majority	of	papers	 including	patients	
with	Fontaine	II	to	IV	disease.	However,	one	paper	only	included	patients	with	intermittent	
claudication155,	 two	 papers	 excluded	 those	 with	 intermittent	 claudication154,158	 and	 three	
papers	did	not	define	the	patient	group	beyond	symptomatic	PAD152,156,157.	As	described	in	
the	 results	 section	 there	was	 also	 variance	 in	 how	 significant	 disease	was	defined.	Within	
each	 paper	 the	 demographics	 for	 each	 group,	 when	 reported,	 were	 comparable	 (Table	
2.3-3).		
Additional	weaknesses	 include	that	the	papers	are	all	 relatively	historical	 (earliest	1964,	
latest	2009)	and	the	variety	in	how	the	arterial	segments	were	described	and	grouped.	This	
grouping	meant	 some	data	was	 not	 able	 to	 be	 included	 in	 the	meta-analysis	 because	 the	
segment	 crossed	 the	 knee,	 weakening	 the	 data	 included.	 During	 data	 collection,	 it	 was	
considered	that	improvements	in	the	medical	management	of	DM	and	PAD	might	have	had	
an	impact	on	the	distribution	of	disease.	Evidence	from	high-quality	randomised	controlled	
trials	on	the	importance	of	tight	blood	glucose	control	in	relation	to	the	complications	of	DM	
was	 published	 in	 the	 late	 nineties59,182.	 When	 studies	 from	 before	 the	 year	 2000	 were	
excluded	from	the	meta-analysis,	the	trends	remained	the	same	although	the	odds	ratio	for	
tibial	disease	was	no	longer	significant	(OR	1.99	(0.94-4.24)).	Between	1964	and	2019	there	
have	 been	 considerable	 improvements	 in	 imaging	 technologies183.	 DSA	 remains	 the	 gold	
standard	for	research	but	in	clinical	practice	duplex	ultrasound,	CTA	and	MRA	are	advised	as	
first	 line	 investigations	 for	planning	 revascularisation184.	 This	means	 that	 there	has	been	a	
relative	reduction	in	the	number	of	DSA’s	performed	compared	to	non-invasive	modalities,	
particularly	in	Europe185,186.	Potentially	this	means	that	the	types	of	patients	included	in	the	
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earlier	studies	will	be	different	to	those	in	the	later	studies.	This	change	may	also	go	some	
way	to	explaining	why	there	are	no	more	recent	studies	available.		
2.5. CONCLUSIONS	
Patients	 with	 DM	 are	 more	 likely	 to	 have	 atherosclerotic	 disease	 in	 the	 tibial	 vessels	
compared	 to	 patients	 without.	 The	 current	 published	 evidence	 supports	 this	 hypothesis.	
There	 is	 very	 limited	 data	 on	 the	 degree	 to	which	 individual	 vessels	 are	 affected.	 Further	
information	on	this	and	a	greater	understanding	of	why	the	distal	vessels	are	more	affected	
are	avenues	for	future	research.	In	the	next	chapter	a	study	that	aims	to	examine	the	distal	
vessels	in	detail	is	presented.	
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CHAPTER	3: METHODOLOGY	 AND	 RESULTS	 FOR	 DISTRIBUTION	 OF	
ARTERIAL	DISEASE	IN	DIABETES	MELLITUS	
3.1. HYPOTHESIS	
Patients	with	diabetes	mellitus	 (DM)	have	a	higher	proportion	of	 infra-popliteal	disease	
compared	to	patients	without	DM.	
3.2. PRIMARY	OUTCOME	
Difference	between	median	Bollinger	score	in	each	arterial	segment	in	patients	with	DM	
compared	to	patients	without	DM.	
3.3. DESIGN	OF	STUDY:	PILOT	STUDY	
All	patients	who	had	a	lower	limb	angiogram	between	September	2010	and	April	2014	at	
Queen	 Elizabeth	 Hospital	 Birmingham	 were	 identified	 from	 the	 prospective	 radiology	
database.	From	this	cohort,	all	the	patients	with	DM	were	identified.	Each	of	these	patients	
was	age	and	sex-matched	with	a	patient	without	DM	(NDM)	who	underwent	an	angiogram	
in	 the	 same	 period.	 The	 cohort	 for	 the	 pilot	 study	 consisted	 of	 216	 patients	 randomly	
selected	 from	all	matched	patients	 combined,	 due	 to	 this	 there	were	 uneven	numbers	 of	
patients	between	the	two	study	cohorts.		
The	 first	 angiogram	 performed	 within	 the	 study	 period	 with	 images	 saved	 on	 the	
hospitals	 imaging	 system	 (IMPAX)	 was	 assessed.	 Each	 arterial	 segment,	 as	 described	 by	
Bollinger,	was	scored	for	all	arteries	imaged	from	the	infra-renal	aorta	down	to	the	proximal	
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anterior	 tibial	 (ATA),	 posterior	 tibial	 (PTA)	 and	peroneal	 arteries	 (PEA).	 A	 limitation	of	 the	
Bollinger	score,	as	 it	was	originally	described82,	 is	that	the	described	segments	only	extend	
3cm	 into	 the	 ATA	 and	 5cm	 into	 the	 PTA	 and	 PEA.	 Due	 to	 this	 the	 decision	was	made	 to	
include	segments	that	encompassed	the	whole	of	the	crural	vessels	and	major	pedal	vessels.	
This	aimed	to	collect	a	fuller	picture	of	the	extent	of	distal	disease	than	would	be	possible	
with	the	original	segments.	The	same	scoring	matrix	was	applied	to	the	whole	of	 the	ATA,	
PTA	and	PEA	divided	 into	 thirds	and	 the	dorsalis	pedis,	medial	 and	 lateral	plantar	arteries	
(LPA)	(Figure	3.3-1).	The	decision	to	divide	the	vessels	into	thirds	was	based	on	advice	from	
consultant	 radiologists	 and	 the	 endovascular	 surgeons	 in	 our	 department	 who	 routinely	
describe	the	vessels	in	these	terms.	For	the	pilot	study,	both	legs	were	scored	if	there	were	
available	images.	
3.3.1. Statistics	
Parametric	 data	 (age)	 is	 reported	 as	mean	 (±	 standard	 deviation	 (SD))	 and	 the	 groups	
compared	 using	 unpaired	 T-test.	 Non-parametric	 data	 (Bollinger	 score)	 is	 reported	 as	
median	 (inter-quartile	 range)	 and	 the	 groups	 compared	 using	 Mann-Whitney	 U	 test.	
Categorical	 data	 (ethnic	 group,	 smoking	 status,	 hypertension,	 hypercholesterolaemia	 and	
renal	 function)	was	 compared	 between	 groups	 using	 Fisher’s	 exact	 test.	 A	 p-value	 of	 less	
than	0.05	was	considered	to	be	statistically	significant.	
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Figure	 3.3-1:	 Schematic	 representation	 of	 arterial	 segments	 described	 by	 Bollinger	
compared	to	the	arterial	segments	examined	in	the	pilot	study.		
A;	 infrarenal	 aorta,	 CIA;	 common	 iliac	 artery,	 IIA;	 internal	 iliac	 artery,	 EIA;	 external	 iliac	
artery,	 PFA;	 profunda	 femoris	 artery,	 SFA;	 superficial	 femoral	 artery,	 PA;	 popliteal	 artery,	
ATA;	proximal	3cm	of	anterior	tibial	artery,	ATA1;	proximal	3rd	of	anterior	tibial	artery,	ATA2	
middle	3rd	of	 anterior	 tibial	 artery,	ATA3;	distal	3rd	of	 anterior	 tibial	 artery,	DPA;	dorsalis	
pedis	artery,	PEA;	proximal	5cm	of	peroneal	artery,	PEA1;	proximal	3rd	of	peroneal	artery,	
PEA2;	middle	3rd	of	peroneal	artery,	PEA3	distal	3rd	of	peroneal	artery,	PTA;	proximal	5cm	
of	posterior	tibial	artery,	PTA1;	proximal	3rd	of	posterior	tibial	artery,	PTA2;	middle	3rd	of	
posterior	tibial	artery,	PTA3;	distal	3rd	of	posterior	tibial	artery,	MPA;	medial	plantar	artery,	
LPA;	lateral	plantar	artery.	 	
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3.4. PILOT	STUDY	RESULTS	
There	were	119	patients	in	the	DM	group	and	97	in	the	NDM	group.	The	mean	age	of	the	
DM	group	was	 70	 years	 (SD	 ±11)	 and	NDM	group	 69	 years	 (SD±13,	 p=0.51).	 Seventy-four	
percent	of	NDM	patients	and	71%	of	DM	were	males	 (p=0.65).	Significantly	more	patients	
without	DM	had	bilateral	angiograms	than	patients	with	DM	(26.8%	vs	9.2%,	p	<0.01).	Due	
to	 this	 difference	 and	 the	 potential	 to	 skew	 the	 data	 the	 decision,	 in	 consultation	 with	
statisticians,	was	made	to	only	report	and	include	in	the	analysis	the	results	for	the	left	leg	in	
those	 who	 had	 bilateral	 imaging.	 In	 the	 diabetes	 group,	 there	 were	 significantly	 higher	
proportions	 of	 patients	 in	 the	Asian	 and	 Black	 ethnic	 groups	 and	 also	more	 patients	with	
hypertension.	 The	 other	 demographic	 groups,	 smoking	 status,	 hypercholesterolaemia	 and	
renal	function,	were	comparable	(Table	3.4-1).	
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Table	3.4-1:	Demographics	for	pilot	study	groups	
	 Percentage	(n)	
p-value	
No	
Diabetes	
(n=97)	
Diabetes	
(n=119)	
Mean	age	(SD)*	 69	(12.8)	 70	(11.20)	 0.51	
	 	 	 	
Sex**	 Male	 74.2	(72)	 70.6	(84)	
0.65	
Female	 25.8	(25)	 29.4	(35)	
	 	 	 	 	
Ethnic	group**	 White	 90.7	(88)	 73.9	(88)	
<0.05	
Asian	 2.1	(2)	 13.4	(16)	
Black	 1.0	(1)	 6.7	(8)	
Other	 6.2	(6)	 5.9	(7)	
	 	 	 	 	
Smoking**	 Never	smoked	 10.3	(10)	 19.3	(23)	
0.19	
Ex-smoker	 48.5	(47)	 50.4	(60)	
Still	smoking	 29.9	(29)	 21.0	(25)	
Unknown	 11.3	(11)	 9.2	(11)	
	 	 	 	 	
Hypertension**	 Yes	 48.5	(47)	 73.9	(88)	
<0.05	No	 40.2	(39)	 17.6	(21)	
Unknown	 11.3	(11)	 8.4	(10)	
	 	 	 	 	
Hypercholesterolaemia**	 Yes	 40.2	(39)	 38.7	(46)	
0.51	No	 29.9	(29)	 24.4	(29)	
Unknown	 29.9	(29)	 37.0	(44)	
	 	 	 	 	
Renal	function**	 Normal	 93.8	(91)	 81.5	(97)	
0.09	
Creatinine	>150	
umol/L	
3.1	(3)	 10.1	(12)	
Dialysis	 2.1	(2)	 4.2	(5)	
Functioning	transplant	 1.0	(1)	 2.5	(3)	
*Unpaired	T-test,	**Fisher	exact	test,	SD	=	standard	deviation	
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The	 external	 iliac	 artery	was	 the	 only	 artery	 to	 have	 a	 significantly	 higher	 score	 in	 the	
NDM	group	(3	(Inter-quartile	range	(IQR)	0-7))	than	the	DM	group	(2	(IQR	0-3)	p<0.05).	The	
DM	group	had	significantly	higher	scores	 in	all	 segments	of	 the	PTA.	The	proximal,	middle	
and	distal	 thirds	of	 the	ATA	 in	the	DM	group	all	had	a	higher	median	score	than	the	NDM	
group;	however,	this	difference	did	not	reach	statistical	significance	(Table	3.4-2).	
Table	3.4-2:	Pilot	study:	comparing	the	median	Bollinger	score	of	patients	with	diabetes	to	
patients	without	diabetes	by	arterial	segment.		
Arterial	segment	
Median	Bollinger	score	(IQR)	
p-value*	No	Diabetes	
(n=97)	
Diabetes	
(n=119)	
Aorta	 3	(1-3)	 3	(3-3)	 0.497	
Common	iliac	 3	(2-7)	 3	(1-3)	 0.192	
Internal	iliac	 3	(0-7)	 3	(0-7)	 0.994	
External	iliac	 3	(0-7)	 2	(0-3)	 <0.05	
Superficial	femoral	 8	(3-13)	 7	(3-13)	 0.411	
Profunda	femoris	 0	(0-3)	 0	(0-3)	 0.889	
Popliteal	 5	(2-13)	 6	(3-10)	 0.369	
Anterior	tibial	(proximal	3cm)	 2	(0-8)	 3	(0-7)	 0.182	
Anterior	tibial	(proximal	3rd)†	 3	(0-13)	 5	(2-13)	 0.109	
Anterior	tibial	(middle	3rd)†	 3	(0-13)	 4	(0-15)	 0.112	
Anterior	tibial	(distal	3rd)†	 3	(0-15)	 7	(0-15)	 0.417	
Dorsalis	pedis†	 13	(0-15)	 13	(0-15)	 0.573	
Peroneal	(proximal	5cm)	 3	(0-7)	 3	(0-10)	 0.386	
Peroneal	(proximal	3rd)†	 3	(0-7)	 3	(0-13)	 0.246	
Peroneal	(middle	3rd)†	 3	(0-7)	 3	(0-13)	 0.675	
Peroneal	(distal	3rd)†	 3	(0-13)	 3	(0-15)	 0.992	
Posterior	tibial	(proximal	5cm)	 3	(0-13)	 6	(0-15)	 <0.05	
Posterior	tibial	(proximal	3rd)†	 3	(0-13)	 8	(2-15)	 <0.05	
Posterior	tibial	(middle	3rd)†	 3	(0-15)	 10	(0-15)	 <0.05	
Posterior	tibial	(distal	3rd)†	 3	(0-15)	 13	(0-15)	 <0.05	
Medial	plantar†	 15	(0-15)	 15	(0-15)	 0.463	
Lateral	plantar†	 15	(0-15)	 15	(0-15)	 0.978	
*	Mann-Whitney	U	Test	
†	Not	originally	included	in	Bollinger	score	
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There	 was	 a	 high	 proportion	 of	missing	 data	 throughout	 the	 dataset	 used	 in	 the	 pilot	
study	(Table	3.4-3).	This	was	due	to	absent	or	incomplete	imaging	of	arterial	segments	with	
eighteen	patients	having	only	data	for	the	supra-inguinal	vessels.	The	proportion	of	missing	
data	points	 ranges	 from	15.5%	 (popliteal	 and	ATA)	 to	 75.3%	 (aorta)	 in	 the	DM	group	and	
3.4%	 (ATA)	 to	 89.2%	 (aorta)	 in	 the	 NDM	 group.	 The	 mean	 proportion	 missing	 for	 those	
without	DM	was	30.6%	(SD	19.3%)	compared	to	23.0%	(32.4%,	p=0.16).	
Table	3.4-3:	Proportion	of	patients	with	missing	data	by	arterial	segment	
	
No	Diabetes	
(n-97)	
Diabetes	
(n=119)	
Difference	
in	
percentage	
missing		
Missing	 %	 Missing	 %	
Aorta	 107	 89.9	 73	 75.3	 14.66	
Common	iliac	 97	 81.5	 60	 61.9	 19.66	
Internal	iliac	 96	 80.7	 60	 61.9	 18.82	
External	iliac	 95	 79.8	 60	 61.9	 17.98	
Superficial	femoral	 5	 4.2	 16	 16.5	 17.98	
Profunda	femoris	 15	 12.6	 20	 20.6	 12.29	
Popliteal	 4	 3.4	 15	 15.5	 8.01	
Anterior	tibial	 4	 3.4	 15	 15.5	 12.10	
Anterior	tibial	1	 4	 3.4	 17	 17.5	 12.10	
Anterior	tibial	2	 5	 4.2	 19	 19.6	 14.16	
Anterior	tibial	3	 6	 5.0	 22	 22.7	 15.39	
Dorsalis	pedis	 16	 13.4	 29	 29.9	 17.64	
Peroneal	 4	 3.4	 16	 16.5	 16.45	
Peroneal	1	 4	 3.4	 17	 17.5	 13.13	
Peroneal	2	 5	 4.2	 19	 19.6	 14.16	
Peroneal	3	 6	 5.0	 22	 22.7	 15.39	
Posterior	tibial	 4	 3.4	 16	 16.5	 17.64	
Posterior	tibial	1	 4	 3.4	 17	 17.5	 13.13	
Posterior	tibial	2	 5	 4.2	 19	 19.6	 14.16	
Posterior	tibial	3	 6	 5.0	 22	 22.7	 15.39	
Medial	plantar	 21	 17.6	 34	 35.1	 17.64	
Lateral	plantar	 21	 17.6	 34	 35.1	 17.40	
Paired	T-test	p=0.016	
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3.4.1. Inter-observer	reliability	
Five	clinicians,	with	experience	of	reading	 lower	 limb	angiograms,	 independently	scored	
twenty-five	randomly	selected	angiograms	from	the	dataset.	The	scorers	included	the	author	
of	 this	 project,	 a	 vascular	 surgery	 consultant,	 a	 radiology	 senior	 trainee	 and	 two	 surgical	
research	 registrars	 with	 vascular	 backgrounds.	 Intra-class	 correlation	 (ICC)	 and	 Cohen’s	
kappa	coefficient	were	calculated	to	assess	the	level	of	agreement.	ICC	was	also	calculated	
for	 those	patients	 that	were	 scored	by	Scorer	1	 for	both	 the	pilot	 study	and	 the	matched	
cohorts.	
3.4.1.1. Inter-class	correlation		
Bland-Altman	plots	were	calculated	for	each	scorer	pair.	These	were	calculated	for	each	
arterial	 segment	 separately	 and	 all	 segments	 combined.	 There	 was	 no	 pattern	 that	
demonstrated	any	significant	disagreement	by	arterial	segment	between	scorers	and	so	only	
the	combined	data	is	presented	here.	Examination	of	the	Bland-Altman	plots	(Figure	3.4-1)	
showed	 that	 scorer	2	had	 significantly	different	 results	 compared	 to	all	 four	other	 scorers	
(Table	3.4-4).	Due	to	this	ICC	was	calculated	both	with	and	without	Scorer	2’s	results.	
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Table	 3.4-4:	 Inter-observer	 reliability:	Mean	 difference	 and	 95%	 limits	 of	 agreement	 for	
combined	arterial	segments	by	scorer	pairs.	
Scorer	pairs	(n)	 Mean	Difference	(SD)	 p-value*	
95%	Limits	of	Agreement	
Lower	 Upper	
1	vs	2	(427)	 -1.76	(4.44)	 <0.001	 6.95	 -10.47	
1	vs	3	(421)	 -0.40	(5.04)	 0.105	 9.49	 -10.29	
1	vs	4	(446)	 -0.45	(4.55)	 0.037	 8.46	 -9.37	
1	vs	5	(442)	 -0.74	(4.25)	 <0.001	 7.58	 -9.07	
2	vs	3	(405)	 1.45	(4.10	 <0.001	 9.49	 -6.58	
2	vs	4	(424)	 1.38	(3.85)	 <0.001	 8.93	 -6.16	
2	vs	5	(425)	 1.04	(3.24)	 <0.001	 7.38	 -5.31	
3	vs	4	(420)	 -0.13	(4.00)	 0.519	 7.72	 -7.97	
3	vs	5	(418)	 -0.46	(3.74)	 0.013	 6.88	 -7.80	
4	vs	5	(438)	 -0.32	(3.07)	 0.032	 5.70	 -6.33	
*One	sample	T-test	(test	value	=	0)	
	
	
A	two-way	random	effects	model	with	measures	of	absolute	agreement	was	used.	For	all	
the	 scorers	 the	 ICC	 coefficient	 was	 0.74(95%	 CI	 0.71-0.78)	 and	 with	 scorer	 2	 removed	
0.76(0.72-0.79).	The	result	with	all	scorers	suggests	moderate	agreement	and	with	scorer	2	
excluded	there	was	good	agreement.	There	was	good	internal	consistency	with	Cronbach’s	
alpha	0.94	for	all	scorers	and	0.93	with	scorer	2	excluded.		
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Figure	3.4-1:	Bland-Altman	plots	for	all	arterial	segments	by	scorer	pairs.		
A:	Scorer	1	vs	Scorer	2.	B:	Scorer	1	vs	Scorer	3.	C:	Scorer	1	vs	Scorer	4.	D:	Scorer	1	vs	Scorer	
5.	E:	Scorer	2	vs	Scorer	3.	F:	Scorer	2	vs	Scorer	4	G:	Scorer	2	vs	Scorer	5	H:	Scorer	3	vs	Scorer	
4	I:	Scorer	3	vs	Scorer	5	J:	Scorer	4	vs	Scorer	5	
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3.4.1.2. Cohen’s	kappa	coefficient	
The	 Bollinger	 scores	 were	 categorised	 as	 1=<3,	 2=3-5,	 3=6-8,	 4=≥9.	 The	 kappa	 values	
ranged	 from	 0.26	 (Standard	 Error	 (SE)	 0.026)	 to	 0.54	 (0.030)	 demonstrating	 a	 fair	 to	
moderate	correlation.	As	before	scorer	2	had	the	lowest	levels	of	agreement	(Table	3.4-5).	
Table	3.4-5:	Cohen’s	kappa	coefficient	by	scorer	pair.	
Scorer	pairs	 Kappa	Value	(SE)	 p-value	
1	vs	2	 0.26	(0.026)	 <0.001	
1	vs	3	 0.39	(0.033)	 <0.001	
1	vs	4	 0.54	(0.032)	 <0.001	
1	vs	5	 0.48	(0.031)	 <0.001	
2	vs	3	 0.36	(0.031)	 <0.001	
2	vs	4	 0.35	(0.028)	 <0.001	
2	vs	5	 0.39	(0.031)	 <0.001	
3	vs	4	 0.53	(0.032)	 <0.001	
3	vs	5	 0.47	(0.032)	 <0.001	
4	vs	5	 0.54	(0.030)	 <0.001	
3.4.2. Intra-observer	reliability	
Sixty-six	 patients	were	 scored	by	 Scorer	 1	 as	 part	 of	 both	 the	pilot	 study	 and	matched	
cohorts,	 twenty	 patients	without	DM	and	 46	with	DM.	 This	 represents	 30.5%	of	 the	 pilot	
cohort	and	21.5%	of	the	matched	cohorts.	Due	to	the	difference	in	how	the	popliteal	artery	
and	 tibial-peroneal	 trunk	 (TPT)	were	 treated	during	 the	pilot	 and	 the	matched	 analyses	 it	
was	not	possible	to	include	them	in	this	analysis.	
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3.4.2.1. Intra-class	correlation	
The	Bland-Altman	plot	was	 similar	 to	 those	obtained	 in	 the	 inter-observer	analysis,	 the	
mean	 of	 the	 difference	 was	 0.34	 (SD3.77,	 p=0.007)	 and	 limits	 of	 agreement	 -7.05-7.74	
(Figure	3.4-2).	The	ICC	was	0.81	(95%	CI	0.80-0.83)	and	Cronbach’s	alpha	0.90	reflecting	good	
correlation	and	internal	consistency.	
	
	
Figure	3.4-2:	Bland-Altman	plot	for	all	arterial	segments	in	intra-observer	reliability.	
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3.5. CONCLUSIONS	FROM	PILOT	STUDY	AND	PLAN	FOR	FULL	STUDY	
The	 results	 from	 the	 pilot	 study	 show	 that	 patients	 with	 DM	 had	 a	 higher	 severity	 of	
disease	in	the	PTA;	there	was	also	a	non-significant	trend	towards	worse	disease	in	the	ATA.	
The	PEA	appeared	to	be	relatively	spared	in	the	DM	group.	Within	the	demographics,	there	
were	potential	sources	of	bias	in	the	results	with	a	significantly	higher	proportion	of	patients	
with	hypertension	and	from	Asian	backgrounds	in	the	DM	group.	During	the	scoring,	it	was	
noted	 that	 the	 popliteal	 segment	 as	 described	 by	 Bollinger	 (from	 the	 distal	 end	 of	 the	
adductor	 canal	 until	 bifurcation	 into	 PTA	 and	 PEA)	 regularly	 had	 a	 different	 pattern	 of	
disease	in	the	TPT,	i.e.	distal	to	the	ATA	branch,	compared	to	rest	of	the	segment.	There	was	
a	high	proportion	of	missing	data	on	 individual	arterial	 segments	particularly	 in	 the	aorto-
iliac	segments,	and	this	proportion	seemed	to	be	higher	in	the	DM	group.	
The	inter-rater	reliability	results	were	mixed	and	in	particular	there	was	poorer	reliability	
between	 the	 trainees	 (0.69	 (0.65-0.74)).	An	attempt	was	made	 to	 recruit	more	 consultant	
level	raters	to	 improve	the	validation	but	unfortunately	 it	was	not	possible	to	achieve	this.	
Of	note,	the	best	agreement	was	between	the	consultant	surgeon	and	the	scorer	who	went	
on	to	interpret	the	angiograms	for	the	rest	of	the	project	(ICC	0.87	(0.84-0.89)	and	Cohen’s	
kappa	coefficient	0.54	(0.030)).	
Due	to	these	findings	and	following	advice	from	a	statistician,	the	following	adjustments	
were	made	to	the	protocol	for	the	full	study.	
• All	patients	with	aorto-iliac	imaging	only	were	excluded.	
• To	improve	matching	between	the	two	cohorts	SPSS	(IBM	Version	22)	was	used	to	
match	for	age	(±5	years),	sex,	ethnicity,	smoking,	hypertension,	
hypercholesterolaemia	and	renal	impairment.	Matching	was	performed	on	a	one-to-
one	basis,	and	only	exact	matches	were	initially	included.	
• Only	infra-inguinal	arterial	segments	were	scored.	
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• The	originally	described	popliteal	segment	was	divided	into	the	popliteal	artery	(PA)	
and	TPT	(Figure	3.6-1).	
• The	crural	vessels	were	assessed	both	in	thirds	as	per	Figure	3.6-1	and	as	a	complete	
vessel.	
• If	bilateral	images	were	available,	only	the	left	leg	was	scored.	
• Outcome	data	for	all	included	patients	were	collected	from	each	patient’s	electronic	
medical	record.	
3.6. SECONDARY	OUTCOMES	
Due	to	the	above	changes,	new	secondary	outcomes	were	decided	on:	
• Difference	in	short	to	medium	term	outcomes	between	cohorts,	particularly;	
amputation-free	survival,	further	revascularisation	(open	or	endovascular),	minor	
amputation,	major	amputation,	all-cause	mortality.	
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Figure	3.6-1:	Schematic	representation	of	arterial	segments	used	in	full	study.	
PFA;	profunda	femoris	artery,	SFA;	superficial	femoral	artery,	PA;	popliteal	artery,	TPT;	tibial-
peroneal	trunk,	ATA;	anterior	tibial	artery,	ATA1;	proximal	3rd	of	anterior	tibial	artery,	ATA2	
middle	3rd	of	 anterior	 tibial	 artery,	ATA3;	distal	3rd	of	 anterior	 tibial	 artery,	DPA;	dorsalis	
pedis	artery,	PEA;	peroneal	artery,	PEA1;	proximal	3rd	of	peroneal	artery,	PEA2;	middle	3rd	
of	 peroneal	 artery,	 PEA3	 distal	 3rd	 of	 peroneal	 artery,	 PTA;	 posterior	 tibial	 artery,	 PTA1;	
proximal	 3rd	 of	 posterior	 tibial	 artery,	 PTA2;	 middle	 3rd	 of	 posterior	 tibial	 artery,	 PTA3;	
distal	3rd	of	posterior	tibial	artery,	MPA;	medial	plantar	artery,	LPA;	lateral	plantar	artery.	
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3.7. STATISTICAL	ANALYSIS	FOR	THE	FULL	STUDY	
All	 angiograms	 were	 assessed	 by	 one	 observer	 (author)	 who	 also	 carried	 out	 the	
statistical	analysis.	During	assessment	of	 the	angiograms	 the	observer	was	unaware	which	
study	group	the	patient	belonged	too	(only	identifying	information	on	the	datasheet,	patient	
number	and	date	of	angiogram).	
As	 our	 cohorts	 are	 matched,	 paired	 statistical	 analysis	 was	 used	 where	 possible.	
Normality	of	continuous	data	(age,	length	of	follow-up)	was	tested	using	Shapiro-Wilk’s	test	
and	Q-Q	plots187.	Parametric	data	were	reported	as	mean	(±	SD)	and	compared	using	paired	
T-tests.	Non-parametric	data	were	reported	as	median	(IQR)	and	compared	using	Wilcoxon	
signed	 rank	 test.	 Categorical	 data	were	 compared	using	 Fisher’s	 exact	 test	 or	 Chi-squared	
test.	
The	Bollinger	score	runs	from	zero	to	15.	It	is	only	possible	to	score	integers,	and	it	is	not	
possible	 to	 score	 eleven	 or	 twelve,	 as	 such	 the	 scores	 are	 non-parametric	 data	 and	were	
reported	 using	median	 (IQR)	 and	 appropriate	 non-parametric	 tests.	 Each	 arterial	 segment	
was	analysed	separately.		
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3.8. RESULTS	
3.8.1. Demographics	
3.8.1.1. Raw	data	
Within	 the	 raw	 data,	 once	 duplicates	 and	 those	 with	 aorto-iliac	 imaging	 only	 were	
removed,	there	were	355	patients	with	DM	and	631	without.	In	this	raw	data,	the	mean	age	
was	69.4	(SD	12.8),	639	of	patients	were	male	(64.8%)	and	347	female	(35.2%).	Seventy-two	
percent	of	the	procedures	were	performed	electively,	and	90%	of	patients	were	of	a	white	
ethnic	origin,	4.2%	were	of	a	black	ethnic	origin,	and	4.5%	were	of	an	Asian	ethnic	origin.		
3.8.1.2. Tests	of	Normality	
Tests	of	normality	were	performed	on	the	matched	cohorts.	For	age	at	 intervention	the	
Shapiro-Wilk	 statistic	 was	 0.993	 (p=0.141)	 meaning	 the	 null	 hypothesis	 that	 the	 data	 is	
normally	distributed	was	accepted.	The	corresponding	statistic	 for	 length	of	 follow-up	was	
0.973	(P<0.001)	meaning	the	null	hypothesis	was	rejected.	The	Q-Q	plots	demonstrated	for	
age	 at	 intervention	 a	 very	 close	 relationship	 between	 the	 observed	 and	 expected	 values	
whereas	 this	 relationship	 was	 weaker	 for	 length	 of	 follow-up	 (Figure	 3.8-1).	 For	 these	
reasons,	age	at	intervention	was	treated	as	parametric	data	and	length	of	follow-up	as	non-
parametric.	
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Figure	3.8-1:	Q-Q	plots	for	age	at	intervention	and	length	of	follow-up	
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3.8.1.3. Matched	Cohorts	
Three	hundred	and	ten	patients	were	identified	as	being	matched	by	the	criteria	set	out	
above	 (Section	 3.5),	 155	 per	 cohort.	 During	 the	 process	 of	 collecting	 the	 data	 for	 the	
Bollinger	score	in	the	DM	cohort,	two	duplicate	entries	were	identified.	This	necessitated	the	
removal	 of	 the	matching	 pairs	 from	 the	NDM	group	 and	 reduced	 the	 cohort	 sizes	 to	 153	
patients.	Eight	other	patients	were	manually	 replaced	with	 the	next	nearest	match	due	 to	
the	 following	 reasons.	 Five	 patients	 had	 iliac	 images	 only	 saved,	 two	 patients	 underwent	
their	angiogram	to	plan	for	plastic	surgery	rather	than	for	peripheral	arterial	disease	(PAD),	
and	one	patient’s	angiogram	failed	with	no	images	stored.		
The	 resulting	 cohorts	 were	 significantly	 matched	 for	 age,	 gender,	 ethnicity,	 smoking	
status,	hypertension,	hypercholesterolaemia	and	renal	function	(Table	3.8-1).	They	were	also	
closely	matched	for	length	of	follow-up,	with	the	median	being	just	under	2.5	years	for	both	
cohorts.	There	were,	however,	differences	between	the	cohorts	 in	indication	and	timing	of	
the	procedure.	Those	with	DM	were	more	likely	to	present	with	critical	ischaemia	(54.9%	v	
32%),	 and	 those	 without	 DM	 more	 like	 to	 present	 with	 claudication	 (60.1%	 v	 37.9%,	
p<0.001).	Those	with	DM	were	also	more	 likely	to	require	the	procedure	as	an	emergency	
(29.4%	v	10.5%,	p<0.001).	
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Table	3.8-1:	Demographics	for	matched	cohorts	
	
Cohort	(%)		
p-value	No	Diabetes	
(n=153)	
Diabetes	
(n=153)	
Mean	age	(SD)*	 	 70.3	(9.4)	 70.3	(9.2)	 0.937	
Median	LoF	(IQR)**	 	 2.3	(1.24-3.34)	 2.4	(1.38-3.78)	 0.292	
Sex‡	 Male	 72.5	 71.9	 1.00	
	 Female	 27.5	 28.1	 	
Ethnic	group‡	 White	 97.4	 97.4	 1.00	
	 Asian	 1.3	 1.3	 	
	 Black	 1.3	 1.3	 	
Smoking‡	 Never	smoked	 11.1	 11.1	 1.00	
	 Ex-smoker	 67.3	 68.0	 	
	 Still	smoking	 21.6	 20.9	 	
Hypertension‡	 Yes	 16.3	 16.3	 1.00	
	 No	 83.7	 83.7	 	
Hypercholesterolaemia‡	 Yes	 38.6	 39.2	 1.00	
	 No	 61.4	 60.8	 	
Renal	function‡	 Normal	 96.7	 96.7	 1.00	
	 Renal	Failure	 3.3	 3.3	 	
Indication‡	 Asymptomatic	 7.8	 7.2	 <0.001	
	 Claudication	 60.1	 37.9	 	
	 Critical	ischaemia	 32.0	 54.9	 	
Timing	of	procedure‡	 Elective	 89.5	 70.6	 <0.001	
	 Emergency	 10.5	 29.4	 	
*Paired	 T-test,	 **Wilcoxon	 signed	 rank	 test,	 ‡Chi-squared	 test,	 LoF:	 Length	 of	 Follow-up,	
SD=standard	deviation	
3.8.2. Bollinger	score	results	
Due	 to	 the	 significant	 difference	 in	 indication	 for	 procedure	 by	 group	 the	 results	 are	
presented	separately	for	each	 indication.	The	only	segments	 in	which	there	was	difference	
where	the	lateral	and	medial	plantar	arteries	 in	the	patients	with	critical	 ischaemia	(Tables	
3.8-2	to	3.8-4).		
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Table	3.8-2:	Results	of	Bollinger	scores	for	asymptomatic	patients	
	
Median	Bollinger	score	(IQR)	 	
No	Diabetes	
(n=12)	
Diabetes	
(n=11)	
p-value*	
Superficial	femoral		 15	(12-15)	 15	(13-15)	 0.880	
Profunda	femoris		 2	(0-2)	 0	(0-2)	 0.606	
Popliteal		 10	(3-14)	 13	(4-13)	 0.674	
TP	Trunk		 3	(0-4)	 3	(0-7)	 0.740	
Anterior	tibial		 13	(2-15)	 3	(0-15)	 0.652	
Peroneal		 0	(0-3)	 0	(0-13)	 0.847	
Posterior	tibial		 2	(0-15)	 15	(3-15)	 0.116	
Dorsalis	pedis		 14	(2-15)	 0	(0-13)	 0.161	
Lateral	plantar	 0	(0-15)	 15	(1-15)	 0.397	
Medial	plantar		 0	(0-15)	 15	(1-15)	 0.281	
*Mann-Whitney	U	Test	
	
	
Table	3.8-3:	Results	of	Bollinger	scores	for	patients	with	claudication	
	
Median	Bollinger	score	(IQR)	 	
No	Diabetes	
(n=91)	
Diabetes	
(n=58)	
p-value*	
Superficial	femoral		 9	(6-13)	 8	(6-13)	 0.871	
Profunda	femoris		 0	(0-0)	 0	(0-0)	 0.225	
Popliteal		 3	(0-13)	 3	(0-5)	 0.339	
TP	Trunk		 0	(0-2)	 0	(0-3)	 0.763	
Anterior	tibial		 0	(0-15)	 13	(2-15)	 0.121	
Peroneal		 2	(0-13)	 2	(0-13)	 0.745	
Posterior	tibial		 0	(0-13)	 0	(0-13)	 0.516	
Dorsalis	pedis		 4	(0-15)	 15	(0-15)	 0.125	
Lateral	plantar	 15	(0-15)	 13	(0-15)	 0.092	
Medial	plantar		 3	(0-15)	 0	(0-15)	 0.508	
*Mann-Whitney	U	Test	
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Table	3.8-4:	Results	of	Bollinger	scores	for	patients	with	critical	ischaemia	
	
Median	Bollinger	score	(IQR)	 	
No	Diabetes	
(n=49)	
Diabetes	
(n=84)	
p-value*	
Superficial	femoral		 7	(4-13)	 7	(3-13)	 0.653	
Profunda	femoris		 0	(0-2)	 0	(0-3)	 0.505	
Popliteal		 3	(3-9)	 5	(3-9)	 0.526	
TP	Trunk		 3	(0-8)	 3	(0-7)	 0.795	
Anterior	tibial		 13	(1-15)	 13	(3-15)	 0.377	
Peroneal		 4	(0-13)	 3	(1-15)	 0.621	
Posterior	tibial		 13	(4-15)	 15	(2-15)	 0.404	
Dorsalis	pedis		 4	(0-15)	 13	(0-15)	 0.643	
Lateral	plantar	 15	(15-15)	 15	(0-15)	 0.015	
Medial	plantar		 15	(4-15)	 13	(0-15)	 0.006	
*Mann-Whitney	U	Test	
	
When	 the	 crural	 vessels	 were	 divided	 into	 thirds	 there	 was	 no	 significant	 difference	
between	 the	 groups	 with	 the	 exception	 of	 the	 distal	 segment	 of	 the	 PTA	 in	 the	
asymptomatic	group	(NDM,	n=11,	0	(0-13)	vs	DM,	n=11,	13	(3-15),	p=0.023).	
Overall	 those	 with	 DM	 had	 a	 higher	 burden	 of	 disease	 throughout	 the	 infra-inguinal	
arterial	 tree	 (median	 total	 Bollinger	 score	 88	 vs	 42)	 this	 difference	 was	 not	 significant	
(p=0.061).		
Within	the	matched	cohorts,	compared	to	the	pilot	study,	there	was	less	missing	data	by	
arterial	segments	(Table	3.8-5).	The	mean	proportion	of	missing	data	in	the	DM	cohort	was	
9.73%	 (SD	 11.60%)	 compared	 to	 10.85%	 (11.23%)	 this	 was	 not	 a	 significant	 difference	
(p=0.127).	
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Table	3.8-5:	Proportion	of	missing	data	by	arterial	segment	in	matched	cohorts	
	 No	diabetes		
(n=153)	
Diabetes		
(n=153)	
Difference	
in	%	
missing	Missing	 %	 Missing	 %	
Superficial	femoral	 2	 1.31	 0	 0.00	 1.31	
Profunda	femoris	 12	 7.84	 17	 11.11	 3.27	
Popliteal	 2	 1.31	 2	 1.31	 0.00	
TP	Trunk	 2	 1.31	 2	 1.31	 0.00	
Anterior	tibial		 10	 6.54	 4	 2.61	 3.93	
Dorsalis	pedis	 34	 22.22	 32	 20.92	 1.31	
Peroneal		 9	 5.88	 4	 2.61	 3.27	
Posterior	tibial		 7	 4.58	 2	 1.31	 3.27	
Medial	plantar	 44	 28.76	 43	 28.10	 0.65	
Lateral	plantar	 44	 28.76	 43	 28.10	 0.65	
Paired	T-test	p=0.127	
	
3.8.3. Outcomes	
The	median	length	of	follow-up	was	2.3	years	(IQR	1.24-3.34)	in	the	NDM	group	and	2.4	
years	(1.38-3.78,	p=0.292)	in	the	DM	group	(Table	3.8-1).	The	estimated	1-year	risk	of	event	
was	 consistently	 lower	 in	 the	 DM	 group	 for	 minor	 and	 major	 amputation,	 mortality,	
amputation-free	 survival	 and	 further	 revascularisation	 (Table	 3.8-6).	 Examination	 of	 the	
Kaplan-Meier	 curves	 shows	 that	 this	 difference	 is	 significant	 for	 amputation	and	mortality	
but	not	for	revascularisation	(Figure	3.8-2).	
Table	3.8-6:	Estimated	1-year	risk	of	event	for	outcomes	
	 Estimated	1-Year	Risk	of	Event	(SE)	
p-value*	
No	Diabetes	 Diabetes	
Minor	Amputation	 98.0	(1.1)	 91.3	(2.3)	 0.011	
Major	Amputation	 98.6	(1.0)	 91.9	(2.2)	 0.009	
Mortality	 91.5	(2.3)	 87.6	(2.7)	 0.002	
Amputation-Free	Survival	 90.2	(2.4)	 81.0	(3.2)	 0.001	
Revascularisation	 72.5	(3.7)	 71.9	(3.7)	 0.681	
*Log-rank	test,	SE=Standard	error	
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Figure	3.8-2:	Kaplan-Meier	curves	for	outcomes.
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CHAPTER	4: ASSESSMENT	OF	THE	MICROCIRCULATION	IN	DIABETIC	FOOT	
DISEASE	
4.1. INTRODUCTION	
As	already	discussed	in	Chapter	1,	patients	with	diabetes	mellitus	(DM)	have	a	high	risk	of	
foot	ulceration	and	subsequent	amputation.	DM	is	known	to	have	a	significant	effect	on	the	
microvasculature,	causing	dysfunction	of	the	arterioles	and	capillaries	supplying	the	retina,	
kidneys	 and	 peripheral	 nerves188.	 Histological	 examination	 of	 capillaries	 has	 shown	
thickening	of	 the	basement	membrane	 compared	 to	non-diabetic	patients37,40,41.	Different	
methods	to	quantifiably	examine	the	microcirculation	and	its	function	have	been	developed;	
these	include	capillary	microscopy	(CM),	transcutaneous	oxygen	pressure	(TcPO2)	and	laser	
Doppler	 fluxmetry	 (LDF).	 For	 the	purposes	of	 this	 thesis	 the	microcirculation	 is	 defined	as	
arterioles,	 capillaries	 and	 venules	 and	 includes	 any	 vessel	 that	 measures	 less	 than	 200-
150µm189.		
The	aim	of	this	paper	 is	to	examine	the	common	non-invasive	tests	that	claim	to	assess	
the	microcirculation	of	 the	 foot.	This	 includes	a	 review	of	 the	current	evidence	within	 the	
literature	 on	 the	 relationship	 between	 the	microcirculation	 in	 the	 ulcerated	 diabetic	 foot	
and	wound	healing.	Specifically,	the	ability	to	predict	healing,	how	the	results	for	those	with	
DM	compare	to	those	without	and	how	the	results	vary	when	repeated	measurements	are	
taken.	
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4.2. CAPILLARY	MICROSCOPY	
CM,	at	its	simplest,	is	the	examination	of	capillaries	in	living	skin	through	a	microscope190.	
Capillaries	 in	 the	 skin	 were	 first	 observed	 using	 a	 microscope	 as	 early	 as	 1879191.	 The	
technique	 was	 formalised	 and	 details	 published	 in	 the	 literature	 in	 the	 1940s	 and	
50s190,192,193.	The	basic	requirements	are	a	binocular	microscope	and	a	powerful	 light192.	As	
the	 technique	 has	 developed	 it	 has	 become	 possible	 to	 record	 both	 static	 and	 dynamic	
images.	 Videocapillaroscopy	 allows	 dynamic	 assessment	 of	 the	 microcirculation	 and	
sequential	 magnification	 of	 areas	 of	 interest194.	 As	 part	 of	 the	 technique	 paraffin	 oil	 is	
applied	 to	 the	 skin	 to	 be	 examined	 to	 aid	 visualisation	 through	 the	 outer	 layers	 of	 the	
epidermis	and	minimise	reflection93,193.	Classically	the	nailfold	of	digits	is	examined	as	in	this	
area	the	vessels	run	parallel	to	the	skin	making	it	possible	to	assess	capillary	morphology195	
and	red	blood	cell	velocity189.	In	other	areas	of	the	skin	the	capillaries	are	perpendicular	to	
the	skin	and	capillary	density	can	be	assessed	but	not	morphology189,196.	Parameters	that	can	
be	 quantitatively	 assessed	 include	 capillary	 density,	 capillary	 diameter	 and	 red	 blood	 cell	
velocity	(at	rest	and	as	part	of	post	occlusive	reactive	hyperaemia	(PORH))	95,197-199.		
As	 light	 only	 penetrates	 a	 few	 micrometres	 into	 the	 epidermis	 the	 nutritional	 skin	
circulation	only	is	visulised198,200.	Of	the	tests	used	to	assess	the	microcirculation	this	is	the	
only	test	that	only	assesses	the	nutritional	flow	of	the	skin95.		
CM	has	been	used,	most	commonly,	in	the	investigation	of	dermatological	disorders	and	
rheumatoid	conditions	among	other	disease	processes	both	systemic	and	localised190,194,201-
207.	In	the	context	of	DM	and	peripheral	arterial	disease	(PAD)	there	is	less	evidence.	Patients	
with	 DM	 have	 been	 found	 to	 have	 dilated	 capillaries	 and	 delayed	 hyperaemia	 following	
occlusion95.	In	ischaemic	ulcers	there	is	a	paucity	of	capillaries	in	areas	with	no	evidence	of	
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granulation,	 areas	 of	 granulation	 had	 significantly	 higher	 capillary	 density	 and	 areas	 of	
normal	 skin	 surrounding	 the	 ulcer	 had	 a	 higher	 density	 again208.	 There	 is	 lower	 capillary	
density	 in	 ischaemic	 ulcers	 compared	 to	 venous200	 but	 on	 dependency	 those	with	 severe	
ischaemia	 show	 an	 increase	 in	 skin	 perfusion	 which	 does	 not	 occur	 in	 patients	 with	 less	
severe	disease198.	There	has	also	been	shown	to	be	lower	capillary	blood	velocity	in	patients	
with	PND	compared	to	those	without209.		
By	 staging	 the	 changes	 in	 the	 morphology	 of	 capillaries	 it	 has	 been	 shown	 that	 it	 is	
possible	 to	 discriminate	 between	 patients	 with	 critical	 limb	 ischaemia	 and	 intermittent	
claudication93.	 There	 is	 good	 sensitivity	 and	 specificity	 when	 discriminating	 between	 the	
stages	of	morphological	changes195,196.	There	is	also	good	inter	and	intra-observer	reliability	
of	for	capillary	density93,195	and	measurement	of	capillary	width195.		
There	 are	 limitations	 to	 the	 use	 of	 CM,	 particularly,	 interpretation	 of	 images	 requires	
significant	 experience192.	 The	 morphological	 appearances	 of	 the	 capillaries	 vary	 between	
patients	and	areas	of	skin	on	the	same	patient	in	the	normal	population	and	so	care	must	be	
taken	that	the	same	area	is	being	assessed95,194.	It	can	also	be	difficult	to	fully	immobilise	the	
area	of	interest	as	small	movements	will	impact	the	area	being	examined	and	can	interfere	
with	velocity	measurments95.	Within	 the	 literature	 there	 is	no	consensus	on	definitions	or	
standardised	 approach	 to	 the	 evaluation	 of	 images194,195.	 Papers	 that	 report	 consistent	
approaches	tend	to	have	originated	from	the	same	research	groups.	In	addition	CM	can	be	
challenging	on	pigmented	skin193.		
Overall	may	be	useful	in	assessing	nutritional	blood	flow	as	opposed	to	total	skin	flow	but	
not	widely	available210	and	cumbersome	to	use95.	
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4.3. TRANSCUTANEOUS	MEASURMENT	OF	OXYGEN	PRESSURE	
The	technique	for	measuring	the	partial	pressure	of	oxygen	(TcPO2)	non-invasively	at	the	
surface	of	the	skin	was	developed	in	the	1970s211,212.	It	was	initially	used	in	the	critical	care	
environment	particularly	for	the	monitoring	of	oxygenation	in	pre-term	infants211,212.	
The	probes	consist	of	a	polarographic	oxygen	sensor	which	is	incorporated	into	a	heating	
element211,212.	The	heating	element	contributes	to	the	measurement	in	three	ways.	Firstly	it	
causes	vasodilatation	of	 the	surface	capillaries	and	 increasing	 local	blood	 flow.	Secondly	 it	
causes	 the	 shift	 of	 the	 haemoglobin	 disassociation	 curve	 to	 the	 right	 causing	 additional	
oxygen	to	be	released	into	the	plasma.	Thirdly	it	enhances	the	diffusion	of	oxygen	through	
the	stratum	corneum211,212.	These	all	contribute	to	raising	the	partial	pressure	of	oxygen	at	
the	skin	from	the	normal	resting	value	of	almost	zero	to	a	level	similar	to	that	of	the	arterial	
blood212.	The	temperature	that	 the	skin	 is	heated	too	 is	between	37-45oC213.	The	resulting	
figure	 reflects	 approximate	 oxygenation	 of	 tissues214.	 The	 correlation	 between	 arterial	
oxygen	pressure	and	TcPO2	is	strong	in	neonates213.	In	adults	the	diffusion	gradient	between	
the	capillaries	and	the	surface	of	the	skin	 is	greater	due	to	thickness	of	the	skin,	 increased	
adiposity	and	pathological	factors	like	oedema215.	This	means	the	measured	TcPO2	may	not	
reflect	the	arterial	partial	pressure	of	oxygen	as	closely	as	in	neonates,	but	it	has	still	been	
shown	to	be	useful	for	a	range	applications215,216.	
Researchers	started	using	TcPO2	to	investigate	to	the	relationship	of	TcPO2	and	PAD	in	the	
early	 eighties	 and	 also	 the	 differences	 between	 patients	 with	 and	 without	 DM213,217-219.	
Areas	of	particular	 interest,	where	TcPO2	has	been	shown	to	be	useful,	are	 in	determining	
levels	of	amputation	and	healing	potential	in	wounds220,221.		
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Whilst	TcPO2	has	been	shown	to	be	reduced	in	both	patients	with	DM	and	patients	with	
PAD	and	to	improve	following	revascularisation216,222	the	relationship	is	not	a	simple	one223-
225.	 Ueno	 et	 al	 demonstrated	 that	 resting	 TcPO2	 was	 influenced	 by	 arterial	 stenosis	 or	
occlusions	in	an	angiosomal	distribution	i.e.	TcPO2	of	the	dorsum	of	the	foot	was	influenced	
by	the	status	of	the	proximal	vessels	and	the	anterior	tibial	artery	and	the	TcPO2	of	the	calf	
was	 influenced	 by	 the	 proximal	 vessels	 and	 the	 posterior	 tibial	 arteries226.	 A	 recent	 study	
performed	in	Greece	has	supported	that	TcPO2	is	low	in	patients	with	DM	and	patients	with	
diabetic	 peripheral	 neuropathy	 but	 these	 results	 were	 independent	 of	 the	 presence	 of	
PAD224.	Other	studies	have	also	demonstrated	that	there	is	not	a	linear	relationship	between	
arterial	 supply	 and	 oxygenation	 of	 distal	 tissues	 in	 patients	 with	 DM223-225.	 As	 these	 are	
cross-sectional	 studies	 they	were	 unable	 to	 comment	 on	 the	 pathophysiology	 behind	 the	
results.	
In	the	lower	limbs	TcPO2	has	been	shown	to	have	variable	reproducibility93,227.	However	
good	sensitivity	and	specificity	 for	 the	detection	of	PAD226,	 for	 the	healing	of	diabetic	 foot	
ulcers228	 and	 the	 prediction	 of	 major	 amputation	 has	 been	 shown229.	 Current	 guidelines	
include	 TcPO2	 of	 <30mmHg	 as	 a	 predictor	 of	 poor	 outcome	 in	 patients	with	 diabetic	 foot	
ulcers	and	critical	limb	ischamia74,184.	
Limitations	 of	 the	 technique	 include	 that	 it	 takes	 a	 relatively	 long	 time	 to	 perform	
compared	the	likes	of	toe	blood	pressure	and	the	results	are	highly	sensitive	to	surrounding	
conditions214.	
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4.4. LASER	DOPPLER	FLUXMETRY	
The	 laser	 Doppler	 technique	 for	 examining	 blood	 flow	 in	 the	 microcirculation	 was	
developed	by	Stern	and	Lappe	in	the	early	1970s97,230.	It	was	developed	as	a	method	to	non-
invasively	 monitor	 the	 microcirculation	 and	 as	 a	 replacement	 for	 techniques	 that	 used	
radioisotopes	to	assess	blood	flow96.	
The	LDF	probe	delivers	a	 laser	via	an	optical	fibre	to	the	tissue	under	investigation.	This	
light	 is	 scattered	 by	 the	 tissue	 encountered,	 and	 if	 that	 tissue	 is	 a	moving	 red	 blood	 cell	
(RBCs)	 the	 light	 is	 Doppler	 shifted.	 The	 scattered	 light	 is	 then	 detected	 within	 the	 same	
probe	and	processed	to	form	a	laser	Doppler	signal.	This	signal	provides	information	on	the	
concentration	of	RBCs	and	their	average	speed	this	is	termed	flux	and	expressed	as	arbitrary	
perfusion	units97,99	(Figure	4.4-1).		
	
Figure	 4.4-1:	 Schematic	 representation	 of	 Laser	 Doppler	 Fluxmetry.	 Courtesy	 of	 Moor	
Instruments.	
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The	laser	penetrates	the	skin	to	approximately	1.5mm93	and	as	such	provides	information	
on	both	the	superficial	and	deep	dermal	capillary	beds	with	the	possibility	of	also	detecting	
flow	in	small	arterioles	and	arterio-venous	anastomoses.	This	means	unlike	CM	it	does	not	
assess	nutritional	blood	flow	only	and	should	be	regarded	as	a	total	measure	of	blood	flow	in	
the	skin94,95.		
Resting	flux	has	been	found	to	have	low	clinical	value	due	to	its	low	sensitivity	and	high	
variability231,232.	 Reactivity	 tests	 have	 been	 shown	 to	 be	more	 reproducible;	 these	 include	
thermal	 challenge,	 iontophoresis,	 post	 occlusive	 reactive	 hyperaemia	 (PORH)	 and	 skin	
perfusion	pressure	(SPP).	A	thermal	challenge	 is	generally	delivered	using	 localised	heating	
to	 the	 same	 area	 where	 the	 probe	 is	 placed	 (ideally	 using	 an	 integrated	 probe)	 and	
monitoring	the	response	over	a	period	of	time100-102.	There	has	been	shown	to	be	a	decrease	
in	response	in	people	with	DM	compared	to	controls41,50,102.		
Iontophoresis	 involves	 the	 delivery	 of	 a	 low	 current	 through	 a	 chamber	 containing	 a	
vasoactive	 solution.	 The	 current	 causes	 ionisation	 of	 the	 substance	 towards	 the	 skin	
resulting	 in	 vasodilatation102.	 The	 probe	 is	 either	 placed	 within	 the	 chamber	 or	 in	 close	
proximity	 to	 it.	 The	 substances	 generally	 used	 are	 acetylcholine	 and	 sodium	nitroprusside	
which	 assess	 endothelium-dependent	 and	 endothelium-independent	 vasodilatation	
respectively101.	 Decreased	 vasodilatation	 in	 response	 to	 both	 acetylcholine	 and	 sodium	
nitroprusside	has	been	demonstrated	in	patients	with	diabetic	neuropathic	ischaemia102,233,	
but	there	is	heterogeneity	in	methods	available	leading	too	poor	to	fair	reproducibility101.	
PORH	is	probably	the	most	commonly	used	of	the	microvascular	reactivity	tests.	The	test	
involves	occluding	 the	blood	 supply	 to	 the	 limb	being	 investigated	using	 a	blood	pressure	
cuff.	The	occlusion	is	maintained	for	anything	between	1	and	5	minutes101	and	then	rapidly	
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deflated.	Reperfusion	occurs	producing	a	characteristic	trace	involving	hyperaemia	followed	
by	a	gradual	return	to	the	resting	flux.	 It	 is	possible	to	measure	various	parameters	on	the	
curve	 which	 are	 based	 on	magnitude	 and	 temporal	 relationships234.	 The	 parameters	 that	
have	been	found	to	have	the	best	reproducibility	and	discrimination	are	time	to	maximum	
flux,	time	to	half	recovery,	time	to	resting	flux,	maximum	flux	(difference	between	maximum	
amplitude	 and	 biological	 zero)	 and	 ratios	 of	 maximum	 flux/resting	 flux	 and	 maximum	
flux/time	to	maximum	flux231,234	(Figure	4.4-2).		
	
Figure	4.4-2:	PORH	trace	of	a	healthy	subject	with	parameters	marked	on.		
RF	resting	flux,	BZ	biological	zero,	TtM	time	to	maximum	flux,	MF	maximum	flux,	Tt1/2	time	
to	half	recovery,	TtR	time	to	recovery.	
	
As	well	as	in	healthy	patients	PORH	has	been	found	to	be	highly	reproducible	in	patients	
with	 rest	 pain	 or	 disabling	 claudication93.	 Diabetic	 patients	 have	 demonstrated	 severely	
impaired	PORH47,49.	Within	the	literature,	there	is	no	evidence	linking	improvement	in	PORH	
to	clinical	improvement.		
SPP	 is	 a	measure	 of	 the	 pressure	 required	 to	 restore	microcirculation	 to	 the	 skin.	 It	 is	
similar	to	toe	blood	pressure	measurements	in	that	it	 is	not	affected	by	calcification	of	the	
vessels	but	has	the	advantage	over	toe	blood	pressure	of	being	able	to	be	carried	out	when	
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the	hallux	has	been	amputated	or	is	gangrenous.	Also,	measurement	can	be	taken	adjacent	
to	ulcers	to	better	reflect	the	disease	status	 in	that	area235,236.	Using	LDF,	SPP	 is	measured	
using	a	modified	low-profile	probe	that	is	placed	underneath	a	blood	pressure	cuff.	The	cuff	
is	 inflated	to	a	supra-systolic	pressure	and	then	slowly	deflated.	The	SPP	is	taken	to	be	the	
first	of	the	two	measurements	that	show	an	increase	in	flux236.	SPP	has	a	strong	correlation	
to	both	 ankle	 and	 toe	pressure	 and	TcP02112,236	 and	has	high	 sensitivity	 and	 specificity	 for	
wound	healing	in	ischaemic	ulcers	and	diagnosis	of	critical	limb	ischaemia112,235.		
LDF	has	been	shown	to	be	responsive	to	room	temperature,	posture,	respiratory	pattern	
and	emotional	stimulation	of	subject97,100,210.	The	spatial	positioning	of	probes	has	also	been	
shown	to	impact	on	the	variability	of	results.	This	is	thought	to	be	due	to	differences	in	the	
density	of	capillaries100.	
4.5. THE	 DIFFERENCE	 BETWEEN	 THE	 HEALING	 AND	 THE	 NON-HEALING	
DIABETIC	 FOOT	 ULCER.	 A	 REVIEW	 OF	 THE	 ROLE	 OF	 THE	
MICROCIRCULATION	
4.5.1. Methods	
A	 search	 of	 the	Medline,	 EMBASE	 and	Web	 of	 Science	 databases	 was	 performed.	 The	
search	 strategy	 consisted	 of	 the	 Medical	 Subject	 Headings	 (MESH)	 “microcirculation”,	
“wound	 healing”,	 “diabetic	 foot”,	 “skin	 ulcer”,	 “laser	 Doppler	 flowmetry”,	 “blood	 gas	
monitoring,	transcutaneous”,	“microscopic	angioscopy”,	“xenon	radioisotopes”.	In	addition,	
a	 keyword	 search	was	 performed.	 The	 terms	 used	 can	 be	 found	Appendix	 II.	 Non-English	
language	and	non-human	studies	were	excluded,	the	date	range	for	the	search	was	1946	to	
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February	2015.	Final	inclusion	in	the	review	was	dependent	on	meeting	the	criteria	set	out	in	
Table	 4.5-1;	 no	 limits	 were	 applied	 to	 length	 of	 follow-up	 or	 the	 number	 of	 patients	
included.	 The	 original	 intention	 was	 to	 perform	 a	 meta-analysis;	 however,	 there	 were	
insufficient	numbers	of	high-quality	studies	to	be	able	to	continue	this	plan,	and	so	a	more	
descriptive	approach	was	taken	to	reporting	the	data.	
Table	4.5-1:	Review	Inclusion	criteria	
Inclusion	criteria	
• English	language	article	
• At	least	one	method	of	assessing	the	microcirculation	
• Patients	with	active	tissue	loss	
• Wound	healing	as	an	outcome	measure	
• Results	from	patients	with	diabetes	to	be	analysed	separately	from	patients	
without	diabetes	in	one	of	the	following	three	formats.	
o Patients	with	diabetes	compared	to	patients	without	diabetes	
o Patients	with	diabetes	who	healed	compared	to	patients	with	diabetes	who	
did	not	heal	
o Repeated	measurements	from	the	same	patient	during	the	period	of	active	
diabetic	ulceration	being	investigated	
4.6. RESULTS	
Two-hundred	and	eighty-seven	articles	were	identified	after	searching	the	databases.	Full	
text	was	obtained	for	all	abstracts	that	met	the	 inclusion	criteria	and	all	relevant	data	was	
extracted.	After	this	assessment	and	review	of	references,	nineteen	studies	were	included	in	
the	 final	 review	 (Figure	 4.6-1)	 225,228,237-253.	 The	 date	 of	 publication	 ranged	 from	 1985	 to	
2014,	 two	 studies	 were	 randomised	 control	 trials,	 there	 were	 three	 pseudo-randomised	
control	trials,	and	the	rest	were	observational	studies	(Table	4.6-1).	Not	all	studies	included	
all	 the	 comparisons	 considered	 below	 and	 some	 studies	 used	more	 than	 one	method	 to	
assess	the	microcirculation.	
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Figure	 4.6-1:	 Flow	 diagram	 illustrating	 study	 identification	 process	 for	 microcirculation	
review	
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Table	4.6-1:	Characteristics	of	included	studies		
Author	 Year	 Country	 Type	of	study	 Microcirculation	method	
Number	of	
subjects	
DM	 Non-DM	
Faris,	I.237	 1985	 Australia	 Cross-sectional	
SPP	using	isotope	
washout	
64	 -	
Karanfilian,	R.238	 1986	 USA	 Cohort	
1)LDF		
2)TcPO2	
34	 22	
Pecoraro,	R.E.225	 1991	 USA	 Cross-sectional	
1)	TcPO2		
2)	TcPCO2	
46	 -	
Jorneskog,	G.239	 1993	 Sweden	 Cross-sectional	
1)LDF-PORH	
2)Capillary	
microscopy	
10	 -	
Padberg,	F.T240	 1996	 USA	 Case-control	 TcPO2	 129	 97	
Kalani,	M.228	 1999	 Sweden	 Cross-sectional	
1)	TcPO2	
2)TBP	using	LDF	
50	 -	
Koblik,	T.241	 2001	 Poland	
Double-blind	
RCT	
LDF,	PORH	and	
resting	flow	
18	 -	
Zimny,	S.242	 2002	 Germany	 Cross-sectional	 TcPO2	 31	 -	
Fife,	C.E.243	 2002	 USA	
Cross-sectional	
(retrospective)	
TcPO2	 1144	 -	
Newton,	D.J.244	 2002	 UK	 Cross-sectional	 LDI	 5	 	
Kalani,	M.245	 2002	 Sweden	 Pseudo-RCT	
1)	TcPO2	+	TcPCO2	
during	O2	inhalation		
2)TBP	using	LDF	
38	 -	
Klingel,	R.246	 2003	 Germany	 Cross-sectional	
1)	TcPO2	
2)LDF		
3)Capillary	
microscopy	
8	 -	
Petrofsky,	J.S.247	 2007	 USA	 Pseudo-RCT	 LDI	 29	 -	
Lawson,	D.248	 2007	 USA	 Pseudo-RCT	 LDI	 10	 10	
Ichioka,	S.249	 2009	 Japan	 Case-control	 TcPO2	 31	 22	
Petrofsky,	J.S.250	 2010	 USA	 RCT	 LDI	 20	 -	
Yang,	C.251	 2013	 China	 Cross-sectional	 TcPO2	 61	 -	
Wang,	A.252	 2014	 China	 Cross-sectional	 TcPO2	 194	 -	
Yotsu,	R.R.253	 2014	 Japan	 Cohort	
1)SPP	using	LDF	2)	
TcPO2	
73	 -	
Abbreviations:	RCT	–	randomised	control	study,	SBF	–	skin	blood	flow,	SPP	–	skin	perfusion	pressure,	SVR	–	skin	
vascular	 resistance,	 LDF	 –	 laser	 Doppler	 fluxmetry,	 TcPO2	 –	 transcutaneous	 oxygen	 pressure,	 TcPCO2	 –	
transcutaneous	carbon	dioxide	pressure,	PORH	–	post	occlusive	reactive	hyperaemia,	TBP	–	toe	blood	pressure,	
LDI	–	laser	Doppler	imaging.	
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4.6.1. Using	the	microcirculation	to	predict	healing	
Twelve	studies	out	of	nineteen	compared	the	microcirculation	 in	patients	with	diabetes	
who	 healed	 to	 those	 who	 did	 not	 heal225,228,237,238,243-246,249,251-253.	 Ten	 of	 these	 studies	
employed	 TcPO2225,228,238,243,245,246,249,251-253,	 five	 used	 LDF228,238,245,246,253,	 one	 used	 laser	
Doppler	 imaging	 (LDI)244	and	one	used	 isotope	washout	 to	measure	SPP237.	These	were	all	
observational	studies	apart	from	one	that	randomised	the	first	14	of	its	participants	but	not	
the	 final	 24245.	 For	 seven	 of	 the	 studies,	 the	 participants	 received	 only	 standard	
therapy225,228,237,238,251,252.	 Two	 studies	 examined	 the	 effects	 of	 HBO	 therapy,	 Kalani	 et	 al.	
(2002)	 had	 two	 cohorts,	 one	 of	 which	 received	 standard	 therapy	 and	 the	 other	 which	
received	HBO.	 The	 healed	 and	 unhealed	 groups	 in	 this	 study	 are	made	up	 of	 participants	
from	 either	 cohort245.	 Fife	 et	 al.	 performed	 a	 retrospective	 study	 of	 1144	 patients	 who	
received	 HBO	 therapy243.	 Klingel	 et	 al.	 reported	 the	 results	 of	 a	 very	 small	 pilot	 study	 (8	
patients)	all	of	whom	received	rheopheresis246.	Two	studies	treated	their	participants	with	
dermal	replacement	therapy;	Ichioka	et	al.	bone	marrow	impregnated	collagen,	Newton	et	
al.,	 collagen	 containing	 glycosaminoglycans)244,249.	 Five	 studies	 only	 investigated	 patients	
with	 both	 diabetes	 and	 ischaemia228,238,243,245,246,	 three	 studies	 excluded	 those	 with	
ischaemia225,244,249,	 in	 one	 study	 it	 was	 unclear251,	 and	 three	 included	 a	 mix	 of	
patients237,252,253.	 Only	 Yotsu	 et	 al.	 divided	 the	 patients	 into	 groups	 depending	 on	 their	
aetiology	(neuropathic,	ischemic	and	neuro-ischemic)253.		
4.6.1.1. Transcutaneous	oxygen	pressure	
Nine	studies	used	TcPO2	to	predict	wound	healing225,228,238,245,246,249,251-253,	the	results	are	
summarised	 in	 Table	 4.6-2.	 Five	 studies	 found	 that	 those	 with	 a	 higher	 TcPO2	 had	 a	
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statistically	 significant	 higher	 chance	 of	 healing,	 with	 results	 ranging	 from	 30±4mmHg	 to	
61.11±21.16mmHg	 228,238,246,251,252.	 Kalani	 et	 al.	 2002	 and	 Yotsu	 failed	 to	 find	 a	 significant	
difference	 between	 the	 two	 groups245,253.	 Pecoraro	 et	 al.	 found	 a	 significant	 difference	
between	 those	 who	 had	 early	 healing	 and	 those	 who	 did	 not	 (56.3±2.72mmHg	 vs	
26.9±8.26mmHg,	 p=0.003)	 however	 was	 unable	 to	 demonstrate	 that	 the	 difference	 had	
persisted	in	those	that	healed	overall	(53.67±2.99mmHg	vs	37.57±11.02mmHg,	p=0.126)225.	
4.6.1.2. Skin	perfusion	pressure	
Two	papers	 used	 SPP	 to	 compare	 the	 healed	 and	 unhealed	 groups237,253.	 Faris	et	 al.	 in	
1985	used	an	isotope	washout	method	on	64	patients	with	diabetes	and	foot	ulceration	or	
gangrene.	Those	who	healed	had	a	mean	SPP	of	59	±	16mmHg	compared	to	those	who	did	
not	 heal	 whose	 mean	 SPP	 was	 35	 ±	 11	 (p<0.001)237.	 Yotsu	 et	 al.	 in	 2014	 employed	 LDF	
instead	 of	 isotope	 washout	 to	 measure	 SPP	 on	 diabetic	 ulcers	 divided	 into	 the	 groups	
described	above.	They	 found	that	neuropathic	ulcers	had	a	higher	SPP	than	both	 ischemic	
and	 neuro-ischemic	 ulcers,	 65	 ±	 13.6mmHg,	 27	 ±	 14.1mmHg	 and	 34	 ±	 23.2mmHg	
respectively	 (p<0.001).	 However,	 there	 was	 no	 significant	 difference	 between	 the	 healed	
and	unhealed	ulcers	in	each	group	(Table	4.6-3)253.	
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Table	4.6-2:	TcPO2	results	for	patients	who	healed	compared	to	patients	who	did	not	heal.	
Author	 Patient	type	
Measurement/	
groups	
TcPO2	(mmHg)	
p-
value	
Healed	
(n)	
Unhealed	
(n)	
	
Klingel
246
	 T2DM	non-healing	ischaemic	
ulcers	
Mean	change	in	TcPO2	week	0-12.		
Improved	and	deteriorated	groups	
13.23±9.57	
(4)	
-2.3	±	6.65	
(2)	
<0.05
*	
Kalani	(2002)
245
	 DM	non-healing	ischaemic	
ulcers.	No	reconstruction	
options	
Basal	TcPO2,	dorsum	of	foot.		
All	patients	
26	±	10	
(23)	
24	±	10	
(9)	
ns	
Karanfilian
238
	 DM	ischaemic	ulcers	 Dorsum	of	foot.		
All	diabetic	patients	
30	±	4	
(16)	
7	±	2.5	
(18)	
<0.05	
Yang
251
	 DM	with	ulcer	 Dorsum	of	foot.		
Group	1	(ulcers	healed	with	intact	skin),		
Group	3	(Ulcers	that	did	not	heal	or	deteriorated	
including	requiring	amputation)	
32	±	10	
(36)	
15	±	12	
(17)	
<0.00
1	
Ichioka
249
	 DM	with	ulcer	 Peri-wound	TcPO2.		
Diabetic	subgroup	(combination	of	treatment	and	
conventional	therapy	group)	
34.5	±19.2	
(32)	
26.4	±16.7	
(10)	
Not	
stated	
Yotsu†
253
	 T2DM	ulcer	>14	days	 Multiple	measures	from	2	areas	on	foot,	lowest	
value	recorded.	Contralateral	foot	used	if	extensive	
ulceration.		
Ischaemic	group	
38,	12-40	
(9)	
30,	3-45	
(11)	
ns	
	
Neuro-ischaemic	group	
38,	22-51	
(9)	
17,	16-32		
(5)	
ns	
	
Neuropathic	group	
48,	40-56	
(34)	
44,	43-50	
(5)	
ns	
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Kalani	(1999)
228
	 DM	ulcer	>2months,	32	
ischaemia	with	no	
reconstruction	options	
Dorsum	of	foot.	Healed	with	intact	skin	compared	
to	impaired	ulcer	healing	
50	±	20	
(20)	
13	±	14	
(13)	
<0.00
1	
Pecoraro
225
	 DM	with	ulcer	
Peri-wound	TcPO2	overall	healing	
53.67±2.99	
(39)	
37.6±11.0	
(7)	
ns	
	
Peri-wound	TcPO2	early	healing	
56.3	±	2.72	
(38)	
26.9	±	8.26		
(8)	
0.003	
Wang
252
	 DM	with	ulcer	requiring	
hospitalisation	
Site	of	measurement	not	stated.	Healing	and	non-
healing	groups	
61.1±21.2	
(162)	
46.5	±	18.1	
(20)	
<0.01	
*Wilcoxon	test	 for	matched	pairs	 for	significance	of	change	between	weeks	0-12	for	each	group	separately.	All	values	mean	±	SD	apart	 from	†median	and	 inter-
quartile	range	(IQR)	reported	
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Table	4.6-3:	Skin	perfusion	pressure	results	for	patients	who	healed	compared	to	patients	
who	did	not	heal253.	
Group	
SPP	(mmHg)	
p-value	
Healed	(n)	 Unhealed	(n)	
Neuropathic	 67,	57-75	(34)	 65,	40-69	(5)	 0.192	
Ischemic	 37,	17-43	(9)	 20,	15-37	(11)	 0.341	
Neuro-ischemic	 38,	22-51	(9)	 17,	16-32	(5)	 0.141	
All	values	median,	IQR	
	
4.6.1.3. Laser	Doppler	
Karanfilian	et	al.	was	the	only	paper	to	use	laser	Doppler	fluxmetry	to	compare	between	
healed	 and	 unhealed	 patients.	 They	 demonstrated	 significantly	 higher	 skin	 blood	 flow	
velocity	(LD-SBFV),	and	pulse	wave	amplitude	(LD-PWA)	results	between	those	who	healed	
and	those	who	did	not	in	both	their	study	groups	(Table	4.6-4)238.		
	
Table	4.6-4:	TcPO2	and	LDF	results	in	patients	with	diabetes	compared	to	patients	without	
diabetes238.	
	 Diabetes	
(Mean	±	SE)	
No	diabetes	
(Mean	±	SE)	
	 Healed	(16)	 Unhealed	(18)	 Healed		
(15)	
Unhealed		
(7)	
TcPO2	(mmHg)	 30	±	4.0	 7	±	2.5*	 42	±	3.5	 2	±	1.6*	
LD-SBFV	(mV)	 98	±	13.0	 50	±	8.0*	 88	±	15.0	 37	±	2.0*	
LD-PWA	(mV)	 14	±	3.0	 4	±	0.5*	 8	±	1.4	 2	±	0.3*	
*	Significant	difference	between	healed	and	unhealed	groups	(p<0.05),	SE=standard	error	
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4.6.1.4. Prediction	of	healing	
Three	 studies	 reported	 the	 accuracy	 of	 cut-off	 values	 for	 healing228,237,243.	 Faris	 and	
Duncan	found	an	SPP	of	 less	than	40mmHg	was	an	 indicator	of	poor	healing	(sensitivity	of	
97%,	specificity	80%,	positive	predictive	value	(PPV)	87%	and	negative	predictive	value	(NPV)	
95%)237.	Kalani	et	al.	(1999)	used	a	cut-off	of	25mmHg	for	TcPO2	and	30mmHg	for	toe	blood	
pressure	 (TBP)	using	LDF.	For	TcPO2	 the	sensitivity	was	85%,	specificity	92%,	PPV	79%	and	
NPV	94%.	For	TBP	the	sensitivity	was	15%,	specificity	97%,	PPV	67%	and	NPV	77%228.	Fife	et	
al.	tested	multiple	potential	cut-offs	for	sea	level	TcPO2	as	a	predictor	of	failure	of	hyperbaric	
therapy.	They	found	that	25mmHg	was	the	best	cut-off	with	a	2.5	times	greater	chance	of	
success.	However,	 the	 accuracy	was	 still	 relatively	 poor	with	 sensitivity	 of	 67%,	 specificity	
50%,	PPV	35%	and	NPV	79%243.	
4.6.2. Diabetes	compared	to	no	diabetes	
Two	 out	 of	 nineteen	 studies	 compared	 subjects	 both	 with	 DM	 and	 without	 DM238,240.	
Both	of	 these	papers	used	TcPO2	 to	make	 their	 comparisons,	 in	addition,	Karanfilian	et	al.	
employed	LDF238		
Padberg	et	al.	reported	the	predictive	accuracy,	using	a	probability	approach,	for	healing	
of	 TcPO2	 in	 critically	 ischaemic	 wounds.	 204	 wounds	 were	 stratified	 depending	 on	 the	
presence	of	DM,	dialysis-dependent	 chronic	 renal	 failure	or	neither	disease.	Probability	of	
healing	curves	for	each	group	were	plotted	and	compared	using	multiple	logistic	regression.	
When	the	estimated	probability	of	healing	was	50%	TcPO2	 in	DM	patients	had	a	predictive	
accuracy,	sensitivity	and	specificity	of	81%,	for	chronic	renal	failure	(all	but	two	patients	also	
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had	DM)	these	figures	were	77%,	73%	and	82%	respectively,	and	for	neither	disease,	84%,	
86%	and	82%240.		
Only	 one	 study	 identified	 compared	 the	 mean	 results	 of	 microcirculatory	 tests	 for	
patients	with	diabetes	and	 those	without238.	 The	patients	were	all	men	with	ulceration	 to	
the	foot	(34	with	diabetes,	22	without).	One-off	measurements	of	TcPO2	and	LDF	(LD-SBFV	
and	LD-PWA)	and	follow-up	of	at	least	30	days	was	performed.	The	results	are	presented	in	
Table	4.6-4.	Patients	without	diabetes	who	did	not	heal	had	a	lower	TcPO2,	LD-SBFV	and	LD-
PWA	 than	patients	with	 diabetes	who	did	 not	 heal.	 In	 the	 healed	 groups	 for	 the	 patients	
without	diabetes,	 the	TcPO2	was	higher	 than	the	patients	with	diabetes.	However,	 the	LD-
SBFV	and	LD-PWA	were	lower	in	the	group	without	diabetes.	The	authors	have	not	reported	
whether	these	differences	are	statistically	significant238.	
4.6.3. Multiple	measurements	during	the	observation	period	
Eight	out	of	nineteen	studies	reported	the	results	of	more	than	one	measurement	on	the	
same	 group	 of	 patients239,241,244,246-250.	 One	 study	 detected	 no	 change,	 and	 two	 noted	 a	
decrease	in	reading,	a	further	two	noted	an	increase	and	three	noted	a	pattern	of	increasing	
then	decreasing.	 Jorneskog	et	al.	 used	LDF	and	CM	to	examine	 ten	patients	with	diabetes	
who	 received	 low	 molecular	 weight	 heparin	 for	 eight	 weeks.	 Measurements	 of	 the	
microcirculation	 (PORH,	 the	 structural	 appearance	 of	 capillaries	 in	 the	 forefoot	 and	 toes)	
were	undertaken	1-2	weeks	before	receiving	heparin,	after	4-7	weeks	of	treatment	and	two	
weeks	after	treatment	was	stopped.	They	found	that	there	was	no	significant	change	in	any	
of	 the	 laser	Doppler	 parameters	during	or	 after	 treatment.	 It	was	however	noted	 that	 six	
patients	who	had	improved	healing	also	had	an	improvement	in	their	capillary	stage,	three	
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others	 also	 improved	 clinically,	 but	 one	 had	 no	 change	 in	 their	 capillaries,	 one	 initially	
improved	 but	 then	 deteriorated	 again	 and	 in	 one	 it	 was	 not	 possible	 to	 determine	 their	
capillary	stage.	One	patient	deteriorated	both	clinically	and	on	microscopic	examination239.		
Petrofsky	et	al.	 published	on	electronic	 stimulation	 (ES)	 for	diabetic	 foot	ulcers	 in	both	
2007	 and	 2010247,250.	 In	 2007	 the	 study	 groups	 were	 ten	 patients	 who	 received	 global	
heating	 and	 ES,	 nine	 who	 received	 local	 heating	 and	 ES	 and	 ten	 patients	 who	 received	
conventional	 therapy	 only.	 The	measure	 of	 the	microcirculation	was	 blood	 flow	 using	 LDI	
(measured	in	arbitrary	unit	flux).	The	control	group	did	not	undergo	LDI	measurement,	only	
wound	 area	 was	 measured.	 In	 2010	 the	 aim	 of	 the	 study	 was	 to	 examine	 the	 role	 that	
heating	 had	 compared	 to	 ES	 and	 heating.	 Ten	 patients	 received	 local	 heating	 only	 and	 a	
further	ten	local	heating	and	ES.	The	treatment	period	for	both	studies	was	four	weeks.	 In	
both	studies,	the	blood	flow	around	and	in	the	ulcer	had	decreased	by	the	end	of	the	study.	
In	 the	 2007	 study,	 the	mean	blood	 flow	 at	 baseline	was	 reported	 for	 1cm	 from	 the	ulcer	
(182.3±26.1	 increasing	 to	 245.0±28.5	 with	 ES)	 and	 the	 edge	 of	 the	 ulcer	 (223.4±34.1	
increasing	to	301.0±29.3	with	ES).	The	result	for	the	centre	of	the	ulcer	is	reported	as	being	
similar	and	is	illustrated	in	a	graph,	but	the	actual	values	are	not	stated.	At	four	weeks	only	
the	values	for	the	centre	of	the	ulcer	are	stated	(228±36.2	increasing	to	256.7±46.3	with	ES).	
The	change	 in	blood	 flow	before	and	during	ES	at	baseline	and	 four	weeks	 is	displayed	 in	
Table	 4.6-5;	 there	 was	 a	 significant	 reduction	 in	 the	 increase	 at	 four	 weeks	 (<0.01).	 The	
results	for	the	local	heating	group	are	illustrated	in	a	graph	and	stated	as	being	similar	but	of	
a	smaller	magnitude	to	the	global	group,	but	the	actual	mean	values	are	not	quoted247.	 In	
2010	Petrofsky	found	that	the	mean	resting	blood	flow	from	all	three	areas	and	both	groups	
had	reduced	by	54.5±22.3%	after	four	weeks250.	
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Table	 4.6-5:	 Change	 in	 blood	 flow	 associated	with	 electrical	 stimulation	 at	 baseline	 and	
four	weeks	(global	heating	group	only)247.	
Position	of	
measurement	
Flux±SD	
p-value	
Baseline	(10)	 Week	four	(10)	
1cm	from	ulcer	 63.5±11.9	 18.3±10.8	
<0.01	Edge	of	ulcer	 77.6±11.6	 48.7±9.6	
Centre	of	ulcer	 33.6±3.1	 28.4±15.8	
	
Lawson	et	al.	as	described	above	also	investigated	the	effect	of	electrical	stimulation	on	
wound	healing.	They	measured	blood	flow	at	the	centre	and	outside	of	the	ulcer	using	LDI	at	
baseline,	 two	 weeks	 and	 four	 weeks.	When	 looking	 at	 the	 outside	 of	 the	 ulcer,	 the	 pre-
stimulation	results	for	the	DM	group	showed	a	larger	increase	in	the	blood	flow	than	for	the	
no	diabetes	mellitus	group	(DM,	0-2	weeks	35%,	0-4	weeks	21%;	Non-DM,	0-2	weeks	0%,	0-4	
weeks	18%).	However,	 at	 the	 centre	of	 the	wound	 the	patients	without	DM	 (NDM)	had	a	
greater	increase	(DM,	0-2	weeks	8%,	0-4	weeks	5%;	NDM,	0-2	weeks	22%,	0-4	weeks	38%).	
The	statistical	significance	of	these	results	is	not	reported248.		
Koblik	et	al.	performed	an	RCT	comparing	optimisation	of	insulin	therapy	and	injection	of	
an	 antithrombotic	 drug	 (sulodexide)	 with	 optimisation	 of	 insulin	 therapy	 and	 placebo	
injections	for	ten	weeks.	Measurements	were	taken	at	baseline	and	eight	weeks	using	LDF.	
The	parameters	measured	were	resting	flux	(RF),	peak	hyperaemic	flow	(pLDF),	time	to	peak	
hyperaemic	 flow	 and	 hyperaemia	 duration	 after	 an	 occlusion	 of	 thirty	 seconds.	 These	
measures	were	repeated	following	a	sixty-second	occlusion	once	the	readings	had	stabilised.	
In	the	placebo	group	(6	patients)	 there	was	no	significant	change	 in	the	RF	at	eight	weeks	
(Baseline:	mean	 flux	11.6±	standard	error	of	mean	1.3.	Eight	weeks	12.3±1.1.	p	=	ns).	The	
pLDF	 for	 both	 the	 thirty	 (51.7±15.2	 to	 147.0±16.2,	 p<0.01)	 and	 sixty	 second	 occlusion	
(110.5±13.0	to	164.8	±15.4,	p<0.01)	significantly	increased	at	eight	weeks241.		
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The	 results	 from	 two	 studies	 with	 small	 numbers	 are	 presented	 in	 graphical	 form	 in	
Figure	4.6-2.	Newton	et	al.’s	seven	ulcers	all	healed	or	showed	improvement	at	eight	weeks.	
Four	measurements	using	LDI	were	performed	at	baseline,	two,	five	and	eight	weeks.	Four	
patients	had	an	 increase	 in	blood	 flow	over	 the	 first	 few	weeks	 followed	by	a	decrease	 to	
below	 baseline	 at	 eight	 weeks.	 One	 increased	 throughout	 the	measurement	 period.	 One	
decreased	at	 two	weeks,	 increased	at	weeks	 five	and	eight	but	did	not	 return	 to	baseline	
level.	One	decreased	throughout	(Figure	4.6-2a).	Those	that	had	healed	at	eight	weeks,	two	
increased	 then	 decreased,	 one	 increased	 throughout	 and	 the	 other	 decreased	
throughout244.	Of	Klingel’s	eight	patients	who	received	rheopheresis	 five	underwent	TcPO2	
at	 baseline,	 twelve	 and	 twenty-four	 weeks	 and	 three	 underwent	 TcPO2	 at	 baseline	 and	
twelve	weeks	(due	to	minor	amputation	in	one	patient	and	major	amputation	in	two).	Of	the	
four	patients	who	showed	an	improvement	in	their	ulcer	two	had	an	increase	in	blood	flow	
followed	by	a	decrease,	 the	other	 two	 increased	 throughout.	 In	 the	patients	whose	ulcers	
were	unchanged	one	increased	TcPO2	at	twelve	weeks,	the	other	 increased	at	both	twelve	
and	twenty-four	weeks.	Of	 the	two	patients	who	deteriorated	one	had	a	small	 increase	at	
twelve	weeks,	and	the	other	had	a	small	decrease	(Figure	4.6-2b)246.	
Ichioka	et	al.	in	their	DM	subgroup	showed,	in	graphical	form,	a	trend	of	increasing	TcPO2	
in	the	healed	group	and	a	decrease	at	four	days	in	the	unhealed	group.	The	mean	TcPO2	at	
four	and	14	days	are	not	reported;	however,	logistic	regression	analysis	showed	the	results	
at	 these	 time	 point	 contributed	 significantly	 to	 the	 prediction	 of	 outcome	 (p<0.001	 and	
0.002	respectively)249.	
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Figure	4.6-2:	Trends	during	healing	for	LDI	and	TcPO2.		
A:	 Adapted	 from	 Newton	 et	 al.244	 Solid	 line,	 ulcers	 healed	 Alternating	 dashed	 line	 ulcers	
improved.	B:	Adapted	from	Klingel	et	al.246	Small	dashed	line	ulcers	deteriorated.	
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4.7. DISCUSSION	
Within	 this	 group	 of	 studies,	 the	 most	 commonly	 used	 method	 to	 assess	 the	
microcirculation	was	TcPO2	(n=12),	 followed	by	LDF	(n=7),	LDI	(n=4),	CM	(n=2)	and	 isotope	
washout	(n=1).	These	proportions	are	probably	representative	of	the	current	state	of	clinical	
usage	of	these	methods	with	TcPO2	and	LDF	being	the	most	common.		
Within	this	group	of	studies,	a	variety	of	methods	for	examining	the	microcirculation	have	
been	 used.	 Some	 of	 these	 methods	 have	 now	 fallen	 out	 of	 favour	 as	 technology	 has	
developed	less	invasive	methods.	This	includes	Xe	clearance	and	SPP	using	isotope	washout.	
LDF,	TcPO2	and	CM	remain	in	regular	use.	LDF	is	relatively	underrepresented	in	this	cohort,	
which	 is	 surprising	 considering	 that	 its	 utility	 in	 evaluating	 patients	 with	 critical	 limb	
ischaemia	is	well-documented93,101,254.	One	reason	for	this	may	be	the	relative	age	of	many	
of	the	studies	included	(only	three	since	2000	and	going	back	as	far	as	1978).	TcPO2	was	the	
most	commonly	used	method	in	this	review,	which	fits	with	its	presence	in	the	literature	on	
critical	limb	ischaemia	and	diabetic	foot	disease	as	a	whole.		
There	 is	 disagreement	 on	 how	 to	 carry	 out	 each	 of	 the	 methods	 of	 assessing	 the	
microcirculation,	 including	 positioning	 of	 the	 probes	 and	 in	 the	 case	 of	 TcPO2	 the	 skin	
temperature	that	recordings	were	made	at.	Probes	were	most	commonly	positioned	on	the	
dorsum	of	the	foot225,228,238,242,245,251,252,	but	they	are	also	positioned	peri-wound225,243,246,249,	
and	in	one	case	it	was	not	stated240.	A	possible	explanation	for	Yotsu	et	al.	not	detecting	a	
significant	 difference	 is	 their	 method	 of	 measurement253.	 Multiple	 measurements	 were	
taken	in	two	areas	of	the	foot	and	the	lowest	result	recorded.	Of	particular	note,	the	contra-
lateral	 foot	 was	 used	 if	 there	 was	 extensive	 ulceration,	 this	 may	 well	 have	 skewed	 their	
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results.	TcPO2	was	most	commonly	measured	at	44oC225,228,243,245,246,249	but	also	at	45oC	238,240	
or	not	stated242,251-253		
Due	 to	 the	 variety	 of	 countries	 and	 inclusion/exclusion	 criteria,	 the	 cohorts	 differed	
across	the	studies.	For	example,	Yang251	and	Lawson248	excluded	patients	with	evidence	of	
osteomyelitis	whereas	most	of	the	other	studies	did	not.		
Due	to	the	larger	number	of	studies,	TcPO2	best	demonstrates	that	if	the	microcirculation	
is	 functioning	 poorly	 then	 outcomes	 are	 likely	 to	 be	worse.	Most	 studies	 demonstrated	 a	
significantly	higher	TcPO2	in	those	patients	who	healed.	What	is	less	clear	is	the	threshold	at	
which	healing	occurs.	The	TcPO2	thresholds	quoted	for	a	successful	outcome	in	this	review	
range	 from	10mmHg	 to	 34mmHg.	 Karanfilian	quotes	 sensitivity	 of	 100%	and	 specificity	 of	
88%	for	healing	if	the	TcPO2	is	>10mmHg238.	Pecoraro	found	that	a	TcPO2	of	<20mmHg	was	
associated	with	a	39	fold	increased	risk	of	early	healing	failure225.	Both	Kalani	and	Yang	used	
the	 threshold	 of	 <25mmHg	 and	 quoted	 sensitivities	 and	 specificities	 of	 85%	 Vs	 92%	 and	
88.6%	Vs	82.4%	respectively228,251.	This	threshold,	when	looking	at	the	collated	results	in	the	
healed	 and	 unhealed	 groups	 in	 Table	 4.6-2,	 appears	 to	 hold	 true	 when	 considering	 the	
healed	groups,	all	the	mean	results	are	above	25mmHg.	However,	it	is	worth	observing	that	
the	mean	TcPO2	 is	also	higher	than	25mmHg	in	six	of	the	unhealed	groups225,249,252,253.	The	
current	consensus	among	experts	is	that	patients	with	an	SPP	≥40mmHg,	TBP	≥45mmHg	or	
TcPO2	≥25mmHg	are	more	likely	to	heal	than	their	counterparts	with	poorer	perfusion	and	
that	a	TBP	<30mmHg	or	TcPO2	<25mmHg	 is	an	 indication	for	urgent	vascular	 imaging15,255.	
This	is	based	on	a	recent	review	examining	the	utility	of	prognostic	markers	in	diabetic	foot	
disease	in	which	the	authors	faced	similar	difficulties	to	us	in	identifying	studies	of	sufficient	
quality	to	draw	conclusions	from255.	Eventually,	eleven	studies	involving	5890	patients	were	
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included	however	 there	was	 still	 significant	 heterogeneity	 and	difference	 in	 the	measures	
used.	 Their	 conclusions	 were	 based	 predominantly	 on	 three	 papers	 of	 acceptable	 rather	
than	high-quality	(Quality	in	Prognosis	Studies	Tool)228,237,256.	
Only	 one	 study	 in	 this	 current	 review	 truly	 compared	 the	 results	 of	 testing	 the	
microcirculation	 in	 patients	with	DM	and	 those	without238.	 Karanfilian	 found	 that	 the	DM	
patients	who	healed	had	a	lower	TcPO2	than	NDM	patients	who	healed.	Conversely,	the	LDF	
results	were	higher	 in	 the	DM	healed	group.	 In	 the	unhealed	groups,	 the	opposite	 is	 true.	
The	accuracy	of	TcPO2	 for	predicting	healing	 is	 shown	 to	be	 reasonable	 in	 those	with	DM,	
slightly	poorer	than	those	without	DM	but	better	than	those	with	CRF.	It	 is	not	possible	to	
draw	 relevant	 conclusions	 from	 this	paper	as	 it	 is	 a	historical	 cohort	of	 low	quality	with	a	
small	number	of	participants.	The	pattern	seen	may	be	due	to	cohort	selection	as	the	NDM	
cohort	had	significant	peripheral	arterial	disease	(PAD)	whereas	the	DM	cohort	was	made	up	
of	a	mix	of	patients	with	diabetic	foot	disease,	with	and	without	PAD238.		
The	 results	 from	 the	 repeated	 measures	 suggest	 that	 there	 is	 a	 change	 in	 the	
microcirculation	during	healing	but	the	true	trend	and	how	it	relates	to	healing	has	not	yet	
been	identified.	
As	 the	 heart,	 arteries,	 microcirculation	 and	 veins	 link	 into	 a	 circuit	 it	 is	 tempting	 to	
consider	that	there	is	a	direct	relationship	between	the	flow	of	blood	as	it	leaves	the	heart	
and	 how	 it	 flows	 through	 the	 microcirculation.	 However,	 anybody	 who	 has	 studied	 the	
basics	 in	fluid	biodynamics	will	be	aware	that	how	fluids,	 like	blood,	behave	is	different	on	
the	macro	and	microscopic	 scale257.	 This	 is	before	 the	 complex	 control	 systems	 related	 to	
maintaining	 homeostasis	 of	 blood	 pressure	 and	 tissue	 perfusion	 become	 involved258.	 A	
patient	with	diseased	macrocirculation	is	 likely	to	have	reduced	overall	blood	flow	through	
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the	 microcirculation	 although	 the	 degree	 of	 collateralisation	 will	 have	 an	 impact	 on	 this	
to210,226.	Patients	with	stenosis	or	occlusions	in	anatomically	appropriate	vessels	have	been	
shown	to	have	reduced	TcPO2	at	the	skin226.	Due	to	this	it	is	not	possible	to	claim	that	any	of	
the	tests	discussed	above	assess	the	microcirculation	in	isolation.	However	in	patients	with	
DM	reduced	TcPO2	has	been	demonstrated	 irrespective	of	 the	presence	of	PAD	or	DPN224,	
highlighting	 that	 the	 test	 is	 examining	 something	 other	 than	 just	 the	 macrocirculation.	
Reactivity	tests	like	PORH	may	be	less	impacted	by	the	macrocirculation	as	the	activation	of	
the	NO	pathway	 is	a	 local	effect	of	the	rapid	return	of	blood	flow	following	occlusion,	and	
impairment	of	the	hyperaemic	response	is	known	to	precede	the	development	of	clinically	
apparent	microvascular	and	atherosclerotic	disease259.	There	is	lack	of	consensus	in	this	area	
though260.	
4.8. CONCLUSIONS	
Due	to	the	heterogeneity	of	the	cohorts	and	the	data	presented	it	is	not	possible	to	draw	
any	 firm	 conclusions	 from	 a	 review	 of	 the	 current	 literature.	 The	 influence	 of	 DM	 and	
associated	neuropathy	 is	not	 clear,	 and	neither	 is	 the	degree	of	 improvement	 required	 to	
achieve	healing.	Studies	that	examine	a	clearly	defined	cohort	both	with	and	without	DM	are	
required.	 Accurate	 quantitative	 assessment	 of	 microcirculation	 will	 greatly	 aid	 predicting	
feet	at	risk,	of	predicting	wound	healing	with	and	without	surgery,	and	for	identifying	those	
at	 greatest	 risk	of	 amputation.	A	 study	was	designed	 to	examine	how	 the	 function	of	 the	
microcirculation	 changed	 through	 the	 process	 of	 wound	 healing,	 particularly	 how	 the	
function	changed	following	percutaneous	angioplasty.	
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CHAPTER	5: WHAT	IS	THE	RELATIONSHIP	OF	REVASCULARISATION	AND	
IMPROVEMENT	IN	MICROCIRCULATION	TO	WOUND	HEALING	AND	
PERIPHERAL	NEUROPATHY	IN	DIABETIC	FOOT	DISEASE?	AN	
OBSERVATIONAL	COHORT	STUDY.	
5.1. INTRODUCTION	
As	demonstrated	 in	 the	 literature	 review	above	 (Chapter	 4)	 there	 is	 a	 need	 for	 further	
evidence	 relating	 to	 the	 relationship	 between	 the	microcirculation	 and	 wound	 healing	 in	
patients	with	DM.	The	following	chapter	describes	work	that	was	carried	out	with	the	aim	of	
addressing	this	question.	Due	to	problems	with	recruitment	it	was	not	possible	to	complete	
the	planned	study	and	the	results	presented	represent	a	truncated	version.	They	should	be	
viewed	as	pilot	data	that	could	be	used	to	guide	the	direction	of	future	research.	
5.2. HYPOTHESIS	
Improving	the	microcirculation	of	the	foot	in	patients	with	diabetic	foot	disease	improves	
wound	healing	and	degree	of	peripheral	neuropathy.		
5.3. PLAN	FOR	COHORT	STUDY		
The	 original	 plan	 for	 the	 cohort	 study	 was	 to	 recruit	 three	 groups	 of	 patients	 all	 with	
active	 pedal	 tissue	 loss.	 The	 groups	would	 have	 comprised	 a	 group	with	 diabetes	 but	 no	
significant	peripheral	arterial	disease	(PAD),	the	diabetic	tissue	loss	group	(DTL).	Two	groups	
with	 significant	 PAD	 which	 required	 a	 revascularisation	 procedure,	 those	 who	 had	 been	
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listed	 for	 a	 percutaneous	 angioplasty	 (PCA)	 and	 those	 that	 had	 been	 listed	 for	 peripheral	
bypass	surgery	(PBS).	The	initial	comparison	would	have	been	between	these	three	groups.	
The	second	comparison	would	have	been	between	the	patients	with	and	without	diabetes	
mellitus	(DM)	in	the	PCA	and	PBS	groups	(Figure	5.3-1).		
5.3.1. Main	questions	to	be	addressed	
To	address	the	hypothesis,	the	following	questions	were	asked.	
• Which	of	PCA	or	PBS	provides	a	greater	improvement	in	the	microcirculation?		
• What	is	the	level	of	improvement	in	the	microcirculation	at	the	time	of	wound	
healing	in	patients	with	DM	and	PAD?	
• Is	there	any	improvement	in	the	neurological	status	of	patients	with	neuro-ischaemic	
ulceration	who	have	undergone	revascularisation?	
	
The	microcirculation	was	 to	 be	 assessed	 using	 laser	Dopper	 fluxmetry	 (LDF),	 toe	 blood	
pressure	 (TBP),	 and	 skin	 perfusion	 pressure	 (SPP).	 Neuropathy	 was	 assessed	 using	 a	
combination	of	vibration	perception	threshold	(VPT),	monofilament	detection,	Ipswich	touch	
test	(ITT)	and	neuropathy	total	symptom	score-6	(NTSS-6).	
5.3.2. Sample	size	calculation	
Data	 previously	 obtained	 at	 our	 institution261	 found	 the	 following	 values	 for	 the	mean	
(Standard	Deviation)	times	(in	seconds)	to	maximum	post-occlusive	reactive	hyperaemia	 in	
patients	who	underwent	PBS	or	PCA:	
PBS	Patients	(N=29):	Preoperative	=	100	(22);	Postoperative	=	59	(38)	
PCA	Patients	(N=9):	Preoperative	=	69	(27);	Postoperative	=	55	(30)	
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The	average	improvement	was	41	seconds	(100-59)	in	the	PBS	group	and	14	seconds	(69-
55)	 in	the	PCA	groups.	Hence,	the	difference	 in	the	 improvement	between	the	two	groups	
was	27	seconds	(41-14).	
The	 pooled	 standard	 deviation	 from	 this	 data	 is	 30.	 If	 the	 pre	 and	 post-operative	
measurements	on	the	same	patient	are	assumed	to	be	independent,	the	standard	deviation	
of	the	change	will	be	30	times	the	square	root	of	2,	i.e.	42	
The	 study	was	 powered	 based	 on	 a	 t-test,	 assuming	 a	 standard	 deviation	 of	 42.	 For	 a	
detectable	difference	of	27,	a	sample	size	of	40	patients	per	group	(i.e.	80	total)	would	be	
sufficient	for	80%	power	at	5%	alpha.		
There	 is	 no	 equivalent	 data	 available	 with	 which	 it	 would	 be	 possible	 to	 calculate	 an	
appropriate	 sample	 size	 for	 the	 group	with	DM	and	 no	 PAD	 (DTL	 group).	 For	 this	 reason,	
they	 have	not	 been	 included	 in	 the	primary	 outcome.	A	 sample	 size	 of	 20	will	 be	 able	 to	
detect	a	difference	of	33	seconds	between	the	initial	measurement	and	the	point	of	healing.	
This	was	agreed	to	be	reasonable	as	a	consensus	within	the	research	group.		
Due	to	the	demographics	of	patients	being	investigated	previous	experience	suggests	that	
a	 high	 dropout	 rate	 (up	 to	 20%)	 should	 be	 expected.	 This	 increases	 the	 size	 of	 our	 study	
groups	 to	 48	 for	 both	 the	 bypass	 and	 angioplasty	 groups	 and	 24	 for	 the	 DTL	 group.	 This	
brings	our	total	sample	size	to	120	participants.	
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Figure	5.3-1:	Inclusion	flow	chart	for	planned	cohort	study	
	102	
5.4. RECRUITMENT	ISSUES	
Recruitment	began	based	on	the	protocol	set	out	in	Appendix	III.	Recruitment	levels	were	
low	 throughout	 the	 study	period,	 reasons	 for	 this	 include	 issues	with	 the	 identification	of	
potential	participants	and	issues	with	the	sites.	At	the	beginning	of	the	study,	at	all	sites,	the	
purpose	of	the	study	and	the	type	of	patient	being	recruited	was	presented	at	relevant	team	
meetings	 (vascular	 surgery	 and	 diabetes	 and	 endocrinology).	 In	 areas	 where	 clinics	 took	
place,	posters	were	placed	with	a	 list	of	 inclusion	criteria	and	contact	details	 for	the	study	
team.	 Despite	 this,	 no	 participants	 were	 identified	 unless	 the	 lead	 recruiter	 (DLL)	 was	
present	 in	 the	 clinic.	 In	 clinics	 which	 were	 specific	 diabetic	 foot	 clinics	 a	 relatively	 high	
proportion	of	patients	could	be	considered	as	potential	participants.	The	majority	of	 these	
would	be	eligible	for	the	DTL	group	rather	than	the	PCA	or	PBS	groups.	Potential	members	of	
the	 PCA	 and	 PBS	 groups	 were	 more	 likely	 to	 be	 identified	 from	 vascular	 surgery	 clinics.	
Within	 an	 individual	 clinic	 of	 fifteen	 to	 thirty	 patients,	 there	 may	 only	 be	 one,	 or	 less,	
patients	 potentially	 eligible	 for	 the	 study.	 It	was	 not	 possible	 for	 DLL	 to	 be	 present	 at	 all	
vascular	 clinics	 across	 all	 sites	 particularly	 after	 the	 follow-up	 of	 recruited	 patients	 had	
started.		
In	an	effort	to	improve	identification	of	PCA	patients,	after	a	review	of	recruitment	at	six	
months,	an	amendment	to	the	study	protocol	was	applied	for.	This	requested	permission	to	
review	clinic	 lists,	angiography	and	theatre	 lists	 for	potential	participants.	Any	patient	who	
appeared	to	meet	the	inclusion	criteria	was	sent	a	letter	of	invitation	and	then	contacted	by	
phone	if	they	responded	favourably.	This	was	only	possible	at	the	UHB	site	as	DLL	was	not	a	
	103	
regular	member	 of	 staff	 at	 the	 other	 sites	 and	 so	would	 not	 normally	 have	 access	 to	 the	
appropriate	procedure	lists.		
This	 did	 improve	 recruitment	 of	 PCA	 patients	 slightly,	 but	 PBS	 patients	 remained	
challenging.	The	main	reason	behind	this	was	due	to	bed	pressures.	 Ideally,	patients	being	
admitted	for	major	surgery	would	be	admitted	on	the	evening	before	surgery.	Pressures	on	
beds	 during	 the	 period	 of	 recruitment	 meant	 that	 predominantly	 patients	 were	 being	
admitted	to	an	admissions	lounge	on	the	morning	of	surgery.	There	was	no	space	within	the	
admissions	lounge	for	the	study	procedures	to	be	undertaken,	in	addition,	the	patients	were	
usually	first	on	the	list,	and	so	there	was	not	the	time	to	organise	an	alternative	room.	
5.4.1. Amendments	
5.4.1.1. Amendment	1:	August	2014	
	 Amendment	 1	was	made	 in	 response	 to	 an	 internal	 review	 of	 the	 protocol	
performed	by	the	University	of	Birmingham	as	part	of	the	application	process	for	an	
MSc	by	Research	Clinical	and	Experimental	Medicine.	The	changes	to	the	protocol	are	
as	follows:	
1. Rewording	of	the	principle	research	question	to	"What	is	the	level	of	
improvement	in	the	microcirculation	at	the	time	of	wound	healing	in	
patients	with	diabetes	mellitus	and	peripheral	arterial	disease?"	
from	"What	is	the	level	of	improvement	in	microcirculation	required	
to	achieve	wound	healing	in	patients	with	diabetes	mellitus	and	
peripheral	arterial	disease?"	
2. Clarification	of	the	timelines	for	assessment	of	the	patients.	
3. Rewritten	description	of	how	10g	monofilament	assessment	will	be	
performed.	
4. Sample	size	recalculated	to	include	a	dropout	rate	of	20%.		
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5. Proposed	statistical	analysis	clarified.	
6. Proposed	handling	of	missing	data	clarified.	
5.4.1.2. Amendment	2:	October	2014	
Amendment	2	requested	permission	to	perform	a	glycated	haemoglobin	(HbA1c)	
on	all	patients	who	were	believed	not	to	have	diabetes	but	had	not	had	a	HbA1c	in	
the	last	six	months.	
If	a	patient	was	found	with	an	HBA1c	of	>6.5%	(diagnostic	of	diabetes	as	per	WHO	
guidance	 2011)	 and	 assuming	 they	 were	 stable	 and	 well	 in	 themselves	 then	 the	
researchers	would	provide	basic	counselling	in	the	clinic	and	then	refer	them	to	their	
GP	 for	 further	 management	 and	 investigation	 of	 their	 diabetes.	 If	 there	 was	 any	
indication	the	patient	was	acutely	unwell,	the	researchers	would	organise	admission	
to	hospital	for	further	management.	In	both	cases,	these	patients	would	be	excluded	
from	 the	 study	 as	 they	 would	 not	 yet	 meet	 the	 inclusion	 criteria	 of	 being	 on	
medication	for	their	diabetes.		
5.4.1.3. Amendment	3:	August	2015	
Amendment	3	requested	permission	to	review	clinic,	theatre	and	angioplasty	lists	
for	 potential	 participants.	 This	 changed	 the	 wording	 on	 how	 patients	 would	 be	
identified	to	that	now	found	in	section	5.6.5.	
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5.5. RECRUITMENT	ACHIEVED	
Recruitment	 started	 on	 the	 1st	 January	 2015.	 As	 the	 recruitment	 period	 went	 on	 it	
became	 clear	 that	 it	 would	 not	 be	 possible	 to	 recruit	 the	 120	 planned	 patients	 in	 the	
available	time	period.	As	of	February	2016,	twenty-six	patients	had	been	recruited,	fourteen	
in	the	DTL	group,	ten	in	the	PCA	group	and	two	in	the	PBS	group	(Figure	5.5-1).	The	decision	
was	made	 to	 stop	 recruitment	 and	 analyse	 the	data	 that	 had	been	 collected	up	until	 this	
point.	The	hope	was	to	use	the	data	for	new	power	calculations	and	to	redesign	the	study.	In	
essence	treating	this	data	as	a	pilot	study.	As	the	PBS	group	only	included	two	patients,	and	
one	of	those	was	the	only	patient	without	DM,	they	were	not	included	in	the	data	analysis.		
The	 following	 sections	 set	 out	 the	 outcome	 measures	 of	 the	 study,	 data	 collection	
protocol	and	data	analysis	that	was	carried	out.		
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Figure	5.5-1:	Inclusion	flow	chart	for	pilot	study	
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5.6. DESIGN	OF	PILOT	STUDY	
5.6.1. Outcome	Measures	
5.6.1.1. Primary	outcome	
• Evidence	of	difference	in	the	level	of	change	in	the	time	to	maximum	flux	between,	
before,	and	after	PCA.	
5.6.1.2. Secondary	outcomes	
• Evidence	of	difference	in	the	level	of	change	in	the	time	to	maximum	flux	between	
when	ulceration	active	and	when	ulceration	healed	in	patients	with	DM	and	no	
significant	PAD.	
• Time	to	wound	healing	
• Time	to	major	amputation	
• The	change	in	skin	perfusion	pressure	(SPP)	at	the	end	of	the	study	
• The	change	in	toe	blood	pressure	(TBP)	at	the	end	of	the	study	
• The	change	in	vibration	perception	threshold	(VPT)	at	the	end	of	the	study	
• The	change	in	monofilament	detection	at	the	end	of	the	study	
• The	change	in	Ipswich	touch	test	(ITT)	at	the	end	of	the	study	
• The	change	in	neuropathy	total	symptom	score	-	6	(NTSS-6)	at	the	end	of	the	study	
	
End	of	the	study	 is	defined	as	either	complete	wound	healing,	major	amputation	of	the	
study	limb	or	time	for	the	conduct	of	the	study	elapsing	(1st	June	2016).	
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5.6.2. Study	groups	(Figure	5.5-1)	
5.6.2.1. Diabetic	tissue	loss	without	peripheral	arterial	disease	(DTL)	
Patients	with	type	I	or	II	DM	and	active	tissue	loss	without	clinically	significant	PAD.	These	
patients	had	no	additional	treatment	other	than	the	standard	wound	care	and	follow-up	in	
the	local	diabetic	foot	clinic.	
5.6.2.2. Percutaneous	angioplasty	(PCA)	
Patients	with	 active	 tissue	 loss	 and	 PAD	 confirmed	 clinically	 and	 on	 duplex	 ultrasound,	
computed	tomography	angiography	or	Magnetic	Resonance	Angiograpy	who	on	assessment	
by	their	named	consultant	require	PCA.		
5.6.3. Inclusion	criteria	
5.6.3.1. For	participants	requiring	percutaneous	angioplasty		
• Type	I	or	II	DM	requiring	medical	therapy	
• Active	tissue	loss	
• Require	endovascular	revascularisation		
• Aged	between	18	and	99	years	
• Able	to	give	informed	consent	
5.6.3.2. For	participants	with	diabetes	mellitus	and	no	peripheral	arterial	disease		
• As	the	first	group,	apart	from	no	evidence	of	PAD	requiring	revascularisation.	As	
assessed	by	a	vascular	surgery	consultant.	
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5.6.4. Exclusion	criteria	
• Unwilling	or	unable	to	give	informed	consent	
• Previous	distal	arterial	bypass	on	the	ulcerated	leg.	
• Angioplasty	to	the	ulcerated	leg	during	this	period	of	active	ulceration.	
• Significant	non-reconstructable	PAD.	
• Previously	diagnosed	peripheral	neuropathy	secondary	to	a	cause	other	than	DM.	
• Medically	unfit	for	the	procedure.	
• Pregnancy	or	breast-feeding	
• Vitamin	B12	deficiency.	
• Alcohol	dependency.	
• Hypothyroidism.	
• Renal	failure	requiring	renal	replacement	therapy.	
5.6.5. Patient	identification	
Potential	patients	were	identified	predominantly	from	diabetic	foot	clinics,	vascular	clinics	
and	inpatient	admissions	at	the	study	sites.	The	patients	were	identified	by	the	investigators	
and	other	doctors	on	the	vascular	and	diabetes	teams.	As	it	was	not	possible	for	a	member	
of	 the	 study	 team	 to	 be	 present	 in	 person	 in	 all	 relevant	 clinics	 review	 of	 referral	
documentation	 to	 clinics,	 theatre	 lists	 and	 angioplasty	 lists	 was	 conducted.	 This	 was	 only	
performed	at	the	University	Hospitals	Birmingham	site	due	to	restrictions	in	distributing	the	
relevant	 lists	beyond	those	who	would	normally	be	 in	 receipt	of	 them	due	to	 their	clinical	
responsibilities.	If	a	potential	patient	was	identified	from	these	lists	a	patient	invitation	letter	
(Appendix	 IV)	 and	 a	 patient	 information	 sheet	 (Appendix	 V)	 was	 posted	 to	 their	 home	
address.	The	patient	invitation	letter	contained	a	reply	slip	and	stamped	addressed	envelope	
which	allowed	the	patient	to	express	their	desire	or	otherwise	to	be	included	in	the	study.	If	
a	reply	slip	was	not	received,	then,	after	1-2	weeks	the	letter	was	followed-up	with	a	phone	
call.	 If	 the	patient	 expressed	an	 interest	 at	 their	 next	 clinic	 appointment	or	on	 the	day	of	
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procedure	 the	 patient	 was	 met	 by	 a	 member	 of	 the	 team	 to	 answer	 any	 questions	 and	
confirm	their	continued	desire	to	participate.	If	appropriate,	consent	was	taken,	and	the	first	
assessment	carried	out	at	this	time.	
5.6.6. Consent	
All	 participants	 were	 verbally	 invited	 to	 take	 part	 in	 the	 study	 by	 the	 clinical	 team	
providing	their	care.	They	were	given	written	information	with	regards	to	the	purpose	and	
design	 of	 the	 study	 (Appendix	 V).	 They	 were	 then	 invited	 to	 participate	 and,	 if	 agreed,	
consented	 using	 a	 standardised	 consent	 form	 (Appendix	 VI).	 This	 was	 performed	 and	
undertaken	by	a	member	of	the	study	team.	
Consent	 to	 participate	 included	 consent	 to	 the	 use	 of	 data	 obtained	 during	 their	
participation	in	the	final	analysis.	Participants	were	free	to	leave	the	study	with	only	a	verbal	
request,	 though	 their	 non-identifiable	 data	 remained	 within	 the	 study	 unless	 a	 written	
request	was	made	to	the	contrary.	This	was	made	clear	at	the	time	of	consent.	
5.6.7. Assessment	
5.6.7.1. Timing	of	assessments	
For	the	PCA	group,	the	initial	assessment	was	carried	out	within	the	24	hours	before	their	
procedure.	 For	 the	 DTL	 group,	 the	 initial	 assessment	 was	 carried	 out	 following	 informed	
consent	being	gained.	If	possible,	this	was	during	the	same	attendance.	
Post-procedure	 assessment	 for	 the	 PCA	 group	 occurred	 at	 initial	 follow-up	 clinic	
appointment	 one	 month	 following	 their	 procedure.	 Subsequent	 re-examination	 occurred	
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monthly	 (within	 a	 week)	 at	 the	 hospital	 appointment	 that	 fell	 nearest	 this	 time.	 This	
included	 vascular,	 diabetes	 and	 podiatry	 appointments.	 Reassessment	 continued	 until	 the	
ulcer	was	decided	to	have	clinically	healed,	the	limb	was	amputated,	or	the	end	of	the	study	
was	reached.	
The	 DTL	 group	 had	 repeat	 assessments	 monthly	 until	 the	 ulcer	 was	 decided	 to	 have	
clinically	healed,	the	limb	was	amputated,	or	the	end	of	the	study	was	reached.	
5.6.7.2. Procedure	for	data	collection	
The	 patient	 was	 asked	 to	 arrive	 for	 their	 appointment	 having	 not	 eaten	 for	 the	 last	 2	
hours	and	not	had	any	caffeinated	drinks	since	the	proceeding	night.	They	were	assessed	in	
a	temperature	controlled	clinic	room	(220C	+/-	20C)	or	if	for	inpatients	this	was	not	possible	
the	temperature	was	recorded.	The	patient	was	positioned	on	a	couch	in	a	semi-recumbent	
position	so	 they	could	acclimatise	 to	 the	 temperature	of	 the	room.	During	 the	 first	 fifteen	
minutes,	 the	NTSS-6	questionnaire	was	completed,	and	monofilament,	 ITT	and	VPT	testing	
was	carried	out	on	both	feet.	The	characteristics	of	the	ulcer/s	were	also	described.	During	
the	 second	 fifteen	 minutes,	 the	 patient	 was	 asked	 to	 relax,	 and	 the	 LDF	 probes	 were	
attached.	The	protocol	for	each	measurement	was	as	follows.	
	
10g	Monofilament	
Three	areas	on	each	foot	was	tested.	These	were	the	plantar	aspects	of	the	hallux,	and	
base	of	 the	 third	 and	 fifth	metatarsals18,120.	A	positive	or	negative	 response	 for	 each	area	
was	recorded.	Abnormal	was	defined	as	an	inability	to	detect	the	monofilament	in	one	area.	
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If	 it	 was	 not	 possible	 to	 test	 any	 of	 the	 areas	 due	 to	 amputation	 or	 ulceration,	 this	 was	
recorded.	
Ipswich	Touch	Test	
The	 tips	 of	 the	1st,	 3rd	 and	5th	 toes	of	 each	 foot	were	 tested	 in	 the	order	described	by	
Diabetes	UK	in	their	 leaflet	"How	to	do	the	Touch	the	Toes	Test"262.	A	positive	or	negative	
response	for	each	area	was	recorded.	 If	 it	was	not	possible	to	test	any	of	the	areas	due	to	
amputation	or	ulceration,	this	was	recorded.		
Vibration	Perception	Threshold	
VPT	 was	 assessed	 on	 the	 pulp	 of	 the	 hallux	 or	 next	 dominant	 toe	 if	 amputation	 had	
occurred	 in	 the	 past	 or	 the	 toe	 was	 necrotic.	 A	 neurothesiometer	 was	 used.	 The	 first	
measurement	was	taken	increasing	from	zero	to	maximum	and	the	level	at	which	vibration	
was	detected	recorded.	The	second	measurement	was	taken	from	maximum	to	zero	and	the	
level	 at	 which	 vibration	 disappears	 was	 recorded.	 An	 average	 of	 these	 two	 readings	 was	
taken.	If	no	vibration	was	detected,	then	50V	was	recorded.	
Ulcer	description	
The	ulcer/s	were	described	 in	the	same	way	as	used	by	the	Eurodiale	study	263.	Area	of	
the	ulcer	was	determined	by	multiplying	the	largest	diameter	by	the	second	largest	diameter	
perpendicular	to	the	first.	Depth	was	described	as	superficial	or	deep:	a	superficial	ulcer	is	a	
full-thickness	 lesion	 of	 the	 skin	 not	 extending	 through	 the	 subcutis,	 and	 a	 deep	 ulcer	 is	 a	
lesion	of	the	skin	extending	through	the	subcutis.	An	infection	was	diagnosed	if	two	or	more	
of	 the	 following	signs	are	present:	 frank	purulence,	 local	warmth,	erythema,	 lymphangitis,	
oedema,	 pain,	 fever	 and	 foul	 smell.	 The	 anatomical	 location	 of	 the	 ulcer/s	 was	 also	
described.	The	ulcer	was	described	as	healed	when	complete	epithelialisation	had	occurred.	
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Laser	Doppler	Fluxmetry	
The	patient’s	 feet	were	placed	on	a	pillow	 to	 stabilise	 them	and	a	 laser	Doppler	probe	
placed	on	the	pulp	of	the	hallux	or	remaining	dominant	toe	and	dorsal	surface	of	the	foot	
between	the	2nd	and	3rd	metatarsals.	A	cuff	was	placed	around	the	patient’s	ankle.	The	LDF	
was	then	turned	on	and	baseline	flux	measured	for	one	minute,	the	cuff	was	then	inflated	
for	 three	 minutes	 followed	 by	 rapid	 deflation	 and	 monitoring	 of	 the	 response	 for	 five	
minutes.		
A	toe	cuff	was	placed	around	the	great	toe	or	remaining	dominant	toe	to	replace	the	cuff	
around	the	ankle.	Toe	blood	pressure	was	then	measured.	
Following	 this,	 the	 low-profile	 probe	 was	 placed	 adjacent	 to	 the	 ulcerated	 tissue	 and	
gently	 secured	with	 clingfilm,	which	 also	 protected	 the	 ulcerated	 area.	 A	 cuff	was	 placed	
over	around	the	foot.	SPP	was	measured	with	slow	deflation	of	the	cuff.	
Probes	 were	 then	 transferred	 to	 the	 other	 leg	 and	 the	 process	 repeated.	 This	 whole	
process	took	approximately	thirty	minutes.	
The	data	obtained	was	processed	using	the	Moor	VMS-PC™	software.	
	
Demographics	
Demographics	that	were	collected	at	first	appointment	are	listed	below.	
• Age	
• Sex	
• Type	of	DM	
• Duration	of	DM	
• Current	medications	
• Recent	blood	results	including	glycosylated	haemoglobin,	cholesterol,	thyroid	
stimulating	hormone,	free	T4	and	vitamin	B12.	
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5.6.8. Data	Analysis	Plan	
Initially,	 the	continuous	variables	were	 tested	 for	normality	The	only	variables	 found	 to	
meet	 the	 assumptions	 of	 normality	were	 systolic	 blood	 pressure,	 diastolic	 blood	 pressure	
and	 room	 temperature.	 Consequently,	 these	 variables	 where	 analysed	 using	 parametric	
tests.	 For	 the	 other	 variables	 comparison	 between	 groups	 was	 made	 using	 independent	
samples	 non-parametric	 tests	 like	 Kruskal-Wallis	 and	 Mann-Whitney	 U	 tests.	 Related	
variables,	i.e.	visits,	were	compared	using	the	related	samples	Freidman’s	test	and	Wilcoxon	
signed	rank	test.	Categorical	data	was	examined	using	Chi-squared	test	or	Fisher’s	exact	test	
as	appropriate.	Related	categorical	data	was	examined	using	McNemar’s	test.	
Demographics	 were	 analysed	 by	 group.	 The	 differences	 between	 characteristics	 of	 the	
ulcers	 and	 the	patients	 (days	 since	 the	 last	 appointment,	 time	of	 assessment,	 hours	 since	
last	 ate,	 hours	 since	 caffeine,	 ulcer	 area,	 neuropathy	 total	 symptom	 score	 –	 6,	 vibration	
perception	 threshold,	 room	 temperature,	 systolic	 blood	 pressure	 and	 diastolic	 blood	
pressure)	were	examined	by	group	and	by	visit.	As	only	three	patients	had	more	than	three	
visits	only	the	data	for	the	first	three	visits	were	analysed.	The	comparisons	for	the	LDF	data	
were	by	group,	by	visit,	patients	who	healed	compared	to	those	who	did	not	and	the	study	
leg	compared	to	the	non-study	leg.	
5.6.8.1. Data	collection	and	management	
Data	was	 recorded	directly	onto	a	standard	data	collection	proforma,	and	 the	LDF	data	
was	recorded	onto	an	encrypted	computer.	The	analysis	also	took	place	on	this	computer.	
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5.6.8.2. Data	storage	
All	identifiable	patient	data	was	collected	and	stored	on	an	encrypted	computer	and	kept	
locked	within	secured	premises	within	the	vascular	department.	This	will	be	maintained	as	
per	 data	 protection	 and	 GCP	 guidelines	 then	 stored	 for	 the	 required	 five	 years	 before	
destruction.	
5.6.8.3. Source	data	
Source	data	was	kept	within	the	source	data	 file	 that	was,	 in	turn,	kept	 locked	within	a	
secure	 office	 locked	 and	 secure	 within	 the	 Vascular	 Department.	 It	 is	 accessible	 only	 by	
those	signatories	within	the	research	group	and	by	the	sponsors	as	requested.	
5.6.9. Ethical	Considerations 
Local	 Research	 Ethics	 Committee	 approval	 was	 sought	 from	 the	 South	 Birmingham	
Research	 Ethics	 Committee.	 Approval	 was	 granted	 on	 26th	 June	 2014.	 Approval	 was	 also	
sought	from	the	Research	and	Development	departments	of	the	three	study	sites,	University	
Hospitals	 Birmingham	 NHS	 Foundation	 Trust,	 Dudley	 Group	 NHS	 Foundation	 Trust	 and	
Sandwell	and	West	Birmingham	Hospitals	NHS	Trust.	These	were	approved	on	24th	July	2014,	
18th	July	2014	and	30th	September	2014	respectively. 
 
All	 research	 was	 conducted	 in	 line	 with	 the	World	 Medical	 Association	 Declaration	 of	
Helsinki.	All	members	of	the	research	group	received	Good	Clinical	Practice	Training	as	per	
the	National	Institute	for	Health	Research,	and	the	research	was	conducted	in	line	with	the	
same	principles.	Funding	to	purchase	the	equipment	(the	laser	Doppler	equipment)	for	the	
	116	
study	was	 sourced	 from	 the	 Vascular	 surgery	 research	 fund	 held	 by	 the	 Queen	 Elizabeth	
Hospital	Birmingham	Charity	and	not	from	commercial	sources.	
5.7. RESULTS	
5.7.1. Numbers	
In	total	twenty-four	patients	were	recruited.	Fourteen	patients	in	the	DTL	group	and	ten	
in	the	PCA	group.	One	patient	 in	the	PCA	group	consented	to	be	 included	in	the	study	but	
was	taken	for	their	procedure	before	any	assessments	could	be	performed,	so	no	data	from	
them	is	included	in	the	study.		
5.7.2. Demographics	(Table	5.7-1)	
The	patients	in	the	PCA	group	were	significantly	older	than	the	DTL	group.	There	was	no	
significant	difference	in	duration	of	DM	or	ulcer.	The	site	of	the	ulcer	was	more	likely	to	be	
on	the	plantar	surface	of	the	foot	in	the	DTL	group	and	the	heel	in	the	PCA	group.	Those	in	
the	 PCA	 group	 had	 a	 significantly	 lower	 estimated	 glomerular	 filtration	 rate	 than	 the	DTL	
group.	 There	 were	 no	 other	 areas	 of	 significant	 difference	 within	 the	 collected	
demographics.	It	is	worth	noting	the	small	number	of	patients	with	information	available	for	
total	cholesterol,	thyroid	stimulating	hormone,	free	T4,	and	vitamin	B12.		
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Table	5.7-1:	Demographics	for	study	groups	
	
Study	Group	
p-value*	
Diabetic	Tissue	Loss	 Percutaneous	Angioplasty	
n	
Median	
(IQR)	
n	
Median	
(IQR)	
Age	(years)	 14	 52	(43-60)	 9	 76	(75-78)	 <0.001	
Male	(%)	 14	 71.4	 9	 66.7	 1.00††	
Type	II	DM	(%)	 14	 78.6	 9	 100	 0.253††	
Glycated	Haemoglobin	(mmol/mol)	 9	 75	(52-84)	 3	 52	(49-53)	 0.209	
Duration	of	DM	(years)	 14	 15	(9-20)	 8	 18	(11-24)	 0.525	
Duration	of	Ulcer	(months)	 14	 2	(1-13)	 9	 5	(3-7)	 0.336	
Ulcer	Site	(%)	
Hallux	
Non-dominant	toe	
MTPJ	
Dorsum	
Plantar	
Heel	
14	 	
21.4	
0.0	
28.6	
0.0	
50.0	
0.0	
9	 	
22.2	
11.1	
22.2	
11.1	
0.0	
33.3	
0.030††	
Study	Leg	(%	Right)	 14	 42.9	 9	 88.9	 0.040††	
Number	of	Comorbidities	 14	 1	(1-3)	 9	 2	(1-3)	 0.688	
Hypertension	(%)	 14	 57.1	 9	 77.8	 0.400††	
Estimated	Glomerular	Filtration	Rate	 14	 87	(61-90)	 8	 55	(43-71)	 0.024	
Total	Cholesterol	(mg/dL)	 7	 4.9	(4.8-5.3)	 4	 4.3	(3.4-4.9)	 0.109	
Thyroid	Stimulating	Hormone	(mU/L)	 7	 2.1	(0.9-3.5)	 3	 3.5	(2.6-4.1)	 0.183	
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Free	T4	(pmol/L)	 4	 15.4	(14.6-17.6)	 3	 19.3	(14.0-22.6)	 1.000	
Vitamin	B12	(pg/ml)	 3	 467	(145-554)	 0	 -	 -	
Number	of	Medications	 13	 7	(2-9)	 9	 8	(7-9)	 0.357	
Cardioactive	Drugs	(%)	 14	 46.2	 9	 44.4	 1.000††	
Alcohol	Units	per	week	 14	 2	(1-6)	 9	 1	(0-7)	 0.439	
Smoking	Status	(%)	
Never	Smoked	
Ex-smoker	
Current	Smoker	
14	 	
78.6	
14.3	
7.1	
9	 	
44.4	
44.4	
11.1	
0.225††	
*Independent	Samples	Mann-Whitney	U	Test,	†Chi-squared	Test,	††Fisher’s	Exact	Test,	MTPJ:	Metatarsal	Phalangeal	Joint	
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5.7.3. Characteristics	of	ulcers	and	patients	
5.7.3.1. Days	since	the	last	appointment	
The	median	 time	between	appointments	was	34	days	 (Inter-quartile	 range	 (IQR)	28-50)	
for	patients	in	the	DTL	group	and	45	days	(35-70)	in	the	PCA	group	(p=	0.030)	(Table	5.7-6).	
There	was	no	significant	difference	in	the	time	between	appointments	for	all	patients	or	by	
group	(Table	5.7-7).		
5.7.3.2. Time	of	assessment	
The	 median	 time	 of	 assessment	 was	 11:30	 (09:50-13:09)	 in	 the	 DTL	 group	 and	 11:00	
(10:07-12:15,	 p=0.382)	 in	 the	 PCA	 group	 (Table	 5.7-6).	 This	 difference	was	 not	 significant,	
and	neither	was	there	a	significant	difference	between	visits	(Table	5.7-7).	
5.7.3.3. Time	since	eating	
The	median	time	since	eating	was	2.75hrs	(1.50-3.25)	in	the	DTL	group	and	2.38hrs	(1.75-
3.00,	 p=0.594)	 in	 the	 PCA	 group	 (Table	 5.7-6).	 These	 values	 remained	 similar	 and	 non-
significant	by	visit	(Table	5.7-7).	
5.7.3.4. Time	since	caffeine	
The	time	since	consuming	caffeine	was	similar	to	the	time	since	eating	(DTL	3.00hrs	(2.25-
5.00)	vs	PCA	2.50hrs	(1.63-3.50),	p=0.084)	both	by	group	and	by	visit	(Table	5.7-6	and	Table	
5.7-7).	
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5.7.3.5. Ulcer	area	
Between	 groups	 over	 all	 visits,	 there	was	 no	 significant	 difference	 in	 ulcer	 area	 (Table	
5.7-6).	When	looked	at	by	visit	in	both	groups	there	was	a	decrease	in	size	at	the	second	visit	
but	an	increase	at	the	third	visit.	In	the	PCA	group,	the	increase	is	to	larger	than	the	baseline	
value	(Table	5.7-7).	
5.7.3.6. Depth	of	ulcer	
At	baseline	sixteen	patients	(69.6%)	had	a	deep	ulcer.	There	was	no	significant	difference	
in	 the	 depth	 of	 the	 ulcer	 by	 the	 second	 visit	 (Table	 5.7-2).	 By	 the	 last	 visit,	 there	 was	 a	
significant	 difference	 in	 the	 DTL	 group	 (Table	 5.7-3)	 with	 a	 high	 proportion	 of	 patients	
changing	from	a	deep	ulcer	to	a	superficial	ulcer.	
Table	5.7-2:	Depth	of	ulcer	at	baseline	compared	to	depth	of	ulcer	at	second	visit	
		
Depth	of	ulcer	at	
second	visit	 p-value*	
Superficial	 Deep	
Depth	 of	 ulcer	
at	baseline	
Diabetic	Tissue	Loss		
Superficial	 2	 1	
0.219	
Deep	 5	 3	
Percutaneous	Angioplasty	
Superficial	 2	 1	
1.000	
Deep	 2	 3	
*McNemar	Test	 		 		 		 		 		
Table	5.7-3:	Depth	of	ulcer	at	baseline	compared	to	depth	of	ulcer	at	last	visit	
		
Depth	of	ulcer	at	
last	visit	 p-value*	
Superficial	 Deep	
Depth	 of	 ulcer	
at	baseline	
Diabetic	Tissue	Loss		
Superficial	 2	 1	
0.039	
Deep	 8	 0	
Percutaneous	Angioplasty	
Superficial	 3	 0	
0.125	
Deep	 4	 1	
*McNemar	Test	 		 		 		 		 		
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5.7.3.7. Infection	
Nine	 patients	 (39.1%)	 had	 evidence	 of	 infection	 at	 baseline	 and	 four	 (21.1%)	 at	 the	
second	visit.	Only	one	of	these	at	the	second	visit	was	a	new	infection	(Table	5.7-4).	There	
was	also	no	significant	difference	at	the	last	visit	(Table	5.7-5).	
Table	5.7-4:	Presence	of	infection	at	baseline	compared	to	presence	of	infection	at	second	
visit	
		
Presence	of	Infection	at	
Second	Visit	 p-value*	
No	 Yes	
Presence	of	
Infection	at	
baseline	
Diabetic	Tissue	Loss		 No	 7	 1	
1.000	
Yes	 2	 1	
Percutaneous	Angioplasty	
No	 4	 0	
0.500	
Yes	 2	 2	
*McNemar	Test		
	
Table	 5.7-5:	 Presence	 of	 infection	 at	 baseline	 compared	 to	 presence	 of	 infection	 at	 last	
visit	
		
Presence	of	Infection	at	
Last	Visit	 p-value*	
No	 Yes	
Presence	of	
Infection	at	
baseline	
Diabetic	Tissue	Loss		
No	 7	 1	
0.625	
Yes	 3	 0	
Percutaneous	Angioplasty	
No	 4	 0	
0.250	
Yes	 3	 1	
*McNemar	Test	
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5.7.3.8. Room	temperature	
The	mean	room	temperature	was	23.06±0.95oC	in	the	DTL	group	and	22.59±1.51oC	in	the	
PCA	 group.	 This	 difference	 was	 not	 significant	 (p=0.117)	 neither	 was	 there	 a	 significant	
difference	by	visit	(Table	5.7-7).	
5.7.3.9. Blood	pressure	
There	was	no	significant	difference	in	systolic	or	diastolic	blood	pressure	by	group	or	by	
visit	(Table	5.7-6	and	Table	5.7-7).	
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Table	5.7-6:	Ulcer	characteristics	by	group	
	
Group	
p-value	**	Diabetic	Tissue	Loss	 Percutaneous	angioplasty	
n	 Median	(IQR)	 n	 Median	(IQR)	
Days	since	last	appointment*	 27	 34	(28-50)	 19	 45	(35-70)	 0.030	
Time	of	assessment	 41	 11:30	(9:50-13:09)	 28	 11:00	(10:07-12:15)	 0.382	
Hours	since	last	ate	 41	 2.75	(1.50-3.25)	 28	 2.38	(1.75-3.00)	 0.594	
Hours	since	caffeine	 41	 3.00	(2.25-5.00)	 28	 2.50	(1.63-3.50)	 0.084	
Ulcer	area	(mm2)	 41	 182	(50-450)	 28	 180	(19-985)	 0.888	
Room	temperature†	(0C)	 41	 23.06±0.95	 28	 22.59±1.51	 0.117††	
Systolic	blood	pressure†	(mmHg)	 41	 138.15±20.63	 28	 139.00±17.89	 0.859††	
Diastolic	blood	pressure†	(mmHg)	 41	 76.63±11.04	 28	 73.25±10.96	 0.214††	
*Visit	1	excluded	**Independent-Samples	Mann-Whitney	U	Test	†Mean	††One-way	ANOVA	
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Table	5.7-7:	Ulcer	characteristics	by	visit	
	 Visit	
p-value*	1	 2	 3	
n	 Median	(IQR)	 n	 Median	(IQR)	 n	 Median	(IQR)	
Days	since	last	appointment	 DTL	 -	 -	 11	 31	(28-60)	 7	 35	(30-42)	 0.075	
PCA	 -	 -	 9	 60	(35-91)	 4	 38.5	(35-47)	 0.893	
Time	of	assessment	 DTL	 14	 11:55	(11:10-13:09)	 11	 10:45	(9:50-12:00)	 7	 11:30	(9:50-14:45)	 0.368	
PCA	 9	 11:45	(11:00-13:00)	 9	 11:30	(10:35-11:45)	 4	 10:07	(9:40-11:22)	 0.504	
Hours	since	ate	 DTL	 14	 2.75	(1.500-3.5)	 11	 3.00	(2.25-4.00)	 7	 2.00	(1.00-3.00)	 0.618	
PCA	 9	 2.50	(2.00-3.00)	 9	 2.75	(2.00-3.25)	 4	 2.13	(1.50-3.13)	 0.623	
Hours	since	caffeine	 DTL	 14	 2.88	(2.00-4.25)	 11	 3.00	(2.25-5.50)	 7	 6.00	(3.00-12.00)	 0.392	
PCA	 9	 2.50	(1.50-3.00)	 9	 3.25	(2.00-3.50)	 4	 2.13	(1.50-7.25)	 0.392	
Ulcer	area	(mm2)	 DTL	 14	 342.5	(80-782)	 11	 90	(10-400)	 7	 125	(0-260)	 0.002	
PCA	 9	 270	(180-1750)	 9	 150	(0-1200)	 4	 458	(195.5-1090.5)	 0.050	
Room	temperature	(0C)**	 DTL	 14	 23.29±1.18	 11	 22.91±0.91	 7	 23.14±0.66	 0.939†	
PCA	 9	 22.87±0.99	 9	 22.900±1.74	 4	 22.43±2.22	 0.943†	
Systolic	BP	(mmHg)**	 DTL	 14	 136.86±24.33	 11	 136.82±15.14	 7	 130.57±23.63	 0.385†	
PCA	 9	 139.78±19.62	 9	 146.78±10.22	 4	 129.75±23.10	 0.659†	
Diastolic	BP	(mmHg)**	 DTL	 14	 76.57±11.66	 11	 77.73±13.02	 7	 75.00±9.71	 0.385†	
PCA	 9	 73.33±11.80	 9	 78.11±10.07	 4	 69.25±14.93	 0.481†	
*Related-Samples	Friedman's	Two-Way	Analysis	of	Variance	by	Ranks,	**mean±SD,	†Two-way	repeated	measures	ANOVA	
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5.7.4. Post	Occlusive	Reactive	Hyperaemia	
The	 variables	 calculated	 for	 post	 occlusive	 reactive	 hyperaemia	 (PORH)	 are	 shown	 in	
Figure	 4.4-2.	 For	 clarity,	 the	 only	 variable	 included	 in	 the	 following	 figures	 is	 the	 time	 to	
maximum	flux	(TtM).	The	full	data	set	is	presented	in	Appendix	VII.		
Patients	in	the	PCA	group	had	a	significantly	longer	TtM	than	the	DTL	group	at	baseline	on	
both	the	study	toe	(220.8s	(200.2-288.78)	vs	13.4s	(3.68-73.85),	p=0.002)	and	study	dorsum	
(220.28s	 (93.65-279.8)	 vs	 8.05s	 (3.45-17.55),	 p<0.001).	 At	 the	 last	 visit	 for	 the	 study	 toe,	
there	 was	 no	 longer	 a	 significant	 difference	 between	 the	 groups	 however	 the	 difference	
remained	on	the	study	dorsum.	There	were	no	significant	differences	between	the	groups	in	
the	non-study	leg	(Table	5.7-8).	
When	the	baseline	results	were	compared	to	the	last	results	(Table	5.7-9	and	Figure	5.7-1	
to	Figure	5.7-4)	there	was	a	significant	increase	in	the	TtM	in	the	DTL	group	for	all	patients	
(13.4s	 (3.68-73.85)	 vs	 27.08s	 (8.5-154.38),	 p=0.021)	 and	 those	 that	 healed	 (13.4s	 (6.33-
73.85)	 vs	 64.43	 (22.5-114.2),	 p=0.028).	 This	 was	 true	 for	 the	 study	 toe	 but	 only	 for	 all	
patients	combined	on	the	study	dorsum.	In	the	PCA	group,	there	was	a	decrease,	this	only	
reached	 significance	 in	 the	 study	 toe	 healed	 group	 (210.5	 (72.18-231)	 vs	 50.71	 (105.18-
105.18),	p=0.046).		
There	 was	 no	 significant	 difference	 between	 the	 baseline	 results	 and	 the	 second	 visit	
results	(Table	5.7-10	and	Figure	5.7-5	to	Figure	5.7-8)	apart	from	on	the	study	dorsum	in	the	
DTL	 unhealed	 group	where	 there	was	 a	 significant	 increase	 in	 TtM	 (11.2s	 (3.83-21.35)	 vs	
20.38s	(9.78-209.2),	p=0.043).		
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There	was	 no	 significant	 difference	 between	 the	 patients	who	had	healed	 by	 their	 last	
visit	and	those	who	did	not	(Table	5.7-11	and	Figure	5.7-9	to	Figure	5.7-12)	apart	from	in	one	
instance.	 In	 the	DTL	group	on	the	study	dorsum	at	 the	second	visit,	 those	 in	 the	unhealed	
group	had	a	significantly	longer	TtM	(3.09s	(2.15-5.28)	vs	20.38	(9.78-209.2),	p=0.030).		
When	the	study	leg	was	compared	to	the	non-study	leg,	both	on	the	toe	and	the	dorsum,	
there	was	a,	non-significant,	 longer	TtM	 in	 the	non-study	 leg	 in	 the	DTL	group	at	baseline	
(13.4s	(3.68-73.85)	vs	38.98s	(12.68-141.05),	p=0.158	and	8.05s	(3.45-17.55)	vs	15.4s	(3.58-
116.9),	p=0.300).	In	the	PCA	group,	the	TtM	was	shorter	in	the	non-study	leg.	On	the	toe	this	
was	significant	at	baseline	(220.8s	(200.2-288.78)	vs	54.8s	(13.95-127.43),	p=0.028)	but	not	
at	the	last	visit	(54.5s	(34.73-158)	vs	35.33s	(15.85-146.280,	p=0.612)	(Table	5.7-12	and	Table	
5.7-13).	
Table	5.7-8:	Post	occlusive	reactive	hyperaemia	Time	to	Maximum	Flux	(s)	by	group	
	
Diabetic	Tissue	Loss	
Median	(IQR)	
(n=14)	
Percutaneous	
Angioplasty	
Median	(IQR)	
(n=9)	
p-
value*	
Study	toe	 Baseline	 13.40	(3.68-73.85)	 220.80	(200.20-288.78)	 0.002	
Last	 27.08	(8.50-154.38)	 54.50	(34.73-158.00)	 0.442	
%	Change	 94.47	(18.87-328.06)	 -42.14	(-80.90--2.17)	 0.001	
Study	
Dorsum	
Baseline	 8.05	(3.45-17.55)	 220.28	(93.65-279.80)	 <0.001	
Last	 13.50	(4.95-20.38)	 127.78	(30.08-227.13)	 0.015	
%	Change	 43.48	(-16.85-253.10)	 -20.03	(-64.01-84.71)	 0.126	
Non-study	
Toe	
Baseline	 38.98	(12.68-141.05)	 54.80	(13.95-127.43)	 0.689	
Last	 18.83	(11.83-215.65)	 35.33	(15.85-146.28)	 0.596	
%	Change	 47.32	(-11.92-115.76)	 2.92	(-72.27-196.30)	 0.884	
Non-study	
Dorsum	
Baseline	 15.40	(3.58-116.90)	 70.68	(31.10-138.60)	 0.149	
Last	 15.40	(12.13-215.65)	 119.03	(42.43-265.28)	 0.122	
%	Change	 278.23	(-38.48-801.20)	 -39.97	(-45.04-43.51)	 0.221	
*Independent-Samples	Mann-Whitney	U	Test	
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Table	5.7-9:	Post	occlusive	 reactive	hyperaemia	Time	 to	Maximum	Flux	 (s)	 baseline	 visit	
compared	to	last	visit	
	 Baseline	Value	
Median	(IQR)	
Last	Value	
Median	(IQR)	
p-
value*	
St
ud
y	
to
e	
DTL	 All	(14/11)	 13.40	(3.68-73.85)	 27.08	(8.50-154.38)	 0.021	
Healed	(6/6)	 13.40	(6.33-73.85)	 64.43	(22.05-114.20)	 0.028	
Unhealed	(8/5)	 27.78	(3.44-83.36)	 9.68	(8.50-154.38)	 0.345	
PCA	 All	(9/8)	 220.80	(200.20-288.78)	 54.50	(34.73-158.00)	 0.050	
Healed	(6/6)	 210.50	(72.18-231.00)	 50.71	(27.38-105.18)	 0.046	
Unhealed	(3/2)	 288.78	(204.98-288.78)	 141.08	(49.65-232.50)	 0.593	
St
ud
y	
Do
rs
um
	 DTL	 All	(14/11)	 8.05	(3.45-17.55)	 13.50	(4.95-20.38)	 0.041	
Healed	(6/6)	 5.23	(2.85-9.28)	 13.15	(5.68-13.60)	 0.345	
Unhealed	(8/5)	 11.25	(3.83-21.35)	 20.38	(4.95-192.98)	 0.080	
PCA	 All	(9/7)	 220.28	(93.65-279.80)	 127.78	(30.08-227.13)	 0.398	
Healed	(6/6)	 198.79	(69.18-287.33)	 175.76	(105.20-227.13)	 0.753	
Unhealed	(3/1)	 220.28	(93.65-271.38)	 30.08	 0.655	
N
on
-s
tu
dy
	T
oe
	 DTL	 All	(14/11)	 38.98	(12.68-141.05)	 18.83	(11.83-215.65)	 0.182	
Healed	(6/6)	 38.98	(12.68-262.10)	 87.20	(18.83-291.13)	 0.600	
Unhealed	(8/5)	 34.05	(10.68-123.23)	 11.83	(11.68-15.53)	 0.080	
PCA	 All	(7/7)	 54.80	(13.95-127.43)	 35.33	(15.85-146.28)	 0.917	
Healed	(4/5)	 34.38	(8.66-62.28)	 69.55	(35.33-146.28)	 0.273	
Unhealed	(3/2)	 127.43	(54.72-237.73)	 15.51	(15.18-15.85)	 0.593	
N
on
-s
tu
dy
	
Do
rs
um
	
DTL	 All	(14/11)	 15.40	(3.58-116.90)	 70.68	(31.10-138.60)	 0.149	
Healed	(6/6)	 10.20	(2.30-55.38)	 17.05	(12.13-142.95)	 0.463	
Unhealed	(8/5)	 15.56	(5.91-117.88)	 13.90	(12.88-215.65)	 0.225	
PCA	 All	(7/6)	 70.68	(31.10-138.60)	 119.03	(42.43-265.28)	 0.686	
Healed	(4/5)	 91.74	(58.41-125.70)	 161.88	(76.18-265.28)	 0.715	
Unhealed	(3/1)	 31.1	(13.23-273.90)	 17.23	 0.180	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Figure	5.7-1:	Time	to	maximum	flux	on	study	toe.	Baseline	compared	to	last	visit.	
	
	
Figure	5.7-2:	Time	to	maximum	flux	on	study	dorsum.	Baseline	compared	to	last	visit.	
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Figure	5.7-3:	Time	to	maximum	flux	on	non-study	toe.	Baseline	compared	to	last	visit.	
	
	
Figure	5.7-4:	Time	to	maximum	flux	on	non-study	dorsum.	Baseline	compared	to	last	visit.	
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Table	5.7-10:	Post	occlusive	reactive	hyperaemia	Time	to	Maximum	Flux	(s)	baseline	visit	
compared	to	second	visit	
	
Baseline	Value	
Median	(IQR)	
Second	Value	
Median	(IQR)	
p-
value*	
St
ud
y	
to
e	
DTL	 All	(14/11)	 13.40	(3.68-73.85)	 11.08	(4.40-27.08)	 0.722	
Healed	(6/6)	 13.40	(6.33-73.85)	 19.19	(6.83-27.08)	 0.753	
Unhealed	(8/5)	 27.78	(3.44-83.36)	 8.50	(4.28-11.08)	 0.686	
PCA	 All	(9/8)	 220.80	(200.20-288.78)	 53.79	(18.09-205.16)	 0.123	
Healed	(6/6)	 210.50	(72.18-231)	 53.79	(27.38-177.83)	 0.116	
Unhealed	(3/2)	 288.78	(204.98-288.78)	 120.65	(8.8-232.5)	 0.655	
St
ud
y	
Do
rs
um
	 DTL	 All	(14/11)	 8.05	(3.45-17.55)	 5.28	(2.50-20.38)	 0.182	
Healed	(6/6)	 5.23	(2.85-9.28)	 3.09	(2.15-5.28)	
	
0.600	
Unhealed	(8/5)	 11.25	(3.83-21.35)	 20.38	(9.78-209.2)	 0.043	
PCA	 All	(9/7)	 220.28	(93.65-279.80)	 127.78	(55.05-227.13)	 0.398	
Healed	(6/6)	 198.79	(69.18-287.33)	 142.33	(80.13-227.13)	 0.753	
Unhealed	(3/1)	 220.28	(93.65-271.38)	 55.05	 0.317	
N
on
-s
tu
dy
	T
oe
	 DTL	 All	(14/11)	 38.98	(12.68-141.05)	 12.23	(8.73-120.95)	 0.790	
Healed	(6/6)	 38.98	(12.68-262.10)	 15.53	(6.98-120.95)	 0.345	
Unhealed	(8/5)	 34.05	(10.68-123.23)	 11.83	(11.68-105.38)	 0.080	
PCA	 All	(7/7)	 54.80	(13.95-127.43)	 30.03	(15.18-69.55)	 0.600	
Healed	(4/5)	 34.38	(8.66-62.28)	 65.4	(30.03-69.55)	 0.465	
Unhealed	(3/2)	 127.43	(54.73-237.73)	 10.85	(6.53-15.18)	 0.180	
N
on
-s
tu
dy
	
Do
rs
um
	
DTL	 All	(14/10)	 15.40	(3.58-116.90)	 24.15	(12.88-118.20)	 0.114	
Healed	(6/5)	 10.20	(2.30-55.38)	 18.7	(18.15-102.18)	 0.500	
Unhealed	(8/5)	 15.56	(5.91-117.88)	 29.6	(12.88-234.58)	 0.138	
PCA	 All	(7/6)	 70.68	(31.10-138.60)	 70.63	(60.08-243.90)	 0.500	
Healed	(4/5)	 91.74	(58.41-125.7)	 76.18	(65.08-243.9)	 1.000	
Unhealed	(3/1)	 31.1	(13.23-273.9)	 60.08	 0.317	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Figure	5.7-5:	Time	to	maximum	flux	on	study	toe.	Baseline	compared	to	second	visit.	
	
	
Figure	5.7-6:	Time	to	maximum	flux	on	study	dorsum.	Baseline	compared	to	second	visit.	
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Figure	5.7-7:	Time	to	maximum	flux	on	non-study	toe.	Baseline	compared	to	second	visit.	
	
	
Figure	5.7-8:	Time	to	maximum	flux	on	non-study	dorsum.	Baseline	compared	to	second	
visit.	
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Table	 5.7-11:	 Post	 occlusive	 reactive	 hyperaemia	 Time	 to	 Maximum	 Flux	 (s),	 healed	
compared	to	unhealed	patients	
	
Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-
value*	
St
ud
y	
to
e	
DTL	 Baseline	(6/8)	 13.40	(6.33-73.85)	 27.78	(3.44-83.36)	 0.662	
Second	(6/5)	 19.19	(6.83-27.08)	 8.50	(4.28-11.08)	 0.429	
Last	(6/5)	 64.43	(22.05-114.20)	 9.68	(8.50-154.38)	 0.792	
PCA	 Baseline	(6/3)	 210.50	(72.18-231.00)	 288.78	(204.98-288.78)	 0.381	
Second	(6/2)	 53.79	(27.38-177.83)	 120.65	(8.80-232.50)	 1.000	
Last	(6/2)	 50.71	(27.38-105.18)	 141.08	(49.65-232.50)	 0.429	
St
ud
y	
Do
rs
um
	 DTL	 Baseline	(6/8)	 5.23	(2.85-9.28)	 11.25	(3.83-21.35)	 0.282	
Second	(6/5)	 3.09	(2.15-5.28)	 20.38	(9.78-209.20)	 0.030	
Last	(6/5)	 13.15	(5.68-13.60)	 20.38	(4.95-192.98)	 0.429	
PCA	 Baseline	(6/3)	 198.79	(69.18-287.33)	 220.28	(93.65-271.38)	 1.000	
Second	(6/1)	 142.33	(80.13-227.13)	 55.05	 0.571	
Last	(6/1)	 175.76	(105.20-227.13)	 30.08	 0.571	
N
on
-s
tu
dy
	T
oe
	 DTL	 Baseline	(6/8)	 38.98	(12.68-262.10)	 34.05	(10.68-123.23)	 0.662	
Second	(6/5)	 15.53	(6.98-120.95)	 11.83	(11.68-105.38)	 0.931	
Last	(6/5)	 87.20	(18.83-291.13)	 11.83	(11.68-15.53)	 0.082	
PCA	 Baseline	(4/3)	 34.38	(8.66-62.28)	 127.43	(54.73-237.73)	 0.299	
Second	(5/2)	 65.40	(30.03-69.55)	 10.85	(6.53-15.18)	 0.095	
Last	(5/2)	 69.55	(35.33-146.28)	 15.51	(15.18-15.85)	 0.095	
N
on
-s
tu
dy
	
Do
rs
um
	
DTL	 Baseline	(6/8)	 10.20	(2.30-55.38)	 15.56	(5.91-117.88)	 0.491	
Second	(5/5)	 18.70	(18.15-102.18)	 29.60	(12.88-234.58)	 0.690	
Last	(6/5)	 17.05	(12.13-142.95)	 13.90	(12.88-215.65)	 1.000	
PCA	 Baseline	(4/3)	 91.74	(58.41-125.70)	 31.1	(13.23-273.9)	 0.629	
Second	(5/1)	 76.18	(65.08-243.90)	 60.08	 0.667	
Last	(5/2)	 161.88	(76.18-265.28)	 17.23	 0.333	
*Independent	Samples	Mann-Whitney	U	Test,	(n=healed/n=unhealed)	
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Figure	5.7-9:	Healed	patients	compared	to	unhealed	patients	at	baseline,	second	visit	and	
last	visit,	study	toe.	
	
	
Figure	5.7-10:	Healed	patients	compared	to	unhealed	patients	at	baseline,	second	visit	and	
last	visit,	study	dorsum.	
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Figure	5.7-11:	Healed	patients	compared	to	unhealed	patients	at	baseline,	second	visit	and	
last	visit,	non-study	toe.	
	
	
Figure	5.7-12:	Healed	patients	compared	to	unhealed	patients	at	baseline,	second	visit	and	
last	visit,	non-study	dorsum.	
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Table	5.7-12:	Time	to	maximum	flux	on	toe,	study	leg	compared	to	non-study	leg	
	 Study	Leg	
Median	(IQR)	
Non-study	Leg	
Median	(IQR)	
p-value*	
DTL	 Baseline	(14/14)	 13.40	(3.68-73.85)	 38.98	(12.68-141.05)	 0.158	
Last	(11/11)	 27.08	(8.50-154.38)	 18.83	(11.83-215.65)	 0.656	
PCA	 Baseline	(9/7)	 220.80	(200.20-288.78)	 54.80	(13.95-127.43)	 0.028	
Last	(8/7)	 54.50	(34.73-158.00)	 35.33	(15.85-146.28)	 0.612	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=study	leg/n=non-study	leg)	
	
Table	5.7-13:	Time	to	maximum	flux	on	dorsum,	study	leg	compared	to	non-study	leg	
	 Study	Leg	
Median	(IQR)	
Non-study	Leg	
Median	(IQR)	
p-value*	
DTL	 Baseline	(14/14)	 8.05	(3.45-17.55)	 15.40	(3.58-116.90)	 0.300	
Last	(11/11)	 13.50	(4.95-20.38)	 15.40	(12.13-215.65)	 0.374	
PCA	 Baseline	(9/7)	 220.28	(93.65-279.80_	 70.68	(31.10-138.60)	 0.237	
Last	(7/6)	 127.78	(30.08-227.13)	 119.03	(42.43-265.28)	 0.753	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=study	leg/n=non-study	leg)	
	
5.7.5. Skin	Perfusion	Pressure	
At	 baseline,	 on	 both	 the	 study	 (76.2mmHg	 (60.2-102.1)	 vs	 46.8mmHg	 (10.1-52.8),	
p=0.036)	 and	 non-study	 leg	 (82.8mmHg	 (72.2-88.8)	 vs	 37.1	 (10.1-57),	 p=0.007),	 the	 PCA	
group	had	a	significantly	lower	SPP.	The	difference	remained	but	was	not	significant	by	the	
last	visit	(Table	5.7-14)	
There	no	significant	difference	between	the	baseline	SPP	and	the	second	or	last	visit	apart	
from	in	three	areas.	On	the	non-study	leg	in	the	DTL	group	the	SPP	was	significantly	higher	
for	 the	 unhealed	 patients	 at	 both	 the	 second	 (77.6mmHg	 (63-91.4)	 vs	 91.5mmHg	 (54.1-
103.2),	p=0.043)	and	last	visit	(77.6mmHg	(63-91.4)	vs	97.6mmHg	(91.5-103.2),	p=0.043).	On	
the	 study	 leg	 in	 the	 DTL	 group	 the	 healed	 patients	 had	 a	 significantly	 lower	 SPP	 at	 the	
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second	 visit	 (98.8mmHg	 (76.1-143.8)	 vs	 66.7mmHg	 (33.6-86.5),	 p=0.046),	 significance	was	
not	 reached	 at	 the	 last	 visit	 (98.8mmHg	 (76.1-143.8)	 vs	 71.5mmHg	 (45.8-98.5),	 p=0.345)	
(Table	5.7-15	and	Table	5.7-16).	
There	was	no	significant	difference	in	SPP	between	those	patients	who	healed	and	those	
who	did	not.	The	median	SPP	for	those	that	healed	in	the	DTL	group	was	98.8mmHg	(76.1-
143.8)	 and	 those	 that	 did	 not	 heal	 74.6mmHg	 (52.3-86.6,	 p=0.138).	 In	 the	 PCA	 group	 the	
value	 for	 those	 that	 healed	 was	 49.9mmHg	 (28.55-85.9)	 and	 for	 those	 that	 did	 not	 heal	
28.3mmHg	(10.1-46.5,	p=0.267)	(Table	5.7-17).	
There	was	no	significant	difference	between	the	study	and	non-study	leg	in	the	DTL	group	
or	the	PCA	group	at	baseline.	In	the	PCA	group,	the	SPP	was	significantly	higher	in	the	non-
study	leg	at	the	last	visit	(Table	5.7-18).	
	
Table	5.7-14:	Skin	Perfusion	Pressure	(mmHg)	by	group	
	
Diabetic	Tissue	Loss	
Median	(IQR)	
Percutaneous	
Angioplasty	
Median	(IQR)	
p-
value*	
Study	Leg	
Baseline	(13/6)	 76.20	(60.20-102.10)	
	
46.80	(10.10-52.80)	
	
0.036	
Last	(11/6)	 82.30	(45.80-99.50)	
	
47.50	(38.70-75.60)	
	
0.122	
%	Change	(11/4)	 -6.37	(-68.15-30.75)	
	
22.29	(-31.59-217.32)	
	
0.571	
Non-
Study	Leg	
Baseline	(14/7)	 82.80	(72.20-88.80)	
	
37.10	(10.10-57.00)	
	
0.007	
Last	(10/5)	 94.30	(83.40-99.00)	
	
60.30	(57.90-94.80)	
	
0.594	
%	Change	(10/4)	 13.49	(0.56-36.87)	
	
171.60	(54.24-401.56)	
	
0.054	
*Independent-Samples	Mann-Whitney	U	Test,	(n=DTL/n=PCA)	
	
	
	
	138	
	
Table	5.7-15:	Skin	Perfusion	Pressure	(mmHg)	by	baseline	visit	compared	to	second	visit	
	 Baseline	value	
Median	(IQR)	
Second	value	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 All	(13/11)	 76.20	(60.20-102.10)	
	
82.30	(37.50-95.60)	
	
0.374	
Healed	(6/6)	 98.80	(76.10-143.80)	 66.70	(33.60-86.50)	 0.046	
Unhealed	(7/5)	 74.60	(52.03-85.60)	
	
92.00	(82.30-95.60)	
	
0.225	
PCA	 All	(6/6)	 46.80	(10.10-52.80)	
	
48.40	(44.00-61.60)	
	
0.715	
Healed	(4/6)	 49.90	(28.55-85.90)	 48.35	(44.00-61.60)	 0.715	
Unhealed	(2/0)	 28.30	(10.10-46.50)	
	
-	
	
-	
Non-
Study	
Leg	
DTL	 All	(14/10)	 82.80	(72.20-88.80)	
	
91.50	(60.80-103.20)	
	
0.110	
Healed	(6/5)	 84.70	(82.00-88.80)	
	
89.70	(83.00-96.30)	
	
0.753	
Unhealed	(8/5)	 77.60	(63.00-91.40)	
	
91.50	(54.10-103.20)	
	
0.043	
PCA	 All	(7/5)	 37.10	(10.10-57.00)	
	
60.30	(48.40-64.80)	
	
0.068	
Healed	(4/5)	 32.30	(18.80-49.70)	 60.30	(48.40-64.80)	 0.068	
Unhealed	(3/0)	 50.30	(10.10-57.00)	 -	
	
-	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=baseline/n=last	value)	
	
Table	5.7-16:	Skin	Perfusion	Pressure	(mmHg)	by	baseline	visit	compared	to	last	visit	
	 Baseline	value	
Median	(IQR)	
Last	value	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 All	(13/11)	 76.20	(60.20-102.10)	
	
82.30	(45.80-99.50)	
	
0.722	
Healed	(6/6)	 98.80	(76.10-143.80)	 71.50	(45.80-98.50)	
	
0.345	
Unhealed	(7/5)	 74.60	(52.03-85.60)	
	
95.60	(82.30-111.50)	
	
0.500	
PCA	 All	(6/6)	 46.80	(10.10-52.80)	
	
47.50	(38.70-75.60)	
	
1.000	
Healed	(4/6)	 49.90	(28.55-85.90)	 47.45	(38.70-75.60)	 1.000	
Unhealed	(2/0)	 28.30	(10.10-46.50)	
	
-	
	
-	
Non-
Study	
Leg	
DTL	 All	(14/10)	 82.80	(72.20-88.80)	
	
94.30	(83.4-099.00)	
	
0.169	
Healed	(6/5)	 84.70	(82.00-88.80)	
	
92.10	(83.40-96.40)	
	
0.686	
Unhealed	(8/5)	 77.60	(63.00-91.40)	
	
97.60	(91.50-103.20)	
	
0.043	
PCA	 All	(7/5)	 37.10	(10.10-57.00)	
	
60.30	(57.90-94.80)	
	
0.068	
Healed	(4/5)	 32.30	(18.80-49.70)	 60.30	(57.90-94.80)	 0.068	
Unhealed	(3/0)	 50.30	(10.10-57.00)	 -	
	
-	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=baseline/n=last	value)	
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Table	5.7-17:	 Skin	Perfusion	Pressure	 (mmHg)	by	healed	patients	 compared	 to	unhealed	
patients	
	 Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 Baseline	(6/7)	 98.80	(76.10-143.80)	 74.60	(52.30-85.60)	 0.138	
Second	(6/5)	 66.70	(33.60-86.50)	 92.00	(82.30-95.60)	 0.247	
Last	(6/5)	 71.50	(45.80-98.50)	 95.60	(82.30-111.50)	 0.429	
PCA	 Baseline	(4/2)	 49.9	(28.55-85.9)	 28.3	(10.1-46.5)	 0.267	
Second	(6/0)	 48.35	(44-61.6)	 -	 -	
Last	(6/0)	 47.45	(38.7-75.6)	 -	 -	
Non-
Study	
Leg	
DTL	 Baseline	(6/8)	 84.70	(82.00-88.80)	 77.60	(63.00-91.40)	 0.414	
Second	(6/5)	 89.70	(83.00-96.30)	 91.50	(54.10-103.20)	 0.792	
Last	(5/5)	 92.10	(83.40-96.40)	 97.60	(91.50-103.20)	 0.421	
PCA	 Baseline	(4/3)	 32.3	(18.8-49.7)	 50.3	(10.1-57)	 0.857	
Second	(5/0)	 60.3	(48.4-64.8)	 -	 -	
Last	(5/0)	 60.3	(57.9-94.8)	 -	 -	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=baseline/n=last	value)	
	
Table	5.7-18:	Skin	Perfusion	Pressure	(mmHg)	study	leg	compared	to	non-study	leg	
	 Study	Leg	
Median	(IQR)	
Non-study	Leg	
Median	(IQR)	
p-value*	
DTL	 Baseline	(13/14)	 76.20	(60.20-102.10)	 82.80	(72.2-88.80)	 0.402	
Last	(11/10)	 82.30	(45.80-99.50)	 94.30	(83.40-99.00)	 0.285	
PCA	 Baseline	(6/7)	 46.80	(10.10-52.80)	 37.10	(10.10-57.00)	 0.715	
Last	(6/5)	 47.50	(38.70-75.60)	 60.30	(57.90-94.80)	 0.028	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=study	leg/n=non-study	leg)	
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5.7.6. Toe	Blood	Pressure		
At	baseline	the	PCA	group	had	significantly	 lower	TBP	 in	both	the	study	 leg	 (92.7mmHg	
(74.1-133.3)	 vs	 50.3mmHg	 (31.4-79),	 p=0.031)	 and	 the	 non-study	 leg	 (100.3mmHg	 (67.5-
122.2)	vs	40.6mmHg	(35.9-41.5),	p=0.046).	 It	remained	lower	at	the	last	visit	for	both	legs,	
but	the	difference	was	no	longer	significant	in	the	study	leg	(Table	5.7-19).		
There	was	no	significant	difference	between	the	baseline	and	second	visit	or	last	visit	 in	
either	group	with	one	exception.	In	the	PCA	group	on	the	non-study	leg	at	the	last	visit,	the	
median	 TBP	 was	 significantly	 higher	 than	 at	 baseline	 (37.1mmHg	 (10.1-57)	 vs	 60.3mmHg	
(57.9-94.8),	p=0.043)	(Table	5.7-20	and	Table	5.7-21).		
Between	healed	and	unhealed	patients	no	significant	difference	was	found.	At	baseline	in	
the	DTL	group	those	who	healed	(117.4mmHg	(107.2-133.3)	had	a	higher	median	TBP	than	
those	who	did	not	heal	 (74.8mmHg	 (64.2-124.2),	p=0.142).	This	pattern	was	 similar	at	 the	
second	 visit,	 but	 by	 the	 last	 visit	 it	 had	 reversed	 (89.3mmHg	 (57.9-125.4)	 vs	 119.9mmHg	
(96.9-144.3),	 p=0.556).	 In	 the	PCA	group,	 the	 values	 stayed	 very	 similar	 at	 all	 visits	 (Table	
5.7-22).	
When	the	study	and	non-study	 leg	were	compared	 in	the	PCA	group,	 the	non-study	 leg	
had	a	significantly	 lower	result	at	the	 last	visit	 (74.9mmHg	(72.6-95.5)	vs	59.7mmHg	(55.7-
70.8),	p=0.028)	(Table	5.7-23).	
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Table	5.7-19:	Toe	Blood	Pressure	(mmHg)	by	group	
	
Diabetic	Tissue	Loss	
Median	(IQR)	
	
Percutaneous	
Angioplasty	
Median	(IQR)	
	
p-
value*	
Study	
Leg	
Baseline	(14/7)	 92.70	(74.10-133.30)	
	
50.30	(31.40-79.00)	
	
0.031	
Last	(9/6)	 112.60	(81.10-127.30)	
	
74.90	(72.60-95.50)	
	
0.388	
%	Change	(9/5)	 5.56	(-25.21-25.88)	 25.99	(-23.67-51.29)	 0.438	
Non-
Study	
Leg	
Baseline	(13/5)	 100.30	(67.50-122.20)	
	
40.60	(35.90-41.50)	
	
0.046	
Last	(11/6)	 105.90	(75.80-133.60)	
	
59.70	(55.70-70.80)	
	
0.027	
%	Change	(11/5)	 9.33	(-13.56-53.04)	 56.55	(24.88-70.60)	 0.115	
*Independent-Samples	Mann-Whitney	U	Test,	(n=DTL/n=PCA)	
	
Table	5.7-20:	Toe	Blood	Pressure	(mmHg)	by	baseline	visit	compared	to	second	visit	
	 Baseline	value	
Median	(IQR)	
Second	value	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 All	(14/10)	 92.70	(74.10-133.30)	 104.20	(60.50-151.70)	
	
0.958	
Healed	(6/5)	 117.40	(107.20-133.30)	
	
132.60	(60.50-151.70)	
	
0.500	
Unhealed	(8/5)	 74.80	(64.20-124.20)	
	
81.10	(79.00-127.30)	
	
0.893	
PCA	 All	(7/6)	 50.30	(31.40-79.00)	
	
76.90	(72.60-81.40)	
	
0.345	
Healed	(4/5)	 63.10	(42.30-89.00)	 73.70	(72.60-80.10)	 0.465	
Unhealed	(3/1)	 31.40	(23.30-79.00)	 81.40	
	
0.317	
Non-
Study	
Leg	
DTL	 All	(13/11)	 100.30	(67.50-122.20)	 104.70	(75.80-127.90)	
	
0.722	
Healed	(6/6)	 119.80	(93.30-136.60)	
	
114.90	(75.80-127.90)	
	
0.600	
Unhealed	(7/5)	 99.80	(54.50-110.50)	
	
86.70	(76.50-118.40)	
	
0.500	
PCA	 All	(7/6)	 40.60	(35.90-41.50	 59.40	(53.40-73.90)	
	
0.345	
Healed	(4/5)	 38.70	(34.00-65.70)	 63.10	(55.70-73.90)	 0.465	
Unhealed	(3/1)	 40.60	(40.60-40.60)	 53.40	
	
0.317	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=baseline/n=second	value)	
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Table	5.7-21:	Toe	Blood	Pressure	(mmHg)	by	baseline	visit	compared	to	last	visit	
	 Baseline	value	
Median	(IQR)	
Last	value	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 All	(14/9)	 92.70	(74.10-133.30)	 112.60	(81.10-127.30)	 0.859	
Healed	(6/5)	 117.40	(107.20-133.30)	
	
89.30	(57.90-125.40)	 0.345	
Unhealed	(8/4)	 74.80	(64.20-124.20)	
	
119.90	(96.90-144.30)	
	
0.465	
PCA	 All	(6/6)	 50.30	(31.40-79.00)	
	
74.90	(72.6-95.5)	 0.500	
Healed	(4/5)	 63.10	(42.30-89.00)	 76.10	(73.70-95.50)	 0.465	
Unhealed	(3/1)	 31.40	(23.30-79.00)	 60.30	
	
0.317	
Non-
Study	
Leg	
DTL	 All	(13/11)	 100.30	(67.50-122.20)	 105.90	(75.80-133.60)	 0.285	
Healed	(6/6)	 119.80	(93.30-136.60)	
	
119.80	(75.80-142.70)	
	
0.345	
Unhealed	(7/5)	 99.80	(54.50-110.50)	
	
86.70	(81.90-118.40)	
	
0.225	
PCA	 All	(7/6)	 40.60	(35.90-41.50)	
	
59.70	(55.70-70.80)	 0.043	
Healed	(4/5)	 38.70	(34.00-65.70)	 63.10	(56.20-70.80)	 0.068	
Unhealed	(3/1)	 40.60	(40.60-40.60)	 50.70	
	
0.317	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=baseline/n=last	value)	
	
Table	 5.7-22:	 Toe	 Blood	 Pressure	 (mmHg)	 by	 healed	 patients	 compared	 to	 unhealed	
patients	
	 Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 Baseline	(6/8)	 117.40	(107.20-133.30)	 74.80	(64.20-124.20)	 0.142	
Second	(5/5)	 132.60	(60.50-151.70)	 81.10	(79.00-127.30)	 0.841	
Last	(5/4)	 89.30	(57.90-125.40)	 119.90	(96.90-144.30)	 0.556	
PCA	 Baseline	(4/3)	 63.10	(42.30-89.00)	 31.40	(23.30-79.00)	 0.400	
Second	(5/1)	 73.70	(72.60-80.10)	 81.40	 0.667	
Last	(5/1)	 76.10	(73.70-95.50)	 60.30	 0.333	
Non-
Study	
Leg	
DTL	 Baseline	(6/7)	 119.80	(93.30-136.60)	 99.80	(54.50-110.50)	 0.295	
Second	(6/5)	 114.90	(75.80-127.90)	 86.70	(76.50-118.40)	 1.000	
Last	(6/5)	 119.80	(75.80-142.70)	 86.70	(81.90-118.40)	 0.537	
PCA	 Baseline	(4/1)	 38.70	(34.00-65.70)	 40.60	 1.000	
Second	(5/1)	 63.10	(55.70-73.90)	 53.40	 0.667	
Last	(5/1)	 63.10	(56.20-70.80)	 50.70	 0.333	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=healed/n=unhealed)	
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Table	5.7-23:	Toe	Blood	Pressure	(mmHg)	study	leg	compared	to	non-study	leg	
	 Study	Leg	
Median	(IQR)	
Non-study	Leg	
Median	(IQR)	
p-value*	
DTL	 Baseline	(14/13)	 92.70	(74.10-133.30)	 100.30	(67.50-122.20)	 0.422	
Last	(9/11)	 112.60	(81.10-127.30)	 105.90	(75.80-133.60)	 0.859	
PCA	 Baseline	(7/5)	 50.30	(31.40-79.00)	 40.60	(35.90-41.50)	 0.345	
Last	(6/6)	 74.90	(72.60-95.50)	 59.70	(55.70-70.80)	 0.028	
*Related-Samples	Wilcoxon	Signed	Rank	Test,	(n=study	leg/n=non-study	leg)	
	
5.7.7. Neuropathy	
5.7.7.1. Vibration	Perception	Threshold	
There	was	no	significant	difference	in	VPT	between	the	groups	at	baseline	or	the	last	visit,	
the	 median	 VPT	 in	 the	 DTL	 group	 at	 baseline	 was	 31.13V	 (29-38.5)	 compared	 to	 42.25V	
(31.5-45)	in	the	PCA	group	(p=0.141).	The	binary	analysis	demonstrated	the	large	majority	of	
patients	in	both	groups	had	an	abnormal	VPT,	78.6%	at	baseline	in	the	DTL	group	and	88.9%	
in	 the	 PCA	 group	 (p=0.237).	 The	 levels	 were	 similar	 at	 the	 last	 visit	 (DTL	 90.9%	 and	 PCA	
85.7%,	p=0.237)	and	on	the	non-study	leg	(baseline	71.4%	vs	87.5%,	p=0.380	and	last	81.8%	
vs	83.3%,	p=0.728).	Whether	 the	patient	went	on	 to	heal	 or	not,	 there	was	no	 significant	
difference	between	the	baseline	and	the	last	VPT	(Table	5.7-24).	
Between	 the	 study	 and	 the	 non-study	 leg,	 there	 was	 no	 significant	 difference	 in	 the	
results.	The	median	VPT	for	 the	study	 leg	at	baseline	 in	 the	DTL	group	was	31.13V	(29.00-
38.5)	and	30.63V	(23.25-37.5,	p=0.196),	in	the	non-study	leg.	In	the	PCA	group,	the	baseline	
results	were	 42.25V	 (31.5-45)	 for	 the	 study	 leg	 and	 34V	 (31.08-49,	 p=0.735)	 for	 the	 non-
study.	The	median	VPT	for	DTL	patients	at	baseline	who	healed	was	30.38V	(29-35.5)	and	for	
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those	that	did	not	heal	32V	(24.38-43.88,	p=0.662).	In	the	PCA	group	the	results	were	44.25V	
(31.5-46)	 and	 41.5V	 (25.5-42.25,	 p=0.381)	 respectively.	 There	 was	 also	 no	 significant	
difference	 in	 the	 proportion	 of	 patients	 with	 abnormal	 VPT	 results	 in	 the	 healed	 and	
unhealed	patients.	
Table	 5.7-24:	 Vibration	 Perception	 Threshold	 (V)	 healed	 patients	 compared	 to	 unhealed	
patients	
	 Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-
value*	
Study	
Leg	
DTL	 Baseline	(6/8)	 30.38	(29.00-35.50)	 32.00	(24.38-43.88)	 0.662	
Last	(6/5)	 33.25	(30.75-33.785)	 29.50	(28.00-37.25)	 1.000	
PCA	 Baseline	(6/3)	 44.25	(31.50-46.00)	 41.50	(25.50-42.25)	 0.381	
Last	(6/1)	 42.50	(34.50-49.00)	 39.25	 1.000	
Non-
Study	
Leg	
DTL	 Baseline	(6/8)	 24.13	(15.25-27.75)	 37.25	(30.13-38.13)	 0.043	
Last	(6/5)	 31.00	(26.75-34.00)	 36.25	(26.80-38.00)	 0.537	
PCA	 Baseline	(5/3)	 49.00	(30.90-49.00)	 32.00	(31.25-36.00)	 0.786	
Last	(5/1)	 42.25	(38.25-49.00)	 27.50	 0.667	
*Independent-Samples	Mann-Whitney	U	Test,	(n=healed/n=unhealed)	
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5.7.7.2. Neuropathy	Total	Symptom	Score-6	
The	 median	 NTSS-6	 at	 baseline	 was	 4.49	 (3-8.99)	 in	 the	 DTL	 group	 and	 2.33	 (2-6.99,	
p=0.277)	in	the	PCA	group.	At	the	last	visit,	the	results	were	3.33	(0-7.33)	and	1.83	(0-8.66,	
p=0.840)	respectively.	At	baseline	five	patients	(35.7%)	in	the	DTL	group	had	a	score	of	more	
than	six	(representing	clinically	significant	symptoms)	and	three	patients	(33.3%)	in	the	PCA	
group.	By	 their	 last	 visit,	 this	 number	had	 reduced	 to	 three	 (21.4%)	 in	 the	DTL	 group	and	
remained	three	(33.3%)	in	the	PCA	group	(p=1.000).	At	both	visits	the	differences	between	
the	groups	were	not	statistically	significant.		
When	the	baseline	NTSS-6	was	compared	to	the	last	result,	in	the	DTL	group,	those	who	
healed	 had	 a	 significantly	 lower	 score	 at	 the	 last	 visit	 (3.66	 (1-10.32)	 vs	 0.00	 (0-3.33),	
p=0.043).	Those	who	did	not	heal	had	a	higher	score	at	 the	 last	visit	although	this	did	not	
reach	 significance	 (4.83	 (3.83-7.99)	 vs	 5.66	 (3.66-10.32),	 p=0.458).	 In	 the	 PCA	 group,	 the	
results	for	the	last	visit	(1.83	(0.00-8.66))	were	lower	than	at	baseline	(4.50	(0.00-6.99))	but	
did	 not	 reach	 significance	 (p=0.500).	 In	 the	DTL	 group	71%	of	 patients	who	had	 a	 normal	
baseline	result	also	had	a	normal	last	result,	in	the	PCA	group	this	was	true	of	60%.	
In	 the	 DTL	 group,	 the	 NTSS-6	 results	 for	 the	 unhealed	 patients	 were	 lower	 than	 the	
healed	patients,	although	the	results	did	not	reach	significance.	In	the	PCA	group	the	NTSS-6	
for	 the	 unhealed	 patients	 was	 lower	 but,	 as	 in	 the	 DTL	 group	 did	 not	 reach	 significance	
(Table	5.7-25).		
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Table	5.7-25:Neuropathy	Total	Symptom	Score-6	Healed	compared	to	Unhealed	
	 Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-
value*	
DTL	 Baseline	(6/8)	 3.66	(1.00-10.32)	 4.83	(3.83-7.99)	 0.662	
Last	(6/5)	 0.00	(0.00-3.33)	 5.66	(3.66-10.32)	 0.126	
PCA	 Baseline	(6/3)	 4.50	(0.00-6.99)	 2.33	(2.00-3.00)	 1.000	
Last	(6/2)	 1.83	(0.00-10.33)	 3.50	(0.00-6.99)	 1.000	
*Independent-Samples	Mann-Whitney	U	Test,	(n=healed/n=unhealed)	
5.7.7.3. 10g	Monofilament	
The	results	of	the	10g	monofilament	testing	were	analysed	as	abnormal,	unable	to	detect	
at	least	one	point,	compared	to	normal.	There	was	significant	neuropathy	present	with	50%	
of	patients	in	the	DTL	group	and	55%	in	the	PCA	group	being	unable	to	detect	any	points	at	
baseline.	There	were	no	significant	differences	between	the	groups	at	baseline	or	at	last	visit	
on	the	study	leg	(Table	5.7-26).	
There	was	no	 significant	difference	 in	 the	proportion	of	 patients	with	 abnormal	 results	
when	the	baseline	result	was	compared	to	the	last	result.	On	the	study	leg,	DTL	group,	90%	
of	patients	who	had	an	abnormal	result	at	baseline	also	had	an	abnormal	result	at	the	last	
visit.	 In	 the	PCA	group,	 this	 proportion	was	86%	 (p=1.000	 for	both	 groups).	 There	was	no	
significant	difference	between	the	study	and	non-study	leg	by	group.	
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Table	5.7-26:	Monofilament	on	study	leg	by	group,	baseline	and	last	visit	
	
Group	
p-value*	Diabetic	Tissue	
Loss	(%)	
Percutaneous	
Angioplasty	(%)	
Baseline	
Co
rr
ec
t	
re
sp
on
se
s	 Abnormal	
13	
(92.9)	
8	
(88.9)	
1.000	
Normal	
1	
(7.1)	
1	
(11.1)	
Last	
Co
rr
ec
t	
re
sp
on
se
s	 Abnormal	
9	
(81.8)	
6	
(75.0)	
1.000	
Normal	
2	
(18.2)	
2	
(25.0)	
*Fishers	Exact	Test,	Abnormal	=	³1	incorrect	responses	
5.7.7.4. Ipswich	touch	test	
The	results	of	the	Ipswich	touch	test	were	treated	in	the	same	way	as	the	monofilament	
with	 abnormal	 being	 defined	 as	 unable	 to	 detect	 at	 least	 one	 point.	 Similarly	 to	 the	
monofilament,	the	results	suggested	that	there	was	significant	neuropathy	present.	A	lower	
proportion	of	patients,	compared	to	the	monofilament,	were	unable	to	detect	any	points	at	
baseline,	 29%	 in	 the	 DTL	 group	 and	 33%	 in	 the	 PCA	 group.	 There	 were	 no	 significant	
differences	between	the	groups	at	baseline	or	last	visit	on	the	study	leg	(Table	5.7-27).	
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There	was	no	 significant	difference	 in	 the	proportion	of	 patients	with	 abnormal	 results	
when	the	baseline	result	was	compared	to	 the	 last	 result.	 In	both	groups,	75%	of	patients	
who	had	an	abnormal	result	at	baseline	also	did	at	the	last	visit	(p=1.000).	This	was	similar	
for	both	the	study	leg	and	the	non-study	leg.	
Table	5.7-27:	Binary	Ipswich	Touch	Test	correct	responses	on	study	leg	by	group	baseline	
and	last	visit	
	
Group	
p-value*	Diabetic	Tissue	
Loss	(%)	
Percutaneous	
Angioplasty	(%)	
Baseline	
Co
rr
ec
t	
re
sp
on
se
s	 Abnormal	
10	
(71.4)	
7	
(77.8)	
1.000	
Normal	
4	
(28.6)	
2	
(22.2)	
Last	
Co
rr
ec
t	
re
sp
on
se
s	 Abnormal	
9	
(81.8)	
5	
(71.4)	
1.000	
Normal	
2	
(18.2)	
2	
(28.6)	
*Fishers	Exact	Test,	Abnormal	=	³1	incorrect	responses	
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5.7.8. Outcomes	
5.7.8.1. Procedures	
In	the	PCA	group	seven	of	the	procedures	reported	immediate	technical	success,	Of	the	
two	patients	who	did	not	have	immediate	technical	success,	one	patient	was	found	to	have	
good	 in-line	 flow	 to	 the	 foot	 and	 so	 no	 angioplasty	was	 performed,	 the	 other	 underwent	
thrombolysis	after	a	superficial	femoral	artery	(SFA)	occlusion	was	crossed	and	immediately	
occluded.	 After	 twenty-four	 hours	 thrombolysis	 and	 an	 SFA	 stent,	 in-line	 flow	 to	 the	 foot	
was	achieved.	Only	two	patients	did	not	have	in-line	flow	by	the	end	of	the	procedure,	they	
both	had	patent	peroneal	run-off.	
One	patient	 in	 each	 study	 group	underwent	 a	major	 amputation,	 there	were	no	minor	
amputations	or	deaths	in	the	study	period.	
5.7.8.2. Wound	healing	
Forty-three	percent	of	patients	in	the	DTL	group	healed	by	the	end	of	the	study	and	56%	
of	the	PCA	group	(p=0.836).	The	median	ulcer	area	at	baseline	in	the	DTL	group	was	343mm2	
(80-782)	 and	 270mm2	 (180-1750,	 p=1.000)	 in	 the	 PCA	 group.	 There	 was	 no	 significant	
difference	in	the	ulcer	area	between	groups	at	either	the	second	or	final	visit	(Figure	5.7-13).	
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Figure	5.7-13:	Ulcer	area	(mm2)	by	group	at	baseline,	second	visit	and	last	visit.	
	
In	 the	DTL	group	between	the	first	and	second	visit	 there	was	a	significant	reduction	 in	
ulcer	 area	 (p=0.003)	 but	 not	 in	 the	 PCA	 group	 (p=1.000).	 By	 the	 last	 visit,	 there	 was	 a	
significant	difference	in	both	groups	(Figure	5.7-14).	
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Figure	 5.7-14:	 Ulcer	 area	 by	 group.	 A)	 Baseline	 compared	 to	 second	 visit.	 B)	 Baseline	
compared	to	last	visit.	
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At	baseline	in	the	DTL	group	there	was	no	significant	difference	in	the	ulcer	area	of	those	
patients	 who	 eventually	 healed	 (343mm2	 (234-748))	 compared	 to	 those	 who	 did	 not	
(340mm2	(50-3384),	p=0.755).	Those	in	the	PCA	group	who	healed	had	significantly	smaller	
ulcers	at	baseline	(180mm2	(150-270))	than	those	who	did	not	heal	(3920mm2	(1750-4950),	
p=0.024)	(Figure	5.7-15).	
	
Figure	5.7-15:	Ulcer	area	by	group	at	baseline,	patients	who	went	on	to	heal	compared	to	
those	who	did	not.	
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CHAPTER	6: DISCUSSION	
In	this	chapter	the	results	of	the	preceding	studies	are	summarised	and	considered	in	the	
context	of	the	literature.	Avenues	for	future	study	are	considered.	
6.1. DISTRIBUTION	OF	ARTERIAL	DISEASE	IN	DIABETES	MELLITUS	
The	 distribution	 of	 macrovascular	 disease	 in	 patients	 with	 diabetes	 mellitus	 (DM)	 was	
examined	by	applying	a	semi-quantitative	scoring	system	to	lower	limb	angiograms.	In	total	
437	angiograms	were	examined,	222	in	patients	with	diabetes	and	215	in	patients	without	
diabetes.	
6.1.1. Inter-observer	reliability	of	the	Bollinger	score	
Assessment	 of	 the	 reliability	 of	 the	 Bollinger	 data	 demonstrated	 good	 correlation	
between	 assessors	 with	 good	 internal	 consistency.	 The	 intra-observer	 reliability	 also	
demonstrated	good	correlation	and	internal	consistency	(Sections	3.4.1	and	3.4.2).	
6.1.2. Primary	 Outcome:	 Difference	 between	 median	 Bollinger	 score	 in	 each	
arterial	segment	in	patients	with	DM	compared	to	patients	without	DM.	
When	the	results	were	separated	by	indication	for	procedure	the	only	vessels	that	had	a	
significantly	 different	 burden	 of	 disease	 were	 the	 medial	 and	 lateral	 plantar	 vessels	 in	
patients	with	critical	 ischaemia	 (Table	3.8-4).	Patients	without	DM	had	a	higher	burden	of	
disease	in	these	vessels.	
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Overall	 those	 with	 DM	 had	 a	 higher	 burden	 of	 disease	 throughout	 the	 infra-inguinal	
arterial	 tree	 (median	 total	 Bollinger	 score	 88	 vs	 42)	 this	 difference	 was	 not	 significant	
(p=0.061).		
6.1.3. Secondary	outcome:	Difference	in	short	to	medium	outcomes	
Those	with	DM	had	a	significantly	higher	risk	of	major	and	minor	amputation	and	death	at	
one	 year.	 There	 was	 no	 significant	 difference	 in	 the	 rates	 of	 further	 revascularisation	
procedure	(section	3.8.3).	
6.2. WHAT	 IS	 THE	 RELATIONSHIP	 OF	 REVASCULARISATION	 AND	
IMPROVEMENT	 IN	 MICROCIRCULATION	 TO	 WOUND	 HEALING	 AND	
PERIPHERAL	 NEUROPATHY	 IN	 DIABETIC	 FOOT	 DISEASE?	 AN	
OBSERVATIONAL	COHORT	STUDY.	
Despite	the	small	recruitment	numbers,	it	was	possible	to	address	some	of	the	outcome	
measures	 of	 the	 cohort	 study.	 Regarding	 the	 demographics,	 the	 patients	 in	 the	
percutaneous	angioplasty	group	(PCA)	were	significantly	older	than	the	diabetic	tissue	 loss	
group	(DTL).	There	was	also	significantly	longer	between	visits	in	the	PCA	group.	At	the	third	
visit,	there	appears	to	be	an	increase	in	the	ulcer	area	(Table	5.7-7).	This	is	more	a	reflection	
of	 those	with	 larger	 ulcers	 continuing	 in	 the	 study	 longer	 than	 an	 actual	 increase	 in	 ulcer	
size,	as	Figure	6.2-1	demonstrates	all	but	a	few	patients	had	an	incremental	decrease	in	their	
ulcer	 area.	 The	 three	 patients	 that	 had	 increased	 at	 the	 second	 visit	 were	 all	 in	 the	 PCA	
group.	
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Figure	6.2-1:	Ulcer	area	by	visit	for	individual	study	participants	
6.2.1. Primary	 Outcome:	 Evidence	 of	 difference	 in	 the	 level	 of	 change	 in	 the	
time	to	maximum	flux	between	before	and	after	PCA.	
Despite	 the	 limitations	 of	 the	 study	 there	 was	 the	 suggestion	 that	 improving	 the	
macrocirculation,	by	way	of	PCA	 lead	 to	an	 improvement	 in	 the	microcirculation.	On	both	
the	 study	 toe	 and	 dorsum	 there	 was	 a	 reduction	 in	 the	 time	 to	 maximum	 flux	 (TtM)	
following	 angiography.	 By	 the	 last	 visit	 for	 the	 healed	 group	 on	 the	 study	 toe	 TtM	 had	
significantly	reduced	from	210.5s	(72.18-231)	to	50.71s	(27.38-105.18,	p=0.046).	At	baseline,	
those	 in	the	PCA	group	had	a	significantly	 longer	TtM	than	those	 in	the	DTL	group.	By	the	
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final	visit,	at	the	toe,	there	was	no	significant	difference	between	to	two	groups,	and	there	
had	been	a	large	decrease	in	the	TtM	in	the	PCA	group.	On	the	dorsum,	there	did	remain	a	
significant	difference	between	the	groups	at	 the	 last	visit,	but	the	TtM	had	also	decreased	
(Table	5.7-8	and	Table	5.7-9).	This	was	also	supported	by	the	change	in	TtM	when	the	study	
leg	was	compared	 to	 the	non-study	 leg.	At	baseline	on	 the	 toe	 in	 the	PCA	group,	 the	TtM	
was	significantly	longer	on	the	study	leg;	there	was	no	significant	difference	by	the	last	visit.	
On	the	dorsum,	the	trend	was	similar	although	statistical	significance	was	not	reached	(Table	
5.7-12	and	Table	5.7-13).	Combined	these	results	suggest	that	PCA	improves	TtM	to	a	level	
that	is	comparable	to	that	of	the	DTL	group.	In	the	DTL	group,	the	trends	between	baseline	
and	last	were	in	the	opposite	direction,	of	a	smaller	magnitude	however	the	changes	were	
statistically	 significant.	 Between	 the	 study	 leg	 and	 non-study	 leg,	 the	 trends	 were	 also	
reversed	compared	to	the	PCA	group	but	statistical	significance	was	not	reached.	A	possible	
explanation	for	this	is	a	reduction	in	inflammation	related	to	having	an	active	wound	leading	
to	a	less	pronounced	hyperaemic	response.		
6.2.2. Secondary	Outcomes	
6.2.2.1. Evidence	 of	 difference	 in	 the	 level	 of	 change	 in	 the	 time	 to	maximum	 flux	
between	when	ulceration	active	and	when	ulceration	healed	in	patients	with	DM	and	
no	significant	peripheral	arterial	disease.	
By	the	end	of	the	study,	six	patients	in	the	DTL	group	had	healed.	Of	these	patients	there	
had	been	a	significant	increase	in	the	TtM	by	the	last	visit	(13.4s	vs	64.43s	p=0.028)	on	the	
study	 toe	 and	 a	 non-significant	 increase	 on	 the	 study	 dorsum	 (5.23s	 vs	 13.15s	 p=0.345)	
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(Table	5.7-9).	Using	TtM,	it	was	not	possible	to	identify	patients	at	baseline	who	were	more	
likely	 to	heal;	 there	was	no	 significant	difference	 in	 those	who	healed	 compared	 to	 those	
who	did	not.	On	both	the	study	toe	and	dorsum,	there	was	a	trend	towards	a	longer	TtM	in	
the	unhealed	patients	at	baseline	(Table	5.7-11).	
6.2.2.2. Time	to	wound	healing	
Six	patients	 in	each	group	reached	the	end	point	of	a	healed	ulcer.	The	median	time	to	
healing	 in	days	was	118	 (63-207)	 in	 the	DTL	group	and	147	 (93-162),	 p=0.937)	 in	 the	PCA	
group.	The	PCA	group	appeared	to	be	slightly	slower	to	start	healing	than	the	DTL	group	as	
between	the	first	and	second	visit	there	was	no	significant	difference	in	ulcer	size	whereas	
there	was	a	significant	reduction	by	the	 last	visit.	 In	the	DTL	group,	there	was	a	significant	
reduction	in	size	at	both	the	second	and	last	visits	(Section	5.7.8).		
6.2.2.3. Time	to	major	amputation	
Two	patients	 underwent	major	 amputation	during	 the	 study	period.	 The	patient	 in	 the	
DTL	group	underwent	the	procedure	thirty	days	following	recruitment,	prior	to	their	second	
measurement	for	the	study.	The	patient	in	the	PCA	group	had	one	follow-up	assessment	and	
underwent	the	procedure	at	seventy-seven	days.	
6.2.2.4. The	change	 in	skin	perfusion	pressure	(SPP)	and	toe	blood	pressure	(TBP)	at	
the	end	of	the	study	
While	SPP	was	significantly	lower	at	baseline	in	the	PCA	group	there	was	minimal	change	
between	the	baseline	and	last	values;	this	pattern	was	the	same	for	TBP	(Sections	5.7.5	and	
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5.7.6).	There	were	no	consistent	trends	between	the	groups	or	visits	 for	both	the	SPP	and	
TBP	with	similar	levels	of	difference	being	seen	on	both	the	study	and	non-study	leg.	
6.2.2.5. Change	in	neuropathy	measures	at	the	end	of	the	study	
None	 of	 the	 tests	 used	 to	 assess	 neuropathy	 demonstrated	 any	 significant	 difference	
between	the	groups	or	visits.	There	were	also	no	consistent	trends	within	the	numbers.	The	
only	comparison	with	a	significant	difference	was	in	the	Neuropathy	Total	Symptom	Score	–	
6	(NTSS-6)	results.	The	patients	who	healed	in	the	DTL	group	had	a	significantly	lower	result	
at	 their	 last	 visit	 compared	 to	 baseline.	 However,	when	 the	 results	 for	 those	who	 healed	
were	compared	to	those	who	did	not	heal	there	was	no	significant	difference.	Throughout	
the	tests	there	was	also	no	significant	difference	between	the	study	 leg	and	non-study	 leg	
(Section	5.7.7).	
6.2.3. Overall	Hypothesis:	Improving	the	microcirculation	of	the	foot	in	patients	
with	 diabetic	 foot	 disease	 improves	 wound	 healing	 and	 degree	 of	
peripheral	neuropathy.	
Due	 to	 the	 low	 numbers	 recruited	 it	 is	 not	 possible	 to	 accept	 or	 reject	 the	 overall	
hypothesis.	 When	 considering	 the	 questions	 asked	 in	 Section	 5.3.1	 the	 outcomes	 are	 as	
follows;	
• Which	of	PCA	or	peripheral	bypass	surgery	(PBS)	provides	a	greater	improvement	in	
the	microcirculation?		
o This	will	require	further	study	with	more	recruits	due	to	too	few	patients,	in	
particular	in	the	PBS	group,	being	recruited	
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• What	is	the	level	of	improvement	in	the	microcirculation	at	the	time	of	wound	
healing	in	patients	with	DM	and	PAD?	
o In	the	PCA	group	the	patients	that	healed	showed	an	improvement	in	post-
occlusive	reactive	hyperaemia	following	intervention.	There	was	also	an	
improvement	in	the	unhealed	patients	but	to	a	lesser	degree.		
• Is	there	any	improvement	in	the	neurological	status	of	patients	with	neuro-ischaemic	
ulceration	who	have	undergone	revascularisation?	
o This	data	set	was	unable	to	demonstrate	any	difference	in	neuropathy	
following	PCA.	
6.3. LIMITATIONS	
6.3.1. Distribution	of	disease	
The	 examination	 of	 the	 distribution	 of	 disease	 was	 based	 on	 a	 large	 prospectively	
maintained	 dataset.	 Following	 the	 pilot	 study,	 adjustments	 were	 made	 to	 the	 design	
including	fine-tuning	the	arterial	segments	examined	and	collecting	data	on	outcomes.	The	
decision	was	also	made	to	match	the	control	and	study	groups	for	risk	factors	for	peripheral	
arterial	disease.	This	was	done	to	control	for	these	risk	factors	and	also	partly	to	rationalise	
the	cohort	size	to	a	volume	that	was	manageable	for	analysis	by	one	investigator.	A	potential	
problem	with	 closely	matching	 cohorts	 is	 that	 they	may	 no	 longer	 represent	 the	 general	
population.	The	demographics	of	the	matched	cohorts	were	compared	to	the	raw	dataset	to	
examine	this	as	a	potential	weakness.	There	was	no	significant	difference	in	age	in	the	DM	
group	 (matched	 70.31	 years	 ±9.17	 vs	 raw	 dataset	 69.74±11.12,	 p=0.552)	 or	 in	 the	 no	
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diabetes	mellitus	group	(NDM)	(70.33±9.4	vs	69.26±13.7,	p=0.256).	A	chi-squared	goodness-
of-fit	test	was	performed	to	compare	the	proportions	of	the	categorical	demographics	in	the	
matched	cohort	to	the	raw	dataset.	When	comparing	the	matched	cohort,	which	contained	
no	 unknown	 data,	 to	 the	 raw	 dataset,	which	 includes	 some	 unknown	 data,	 the	 unknown	
group	was	excluded.	The	summary	of	the	areas	of	significant	difference	is	presented	in	Table	
6.3-1.	The	full	breakdown	of	observed	values,	expected	values	and	residuals	can	be	found	in	
Appendix	 VIII.	 Smoking	 was	 the	 only	 demographic	 that	 had	 significantly	 different	
proportions	 in	both	groups.	The	NDM	group	had	more	areas	of	 significant	difference	 than	
the	DM	group	(four	compared	to	three).	This	suggests	that	the	NDM	group	had	been	more	
altered	from	the	general	population	than	the	DM	group.		
Table	 6.3-1:	 Significance	 results	 for	 comparisons	 of	 demographic	 proportions	 in	 the	
matched	cohort	compared	to	the	raw	dataset.	
	
p-value*	
Diabetes	mellitus	 No	Diabetes	mellitus	
Sex	 0.326	 0.013	
Ethnicity	 <0.001	 0.300	
Smoking	 0.003	 0.001	
Hypertension	 0.356	 <0.001	
High	Cholesterol	 0.407	 0.181	
Renal	Function	 <0.001	 0.080	
Timing	of	procedure	 0.110	 0.001	
*Chi2	Goodness-of-Fit	Test	
6.3.2. Cohort	study	
The	study	was	designed	to	prospectively	collect	data	on	how	the	microcirculation	around	
foot	ulcers	changed	during	their	lifespan.	The	main	technique	aimed	at	achieving	this	was	to	
perform	repeated	measures	on	 the	 same	ulcer.	The	majority	of	patients	had	 two	or	more	
follow-up	measurements	after	their	initial	assessment.	Unfortunately,	there	were	significant	
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problems	with	recruitment	and	only	22.5%	of	the	number	proposed	in	the	power	calculation	
(27/120)	 were	 recruited.	 This	 was	 particularly	 true	 in	 the	 peripheral	 bypass	 group	 where	
only	 two	 patients	 out	 of	 the	 proposed	 48	were	 recruited	 (4.2%).	 In	 the	 PCA	 group	 18.8%	
(9/48)	 were	 recruited	 and	 58.3%	 (14/24)	 in	 the	 DTL	 group.	 Much	 of	 the	 problem	 with	
recruitment	revolved	around	difficulties	 in	 identifying	patients	without	DM	as	described	 in	
Section	1.1.1.1.		
Of	 the	 twenty-six	 patients	 recruited	 only	 fifteen	 patients	 reached	 a	 defined	 endpoint	
during	 the	 period	 for	 recruitment	 and	 follow-up.	 Thirteen	 patients	 (50%)	 healed	 and	 two	
patients	 had	 a	major	 amputation	 (7.7%).	 Six	 patients	 were	 lost	 to	 follow-up	 (23%),	 three	
requested	to	 leave	the	study	(11.5%),	and	two	had	continuing	ulceration	at	the	end	of	the	
study	(7.7%).	Of	the	three	that	requested	to	leave	the	study,	one	was	an	elderly	patient	who	
found	the	 testing	process	exhausting	and	so	did	not	wish	 to	continue,	one	 found	the	post	
occlusive	reactive	hyperaemia	(PORH)	painful	at	the	baseline	tests	and	the	third	had	a	family	
member	become	ill	and	they	did	not	feel	they	had	the	time	to	continue	in	the	study.	
There	was	a	wide	timescale	for	the	duration	of	the	ulcer	before	recruitment	of	less	than	
one	month	up	to	eighty-four	months,	in	the	DTL	group	the	median	duration	was	two	months	
(1-13)	and	PCA	group	five	months	 (3-7,	p=0.336).	A	more	consistent	approach	would	have	
been	 only	 to	 recruit	 those	 attending	 for	 their	 first	 clinic	 appointment	 for	 the	 ulcer	 in	
question.	Published	data	on	time	to	first	assessment	 in	a	specialist	clinic	suggests	that	this	
would	 have	 reduced	 the	 prior	 duration.	 In	 the	 most	 recent	 publication	 of	 the	 National	
Diabetes	Foot	Care	Audit	71.9%	of	patients	had	their	first	assessment	in	thirteen	days	or	less	
or	 self-referred	 (period	 of	 time	 not	 recorded	 but	 suggested	 to	 be	 shorter	 than	 other	
pathways)	and	only	8.6%	waited	over	2	months264.	
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6.4. CONTEXT	OF	CURRENT	EVIDENCE	
6.4.1. Distribution	of	disease	
The	results	of	examination	of	the	distribution	disease	generally	agree	with	the	results	of	
the	review	presented	in	Chapter	2.	Patients	with	DM	had	more	disease	overall	compared	to	
those	 without	 and	 this	 was	 particularly	 true	 below	 the	 knee.	 When	 our	 results	 were	
compared	 to	 the	 other	 two	 studies	 that	 had	 previously	 used	 the	 Bollinger	 score83,90	 the	
median	scores	were	generally	higher	than	ours.	This	was	true	of	both	study	groups.	Of	the	
studies	 that	 separated	 out	 the	 infrageniculate	 vessels	 both	 Jude	 et	 al.83	 and	Diehm	 et	 al.	
(2008)90,	using	the	Bollinger	score,	found	lower	scores	 in	the	peroneal	artery	(PEA)	 in	both	
the	control	and	the	DM	group.	However,	Menzoian	et	al.159	and	Ciavarella	et	al.157,	using	an	
alternative	 scoring	 system	 and	 presence	 of	 occlusion	 respectively,	 were	 unable	 to	
demonstrate	this.		
It	 would	 seem	 that	 the	 Bollinger	 score	 is	 a	 more	 sensitive	 method	 of	 detecting	 the	
differences	in	degree	of	disease	between	vessels.	An	aim	of	our	study	was	to	further	explore	
the	 differences	 between	 each	 arterial	 segment,	which	 included	 dividing	 each	 of	 the	 tibial	
vessels	 into	 three	 segments.	 These	 segments	 demonstrated	 that,	 when	 all	 patients	 were	
considered,	 the	only	vessels	 in	which	 there	was	 significant	difference	across	 the	segments	
were	the	anterior	tibial	artery	(ATA)	and	PEA	in	patients	with	claudication.	There	was	a	non-
significant	 trend	 towards	 worse	 disease	 distally	 (Table	 6.4-1).	 There	 were,	 however,	 no	
significant	differences	between	the	DM	group	and	the	control	group	in	the	individual	tibial	
segments	 (Section	 3.8.2).	 For	 this	 reason,	 it	 can	 be	 argued	 that	 the	 division	 of	 the	 crural	
vessels	 into	thirds	has	only	added	 limited	 information.	 In	Bollinger’s	original	description	of	
his	 scoring	 system,	 only	 the	 first	 3cm	of	 the	ATA	 and	5cm	of	 the	PEA	 and	posterior	 tibial	
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artery	 (PTA)	were	 included.	The	results	 from	these	segments	were	significantly	 lower	 than	
the	scores	for	the	whole	vessel	(Table	6.4-2).	This	shows	that	extending	the	segments	gives	a	
fuller	picture	of	the	extent	of	disease	present.	
Table	 6.4-1:	 Comparison	 of	 Bollinger	 score	 of	 proximal,	 middle	 and	 distal	 tibial	 arterial	
segments	for	all	patients	
  Proximal	
segment	
Middle	segment	 Distal	segment	
p-
value*		
n	
Median	
(IQR)	
n	
Median	
(IQR)	
n	
Median	
(IQR)	
	 ATA	 23	 4	(0-15)	 23	 4	(0-15)	 22	 13	(0-15)	 0.201	
Asymptomatic	 PEA	 23	 0	(0-2)	 23	 0	(0-3)	 22	 0	(0-3)	 0.961	
	 PTA	 23	 2	(0-15)	 23	 4	(0-15)	 22	 11	(0-15)	 0.832	
Claudication	
ATA	 148	 2	(0-6)	 139	 0	(0-13)	 140	 1	(0-15)	 0.005	
PEA	 148	 0	(0-3)	 140	 0	(0-13)	 138	 0	(0-13)	 0.002	
PTA	 148	 0	(0-4)	 139	 0	(0-4)	 140	 0	(0-7)	 0.082	
Critical	
Ischaemia	
ATA	 133	 6	(0-13)	 131	 3	(0-15)	 130	 13	(0-15)	 0.407	
PEA	 132	 3	(0-13)	 131	 1	(0-15)	 130	 0	(0-15)	 0.598	
PTA	 133	 10	(1-15)	 131	 13	(0-15)	 129	 15	(0-15)	 0.528	
*Related	samples	Friedman’s	two-way	analysis	of	variance	by	ranks,	ATA	Anterior	tibial	
artery,	PEA	Peroneal	artery,	PTA	Posterior	tibial	artery	
Table	6.4-2:	Comparison	of	Bollinger	score	for	the	originally	described	tibial	segment	to	the	
score	for	the	whole	vessel		
  
Original	segment	
Score	for	whole	
vessel	
p-
value*	
	 n	 Median	(IQR)	 n	 Median	(IQR)	
	 Anterior	tibial	 23	 2	(0-13)	 22	 13	(0-15)	 0.011	
Asymptomatic	 Peroneal	 23	 0	(0-0)	 22	 0	(0-3)	 0.077	
	 Posterior	tibial	 23	 3	(0-15)	 22	 13	(0-15)	 0.078	
Claudication	
Anterior	tibial	 148	 0	(0-3)	 140	 5	(0-15)	 <0.001	
Peroneal	 148	 0	(0-1)	 140	 2	(0-13)	 <0.001	
Posterior	tibial	 148	 0	(0-3)	 143	 0	(0-13)	 <0.001	
Critical	
Ischaemia	
Anterior	tibial	 133	 3	(0-7)	 130	 13	(2-15)	 <0.001	
Peroneal	 132	 1	(0-13)	 131	 3	(0-15)	 <0.001	
Posterior	tibial	 133	 4	(0-15)	 132	 14	(2-15)	 <0.001	
*Mann-Whitney	U	Test	
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Our	 results	 suggested	 that	 patients	without	 DM	 and	 presenting	with	 critical	 ischaemia	
had	more	 disease	 in	 the	 pedal	 vessels	 than	 patients	with	 DM.	 The	 trend	was	 also	 in	 this	
direction	in	the	claudication	group	but	not	in	the	asymptomatic	group	(Section	3.8.2).	In	the	
literature,	 this	 has	 been	 an	 inconsistent	 finding.	 Conrad	 in	 1967	 examined	 casts	 of	 the	
vascular	tree	from	amputated	limbs.	In	this	cohort	of	twenty	patients,	the	NDM	group	had	
more	pedal	disease.	The	groups	 from	this	 study	are	a	bit	unusual	 in	 that	almost	all	of	 the	
NDM	 group	 presented	 with	 acute	 symptoms	 whereas	 the	 DM	 group	 had	 chronic	
presentations169.	Ciavarella	et	al	also	 found	more	plantar	disease	 in	 the	DM	group	 in	 their	
1993	study	that	examined	patients	with	symptomatic	PAD157.	Menzoian	et	al	 in	1989	using	
LaMorte	et	 al’s	 scoring	 system	 (described	 in	 Section	 2.3.2)	 found	no	 significant	 difference	
between	 the	 groups159,161.	 Diehm	 et	 al	 in	 2008	 or	 Haine	 et	 al	 in	 2018	 were	 not	 able	 to	
demonstrate	a	significant	difference	between	patients	with	and	without	DM	either90,171.	The	
trend	 in	 both	 studies	 was	 for	 patients	 with	 DM	 to	 have	 a	 higher	 burden	 of	 disease	 than	
patients	without90,171.	Both	Haine	and	Diehm	separated	patients	with	DM	from	patients	with	
chronic	 kidney	 disease	 (CKD)	 and	 found	 that	 these	 patients	 had	 a	 higher	 burden	of	 pedal	
disease	than	patients	with	DM	or	patients	with	PAD	and	no	DM90,171.	 In	Ciavarella’s	cohort	
61%	of	DM	patients	also	had	CKD,	none	of	the	patients	in	the	NDM	cohort	did157.	Conrad	and	
Menzoian	do	not	record	the	proportions	of	patients	with	CKD169.	The	assumption	would	be	
that	a	proportion	of	these	patients	would	have	had	CKD	and	this	may	have	 influenced	the	
results.	 From	 this	 evidence,	 it	 is	 not	 possible	 to	 conclude	 that	 there	 is	 any	 significant	
difference	 in	the	 incidence	of	pedal	disease	between	patients	with	and	without	DM.	It	has	
been	suggested	that	patients	with	crural	disease	related	to	DM	will	have	relative	sparing	of	
the	pedal	vessels.	Graziani	et	al	in	2007,	in	a	cohort	all	with	DM	and	tissue	loss	secondary	to	
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ischaemia,	found	that	of	the	118	patients,	whose	crural	vessels	were	all	occluded,	88%	had	
at	least	one	patent	pedal	vessel265.	However,	Diehm,	in	a	much	smaller	cohort	(n=25),	found	
that	the	DM	patients	had	more	disease	 in	the	foot	compared	to	the	calf.	The	presence,	or	
not,	of	pedal	disease	is	important	as	when	there	is	significant	crural	disease	the	pedal	vessels	
can	be	a	potential	 target	 for	bypass	and,	as	endovascular	 techniques	are	 improving,	are	a	
potential	 target	 or	 retrograde	 conduit	 for	 endovascular	 therapy266-271.	 In	 addition	 to	 that	
patients	 with	 pedal	 disease	 have	 been	 found	 to	 have	 higher	 rates	 of	 amputation	 and	
mortality	and	it	is	an	independent	predictor	of	failure	of	revascularisation269.	
Other	 studies	 have	 considered	 the	 outcomes	 of	 patients	 with	 DM	 following	 PCA	 or	
stenting.	Many	have	not	demonstrated	any	significant	difference	in	the	outcomes	between	
patients	 with	 DM	 and	 those	 without158,168,272-276.	 With	 the	 exception	 of	 Melliere	 et	 al275,	
these	are	all	studies	with	small	numbers.	There	are	however	studies	that	have	found	similar	
results	to	us,	many	of	these	also	have	small	numbers83,277-280.	However	a	recently	published	
study281,	which	included	714	patients	(58.5%	with	DM)	who	underwent	PCA	for	popliteal	or	
infrapopliteal	disease,	found	on	survival	analysis	that	patients	with	DM	had	poorer	outcomes	
for	 major	 adverse	 events	 (p<0.001),	 all-cause	 mortality	 (p=0.001),	 major	 amputation	
(p=0.001)	 and	 further	 revascularisation	 (p=0.03).	 On	 multivariate	 analysis,	 DM	 remained	
associated	with	 significantly	 higher	 rates	 of	major	 adverse	 events,	 all-cause	mortality	 and	
major	 amputation	 (hazard	 ratio	 (HR)	 1.73	 (95%	 confidence	 interval	 1.35-2.23),	 1.83	 (1.33-
2.52)	and	5.52	(1.82-16.71)	respectively).	However	further	revascularisation	did	not	have	a	
statistically	 significant	 association	 (HR	 1.35,	 95%	 CI	 0.98-1.87).	 Darling	 et	 al.	 separately	
analysed	patients	with	insulin	dependent	diabetes	(IDDM)	from	those	who	were	non-insulin	
dependent	(NIDDM)282.	They	found	that	the	IDDM	group	(342	patients)	had	a	higher	risk	of	
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incomplete	wound	healing	 (HR	1.4	95%	CI	1.1-2.6),	major	amputation	 (HR	4.1,	95%	CI	1.3-
12.6)	and	RAS	(a	combination	of	re-intervention,	major	amputation	and	restenosis,	HR	1.5,	
95%	 CI	 1.1-2.2).	 Compared	 to	 the	 NDM	 group	 (171	 patients)	 there	was	 no	 increased	 risk	
associated	with	NIDDM	(133	patients),	in	fact	it	appeared	to	be	associated	with	lower	risk	of	
mortality	(HR	0.7,	95%	CI	0.4-0.9).	Abularrage	et	al.	compared	the	outcomes	for	533	limbs	of	
patients	with	DM	and	542	without	DM174.	They	also	found	on	survival	analysis	that	patients	
with	DM	had	worse	 limb	 salvage	 (p<0.001),	 and	 survival	 (p=0.001).	 In	 addition,	 there	was	
worse	 primary	 patency	 (defined	 as	 the	 return	 of	 symptoms	 and	worsening	 ankle-brachial	
indices	 or	 pulse	 volume	 recordings,	 p=0.009)	 but	 comparable	 assisted	 patency	 (further	
endovascular	procedure,	excluding	surgical	bypass,	p=0.18).		
Inter	 and	 intra-observer	 reliability	 for	 the	 Bollinger	 score	was	 examined	 as	 part	 of	 the	
study	 to	 consider	whether	 the	 adjustments	 to	 the	 scoring	 system	were	 reproducible.	 The	
results	showed	good	inter-observer	agreement	and	good	intra-observer	agreement	(Section	
3.4.1).	 In	 Bollinger’s	 original	 description	 of	 the	 scoring	 system,	 they	 examined	 agreement	
between	 five	 scorers	on	six	angiograms	using	Kendall’s	 coefficient	of	 concordance	 (KCC)82.	
They	 state	 that	 the	 agreement	 appeared	 to	 be	 excellent	 with	 a	 p-value	 <0.001	 but	
unfortunately	do	not	quote	the	actual	value	of	KCC,	so	the	accuracy	of	this	statement	is	hard	
to	 assess.	 Since	 then	 a	 few	 other	 studies	 have	 addressed	 this	 question	 using	 a	 variety	 of	
methods.	Bradbury	et	al.	 (2010)84	 compared	 the	mean	 score	 for	 the	whole	 leg,	 above	 the	
knee	 and	below	 the	 knee,	 for	 two	observers.	 These	 scores	were	 further	 divided	 into	 four	
groups	 (<3,	 3-5,	 6-8,	 ³9)	 to	 allow	 comparison	 to	 the	 second	 Trans-Atlantic	 Inter-Society	
Consensus	Document	on	Management	of	Peripheral	Arterial	Disease	(TASC	II)	classification	
which	 was	 also	 being	 assessed.	 They	 found	 that	 in	 approximately	 75%	 of	 cases	 the	 two	
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observers	placed	the	patient	in	the	same	Bollinger	score	group.	Morris	et	al.	compared	two	
observers	scores	of	 twenty	patients	using	weighted	k	values283.	They	found	poor	 intra	and	
inter-observer	agreement	for	the	profunda-femoris	segment	(	-0.07(standard	error	0.14)	and	
0.26	 (0.16)	 respectively),	 but	 the	 rest	 of	 the	 values	 were	 moderate	 to	 very	 good	 and	
particularly	 strong	 on	 the	 tibial	 vessels.	 Müller-Bühl	 et	 al.	 calculated	 an	 intra-class	
correlation	coefficient	between	three	observers	of	0.85284.	This	was	only	based	on	the	iliac	
and	femoro-popliteal	segments	though.	Due	to	the	variation	in	methods	used	it	is	difficult	to	
compare	our	results	to	these,	but	it	would	seem	that	the	agreement	between	observers	was	
comparable	to	other	studies.		
6.4.2. Cohort	study	
6.4.2.1. Post	occlusive	reactive	hyperaemia	
There	is	a	wide	range	of	TtM	values	reported	in	the	literature	both	for	patients	with	DM	
and	 no	 PAD	 and	 those	with	 PAD.	 Lanting	 et	 al.107	 in	 patients	with	 type	 2	 DM	 found	 that	
patients	with	no	history	of	complications	had	a	mean	TtM	of	17.11	seconds	whereas	those	
with	a	history	of	ulceration	or	amputation	took	47.49s	and	those	with	an	active	ulcer	19.17s.	
These	 figures	are	based	on	PORH	tests	being	performed	with	occlusion	of	 the	hallux	only.	
Our	values	from	the	study	toe	are	shorter	than	Lanting’s	measurements	in	active	ulceration	
(DTL	all	patients	at	baseline	13.4s	 (3.68-73.85)	and	 longer	 in	 those	 that	had	healed	at	 the	
final	 visit	 (comparable	 to	 those	 with	 a	 history	 of	 ulceration).	 Lanting	 et	 al.	 found	 that	 a	
longer	TtM	was	associated	with	increased	odds	of	a	history	of	ulceration	but	not	with	active	
ulceration.		
	168	
Morales	et	al.231	compared	patients	with	Fontaine	class	II	or	III	peripheral	arterial	disease	
and	 no	 DM	with	 healthy	 controls.	 Occlusion	 was	 performed	 at	 the	 thigh	 rather	 than	 the	
ankle	and	measurements	were	taken	on	the	dorsum	of	the	foot.	Their	median	TtM	was	56.3s	
(50.92-87.74)	which	is	much	shorter	than	our	baseline	values	(220.28s	(93.65-279.8)),	similar	
to	the	post-treatment	second	values	(53.79s	(18.09-205.16))	but	shorter	than	the	last	values	
particularly	in	the	healed	group	(175.76s	(105.2-227.13)).	
Ray	et	al.110	examined	patients	with	severe	PAD	prior	to	undergoing	revascularisation.	Of	
those	in	their	cohort	with	DM	(n=16)	the	patients	who	had	clinically	improved	at	six	months	
had	a	mean	TtM	of	79s	and	those	who	had	not	183s.	Those	who	healed,	at	baseline,	in	our	
PCA	 group	 had	 a	median	 TtM	of	 198.79s	 (69.18-287.33).	 Those	who	 did	 not	 heal	median	
measurement	was	220.28s	 (93.65-271.38).	The	trend	 is	 in	 the	same	direction	but	 the	time	
scales	are	much	longer.	Overall	 it	 is	not	possible	to	compare	or	draw	conclusions	from	the	
evidence	above	as	our	study	is	small	and	underpowered	and	many	of	these	studies	can	also	
be	described	that	way.	This	and	differences	in	cohort	characteristics	will	explain,	at	least	in	
part,	why	the	values	vary	so	much.	
There	are	no	published	direct	comparisons	of	patients	with	DM	pre-and	post-PCA	using	
laser	Doppler	 fluxmetry	 (LDF).	Data	previously	 obtained	at	 our	 institution	 showed	a	mean	
improvement	of	fourteen	seconds	at	six-weeks	following	PCA	in	ten	patients,	four	of	whom	
had	DM	(69±27	vs	55±30,	p=non-significant)261.	This	is	a	much	smaller	change	than	observed	
in	 the	 current	 study	 with	 the	 smallest	 difference	 at	 the	 second	 visit	 being	 92s.	 Using	
alternative	 methods	 to	 assess	 the	 microcirculation	 others	 have	 demonstrated	 this	
improvement	 following	 revascularisation51,78.	 Like	 Arora	 et	 al.	 I	 have	 been	 able	 to	
demonstrate	that	following	PCA	the	treated	leg	has	improved	microcirculation	but	it	has	not	
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quite	improved	to	the	level	of	the	leg	that	does	not	require	revascularisation	(Table	5.7-12	
and	Table	5.7-13)51.		
The	only	PORH	variable	that	was	presented	 in	the	results	was	TtM	(see	Figure	4.4-2	for	
examples	 of	 other	 variables).	 This	 was	 chosen	 as	 throughout	 the	 comparisons	 it	 most	
frequently	 demonstrated	 a	 significant	 difference	 between	 measures.	 In	 addition	 to	 this	
within	 the	 literature	 TtM	 has	 regularly	 been	 found	 to	 be	 able	 to	 discriminate	 between	
groups107,231,232,285,286.	Other	variables	that	have	been	found	to	discriminate	include	time	to	
resting	flux	(time	from	release	of	cuff	until	value	of	resting	flux	reached),	 time	to	recovery	
(TtR),	 time	 to	half	 recovery	 (Tt1/2),	maximum	 flux	and	a	 ratio	of	maximum	 flux	 to	 resting	
flux231,232,285,286.	 Variables	 that	 have	 been	 found	 to	 be	 reliable	 and	 reproducible	 include	
resting	 flux,	 latency	 between	 cuff	 release	 and	 start	 of	 recovery,	 maximum	 flux,	 TtM,	
maximum	flux	above	resting	flux,	a	ratio	of	maximum	flux	to	biological	zero	and	reperfusion	
rate93,234,259.	 The	 other	 variables	 that	 we	 measured	 can	 be	 found	 in	 Appendix	 VII	 In	 this	
dataset,	 other	 than	 TtM,	 the	 variables	 that	 most	 commonly	 demonstrated	 a	 significant	
difference	were	Tt1/2	and	TtR.	The	trends	that	they	demonstrated	mirrored	that	of	TtM	and	
so	do	not	offer	up	any	further	insights	into	the	relationship.		
As	 discussed	 in	 Section	 4.7	 the	 relationship	 between	 the	macro	 and	microcirculation	 is	
complex	and	poorly	understood.	Few	studies	have	examined	the	relationship	between	lower	
limb	PAD,	DM	and	their	respective	and	related	impacts	on	the	microcirculation.	Williams	et	
al	in	2006	compared	the	transcutaneous	oxygen	pressure	(TcPO2)	in	130	limbs.	Patients	were	
divided	into	controls	with	no	PAD	or	DM	(n=27),	PAD	with	no	DM	(n=14),	DM	with	no	PAD	
(n=25),	DM	and	PAD	(n=7),	DM	with	peripheral	neuropathy	(DPN)	(n=41)	and	DM	with	PAD	
and	DPN	(n=16)287.	No	patients	had	critical	 ischaemia	or	active	tissue	loss.	The	presence	or	
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absence	of	PAD	was	confirmed	with	duplex	ultrasound.	Toe	blood	pressure	index	(TBPI)	was	
measured	and	compared	to	TcPO2	of	the	dorsum	of	the	foot.	They	found	that	there	was	a	
significant	positive	correlation	between	TBPI	and	TCPO2	in	the	patients	with	PAD.	In	the	DM	
groups	without	PAD	there	was	no	strong	correlation	between	the	two	variables	apart	from	a	
negative	correlation	in	patients	with	abnormally	high	TBPI	(>1.2)	and	associated	low	TcPO2.	
Whilst	the	groups	with	PAD	had	significantly	lower	TBPI	than	the	DM	groups	the	results	for	
TcPO2	were	much	more	similar	across	the	groups.	The	PAD	group	with	no	DM	had	normal	
TcPO2	 despite	 low	 TBPI.	 The	 only	 group	with	 significantly	 lower	 TcPO2	was	 those	with	 all	
three	pathologies.	They	concluded	that	there	were	two	major	 influences	on	the	cutaneous	
perfusion	 in	 patients	with	 DM	 and	 PAD	 and	 those	were	 the	macrovascular	 disease	 and	 a	
global	 microcirculatory	 change	 related	 to	 DM287.	 Pardo	 et	 al	 in	 2014	 correlated	 ankle	
brachial	pressure	index	(ABPI)	with	TcPO2	in	patients	with	both	DM	and	PAD	before,	during	
and	 after	 PCA288.	 They	 found	 that	 both	 ABPI	 and	 TcPO2	 improved	 following	 PCA	 but	 the	
correlation	 between	 the	 two	 was	 poor288.	 No	 studies	 that	 correlated	 LDF	 parameters	 to	
degree	of	macrovascular	disease	were	identified.		
In	 our	 data	 the	 DM	 group	 had	 been	 clinically	 assessed	 to	 have	 no	 significant	
macrovascular	disease	and	this	was	assumed	to	remain	stable	through	the	study.	In	the	PCA	
group,	one	patient	was	found	to	not	have	significant	PAD	at	angiography	whilst	all	the	others	
had	 a	 procedure	 that	 improved	 the	 macrovascular	 flow.	 In	 one	 case	 thrombolysis	 was	
required	for	twenty-four	hours	before	flow	was	achieved	and	in	two	cases	the	flow	achieved	
was	 not	 in-line	 to	 the	 foot	 but	 via	 the	 peroneal	 artery	 only	 (Section	 5.7.8.1).	 The	
thrombolysis	patient	went	on	to	heal	and	had	a	reduction	from	231s	to	48s	in	TtM	at	second	
visit.	 Unfortunately,	 both	 patients	 with	 peroneal	 run-off	 only	 left	 the	 study	 early	 for	 the	
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reasons	discussed	in	Section	6.3.2.	One	only	had	baseline	measurements	the	other	had	two	
measurements	 post-procedure	 and	 demonstrated	 a	 reduction	 in	 TtM	 from	 289s	 to	 9s	 at	
second	visit.	The	patient	with	a	diagnostic	only	procedure	had	more	favourable	parameters	
than	the	other	members	of	the	group	at	baseline,	TtM	13.15s,	there	was	also	a	reduction	at	
second	 visit	 to	 3s.	 Using	 Spearman’s	 correlation	 coefficient,	 there	 was	 no	 significant	
correlation	 between	 TtM	 and	 SPP	 or	 TBP	 in	 either	 the	 DM	 or	 PCA	 group	 (Baseline	 SPP	
compared	to	toe	DM	correlation	0.47	p=0.117,	PCA	0.35	p=0.499,	baseline	TBP	compared	to	
toe	DM	0.04	p=0.161,	PCA	0.12	p=0.818).		
6.4.2.2. Skin	perfusion	pressure	
Our	 results	 for	 SPP	were	 higher	 than	many	 published	 results	 in	 both	 the	DTL	 and	 PCA	
group.	 Yotsu	 et	 al.253,	 in	 their	 neuropathic	 group,	who	 are	 comparable	 to	 our	 DTL	 group,	
quoted	median	SPP	of	67mmHg	(57-75)	for	those	who	healed	and	65mmHg	(40-69)	for	those	
who	did	not.	Like	us,	 they	 found	no	significant	difference	between	the	groups.	The	neuro-
ischaemic	 group	 as	 a	 comparison	 to	 our	 PCA	 group	 results	 were	 38mmHg	 (22-51)	 and	
17mmHg	(10-32)	respectively.	Utsunomiya	et	al.289	recorded	the	SPP	prior	to	and	up	to	forty-
eight	hours	after	PCA	on	a	cohort	of	patients	with	critical	ischaemia	and	tissue	loss	of	whom	
72%	had	DM.	Their	mean	SPP	before	the	procedure	was	24.3±13mmHg	and	40.7±16.1mmHg	
following	 the	 procedure.	 Kawarada	 et	 al.290	 demonstrated	 a	 significant	 increase	 in	 SPP	
following	PCA	of	the	ATA	in	patients	with	DM	or	end-stage	renal	failure	(35mmHg	(28-41)	vs	
52mmHg	(38-65),	p=0.001).	The	increase	following	angioplasty	of	the	posterior	tibial	artery	
was	not	significant	(27mmHg	(21-33)	vs	42mmHg	(31-56),	p=0.005).	
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An	SPP	of	less	than	40mmHg	has	been	proposed	as	a	poor	predictor	of	healing237,255.	Only	
one	patient	(7.7%)	in	the	DTL	group	had	an	SPP	of	less	than	40mmHg;	they	did	not	heal.	In	
the	PCA	group	two	patients	(33.3%)	had	SPP	of	less	than	40mmHg,	one	healed	and	the	other	
did	not.		
The	variability	 in	results	both	within	the	 literature	and	when	compared	to	our	results	 is	
probably	 related	 to	 the	 small	 numbers	 in	 the	 cohorts.	 This	 is	 going	 to	 increase	 the	
heterogeneity	between	groups.	While	reliability,	sensitivity	and	specificity	have	been	shown	
to	be	good,	overall	the	quality	of	the	evidence	is	poor112,221.	Having	said	that	there	are	very	
few	patients	in	which	is	not	possible	to	perform	SPP,	unlike	TBP,	where	previous	amputation	
can	preclude	many	patients	with	diabetic	foot	disease.	
6.4.2.3. Toe	Blood	pressure	
Within	published	guidelines	toe	blood	pressure	index	is	advised	in	patients	with	ABPI	of	
more	that	1.415,74,184.	There	is	not,	however,	consensus	on	the	parameters	which	represent	
critical	 ischaemia.	 TASC	 II	 considers	 that	 a	 TBP	 of	 <50mmHg	 is	 indicative	 of	 critical	 limb	
ischaemia	 (definition:	 ischaemic	 rest	 pain	 for	 more	 than	 two	 weeks,	 ulcers	 or	 gangrene	
related	to	arterial	disease)81.	The	International	Working	Group	on	the	Diabetic	Foot	felt	that	
a	 TBP	 of	 <30mmHg	 was	 an	 indication	 for	 revascularisation	 and	 patients	 with	 a	 TBP	 of	
³30mmHg	 should	 heal15.	 The	 most	 recent	 European	 guidelines	 on	 the	 diagnosis	 and	
treatment	of	PAD	includes	the	Wound,	Ischaemia	and	Foot	infection	(WIfI)	classification	for	
risk	 stratification	 of	 chronic	 limb	 threatening	 ischaemia184.	 In	 this	 classification	 a	 TBP	 of	
<30mmHg	 puts	 a	 patient	 in	 the	 highest	 category	 of	 risk	 of	 amputation291.	 In	 this	 current	
cohort,	only	one	patient	had	a	TBP	of	<30mmHg	at	baseline,	in	the	PCA	group,	they	did	not	
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heal.	If	<50mmHg	was	used	as	a	cut	off	four	patients	were	affected,	only	one	of	these	was	in	
the	DTL	group,	and	they	did	not	heal.	 In	 the	PCA	group	one	healed	and	the	other	two	did	
not.		
The	 reliability	 of	 TBP	 using	 laser	 Doppler	 has	 been	 found	 to	 be	 good	 in	 patients	 with	
PAD292.	In	patients	with	diabetic	foot	ulcers,	specifically,	there	are	only	two	studies	that	have	
considered	this,	and	it	would	seem	that	the	sensitivity	and	specificity	are	slightly	weaker	in	
this	cohort221.	As	with	SPP,	our	values	of	TBP	are	higher	than	many	of	those	that	have	been	
published.	Most	 cohorts,	of	patients	with	 tissue	 loss,	 in	 the	published	 literature,	 include	a	
mixture	 of	 patients	 with	 and	 without	 PAD	 and	 so	 are	 different	 to	 the	 cohorts	 presented	
here.	In	addition	to	this	TBP	values	vary	greatly	depending	on	the	device	use	and	so	it	can	be	
hard	 to	 compare	 between	 cohorts293.	 TBP	 whilst	 is	 a	 good	 marker	 for	 PAD	 it	 can	 be	
influenced	 by	 factors	 that	 cause	 vasoconstriction.	 For	 example,	 room	 temperature	 and	
consumption	of	caffeine.	These	factors	were	considered	and	controlled	for	in	the	design	of	
the	study,	and	there	was	no	significant	difference	found	between	the	groups	or	visits	(Table	
5.7-6	and	Table	5.7-7).	A	cool	room	temperature	or	recent	consumption	of	caffeine	would	be	
expected	 to	 reduce	 the	 TBP,	 and	 so	 it	 is	 unlikely	 these	 factors	 contributed	 to	 the	 higher	
results294.	
6.4.2.4. Neuropathy	
The	aetiology	on	diabetic	peripheral	neuropathy	(DPN)	is	complex.	Various	pathways	and	
mechanisms	have	been	proposed	 involving	metabolic	 defects,	 inflammatory	 and	oxidative	
stress	and	vascular	disease295.	The	only	treatment	that	has	been	convincingly	found	to	have	
an	 impact	 on	 the	 development	 and	 progression	 of	 DPN	 is	 good	 glycaemic	 control63.	 No	
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studies	 have	 been	 able	 to	 demonstrate	 a	 causal	 relationship	 between	 improvement	 in	
macrovascular	disease	and	DPN.		
The	 improvement	 that	was	seen	 in	NTSS-6	 in	 the	DTL	group	can	also	be	explained	by	a	
reduction	in	the	symptoms	of	active	ulceration	or	infection.	
6.5. PLANS	FOR	FUTURE	STUDY	
From	 the	 studies	 presented	 above	 it	 is	 not	 possible	 to	 answer	 the	 overall	 hypothesis	
(Section	6.2.3).	One	option	for	future	work	would	be	to	refine	the	cohort	study	and	continue	
recruitment	 with	 a	 focus	 on	 recruiting	 patients	 without	 DM	 and	 those	 undergoing	 PBS.	
When	considering	this	as	an	option	the	sample	size	calculation	performed	 in	the	design	of	
the	pilot	study	(Section	5.3.2)	was	repeated	using	data	gained	from	this	study.	
When	 the	sample	 size	calculation	was	originally	performed	 there	was	no	available	data	
for	 the	DTL	 group.	 The	 results	 from	 the	 pilot	 study	make	 it	 possible	 to	 repeat	 the	 power	
calculation	 for	 the	 DTL	 and	 PCA	 groups.	 The	 results	 included	 in	 the	 calculation	 were	 the	
baseline	mean	values	compared	to	the	last	value	of	time	to	maximum	flux	on	the	study	toe		
DTL	Patients	(N=14):	Baseline	=	53	(78);	Last	=	89	(102)	
PCA	Patients	(N=10):	Baseline	=	202	(99);	Last	=	94	(83)	
The	average	change	was	36	seconds	(89-53)	in	the	DTL	group	and	108	seconds	(202-94)	in	
the	 PCA	 groups.	 Hence,	 the	 difference	 in	 the	 change	 between	 the	 two	 groups	 was	 72	
seconds	(108-36).	
The	 pooled	 standard	 deviation	 from	 this	 data	 is	 103.	 If	 the	 baseline	 and	 last	
measurements	on	the	same	patient	are	assumed	to	be	independent,	the	standard	deviation	
of	the	change	will	be	103	times	the	square	root	of	2,	i.e.	146	
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The	calculation	was	powered	based	on	a	t-test,	assuming	a	standard	deviation	of	146.	For	
a	detectable	difference	of	72,	a	sample	size	of	65	patients	per	group	would	be	sufficient	for	
80%	power	at	5%	alpha.		
Due	 to	 the	 lack	 of	 recruitment	 in	 the	 PBS	 group	 the	 best	 data	 remains	 that	which	 the	
initial	 power	 calculation	 was	 performed	 using.	 However,	 it	 would	make	 sense	 to	 aim	 for	
equal	group	sizes	if	further	recruitment	was	to	take	place.	Therefore,	if	the	same	proportion	
of	 drop	 outs	was	 to	 be	 expected	 (20%)	 the	 group	 size	would	 increase	 to	 80	meaning	 the	
target	for	recruitment	would	be	240	patients.	
Based	 on	 the	 difficulties	 with	 the	 pilot	 study	 it	 is	 highly	 unlikely	 that	 this	 level	 of	
recruitment	 would	 be	 possible	 without	 involving	 a	 large	 number	 of	 sites.	 There	 are	 also	
questions	whether	 the	results	would	answer	the	hypothesis	proposed	and	so	 it	 is	 felt	 that	
proceeding	with	this	study	would	be	fruitless.	
To	 move	 forward	 with	 addressing	 the	 question	 of	 how	 the	microcirculation	 relates	 to	
wound	healing	 it	 is	 felt	that	a	better	understanding	of	how	the	macrocirculation	relates	to	
microcirculation	 is	 required	 first.	 In	addition,	how	the	microcirculation	 in	 the	 foot	changes	
during	 ulcer	 healing	 needs	 to	 be	 better	 defined.	 To	 this	 end	 two	 new	 hypotheses	 are	
proposed	below:	
1. In	patients	with	PAD	with	or	without	DM	a	higher	burden	of	macrovascular	
disease,	as	measured	by	the	Bollinger	score,	correlates	to	reduced	skin	
perfusion	of	the	foot.	
2. As	an	ulcer	of	the	lower	extremity	heals	there	is	a	reduction	in	skin	perfusion.	
For	the	first	hypothesis	the	plan	would	be	to	recruit	patients	with	Rutherford	category	3	
or	4	disease296,	i.e.	significant	symptomatic	PAD	but	no	tissue	loss,	who	are	to	undergo	PCA.	
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Patients	would	be	grouped	by	a	history	of	DM.	Bollinger	score	would	be	calculated	based	on	
PCA	and	correlated	to	a	measure	of	pedal	skin	perfusion	performed	within	the	twenty-four	
hours	 preceding	 PCA.	 This	 is	 a	 development	 of	Williams’s287	 and	 Pardo’s288	 studies	with	 a	
focus	 on	 the	 burden	 of	 macrovascular	 disease.	 A	 progression	 of	 this	 study	 could	 be	 to	
recalculate	 Bollinger	 score	 and	 repeat	 skin	 perfusion	 tests	 following	 PCA	 as	 a	measure	 of	
success	of	the	procedure.	
The	 second	hypothesis	 is	 aimed	at	 further	examining	 the	 finding	 that	 in	our	DTL	group	
there	was	a	significant	reduction	in	TtM	on	the	study	toe	between	the	baseline	and	last	visit	
(Table	 5.7-9).	 Patients	 with	 active	 diabetic	 foot	 ulcers	 but	 no	 significant	 PAD	 would	 be	
recruited.	Patients	would	be	 recruited	at	 first	attendance	 for	 the	 index	ulcer	and	accurate	
volumes	 of	 the	 ulcer	 measured	 at	 the	 same	 time	 as	 assessment	 of	 skin	 perfusion	
surrounding	 the	 ulcer	 and	 foot	 as	 a	 whole.	 To	 improve	 the	 cohort	 selection	 an	 objective	
measure	of	absence	of	PAD	would	need	to	be	included	within	recruitment,	possibly	duplex	
ultrasound.	There	would	be	regular	 reassessment	until	ulcer	healing.	Potential	comparison	
groups	include	patients	with	venous	ulceration	and	no	significant	PAD.	
For	both	these	potential	studies	careful	consideration	needs	to	be	made	of	whether	LDF	
is	 the	most	appropriate	measure	of	skin	perfusion	to	utilise.	This	 is	particularly	true	of	 the	
second	 study	 due	 to	 the	 number	 of	 assessments	 that	would	 be	 required.	 The	process	 for	
performing	 PORH	 is	 quite	 lengthy	 and	 cumbersome.	 In	 addition,	 using	 the	 placement	 of	
single	probes	adjacent	to	the	ulcers	it	is	hard	to	form	a	generalised	view	of	the	status	of	the	
microcirculation	surrounding	the	ulcer.	A	modality	that	 images	the	whole	of	the	ulcer	area	
with	surrounding	skin	 from	which	 it	 is	possible	 to	 take	an	average	of	clearly	defined	areas	
may	 be	 more	 appropriate.	 Examples	 include	 laser	 Doppler	 perfusion	 imaging	 and	 laser	
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speckle	contrast	 imaging297.	TcPO2	as	an	alternative	measure	should	also	be	considered	as	
this	 is	the	modality	that	 is	 increasingly	being	 included	in	guidelines	on	the	management	of	
PAD	and	diabetic	foot	disease,	whereas	LDF	is	not74,184.	
6.6. CONCLUSIONS	
The	results	of	both	of	these	studies	have	to	be	taken	in	the	context	of	issues	with	design	
and	poor	recruitment.	In	the	examination	of	the	arterial	tree	it	has	been	demonstrated	that	
it	is	possible	to	extend	Bollinger’s	original	segments	down	to	include	the	whole	of	the	crural	
vessels	 and	 the	 pedal	 vessels	 with	 good	 inter	 and	 intra-rater	 reliability.	 In	 well	 matched	
cohorts	 those	without	 DM	 and	 critical	 ischaemia	 were	 found	 to	 have	 a	 higher	 burden	 of	
disease	in	the	pedal	vessels	but	patients	with	DM	had	a	higher	burden	of	disease	overall.	In	
addition	 to	 this,	 it	 has	 been	 shown	 that	 there	 is	 no	 difference	 in	 the	 need	 for	 further	
revascularisation	 in	 the	 DM	 patients	 despite	 having	 poorer	 outcomes	 overall.	 The	 studies	
then	 moved	 on	 to	 examine	 the	 microcirculation	 in	 patients	 with	 DM	 and	 active	 foot	
ulceration.	This	demonstrated	that	patients	who	had	arterial	disease	and	required	a	PCA	had	
significantly	 impaired	 microcirculatory	 reactivity	 compared	 to	 patients	 without	 significant	
PAD.	The	study	showed	that	microvascular	reactivity	significantly	improved	following	a	PCA	
bringing	this	group	up	to	a	level	comparable	to	the	DTL	group.		
Overall	 these	 studies	 have	 added	 to	 the	 literature	 considering	 the	 nature	 of	 PAD	 in	
patients	 with	 DM.	 Further	 work	 to	 investigate	 and	 clarify	 the	 relationship	 between	 the	
macro	and	microcirculation	has	been	proposed.	
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Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
98	
	 Embase	Classic	1947	to	1973	 2	
22	
(lower	adj	extremity	adj	 arterial	 adj	disease).mp.	 [mp=ti,	 ab,	hw,	 tn,	
ot,	dm,	mf,	dv,	kw,	nm,	kf,	px,	rx,	ui]	
440	
	 Embase	1974	to	2016	July	26	 246	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
193	
	 Embase	Classic	1947	to	1973	 1	
23	 exp	Peripheral	Arterial	Disease/	 149371	
	 Embase	1974	to	2016	July	26	 138066	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
3981	
	 Embase	Classic	1947	to	1973	 7324	
24	
(peripheral	adj	arterial	adj	disease).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	
dv,	kw,	nm,	kf,	px,	rx,	ui]	
20716	
	 Embase	1974	to	2016	July	26	 10977	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
9587	
	 Embase	Classic	1947	to	1973	 152	
25	 PAD.mp.	 49705	
	 Embase	1974	to	2016	July	26	 28910	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
18807	
	 Embase	Classic	1947	to	1973	 1988	
26	 claudication.mp.	 30982	
	 Embase	1974	to	2016	July	26	 17693	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
12016	
	 Embase	Classic	1947	to	1973	 1273	
27	 exp	Intermittent	Claudication/	 17685	
	 Embase	1974	to	2016	July	26	 9355	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
7350	
	 Embase	Classic	1947	to	1973	 980	
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28	
(critical	adj	ischaemia).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	nm,	
kf,	px,	rx,	ui]	
859	
	 Embase	1974	to	2016	July	26	 481	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
375	
	 Embase	Classic	1947	to	1973	 3	
29	 exp	Ischemia/	 732052	
	 Embase	1974	to	2016	July	26	 646932	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
53923	
	 Embase	Classic	1947	to	1973	 31197	
30	 ulceration.mp.	 63936	
	 Embase	1974	to	2016	July	26	 33445	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
25013	
	 Embase	Classic	1947	to	1973	 5478	
31	 exp	Skin	Ulcer/	 100281	
	 Embase	1974	to	2016	July	26	 58437	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
38675	
	 Embase	Classic	1947	to	1973	 3169	
32	
(anatomical	adj1	distribution).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	
kw,	nm,	kf,	px,	rx,	ui]	
3913	
	 Embase	1974	to	2016	July	26	 2049	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
1694	
	 Embase	Classic	1947	to	1973	 170	
33	
(distribution	adj2	disease).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	
nm,	kf,	px,	rx,	ui]	
3867	
	 Embase	1974	to	2016	July	26	 2205	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
1567	
	 Embase	Classic	1947	to	1973	 95	
34	
(extent	adj2	disease).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	nm,	
kf,	px,	rx,	ui]	
14300	
	 Embase	1974	to	2016	July	26	 8190	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
5845	
	 Embase	Classic	1947	to	1973	 265	
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35	
(disease	adj2	location).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	nm,	
kf,	px,	rx,	ui]	
3160	
	 Embase	1974	to	2016	July	26	 2045	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
1092	
	 Embase	Classic	1947	to	1973	 23	
36	
(distribution	adj1	pattern).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	
nm,	kf,	px,	rx,	ui]	
22369	
	 Embase	1974	to	2016	July	26	 11520	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
10107	
	 Embase	Classic	1947	to	1973	 742	
37	
(pattern*	adj2	arter*	adj	disease).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	
dv,	kw,	nm,	kf,	px,	rx,	ui]	
16	
	 Embase	1974	to	2016	July	26	 9	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
6	
	 Embase	Classic	1947	to	1973	 1	
38	
(distribution	adj2	disease).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	
nm,	kf,	px,	rx,	ui]	
3867	
	 Embase	1974	to	2016	July	26	 2205	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
1567	
	 Embase	Classic	1947	to	1973	 95	
39	
(anatomical	 adj	 distribution).mp.	 [mp=ti,	 ab,	 hw,	 tn,	 ot,	 dm,	mf,	 dv,	
kw,	nm,	kf,	px,	rx,	ui]2031	
3879	
	 Embase	1974	to	2016	July	26	 2031	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
1679	
	 Embase	Classic	1947	to	1973	 169	
40	
(computed	adj	tomography	adj	angiogra*).mp.	[mp=ti,	ab,	hw,	tn,	ot,	
dm,	mf,	dv,	kw,	nm,	kf,	px,	rx,	ui]	
11979	
	 Embase	1974	to	2016	July	26	 7019	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
4960	
	 Embase	Classic	1947	to	1973	 0	
41	 exp	Tomography,	X-Ray	Computed/	 1082569	
	 Embase	1974	to	2016	July	26	 735608	
	 Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	 346944	
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Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
	 Embase	Classic	1947	to	1973	 17	
42	 CTA.mp.	 20590	
	 Embase	1974	to	2016	July	26	 13007	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
7542	
	 Embase	Classic	1947	to	1973	 41	
43	
(magnetic	adj	resonance	adj	angiogr*).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	
mf,	dv,	kw,	nm,	kf,	px,	rx,	ui]	
51966	
	 Embase	1974	to	2016	July	26	 29759	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
2207	
	 Embase	Classic	1947	to	1973	 0	
44	 exp	Magnetic	Resonance	Angiography/	 47625	
	 Embase	1974	to	2016	July	26	 28117	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
19508	
	 Embase	Classic	1947	to	1973	 0	
45	 MRA.mp.	 17643	
	 Embase	1974	to	2016	July	26	 10903	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
6731	
	 Embase	Classic	1947	to	1973	 9	
46	 exp	Angioplasty/	 132373	
	 Embase	1974	to	2016	July	26	 74904	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
57373	
	 Embase	Classic	1947	to	1973	 96	
47	 angioplasty.mp.	 155315	
	 Embase	1974	to	2016	July	26	 84658	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
70561	
	 Embase	Classic	1947	to	1973	 96	
48	 angiogra*.mp.	 607552	
	 Embase	1974	to	2016	July	26	 330601	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
261871	
	 Embase	Classic	1947	to	1973	 15080	
49	 exp	Angiography/	 589727	
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	 Embase	1974	to	2016	July	26	 346952	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
216190	
	 Embase	Classic	1947	to	1973	 26585	
50	 exp	Ultrasonography,	Doppler/	 92873	
	 Embase	1974	to	2016	July	26	 30325	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
62329	
	 Embase	Classic	1947	to	1973	 219	
51	
(Doppler	adj	ultrasound).mp.	 [mp=ti,	 ab,	hw,	 tn,	ot,	dm,	mf,	dv,	 kw,	
nm,	kf,	px,	rx,	ui]	
29208	
	 Embase	1974	to	2016	July	26	 17388	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
11757	
	 Embase	Classic	1947	to	1973	 63	
52	
(arterial	adj	duplex).mp.	[mp=ti,	ab,	hw,	tn,	ot,	dm,	mf,	dv,	kw,	nm,	kf,	
px,	rx,	ui]	
242	
	 Embase	1974	to	2016	July	26	 149	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
93	
	 Embase	Classic	1947	to	1973	 0	
53	 exp	Ultrasonography,	Doppler,	Duplex/	 55717	
	 Embase	1974	to	2016	July	26	 32340	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
23359	
	 Embase	Classic	1947	to	1973	 18	
54	
1	or	2	or	3	or	4	or	5	or	6	or	7	or	8	or	9	or	10	or	11	or	12	or	13	or	14	or	
15	
2207660	
	 Embase	1974	to	2016	July	26	 1233883	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
935467	
	 Embase	Classic	1947	to	1973	 38310	
55	
16	or	17	or	18	or	19	or	20	or	21	or	22	or	23	or	24	or	25	or	26	or	27	or	
28	or	29	or	30	or	31	
2037322	
	 Embase	1974	to	2016	July	26	 1621995	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
316778	
	 Embase	Classic	1947	to	1973	 98549	
56	 32	or	33	or	34	or	35	or	36	or	37	or	38	or	39	 1883742	
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	 Embase	1974	to	2016	July	26	 1157143	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
697678	
	 Embase	Classic	1947	to	1973	 28921	
57	
40	or	41	or	42	or	43	or	44	or	45	or	46	or	47	or	48	or	49	or	50	or	51	or	
52	or	53	
47198	
	 Embase	1974	to	2016	July	26	 25758	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
20151	
	 Embase	Classic	1947	to	1973	 1289	
58	 54	and	55	and	56	and	57	 151	
	 Embase	1974	to	2016	July	26	 120	
	
Ovid	 MEDLINE(R)	 and	 MEDLINE(R)	 Daily	 1946	 to	 Present,	 Epub	
Ahead	of	Print,	In-Process	&	Other	Non-Indexed	Citations,	Ovid		
29	
	 Embase	Classic	1947	to	1973	 2	
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 SEARCH	STRATEGY	FOR	WOUND	HEALING	REVIEW	
	
	
	
	
	
MESH	Search	
Search	 Search	terms	
1	 microcirculation	
2	 wound	healing	
3	 diabetic	foot	
4	 skin	ulcer	
5	 Laser	Doppler	flowmetry	
6	 blood	gas	monitoring,	transcutaneous	
7	 Microscopic	angioscopy	
8	 Xenon	radioisotopes	
9	 3	or	4		
10	 5	or	6	or	7	or	8	
11	 1	and	2	and	9	and	10	
12	 11	limited	to	English	and	humans	
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Keyword	search	
Search	 Search	terms	
1	
capillar*	or	venule*	or	arteriole*	or	small	adj2	vessels	or	skin	microcirculation	or	
skin	 blood	 supply	 or	 skin	 blood	 flow	 or	 microangiopath*	 or	 microcircula*	
disturbance*	
	 	
2	
transcutaneous	adj3	oxygen*	or	transcutaneous	PO2	or	transcutaneous	oximetry	
or	transcutaneous	adj3	carbon	dioxide	or	TcPO2	or	TcPCO2	
	 	
3	
laser	 Doppler*	 or	 laser	 Doppler	 fluxmetry	 or	 laser	 Doppler	 Imaging	 or	 laser	
Doppler	velocimetry	or	laser	Doppler	flux	or	LDF	or	LDI	or	Post	occlusive	reactive	
hyperaemia	or	PORH	
	 	
4	 capillary	microscopy	or	capillary	pressure	or	capillaroscopy		
	 	
5	 skin	adj2	pressure	or	skin	adj2	perfusion	
	 	
6	
xenon	 clearance	 or	 isotope	 clearance	 or	 haemodynamic	 test*	 or	 venoarteriolar	
response	
	 	
7	 2	or	3	or	4	or	5	or	6	
8	
wound*	or	ulcer*	or	ulcer	healing	or	tissue	loss	or	healing	or	wound	complication*	
or	non-healing	or	nonhealing	or	granulation	tissue	or	amputat*	
	 	
9	 1	and	7	and	8		
	 	
10	 9	limited	to	English	and	humans	only	
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 PLAN	FOR	COHORT	STUDY	AS	PRESENTED	IN	RESEARCH	
PROPOSAL	
HYPOTHESIS	
Improving	the	microcirculation	of	the	foot	in	patients	with	diabetic	foot	disease	improves	
wound	healing	and	degree	of	peripheral	neuropathy.		
MAIN	QUESTIONS	TO	BE	ADDRESSED	
To	address	the	hypothesis,	I	am	asking	the	following	questions.	
• What	is	the	level	of	improvement	in	the	microcirculation	at	the	time	of	wound	
healing	in	patients	with	DM	and	PAD?	
• Which	of	PCA	or	peripheral	bypass	surgery	(PBS)	provide	a	greater	improvement	in	
the	microcirculation?	
• Is	there	any	improvement	in	the	neurological	status	of	patients	with	neuro-ischaemic	
ulceration	who	have	undergone	revascularisation?	
• Is	there	a	change	in	mean	foot	temperature	immediately	following	revascularisation?	
	
OUTCOME	MEASURES	
Primary	outcome	
• Evidence	of	difference	in	the	level	of	change	in	the	time	to	maximum	flux	between,	
before,	and	after	PCA	or	PBS.	
	
Secondary	outcomes	
• Evidence	of	difference	in	the	level	of	change	in	the	time	to	maximum	flux	between	
when	ulceration	active	and	when	ulceration	healed	in	patients	with	DM	and	no	
significant	PAD.	
• Time	to	wound	healing	
• Time	to	major	amputation	
• The	change	in	skin	perfusion	pressure	(SPP)	at	the	end	of	the	study	
• The	change	in	toe	blood	pressure	index	(TBPI)	at	the	end	of	the	study	
• The	change	in	VPT	at	the	end	of	the	study	
• The	change	in	monofilament	detection	at	the	end	of	the	study	
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• The	change	in	Ipswich	touch	test	(ITT)	at	the	end	of	the	study	
• The	change	in	neuropathy	total	symptom	score	-	6	(NTSS-6)	at	the	end	of	the	study	
	
End	of	the	study	 is	defined	as	either	complete	wound	healing,	major	amputation	of	the	
study	limb	or	time	for	the	conduct	of	the	study	elapsing.	
	
RESEARCH	PLAN	
To	 conduct	 an	 observational	 cohort	 study	 of	 patients	with	 active	 diabetic	 foot	 disease	
who	require	lower	limb	revascularisation,	either	by	arterial	bypass	graft	or	angioplasty.	This	
will	be	based	at	three	NHS	hospital	sites	in	the	West	Midlands.	
	
STUDY	GROUPS	
Peripheral	bypass	surgery	
Patients	with	 active	 tissue	 loss	 and	 PAD	 confirmed	 clinically	 and	 on	Duplex	Ultrasound	
(DUS),	 Computed	 Tomography	 Angiography	 (CTA)	 or	 Magnetic	 Resonance	 Angiography	
(MRA)	who	on	assessment	by	their	named	consultant	require	PBS.	This	group	will	be	further	
divided	into	those	with	DM	and	those	without.	
	
Percutaneous	angioplasty	(PCA)	
Patients	with	active	tissue	loss	and	PAD	confirmed	clinically	and	on	DUS,	CTA	or	MRA	who	
on	assessment	by	their	named	consultant	require	PCA.	This	group	will	be	further	divided	into	
those	with	DM	and	those	without.	
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Diabetic	tissue	loss	without	PAD	(DTL)	
Patients	with	type	I	or	II	DM	and	active	tissue	loss	without	clinically	significant	PAD.	
	
INCLUSION	CRITERIA	
For	participants	requiring	either	PBS	or	PCA	with	DM	and	PAD.	
• Type	I	or	II	DM	requiring	medical	therapy	
• Active	tissue	loss	
• Require	revascularisation	(open	or	endovascular)	
• Aged	between	18	and	99	years	
• Able	to	give	informed	consent	
	
For	participants	requiring	either	PBS	or	PCA	with	PAD	but	no	DM	
• As	the	first	group	apart	from	no	previous	history	of	DM	and	a	normal	random	
glycated	haemoglobin	level	(HBA1c)	within	the	last	six-months.	
For	participants	with	DM	and	no	PAD		
• As	the	first	group	apart	from	no	evidence	of	PAD	requiring	revascularisation.	
	
EXCLUSION	CRITERIA	
• Unwilling	or	unable	to	give	informed	consent	
• Previous	distal	arterial	bypass	on	the	ulcerated	leg.	
• Angioplasty	to	the	ulcerated	leg	during	this	period	of	active	ulceration.	
• Significant	non-reconstructable	PAD.	
• Previously	diagnosed	peripheral	neuropathy	secondary	to	a	cause	other	than	DM.	
• Medically	unfit	for	the	procedure.	
• Pregnancy	or	breast-feeding	
• Vitamin	B12	deficiency.	
• Alcohol	dependency.	
• Hypothyroidism.	
• Renal	failure	requiring	renal	replacement	therapy.	
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PATIENT	IDENTIFICATION	
Potential	 patients	 will	 be	 identified	 predominantly	 from	 diabetic	 foot	 clinics,	 vascular	
clinics	 and	 inpatient	 admissions	 at	 the	 study	 sites.	 The	 patients	 will	 be	 identified	 by	 the	
investigators	and	other	doctors	on	the	vascular	and	diabetes	teams.	As	it	will	not	be	possible	
for	a	member	of	 the	study	to	be	present	 in	person	at	all	 relevant	clinics	review	of	referral	
documentation	to	clinics,	theatre	lists	and	angioplasty	lists	will	be	conducted.	This	will	only	
be	 performed	 at	 the	 University	 Hospitals	 Birmingham	 site	 as	 I	 only	 have	 clinical	
responsibilities	at	 this	 site	and	 so	am	already	 in	 receipt	of	 the	 relevant	 lists.	 If	 a	potential	
patient	 is	 identified	 from	 these	 lists	 a	patient	 invitation	 letter	 (Appendix	 IV)	 and	a	patient	
information	sheet	(Appendix	V)	will	be	posted	to	their	home	address.	The	patient	invitation	
letter	contains	a	reply	slip	and	stamped	addressed	envelope	which	will	allow	the	patient	to	
express	their	desire	or	otherwise	to	be	included	in	the	study.	If	I	do	not	receive	a	reply	slip,	
that	states	the	patient	does	not	wish	to	be	contacted,	then,	after	1-2	weeks	the	letter	will	be	
followed-up	with	a	phone	call.	On	the	day	of	their	procedure	or	next	clinic	appointment,	the	
patient	will	be	met	by	myself	to	answer	any	questions	and	confirmed	that	they	still	wish	to	
participate.	If	appropriate,	consent	will	be	taken,	and	the	first	assessment	carried	out	at	this	
time.	
CONSENT	
All	 participants	 will	 be	 verbally	 invited	 to	 take	 part	 in	 the	 study	 by	 the	 clinical	 team	
providing	their	care.	They	will	be	given	written	information	with	regards	to	the	purpose	and	
design	 of	 the	 study	 (Appendix	 V).	 They	 will	 then	 be	 invited	 to	 participate	 and	 if	 agreed,	
consented	 using	 a	 standardised	 consent	 form	 (Appendix	 VI).	 This	 will	 be	 performed	 and	
undertaken	by	a	member	of	the	study	team.	
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Consent	 to	 participate	 will	 include	 consent	 to	 the	 use	 of	 data	 obtained	 during	 their	
participation	 in	 the	 final	 analysis.	 Participants	 will	 be	 free	 to	 leave	 the	 study	with	 only	 a	
verbal	 request,	 though	their	non-identifiable	data	will	continue	to	remain	within	the	study	
unless	 a	 written	 request	 is	 made	 to	 the	 contrary.	 This	 will	 be	made	 clear	 at	 the	 time	 of	
consent.	
	
ASSESSMENT	
Timing	of	assessments	
For	the	PBS	and	PCA	groups,	the	initial	assessment	will	be	carried	out	within	the	24	hours	
before	 their	 procedure.	 For	 the	 DTL	 group,	 the	 initial	 assessment	 will	 be	 carried	 out	
following	 informed	 consent	 being	 gained.	 If	 possible,	 this	 will	 be	 during	 the	 same	
attendance.	
Post-procedure	assessment	for	the	PBS	and	PCA	groups	will	occur	at	initial	follow-up	clinic	
appointment	one	month	following	their	procedure.	The	infrared	temperature	measurement	
will	be	performed	only	once	post	procedure,	within	the	first	24	hours	after	revascularisation.	
Subsequent	re-examination	will	occur	monthly	(within	a	week)	at	the	hospital	appointment	
that	 falls	 nearest	 this	 time.	 This	 includes	 vascular,	 diabetes	 and	 podiatry	 appointments.	
Reassessment	will	 continue	until	 the	ulcer	 is	 decided	 to	 have	 clinically	 healed,	 the	 limb	 is	
amputated,	or	the	end	of	the	study	is	reached.	
The	DTL	group	will	have	 repeat	assessments	monthly	until	 the	ulcer	 is	decided	 to	have	
clinically	healed,	the	limb	is	amputated,	or	the	end	of	the	study	is	reached.	
	
Procedure	for	data	collection	
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The	patient	will	be	asked	to	arrive	for	their	appointment	having	not	eaten	for	the	last	2	
hours	and	not	had	any	caffeinated	drinks	since	the	proceeding	night.	They	will	be	assessed	in	
a	temperature	controlled	clinic	room	(220C	+/-	20C)	or	if	for	inpatients	this	is	not	possible	the	
temperature	will	be	recorded.	The	patient	will	be	positioned	on	a	couch	in	a	semi-recumbent	
position	 so	 they	 can	 acclimatise	 to	 the	 temperature	 of	 the	 room.	 During	 the	 first	 fifteen	
minutes,	 the	 NTSS-6	 questionnaire	 will	 be	 completed,	 and	 monofilament,	 ITT	 and	 VPT	
testing	 carried	 out	 on	 both	 feet.	 The	 characteristics	 of	 the	 ulcer/s	will	 also	 be	 described.	
During	the	second	fifteen	minutes,	the	patient	will	be	asked	to	relax,	and	the	laser	Doppler	
fluxmetry	(LDF)	probes	will	be	attached.	The	protocol	for	each	measurement	is	as	follows.	
	
10g	Monofilament	
Three	areas	on	each	foot	will	be	tested.	These	are	plantar	aspects	of	the	hallux,	and	base	
of	the	third	and	fifth	metatarsals18,120.	A	positive	or	negative	response	for	each	area	will	be	
recorded.	Abnormal	will	be	defined	as	an	inability	to	detect	the	monofilament	in	one	area.	If	
it	 is	 not	 possible	 to	 test	 any	 of	 the	 areas	 due	 to	 amputation	 or	 ulceration,	 this	 will	 be	
recorded.	
	
Ipswich	Touch	Test	
The	tips	of	the	1st,	3rd	and	5th	toes	of	each	foot	will	be	tested	 in	the	order	described	by	
Diabetes	UK	in	their	 leaflet	"How	to	do	the	Touch	the	Toes	Test"262.	A	positive	or	negative	
response	for	each	area	will	be	recorded.	If	 it	 is	not	possible	to	test	any	of	the	areas	due	to	
amputation	or	ulceration,	this	will	be	recorded.		
VPT	
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VPT	will	 be	assessed	on	 the	pulp	of	 the	hallux	or	next	dominant	 toe	 if	 amputation	has	
occurred	 in	 the	 past	 or	 the	 toe	 is	 necrotic.	 A	 neurothesiometer	 will	 be	 used.	 The	 first	
measurement	 will	 be	 taken	 increasing	 from	 zero	 to	 maximum	 and	 the	 level	 at	 which	
vibration	 is	 detected	 recorded.	 The	 second	measurement	will	 be	 taken	 from	maximum	 to	
zero	and	the	level	at	which	vibration	disappears	recorded.	An	average	of	these	two	readings	
will	be	taken.	If	no	vibration	is	detected,	then	50V	will	be	recorded.	
	
Ulcer	description	
The	ulcer/s	will	be	described	in	the	same	way	as	used	by	the	Eurodiale	study	263.	Area	of	
the	 ulcer	 will	 be	 determined	 by	 multiplying	 the	 largest	 diameter	 by	 the	 second	 largest	
diameter	 perpendicular	 to	 the	 first.	 Depth	 will	 be	 described	 as	 superficial	 or	 deep:	 a	
superficial	ulcer	is	a	full-thickness	lesion	of	the	skin	not	extending	through	the	subcutis,	and	
a	 deep	 ulcer	 is	 a	 lesion	 of	 the	 skin	 extending	 through	 the	 subcutis.	 An	 infection	 will	 be	
diagnosed	if	two	or	more	of	the	following	signs	are	present:	frank	purulence,	local	warmth,	
erythema,	lymphangitis,	oedema,	pain,	fever	and	foul	smell.	The	anatomical	location	of	the	
ulcer/s	 will	 also	 be	 described.	 The	 ulcer	 will	 be	 described	 as	 healed	 when	 complete	
epithelialisation	has	occurred.	
	
Laser	Doppler	Fluxmetry	
The	patient’s	feet	will	be	placed	on	a	pillow	to	stabilise	them	and	a	laser	Doppler	probe	
placed	on	the	pulp	of	the	hallux	or	remaining	dominant	toe	and	dorsal	surface	of	the	foot	
between	the	2nd	and	3rd	metatarsals.	A	cuff	will	be	placed	around	the	patient’s	ankle.	The	
LDF	will	then	be	turned	on	and	baseline	flux	measured	for	one	minute,	the	cuff	will	then	be	
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inflated	 for	 three	minutes	 followed	by	 rapid	deflation	 and	monitoring	of	 the	 response	 for	
five	minutes.		
A	toe	cuff	placed	around	the	great	toe	or	remaining	dominant	toe	will	 then	replace	the	
cuff	around	the	ankle.	Toe	blood	pressure	will	then	be	measured.	
Following	this,	the	low-profile	probe	will	be	placed	adjacent	to	the	ulcerated	tissue	and	a	
cuff	placed	over.	SPP	will	then	be	measured	with	slow	deflation	of	the	cuff.	
Probes	will	 then	 be	 transferred	 to	 the	 other	 leg	 and	 the	 process	 repeated.	 Finally,	 the	
probes	will	be	moved,	one	to	the	ventral	surface	of	each	forearm	and	a	cuff	placed	around	
the	upper	arm	and	brachial	pressure	measured.	This	whole	process	will	take	approximately	
thirty	minutes.	
The	data	obtained	will	be	processed	using	the	Moor	VMS-PC™	software.	
	
Demographics	
Demographics	that	will	be	collected	at	first	appointment	are	listed	below.	
• Age	
• Sex	
• Type	of	DM	
• Duration	of	DM	
• Current	medications	
• Recent	blood	results	including	glycosylated	haemoglobin,	cholesterol,	thyroid	
stimulating	hormone,	free	T4	and	vitamin	B12.	
	
	
	
DATA	COLLECTION	AND	MANAGEMENT	
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Data	will	be	recorded	directly	onto	a	standard	data	collection	proforma,	and	the	LDF	data	
will	 be	 recorded	 onto	 an	 encrypted	 computer.	 The	 analysis	 will	 also	 take	 place	 on	 this	
computer.	
Data	storage	
All	identifiable	patient	data	will	be	collected	and	stored	on	an	encrypted	computer	to	be	
kept	locked	within	secured	premises	within	the	vascular	department.	This	will	be	maintained	
as	 per	 data	 protection	 and	 GCP	 guidelines	 then	 stored	 for	 the	 required	 five	 years	 before	
destruction.	
Source	data	
Source	data	will	be	kept	within	the	source	data	file	that	will,	in	turn,	be	kept	locked	within	
a	secure	office	locked	and	secure	within	the	Vascular	Department.	It	will	be	accessible	only	
by	those	signatories	within	the	research	group	and	by	the	sponsors	as	requested.	
	
DATA	ANALYSIS	PLAN	
Sample	size	calculation	
Data	 previously	 obtained	 at	 our	 institution261	 found	 the	 following	 values	 for	 the	mean	
(Standard	Deviation)	times	(in	seconds)	to	maximum	post-occlusive	reactive	hyperaemia:	
Bypass	Patients	(N=29):	Preoperative	=	100	(22);	Postoperative	=	59	(38)	
PCA	Patients	(N=9):	Preoperative	=	69	(27);	Postoperative	=	55	(30)	
The	average	improvement	was	41	seconds	(100-59)	in	the	bypass	group	and	14	seconds	
(69-55)	 in	 the	 PCA	 groups.	 Hence,	 the	 difference	 in	 the	 improvement	 between	 the	 two	
groups	was	27	seconds	(41-14).	
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The	 pooled	 standard	 deviation	 from	 this	 data	 is	 30.	 If	 the	 pre	 and	 post-operative	
measurements	on	the	same	patient	are	assumed	to	be	independent,	the	standard	deviation	
of	the	change	will	be	30	times	the	square	root	of	2,	i.e.	42	
The	 study	was	 powered	 based	 on	 a	 t-test,	 assuming	 a	 standard	 deviation	 of	 42.	 For	 a	
detectable	difference	of	27,	a	sample	size	of	40	patients	per	group	(i.e.	80	total)	would	be	
sufficient	for	80%	power	at	5%	alpha.		
There	 is	 no	 equivalent	 data	 available	 with	 which	 it	 would	 be	 possible	 to	 calculate	 an	
appropriate	sample	size	for	the	group	with	DM	and	no	PAD.	For	this	reason,	they	have	not	
been	included	in	the	primary	outcome.	A	sample	size	of	20	will	be	able	to	detect	a	difference	
of	33	seconds	between	the	initial	measurement	and	the	point	of	healing.	This	was	agreed	to	
be	reasonable	as	a	consensus	within	the	research	group.		
Due	to	the	demographics	of	patients	being	investigated	previous	experience	suggests	that	
a	 high	 dropout	 rate	 (up	 to	 20%)	 should	 be	 expected.	 This	 increases	 the	 size	 of	 our	 study	
groups	to	48	for	both	the	bypass	and	angioplasty	groups	and	24	for	the	control	group.	This	
brings	our	total	sample	size	to	120	participants.	
Proposed	analyses	
The	initial	comparison	will	be	made	between	the	three	main	study	groups	PCA,	PBS	and	
DTL,	as	described	in	Section	5.6.2.	For	the	PCA	and	PBS	group,	there	will	then	be	a	further	
comparison	of	those	with	DM	and	those	without.	
The	outcome	variables	considered	are	made	up	of	three	different	types	of	data,	each	of	
which	will	be	analysed	using	a	different	approach	(Table	III-1).	
	
Continuous	data	(e.g.	PORH)	
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Initially,	 the	 data	 will	 be	 tested	 for	 normality,	 as	 this	 is	 an	 assumption	 underlying	
parametric	analyses.	If	the	data	are	normally	distributed,	then	a	t-test	will	be	performed	to	
compare	 means	 for	 mean	 temperature	 measurements	 and	 a	 repeated	 measures	 ANOVA	
model	will	be	produced,	to	compare	the	serial	measurements	of	the	outcome	between	the	
three	 study	 arms.	 A	 second	 analysis	 will	 then	 be	 performed,	 including	 other	 potentially	
relevant	variables,	to	account	for	the	potentially	confounding	effects	of	baseline	differences	
between	the	treatment	arms.	
	
Binary	data	(e.g.	Wound	healing)		
For	 binary	 data,	 the	 outcome	 rates	will	 initially	 be	 compared	 between	 the	 study	 arms	
using	 Fisher's	 exact	 tests.	 Multivariable	 binary	 logistic	 regression	 models	 will	 then	 be	
produced,	to	account	for	the	effects	of	other	potentially	confounding	factors.	
	
Time	to	event	data	(e.g.	Major	amputation)		
Time	to	event	data	will	be	analysed	using	survival	analysis	methods.	Kaplan-Meier	survival	
curves	will	be	produced	for	each	of	 the	study	arms,	and	comparisons	made	using	 log-rank	
tests.	Cox	regression	models	will	 then	be	used	to	account	 for	the	effects	of	other	relevant	
factors.	
	
Table	III-1:	Summary	of	proposed	data	analysis	
Data	type	 Variables	 Analysis	
Baseline	value	 PORH	
VPT	
SPP	
TBPI	
One	way	ANOVA/Kruskal-
Wallis	
	
	236	
NTSS-6	
Repeated	value/	
Percentage	 change	
from	baseline	
PORH	
VPT	
SPP	
TBPI	
NTSS-6	
Repeated	measure	ANOVA	
	
Event		 Wound	healing	
Major	amputation	
Fisher	exact	test/binary	
logistic	regression	
Time	to	event	 Wound	healing	
Major	amputation	
Survival	curve	with	Log-rank	
test/Cox	regression	
Categorical		 VPT	(£25	to	>25V)	
Monofilament	 (0	 to	 ³1	 points	
detected)	
ITT	(£2	to	>2	points	detected)	
NTSS-6	(£6	to	>6	scored)	
Binary	logistic	regression	
PORH=Post-occlusive	reactive	hyperaemia,	VPT=Vibration	perception	threshold,	SPP=Skin	
perfusion	pressure,	TBPI=Toe	blood	pressure	index,	NTSS-6=	Neuropathy	Total	Symptom	
Score	–	6,	ITT=Ipswich	touch	test	
	
Missing	data	
All	available	data	will	be	included	in	the	analysis.	This	makes	the	assumption	that	missing	
values	can	be	assumed	to	be	missing	at	random.	However,	this	may	not	be	the	case.		
In	 order	 to	 verify	 this,	 comparisons	 will	 be	 made	 between	 those	 patients	 with	 data	
available	and	those	with	missing	values.	 If	no	significant	differences	 in	the	demographic	or	
clinical	factors	of	these	groups	are	detected,	then	it	will	be	assumed	that	the	assumption	of	
data	 missing	 at	 random	 has	 been	 met.	 If	 differences	 between	 those	 patients	 with	 and	
without	missing	data	are	present,	then	the	degree	of	this	bias	will	be	compared	between	the	
treatment	 groups.	 If	 the	 levels	 of	 bias	 are	 similar	 in	 the	 three	 groups,	 then	 the	 effect	 of	
missing	data	on	the	conclusions	of	the	final	analysis	can	be	assumed	to	be	negligible.		
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If	 significant	 bias	 is	 present,	 and	 to	 a	 different	 degree	 in	 the	 three	 groups,	 this	will	 be	
quantified	as	a	limitation	in	the	results,	and	the	conclusions	of	the	analyses	interpreted	with	
caution.	
We	 anticipate	 that	 the	 data	 collection	 from	 follow-up	 appointments	 will	 be	 relatively	
complete,	 with	 the	 majority	 of	 missing	 data	 being	 as	 a	 result	 of	 patients	 either	 not	
attending,	 or	 choosing	 to	 be	 withdrawn	 from	 the	 study.	 If	 this	 proves	 to	 be	 the	 case,	 a	
sensitivity	analysis	will	be	performed.	This	will	only	consider	data	from	a	truncated	period	of	
follow-up,	 in	which	the	number	of	missing	values	are	minimal.	Whilst	 this	will	not	have	as	
much	statistical	power	as	the	main	analysis	(on	account	of	the	smaller	amount	of	data),	the	
effect	sizes	observed	should	be	similar.	Where	this	is	the	case,	the	conclusions	of	the	main	
analysis	 will	 be	 accepted.	 However,	 if	 there	 are	 discrepancies	 between	 the	 main	 and	
sensitivity	analyses,	the	conclusions	will	be	interpreted	in	light	of	this	potential	bias.		
ETHICAL	CONSIDERATIONS 
Local	 Research	 Ethics	 Committee	 approval	 was	 sought	 from	 the	 South	 Birmingham	
Research	 Ethics	 Committee.	 Approval	 was	 granted	 on	 26th	 June	 2014.	 Approval	 was	 also	
sought	from	the	Research	and	Development	departments	of	the	three	study	sites,	University	
Hospitals	 Birmingham	 NHS	 Foundation	 Trust,	 Dudley	 Group	 NHS	 Foundation	 Trust	 and	
Sandwell	and	West	Birmingham	Hospitals	NHS	Trust.	These	were	approved	on	24th	July	2014,	
18th	July	2014	and	30th	September	2014	respectively. 
 
All	 research	 was	 conducted	 in	 line	 with	 the	World	 Medical	 Association	 Declaration	 of	
Helsinki.	All	members	of	the	research	group	received	Good	Clinical	Practice	Training	as	per	
the	National	Institute	for	Health	Research,	and	the	research	was	conducted	in	line	with	the	
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same	principles.	Funding	to	purchase	the	equipment	(the	laser	Doppler	equipment)	for	the	
study	was	 sourced	 from	 the	 Vascular	 surgery	 research	 fund	 held	 by	 the	 Queen	 Elizabeth	
Hospital	Birmingham	Charity	and	not	from	commercial	sources.	
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 PATIENT	INVITATION	LETTER	
	
	
	
Patient	Invitation	Letter	1.1	 	 03/08/2015	
	
 
 
 
 
 
	
Dear	Sir/Madam,	
	
As	 you	 may	 be	 aware	 University	 Hospitals	 Birmingham	 NHS	 Foundation	 Trust	 is	
actively	involved	in	clinical	research	within	many	medical	specialities.		In	the	Vascular	
Surgery	 department	 we	 are	 currently	 conducting	 a	 study	 called	 “What	 is	 the	
relationship	 of	 revascularisation	 and	 improvement	 in	microcirculation	 to	 wound	
healing	 and	 peripheral	 neuropathy	 in	 diabetic	 foot	 disease?	 An	 observational	
cohort	study.”	You	may	be	suitable	to	be	included	in	this	study	and	I	have	attached	
some	further	information	to	this	letter.	
I	will	be	phoning	you	before	your	next	hospital	appointment	to	discuss	this	with	you,	
or	 if	 you	 prefer	 please	 return	 the	 attached	 reply	 slip	 in	 the	 provided	 stamped	
addressed	envelope.		Alternatively	you	may	contact	me	by	the	methods	below.	
	
Office: 	
Email:	 		
	
Yours	Sincerely	
	
Danielle	Lowry	MBChB,	MRCS	
Vascular	Research	Registrar		
	
	
	
	
	
	
Mindelsohn	Way,	
Edgbaston,		
Birmingham,	
B15	2GW	
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Patient	Invitation	Letter	1.1	 	 03/08/2015	
Reply	Slip	
	
	
Name:	______________________________________________________________		
Date	of	Birth:	____/____/_______	
Address:	____________________________________________________________	
																____________________________________________________________		
																____________________________________________________________	
																____________________________________________________________	
																Postcode:	_______________	
	
I	am	happy	to	be	contacted	to	discuss	this	study	further	
	
I	do	not	wish	to	participate	in	this	study.	
	
	
Signature:	________________													Date:	_______________	
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 	PATIENT	INFORMATION	SHEET	
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 PATIENT	CONSENT	FORM	
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 POST	OCCLUSIVE	REACTIVE	HYPERAEMIA	TABLES	WITH	ALL	VARIABLES	
	
Table	I:	Post	occlusive	reactive	hyperaemia	results	at	baseline	by	group	
	
Diabetic	Tissue	Loss		
Median	(IQR)	
(n=14)	
Percutaneous	Angioplasty	
Median	(IQR)	
(n=9)	
p-value*	
Study	Toe	
	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 74.50	(66.00-106.60)	 0.277	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.80	(3.20-4.50)	 0.781	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 84.60	(74.50-168.30)	 0.159	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 22.27	(15.26-41.18)	 0.336	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 1.27	(1.13-1.74)	 0.016	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 3.58	(2.58-45.13)	 0.013	
Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 220.80	(200.20-288.78)	 0.002	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 213.74	(140.11-261.53)	 0.005	
Study	
Dorsum	
	
Resting	Flux	(flux)	 16.80	(8.70-22.90)	 28.70	(22.60-37.40)	 0.013	
Biological	Zero	(flux)	 4.60	(3.40-4.90)	 5.80	(4.10-10.20)	 0.201	
Maximum	Flux	(flux)	 45.75	(23.30-63.20)	 49.00	(37.80-86.50)	 0.403	
Maximum	Flux/Biological	Zero		 9.43	(6.98-17.11)	 9.61	(8.04-15.09)	 0.975	
Maximum	Flux/Resting	Level		 2.63	(1.70-3.85)	 1.76	(1.55-2.15)	 0.124	
Time	to	Recovery	(s)	 1.03	(0.75-2.05)	 2.68	(1.70-4.33)	 0.028	
Time	to	Maximum	Flux	(s)	 8.05	(3.45-17.55)	 220.28	(93.65-279.80)	 <0.001	
Time	to	Half	Recovery	(s)	 13.64	(8.40-20.48)	 171.00	(82.31-282.03)	 <0.002	
Non-study	 Resting	Flux	(flux)	 51.00	(32.80-95.60)	 37.40	(21.90-78.50)	 0.400	
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Toe	
	
Biological	Zero	(flux)	 3.70	(3.10-9.10)	 3.80	(3.10-5.50)	 0.971	
Maximum	Flux	(flux)	 124.40	(49.10-178.60)	 106.10	(38.70-147.10)	 0.400	
Maximum	Flux/Biological	Zero		 18.02	(5.40-29.78)	 17.09	(7.04-40.87)	 0.743	
Maximum	Flux/Resting	Level		 2.26	(1.32-2.89)	 2.09	(1.82-2.57)	 0.856	
Time	to	Recovery	(s)	 1.51	(1.00-18.88)	 2.45	(1.78-3.75)	 0.287	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-141.05)	 54.80	(13.95-127.43)	 0.689	
Time	to	Half	Recovery	(s)	 53.20	(23.48-141.25)	 101.98	(17.4-133.98)	 1.000	
Non-study	
Dorsum	
	
Resting	Flux	(flux)	 9.00	(7.60-10.90)	 16.20	(12.60-47.50)	 0.003	
Biological	Zero	(flux)	 4.30	(3.10-5.40)	 5.60	(4.20-9.10)	 0.110	
Maximum	Flux	(flux)	 23.55	(13.60-36.40)	 73.20	(22.30-97.30)	 0.016	
Maximum	Flux/Biological	Zero		 4.01	(3.61-6.91)	 10.69	(5.30-13.92)	 0.046	
Maximum	Flux/Resting	Level		 2.21	(1.75-2.80)	 2.23	(1.54-4.59)	 0.856	
Time	to	Recovery	(s)	 0.91	(0.68-1.48)	 1.75	(1.53-2.50)	 0.010	
Time	to	Maximum	Flux	(s)	 15.40	(3.58-116.90)	 70.68	(31.10-138.60)	 0.149	
Time	to	Half	Recovery	(s)	 22.03	(7.43-56.18)	 113.13	(53.18-139.78)	 0.037	
*Independent-Samples	Mann-Whitney	U	Test	
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Table	II:	Post	occlusive	reactive	hyperaemia	results	at	last	visit	by	group	
	
Diabetic	Tissue	Loss		
Median	(IQR)	
(n=11)	
Percutaneous	Angioplasty	
Median	(IQR)	
(n=7)	
p-value*	
Study	Toe	
	
Resting	Flux	(flux)	 104.80	(32.30-138.90)	 33.80	(24.70-84.45)	 0.109	
Biological	Zero	(flux)	 3.70	(2.70-7.30)	 5.75	(3.70-7.80)	 0.351	
Maximum	Flux	(flux)	 170.00	(128.10-269.50)	 80.35	(54.05-138.10)	 0.007	
Maximum	Flux/Biological	Zero		 37.69	(23.27-90.92)	 22.21	(4.75-27.32)	 0.041	
Maximum	Flux/Resting	Level		 2.58	(1.39-3.97)	 1.94	(1.27-2.62)	 0.492	
Time	to	Recovery	(s)	 1.33	(0.98-6.35)	 3.04	(1.89-7.20)	 0.272	
Time	to	Maximum	Flux	(s)	 27.08	(8.50-154.38)	 54.50	(34.73-158.00)	 0.442	
Time	to	Half	Recovery	(s)	 36.13	(15.18-154.38)	 72.31	(35.61-158.66)	 0.545	
Study	
Dorsum	
	
Resting	Flux	(flux)	 16.20	(10.70-29.40)	 22.80	(15.00-30.40)	 0.536	
Biological	Zero	(flux)	 3.80	(3.30-4.60)	 5.40	(4.60-6.50)	 0.027	
Maximum	Flux	(flux)	 32.90	(21.10-87.30)	 38.00	(30.50-60.40)	 1.000	
Maximum	Flux/Biological	Zero		 7.14	(5.90-21.46)	 7.06	(4.72-9.95)	 0.536	
Maximum	Flux/Resting	Level		 1.99	(1.68-3.01)	 1.77	(1.20-3.34)	 0.479	
Time	to	Recovery	(s)	 0.93	(0.80-1.53)	 2.40	(0.78-4.53)	 0.179	
Time	to	Maximum	Flux	(s)	 13.50	(4.95-20.38)	 127.78	(30.08-227.13)	 0.015	
Time	to	Half	Recovery	(s)	 16.28	(10.30-39.65)	 128.93	(43.38-228.68)	 0.020	
Non-study	
Toe	
	
Resting	Flux	(flux)	 109.30	(21.00-184.50)	 34.60	(25.10-54.30)	 0.375	
Biological	Zero	(flux)	 4.00	(2.60-11.50)	 4.80	(3.20-6.50)	 0.791	
Maximum	Flux	(flux)	 220.00	(153.60-273.40)	 83.90	(56.80-208.80)	 0.085	
Maximum	Flux/Biological	Zero		 38.40	(12.24-85.43)	 22.43	(17.76-43.50)	 0.425	
Maximum	Flux/Resting	Level		 2.01	(1.41-4.04)	 2.27	(1.50-3.85)	 1.000	
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Time	to	Recovery	(s)	 2.03	(1.20-2.83)	 2.38	(1.75-3.93)	 0.375	
Time	to	Maximum	Flux	(s)	 18.83	(11.83-215.65)	 35.33	(15.85-146.28)	 0.596	
Time	to	Half	Recovery	(s)	 23.70	(19.33-216.80)	 76.13	(20.10-163.45)	 0.791	
Non-study	
Dorsum	
	
Resting	Flux	(flux)	 15.20	(8.00-17.90)	 15.60	(13.70-20)	 0.660	
Biological	Zero	(flux)	 3.90	(3.50-5.00)	 4.75	(3.90-5.90)	 0.301	
Maximum	Flux	(flux)	 24.80	(18.60-54.00)	 30.00	(21.00-55.60)	 0.884	
Maximum	Flux/Biological	Zero		 6.09	(5.27-10.81)	 5.41	(4.96-6.56)	 0.404	
Maximum	Flux/Resting	Level		 2.57	(1.22-3.67)	 1.74	(1.32-4.30)	 0.884	
Time	to	Recovery	(s)	 0.95	(0.30-1.43)	 2.90	(1.50-3.58)	 0.048	
Time	to	Maximum	Flux	(s)	 15.40	(12.13-215.65)	 119.03	(42.43-265.28)	 0.122	
Time	to	Half	Recovery	(s)	 29.60	(15.60-216.83)	 120.69	(42.55-266.98)	 0.149	
*Independent-Samples	Mann-Whitney	U	Test	
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Table	III:	Percentage	change	in	Post	occlusive	reactive	hyperaemia	between	baseline	and	last	visit	by	group	
	
Diabetic	Tissue	Loss		
Median	(IQR)	
(n=11)	
Percutaneous	Angioplasty	
Median	(IQR)	
(n=7)	
p-value*	
Study	Toe	
	
Resting	Flux	(flux)	 98.11	(-32.85-447.37)	 -49.07	(-62.14-38.68)	 0.051	
Biological	Zero	(flux)	 -5.71	(-16.67-54.17)	 18.32	(-15.97-87.18)	 0.657	
Maximum	Flux	(flux)	 -4.40	(-29.67-154.97)	 -20.31	(-51.41-32.62)	 0.310	
Maximum	Flux/Biological	Zero		 5.14	(-29.38-123.73)	 -33.54	(-67.06-6.59)	 0.129	
Maximum	Flux/Resting	Level		 -30.36	(-59.24-72.73)	 32.61	(-2.24-74.07)	 0.206	
Time	to	Recovery	(s)	 25.57	(-33.33-85.71)	 -45.52	(-85.26--15.69)	 0.101	
Time	to	Maximum	Flux	(s)	 94.47	(18.87-328.06)	 -42.14	(-80.90--2.17)	 0.001	
Time	to	Half	Recovery	(s)	 120.00	(58.47-290.89)	 -53.72	(-81.39-25.27)	 0.003	
Study	
Dorsum	
	
Resting	Flux	(flux)	 22.99	(-22.54-86.21)	 2.36	(-65.41-38.81)	 0.285	
Biological	Zero	(flux)	 -3.13	(-24.00-15.38)	 -7.14	(-20.69-38.30)	 0.724	
Maximum	Flux	(flux)	 2.49	(-65.01-44.83)	 -22.65	(-50.49--14.80)	 0.536	
Maximum	Flux/Biological	Zero		 -4.70	(-38.92-16.02)	 -34.58	(-66.56-15.55)	 0.375	
Maximum	Flux/Resting	Level		 -21.89	(-35.51--1.18)	 -35.22	(-45.95-67.00)	 0.930	
Time	to	Recovery	(s)	 6.67	(-26.53-27.27)	 -58.82	(-68.37-50.00)	 0.126	
Time	to	Maximum	Flux	(s)	 43.48	(-16.85-253.10)	 -20.03	(-64.01-84.71)	 0.126	
Time	to	Half	Recovery	(s)	 9.09	(-10.44-93.75)	 -33.66	(-71.97-84.18)	 0.180	
Non-study	
Toe	
	
Resting	Flux	(flux)	 112.97	(-29.46-212.71)	 -16.92	(-37.67-45.19)	 0.180	
Biological	Zero	(flux)	 -21.21	(-33.33-155.56)	 -9.50	(-25.81-30.77)	 0.808	
Maximum	Flux	(flux)	 101.55	(56.46-324.54)	 8.11	(-42.96-81.76)	 0.037	
Maximum	Flux/Biological	Zero		 126.38	(-4.07-304.92)	 -0.68	(-23.11-17.55)	 0.122	
Maximum	Flux/Resting	Level		 41.35	(-24.56-92.42)	 12.97	(-8.24-35.56)	 0.660	
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Time	to	Recovery	(s)	 -4.58	(-40.98-40.00)	 -17.72	(-74.65-32.31)	 0.958	
Time	to	Maximum	Flux	(s)	 47.32	(-11.92-115.76)	 2.92	(-72.27-196.30)	 0.884	
Time	to	Half	Recovery	(s)	 1.32	(-48.56-136.36)	 20.56	(-86.58-66.38)	 0.660	
Non-study	
Dorsum	
	
Resting	Flux	(flux)	 47.71	(0.00-123.68)	 -18.70	(-43.65-13.57)	 0.221	
Biological	Zero	(flux)	 2.94	(-25.53-73.91)	 5.36	(-20.41-30.56)	 0.827	
Maximum	Flux	(flux)	 56.62	(8.02-77.63)	 -62.56	(-67.24--42.86)	 0.052	
Maximum	Flux/Biological	Zero		 52.63	(-3.82-89.77)	 -58.82	(-63.42--28.96)	 0.052	
Maximum	Flux/Resting	Level		 19.64	(-44.19-65.32)	 -53.63	(-66.44--24.03)	 0.221	
Time	to	Recovery	(s)	 0.00	(-60.71-33.90)	 86.96	(68.85-225.71)	 0.180	
Time	to	Maximum	Flux	(s)	 278.23	(-38.48-801.20)	 -39.97	(-45.04-43.51)	 0.221	
Time	to	Half	Recovery	(s)	 133.66	(31.24-448.57)	 -43.91	(-44.03-44.07)	 0.075	
*Independent-Samples	Mann-Whitney	U	Test	
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Table	IV:	Post	occlusive	reactive	hyperaemia,	baseline	results	compared	to	last	results	
	
Baseline	Value	
Median	(IQR)	
Last	Value	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=14/11)	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 104.80	(32.30-138.90)	 0.248	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.70	(2.70-7.30)	 0.477	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 170.00	(128.10-269.50)	 0.790	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 37.69	(23.27-90.92)	 0.859	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 2.58	(1.39-3.97)	 0.213	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 1.33	(0.98-6.35)	 0.424	
Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 27.08	(8.50-154.38)	 0.021	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 36.13	(15.18-154.38)	 0.021	
Percutaneous	
Angioplasty	
(n=9/8)	
Resting	Flux	(flux)	 74.50	(66.00-106.60)	 33.80	(24.70-84.45)	 0.093	
Biological	Zero	(flux)	 3.80	(3.20-4.50)	 5.75	(3.70-7.80)	 0.575	
Maximum	Flux	(flux)	 84.60	(74.50-168.30)	 80.35	(54.05-138.10)	 0.401	
Maximum	Flux/Biological	Zero		 22.27	(15.26-41.18)	 22.21	(4.75-27.32)	 0.208	
Maximum	Flux/Resting	Level		 1.27	(1.13-1.74)	 1.94	(1.27-2.62)	 0.161	
Time	to	Recovery	(s)	 3.58	(2.58-45.13)	 3.04	(1.89-7.20)	 0.069	
Time	to	Maximum	Flux	(s)	 220.80	(200.20-288.78)	 54.50	(34.73-158.00)	 0.050	
Time	to	Half	Recovery	(s)	 213.74	(140.11-261.53)	 72.31	(35.61-158.66)	 0.176	
Study	
Dorsum	
Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 16.80	(8.7-22.90)	 16.20	(10.70-29.40)	 0.722	
Biological	Zero	(flux)	 4.60	(3.4-4.90)	 3.80	(3.30-4.60)	 0.646	
Maximum	Flux	(flux)	 45.75	(23.3-63.20)	 32.90	(21.10-87.30)	 0.859	
Maximum	Flux/Biological	Zero		 9.43	(6.98-17.11)	 7.14	(5.90-21.46)	 0.477	
Maximum	Flux/Resting	Level		 2.63	(1.70-3.85)	 1.99	(1.68-3.01)	 0.021	
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Time	to	Recovery	(s)	 1.03	(0.75-2.05)	 0.93	(0.80-1.53)	 0.929	
Time	to	Maximum	Flux	(s)	 8.05	(3.45-17.55)	 13.50	(4.95-20.38)	 0.041	
Time	to	Half	Recovery	(s)	 13.64	(8.40-20.48)	 16.28	(10.30-39.65)	 0.091	
Percutaneous	
Angioplasty	
(n=9/7)	
Resting	Flux	(flux)	 28.70	(22.60-37.40)	 22.80	(15.00-30.40)	 0.735	
Biological	Zero	(flux)	 5.80	(4.10-10.20)	 5.40	(4.60-6.50)	 0.735	
Maximum	Flux	(flux)	 49.00	(37.80-86.50)	 38.00	(30.50-60.40)	 0.091	
Maximum	Flux/Biological	Zero		 9.61	(8.04-15.09)	 7.06	(4.72-9.95)	 0.128	
Maximum	Flux/Resting	Level		 1.76	(1.55-2.15)	 1.77	(1.20-3.34)	 0.866	
Time	to	Recovery	(s)	 2.68	(1.70-4.33)	 2.40	(0.78-4.53)	 0.237	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-279.80)	 127.78	(30.08-227.13)	 0.398	
Time	to	Half	Recovery	(s)	 171.00	(82.31-282.03)	 128.93	(43.38-228.68)	 0.463	
Non-study	
Toe	
Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 51.00	(32.80-95.60)	 109.3	(21.00-184.50)	 0.091	
Biological	Zero	(flux)	 3.70	(3.10-9.10)	 4.00	(2.60-11.50)	 0.929	
Maximum	Flux	(flux)	 124.40	(49.10-178.60)	 220.00	(153.60-273.40)	 0.026	
Maximum	Flux/Biological	Zero		 18.02	(5.40-29.78)	 38.40	(12.24-85.43)	 0.075	
Maximum	Flux/Resting	Level		 2.26	(1.32-2.89)	 2.01	(1.41-4.04)	 0.155	
Time	to	Recovery	(s)	 1.51	(1-18.88)	 2.03	(1.20-2.83)	 0.790	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-141.05)	 18.83	(11.83-215.65)	 0.182	
Time	to	Half	Recovery	(s)	 53.20	(23.48-141.25)	 23.70	(19.33-216.80)	 0.477	
Percutaneous	
Angioplasty	
(n=7/7)	
Resting	Flux	(flux)	 37.40	(21.90-78.50)	 34.60	(25.10-54.30)	 0.463	
Biological	Zero	(flux)	 3.80	(3.10-5.50)	 4.80	(3.20-6.50)	 0.753	
Maximum	Flux	(flux)	 106.10	(38.70-147.10)	 83.90	(56.80-208.80)	 0.917	
Maximum	Flux/Biological	Zero		 17.09	(7.04-40.87)	 22.43	(17.76-43.50)	 0.753	
Maximum	Flux/Resting	Level		 2.09	(1.82-2.57)	 2.27	(1.50-3.85)	 0.345	
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Time	to	Recovery	(s)	 2.45	(1.78-3.75)	 2.38	(1.75-3.93)	 0.600	
Time	to	Maximum	Flux	(s)	 54.80	(13.95-127.43)	 35.33	(15.85-146.28)	 0.917	
Time	to	Half	Recovery	(s)	 101.98	(17.40-133.98)	 76.13	(20.10-163.45)	 0.753	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 9.00	(7.60-10.90)	 15.20	(8.00-17.90)	 0.074	
Biological	Zero	(flux)	 4.30	(3.10-5.40)	 3.90	(3.50-5.00)	 0.721	
Maximum	Flux	(flux)	 23.55	(13.60-36.40)	 24.80	(18.60-54.00)	 0.008	
Maximum	Flux/Biological	Zero		 4.01	(3.61-6.91)	 6.09	(5.27-10.81)	 0.248	
Maximum	Flux/Resting	Level		 2.21	(1.75-2.80)	 2.57	(1.22-3.67)	 0.859	
Time	to	Recovery	(s)	 0.91	(0.68-1.48)	 0.95	(0.30-1.43)	 0.610	
Time	to	Maximum	Flux	(s)	 15.40	(3.58-116.90)	 15.40	(12.13-215.65)	 0.182	
Time	to	Half	Recovery	(s)	 22.03	(7.43-56.18)	 29.60	(15.60-216.83)	 0.028	
Percutaneous	
Angioplasty	
(n=7/6)	
Resting	Flux	(flux)	 16.20	(12.60-47.50)	 15.60	(13.70-20.00)	 0.500	
Biological	Zero	(flux)	 5.60	(4.20-9.10)	 4.75	(3.90-5.90)	 0.893	
Maximum	Flux	(flux)	 73.20	(22.30-97.30)	 30.00	(21.00-55.60)	 0.080	
Maximum	Flux/Biological	Zero		 10.69	(5.30-13.92)	 5.41	(4.96-6.56)	 0.138	
Maximum	Flux/Resting	Level		 2.23	(1.54-4.59)	 1.74	(1.32-4.30)	 0.225	
Time	to	Recovery	(s)	 1.75	(1.53-2.50)	 2.90	(1.50-3.58)	 0.500	
Time	to	Maximum	Flux	(s)	 70.68	(31.10-138.60)	 119.03	(42.43-265.28)	 0.686	
Time	to	Half	Recovery	(s)	 113.13	(53.18-139.78)	 120.69	(42.55-266.98)	 0.686	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Table	V:	Post	occlusive	reactive	hyperaemia,	baseline	results	compared	to	last	results.	Healed	patients	only	
	
Baseline	Value	
Median	(IQR)	
Last	Value	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/6)	
Resting	Flux	(flux)	 83.50	(48.10-151.50)	 59.75	(32.30-122.70)	 0.600	
Biological	Zero	(flux)	 5.00	(3.10-7.20)	 5.20	(2.60-7.30)	 0.917	
Maximum	Flux	(flux)	 171.55	(140.00-254.60)	 166.95	(128.00-190.90)	 0.463	
Maximum	Flux/Biological	Zero		 41.37	(21.21-58.72)	 35.19	(23.27-49.22)	 0.463	
Maximum	Flux/Resting	Level		 1.87	(1.68-2.91)	 3.00	(1.39-3.97)	 0.600	
Time	to	Recovery	(s)	 1.50	(1.25-1.73)	 1.50	(0.80-6.35)	 0.463	
Time	to	Maximum	Flux	(s)	 13.40	(6.33-73.85)	 64.43	(22.05-114.20)	 0.028	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 69.06	(28.53-121.43)	 0.028	
Percutaneous	
Angioplasty	
(n=6/6)	
Resting	Flux	(flux)	 66.40	(15.3-172.80)	 33.80	(29.7-56)	 0.116	
Biological	Zero	(flux)	 3.80	(3.20-4.20)	 5.30	(3.30-9.10)	 0.917	
Maximum	Flux	(flux)	 81.40	(74.50-168.30)	 80.40	(55.70-125.60)	 0.600	
Maximum	Flux/Biological	Zero		 20.01	(7.01-27.89)	 22.21	(6.12-25.12)	 0.463	
Maximum	Flux/Resting	Level		 1.25	(1.13-1.74)	 2.38	(1.56-2.79)	 0.116	
Time	to	Recovery	(s)	 3.23	(2.25-45.13)	 2.26	(1.68-4.88)	 0.028	
Time	to	Maximum	Flux	(s)	 210.50	(72.18-231.00)	 50.71	(27.38-105.18)	 0.046	
Time	to	Half	Recovery	(s)	 200.20	(80.03-222.50)	 67.24	(29.15-106.15)	 0.225	
Study	
Dorsum	
Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 18.85	(11.80-22.90)	 11.15	(10.20-19.90)	 0.600	
Biological	Zero	(flux)	 4.85	(4.60-5.00)	 4.00	(3.40-4.60)	 0.686	
Maximum	Flux	(flux)	 45.75	(32.10-63.20)	 29.20	(20.10-37.40)	 0.600	
Maximum	Flux/Biological	Zero		 9.43	(6.98-9.66)	 6.61	(5.90-8.92)	 0.249	
Maximum	Flux/Resting	Level		 2.79	(2.49-2.92)	 2.19	(1.78-3.01)	 0.249	
Time	to	Recovery	(s)	 0.83	(0.48-1.15)	 0.86	(0.58-1.28)	 0.916	
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Time	to	Maximum	Flux	(s)	 5.23	(2.85-9.28)	 13.15	(5.68-13.60)	 0.345	
Time	to	Half	Recovery	(s)	 8.60	(5.13-14.48)	 15.80	(9.60-18.48)	 0.116	
Percutaneous	
Angioplasty	
(n=6/6)	
Resting	Flux	(flux)	 28.80	(21.90-43.30)	 24.80	(15.00-30.40)	 0.917	
Biological	Zero	(flux)	 5.50	(4.10-10.20)	 5.70	(4.60-6.50)	 0.916	
Maximum	Flux	(flux)	 65.60	(37.80-94.30)	 45.90	(32.50-60.40)	 0.173	
Maximum	Flux/Biological	Zero		 12.35	(8.04-15.21)	 8.18	(4.72-9.95)	 0.249	
Maximum	Flux/Resting	Level		 1.88	(1.59-2.22)	 1.88	(1.20-3.34)	 0.917	
Time	to	Recovery	(s)	 2.08	(1.60-2.68)	 2.13	(0.78-4.53)	 0.345	
Time	to	Maximum	Flux	(s)	 198.79	(69.18-287.33)	 175.76	(105.20-227.13)	 0.753	
Time	to	Half	Recovery	(s)	 119.83	(70.00-291.73)	 176.43	(106.03-228.68)	 0.893	
Non-study	
Toe	
Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 65.65	(36.40-112.70)	 122.10	(51.00-184.50)	 0.463	
Biological	Zero	(flux)	 4.55	(3.10-10.20)	 5.55	(3.20-11.50)	 0.600	
Maximum	Flux	(flux)	 138.90	(120.00-303.20)	 221.50	(173.90-273.40)	 0.249	
Maximum	Flux/Biological	Zero		 18.02	(13.95-36.81)	 32.11	(22.57-85.43)	 0.116	
Maximum	Flux/Resting	Level		 1.75	(1.32-3.30)	 1.98	(1.21-9.29)	 0.345	
Time	to	Recovery	(s)	 1.64	(1.00-8.18)	 2.06	(1.40-6.48)	 0.600	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-262.10)	 87.20	(18.83-291.13)	 0.600	
Time	to	Half	Recovery	(s)	 53.20	(38.25-268.18)	 92.98	(19.68-292.73)	 0.917	
Percutaneous	
Angioplasty	
(n=4/5)	
Resting	Flux	(flux)	 41.50	(32.60-63.20)	 50.30	(34.60-54.30)	 0.465	
Biological	Zero	(flux)	 4.40	(3.40-5.90)	 4.80	(3.20-6.50)	 0.465	
Maximum	Flux	(flux)	 111.70	(83.80-132.20)	 145.30	(83.90-208.80)	 0.715	
Maximum	Flux/Biological	Zero		 19.83	(16.59-35.01)	 36.49	(21.37-43.5)	 1.000	
Maximum	Flux/Resting	Level		 2.39	(2.02-2.71)	 2.27	(1.67-3.85)	 0.273	
Time	to	Recovery	(s)	 2.03	(1.70-10.95)	 2.38	(2.15-3.93)	 1.000	
Time	to	Maximum	Flux	(s)	 34.38	(8.66-62.75)	 69.55	(35.33-146.28)	 0.273	
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Time	to	Half	Recovery	(s)	 55.79	(11.19-98.08)	 126.33	(76.13-163.45)	 0.273	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 8.65	(8.10-10.90)	 17.00	(9.60-20.70)	 0.028	
Biological	Zero	(flux)	 4.15	(3.10-4.70)	 4.85	(3.90-5.50)	 0.249	
Maximum	Flux	(flux)	 24.45	(12.10-39.90)	 33.95	(20.10-54.00)	 0.028	
Maximum	Flux/Biological	Zero		 5.31	(3.40-10.22)	 5.50	(4.26-10.81)	 0.463	
Maximum	Flux/Resting	Level		 1.91	(1.70-2.80)	 2.38	(1.22-3.35)	 0.753	
Time	to	Recovery	(s)	 0.74	(0.68-0.85)	 0.95	(0.55-1.43)	 0.249	
Time	to	Maximum	Flux	(s)	 10.20	(2.30-55.38)	 17.05	(12.13-142.95)	 0.463	
Time	to	Half	Recovery	(s)	 17.53	(5.85-23.05)	 24.73	(15.60-143.58)	 0.043	
Percutaneous	
Angioplasty	
(n=4/5)	
Resting	Flux	(flux)	 16.20	(14.00-24.60)	 15.90	(13.70-20.00)	 1.000	
Biological	Zero	(flux)	 5.60	(4.90-9.10)	 4.80	(4.70-5.90)	 0.273	
Maximum	Flux	(flux)	 78.00	(64.10-97.30)	 30.80	(29.20-55.60)	 0.144	
Maximum	Flux/Biological	Zero		 13.09	(10.69-13.92)	 5.39	(4.96-6.56)	 0.144	
Maximum	Flux/Resting	Level		 4.59	(3.17-5.99)	 2.01	(1.47-4.30)	 0.273	
Time	to	Recovery	(s)	 1.73	(0.53-1.75)	 3.23	(1.50-3.58)	 0.715	
Time	to	Maximum	Flux	(s)	 70.68	(46.15-112.80)	 161.88	(76.18-265.28)	 0.715	
Time	to	Half	Recovery	(s)	 76.03	(53.18-113.13)	 162.98	(78.4-266.98)	 0.715	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Table	VI:	Post	occlusive	reactive	hyperaemia,	baseline	results	compared	to	last	results.	Unhealed	patients	only	
	
Baseline	Value	
Median	(IQR)	
Last	Value	
Median	(IQR)	
p-
value*	
Study	Toe	
Diabetic	 Tissue	 Loss	
(n=8/5)	
Resting	Flux	(flux)	 50.10	(13.05-67.35)	 107.70	(104.80-138.90)	 0.043	
Biological	Zero	(flux)	 4.70	(2.75-7.10)	 3.40	(3.30-3.70)	 0.225	
Maximum	Flux	(flux)	 149.40	(105.95-204.50)	 192.90	(138.30-277.80)	 0.225	
Maximum	Flux/Biological	Zero		 30.46	(18.60-56.96)	 58.46	(37.69-97.10)	 0.225	
Maximum	Flux/Resting	Level		 4.16	(2.24-11.82)	 2.23	(1.84-2.58)	 0.080	
Time	to	Recovery	(s)	 0.85	(0.68-2.25)	 1.18	(1.03-1.38)	 0.500	
Time	to	Maximum	Flux	(s)	 27.78	(3.44-83.36)	 9.68	(8.50-154.38)	 0.345	
Time	to	Half	Recovery	(s)	 36.75	(13.68-92.81)	 36.13	(15.18-154.38)	 0.345	
Percutaneous	
Angioplasty	
(n=3/2)	
Resting	Flux	(flux)	 84.00	(74.50-106.60)	 69.30	(16.40-122.10)	 0.655	
Biological	Zero	(flux)	 4.50	(2.90-4.70)	 5.80	(5.10-6.40)	 0.180	
Maximum	Flux	(flux)	 137.40	(68.60-193.50)	 86.10	(21.50-150.60)	 0.180	
Maximum	Flux/Biological	Zero		 41.18	(15.26-47.39)	 16.45	(3.37-29.52)	 0.180	
Maximum	Flux/Resting	Level		 1.64	(0.92-1.82)	 1.27	(1.23-1.31)	 0.655	
Time	to	Recovery	(s)	 3.58	(2.93-117.55)	 8.35	(3.65-13.05)	 0.655	
Time	to	Maximum	Flux	(s)	 288.78	(204.98-288.78)	 141.08	(49.65-232.50)	 0.655	
Time	to	Half	Recovery	(s)	 290.63	(204.98-295.23)	 142.73	(52.23-233.23)	 0.655	
Study	
Dorsum	
Diabetic	 Tissue	 Loss	
(n=8/5)	
Resting	Flux	(flux)	 16.05	(8.25-21.95)	 23.60	(16.20-29.40)	 0.345	
Biological	Zero	(flux)	 3.75	(3.05-4.70)	 3.30	(3.10-4.50)	 0.892	
Maximum	Flux	(flux)	 45.35	(21.90-63.50)	 72.40	(24.80-87.30)	 0.686	
Maximum	Flux/Biological	Zero		 12.93	(6.07-23.75)	 21.46	(6.82-26.45)	 0.893	
Maximum	Flux/Resting	Level		 2.06	(1.64-6.05)	 1.84	(1.68-2.46)	 0.043	
Time	to	Recovery	(s)	 1.44	(0.84-2.50)	 1.05	(0.90-1.58)	 0.893	
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Time	to	Maximum	Flux	(s)	 11.25	(3.83-21.35)	 20.38	(4.95-192.98)	 0.080	
Time	to	Half	Recovery	(s)	 16.69	(11.93-27.03)	 39.65	(12.40-193.23)	 0.225	
Percutaneous	
Angioplasty	
(n=3/1)	
Resting	Flux	(flux)	 28.70	(22.60-37.40)	 22.80	 0.317	
Biological	Zero	(flux)	 5.80	(4.00-10.70)	 4.60	 0.317	
Maximum	Flux	(flux)	 49.00	(35.00-61.60)	 30.50	 0.317	
Maximum	Flux/Biological	Zero		 8.76	(4.58-10.62)	 6.63	 0.317	
Maximum	Flux/Resting	Level		 1.55	(1.31-2.15)	 1.34	 0.317	
Time	to	Recovery	(s)	 4.33	(3.08-5.93)	 2.40	 0.317	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-271.38)	 30.08	 0.317	
Time	to	Half	Recovery	(s)	 222.18	(94.63-272.33)	 43.38	 0.317	
Non-study	
Toe	
Diabetic	 Tissue	 Loss	
(n=8/5)	
Resting	Flux	(flux)	 46.25	(17.25-75.10)	 109.30	(21.00-144.20)	 0.043	
Biological	Zero	(flux)	 3.60	(3.15-7.20)	 3.10	(2.60-6.90)	 0.686	
Maximum	Flux	(flux)	 95.20	(32.30-168.20)	 220.00	(84.80-269.60)	 0.043	
Maximum	Flux/Biological	Zero		 19.10	(5.05-28.47)	 42.39	(10.64-50.76)	 0.345	
Maximum	Flux/Resting	Level		 2.33	(1.66-2.68)	 2.01	(1.87-3.35)	 0.500	
Time	to	Recovery	(s)	 1.31	(0.95-27.29)	 1.48	(1.20-2.03)	 0.893	
Time	to	Maximum	Flux	(s)	 34.05	(10.68-123.23)	 11.83	(11.68-15.53)	 0.080	
Time	to	Half	Recovery	(s)	 66.96	(14.99-128.04)	 22.88	(16.63-23.70)	 0.138	
Percutaneous	
Angioplasty	
(n=3/2)	
Resting	Flux	(flux)	 21.90	(8.10-78.50)	 26.40	(20.60-32.10)	 0.655	
Biological	Zero	(flux)	 3.80	(3.10-5.50)	 4.20	(3.50-4.80)	 0.655	
Maximum	Flux	(flux)	 38.70	(17.00-155.30)	 54.70	(30.90-78.50)	 0.655	
Maximum	Flux/Biological	Zero		 7.04	(5.47-40.87)	 14.43	(6.43-22.43)	 0.655	
Maximum	Flux/Resting	Level		 1.98	(1.77-2.09)	 1.97	(1.5-2.44)	 0.655	
Time	to	Recovery	(s)	 2.55	(2.45-3.75)	 2.06	(1.75-2.38)	 0.180	
Time	to	Maximum	Flux	(s)	 127.43	(54.73-237.73)	 15.51	(15.18-15.85)	 0.180	
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Time	to	Half	Recovery	(s)	 133.98	(128.93-240.75)	 19.04	(17.98-20.10)	 0.180	
Non-study	
Dorsum	
Diabetic	 Tissue	 Loss	
(n=8/5)	
Resting	Flux	(flux)	 9.25	(7.05-12.35)	 8.00	(6.80-15.20)	 1.000	
Biological	Zero	(flux)	 4.80	(2.85-6.95)	 3.50	(2.50-3.80)	 0.465	
Maximum	Flux	(flux)	 23.55	(15.25-34.55)	 21.30	(18.60-32.30)	 0.225	
Maximum	Flux/Biological	Zero		 4.01	(3.76-5.74)	 7.42	(6.09-8.07)	 0.345	
Maximum	Flux/Resting	Level		 2.27	(1.99-3.27)	 3.11	(1.90-3.67)	 0.500	
Time	to	Recovery	(s)	 1.21	(0.75-1.51)	 1.10	(0.30-1.43)	 0.144	
Time	to	Maximum	Flux	(s)	 15.56	(5.91-117.88)	 13.90	(12.88-215.65)	 0.225	
Time	to	Half	Recovery	(s)	 31.31	(14.40-141.03)	 29.60	(17.85-216.83)	 0.345	
Percutaneous	
Angioplasty	
(n=3/1)	
Resting	Flux	(flux)	 47.50	(11.30-86.60)	 15.30	 0.317	
Biological	Zero	(flux)	 6.40	(4.20-9.60)	 3.30	 0.317	
Maximum	Flux	(flux)	 73.20	(22.30-192.90)	 17.90	 0.317	
Maximum	Flux/Biological	Zero		 7.63	(5.30-30.15)	 5.42	 0.317	
Maximum	Flux/Resting	Level		 1.97	(1.54-2.23)	 1.17	 0.317	
Time	to	Recovery	(s)	 2	(1.53-2.50)	 2.58	 0.317	
Time	to	Maximum	Flux	(s)	 31.10	(13.23-273.90)	 17.23	 0.317	
Time	to	Half	Recovery	(s)	 120.08	(34.78-282.78)	 21.45	 0.317	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Table	VII:	Post	occlusive	reactive	hyperaemia,	baseline	results	compared	to	second	visit	
	
Baseline	Value	
Median	(IQR)	
Second	Value	
Median	(IQR)	
p-
value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=14/11)	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 98.00	(14.80-107.70)	 0.286	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.30	(2.70-7.80)	 0.182	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 190.90	(75.40-258.40)	 1.000	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 56.06	(25.33-90.92)	 0.534	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 2.58	(1.84-5.03)	 0.286	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 1.18	(0.88-1.38)	 0.540	
Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 11.08	(4.40-27.08)	 0.722	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 16.65	(12.55-36.13)	 0.929	
Percutaneous	
Angioplasty	
(n=9/8)	
Resting	Flux	(flux)	 74.50	(66.00-106.60)	 38.35	(23.05-76.05)	 0.123	
Biological	Zero	(flux)	 3.80	(3.20-4.50)	 4.40	(4.15-8.65)	 0.575	
Maximum	Flux	(flux)	 84.60	(74.50-168.30)	 102.85	(63.20-142.35)	 0.575	
Maximum	Flux/Biological	Zero		 22.27	(15.26-41.18)	 22.18	(8.68-29.00)	 0.263	
Maximum	Flux/Resting	Level		 1.27	(1.13-1.74)	 2.20	(1.37-3.78)	 0.263	
Time	to	Recovery	(s)	 3.58	(2.58-45.13)	 2.01	(1.13-3.49)	 0.017	
Time	to	Maximum	Flux	(s)	 220.80	(200.20-288.78)	 53.79	(18.09-205.16)	 0.123	
Time	to	Half	Recovery	(s)	 213.74	(140.11-261.53)	 74.01	(22.94-206.06)	 0.345	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 98.00	(14.80-107.70)	 0.505	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.30	(2.70-7.80)	 0.373	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 190.90	(75.40-258.40)	 0.722	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 56.06	(25.33-90.92)	 0.477	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 2.58	(1.84-5.03)	 0.328	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 1.18	(0.88-1.38)	 0.374	
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Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 11.08	(4.40-27.08)	 0.182	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 16.65	(12.55-36.13)	 0.722	
Percutaneous	
Angioplasty	
(n=9/7)	
Resting	Flux	(flux)	 74.50	(66.00-106.60)	 38.35	(23.05-76.05)	 0.398	
Biological	Zero	(flux)	 3.80	(3.20-4.50)	 4.40	(4.15-8.65)	 0.128	
Maximum	Flux	(flux)	 84.60	(74.50-168.30)	 102.85	(63.20-142.35)	 0.499	
Maximum	Flux/Biological	Zero		 22.27	(15.26-41.18)	 22.18	(8.68-29.00)	 0.735	
Maximum	Flux/Resting	Level		 1.27	(1.13-1.74)	 2.20	(1.37-3.78)	 0.263	
Time	to	Recovery	(s)	 3.58	(2.58-45.13)	 2.01	(1.13-3.49)	 0.176	
Time	to	Maximum	Flux	(s)	 220.80	(200.20-288.78)	 53.79	(18.09-205.16)	 0.398	
Time	to	Half	Recovery	(s)	 213.74	(140.11-261.53)	 74.01	(22.94-206.06)	 0.600	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 16.80	(8.70-22.90)	 16.60	(11.60-29.40)	 0.533	
Biological	Zero	(flux)	 4.60	(3.40-4.90)	 4.00	(3.10-4.70)	 0.248	
Maximum	Flux	(flux)	 45.75	(23.30-63.20)	 46.10	(35.70-87.30)	 0.021	
Maximum	Flux/Biological	Zero		 9.43	(6.98-17.11)	 11.01	(6.89-26.45)	 0.041	
Maximum	Flux/Resting	Level		 2.63	(1.70-3.85)	 2.60	(2.15-3.22)	 0.328	
Time	to	Recovery	(s)	 1.03	(0.75-2.05)	 0.93	(0.85-1.05)	 0.286	
Time	to	Maximum	Flux	(s)	 8.05	(3.45-17.55)	 5.28	(2.50-20.38)	 0.790	
Time	to	Half	Recovery	(s)	 13.64	(8.40-20.48)	 12.40	(3.70-39.65)	 0.790	
Percutaneous	
Angioplasty	
(n=7/7)	
Resting	Flux	(flux)	 28.70	(22.60-37.40)	 15.00	(10.60-30.40)	 0.249	
Biological	Zero	(flux)	 5.80	(4.10-10.20)	 5.00	(3.10-5.40)	 0.128	
Maximum	Flux	(flux)	 49.00	(37.80-86.50)	 35.50	(22.40-68.50)	 0.753	
Maximum	Flux/Biological	Zero		 9.61	(8.04-15.09)	 9.95	(4.72-13.71)	 0.735	
Maximum	Flux/Resting	Level		 1.76	(1.55-2.15)	 2.11	(1.33-3.12)	 0.116	
Time	to	Recovery	(s)	 2.68	(1.70-4.33)	 1.85	(0.93-4.08)	 0.600	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-279.80)	 127.78	(55.05-227.13)	 0.600	
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Time	to	Half	Recovery	(s)	 171.00	(82.31-282.03)	 128.93	(60.43-228.68)	 0.345	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=14/10)	
Resting	Flux	(flux)	 9.00	(7.60-10.90)	 8.80	(6.50-17)	 0.953	
Biological	Zero	(flux)	 4.30	(3.10-5.40)	 3.80	(3.50-4.00)	 0.767	
Maximum	Flux	(flux)	 23.55	(13.60-36.40)	 24.20	(14.40-68.60)	 0.032	
Maximum	Flux/Biological	Zero		 4.01	(3.61-6.91)	 6.70	(4.73-9.94)	 0.114	
Maximum	Flux/Resting	Level		 2.21	(1.75-2.80)	 3.12	(2.65-3.94)	 0.241	
Time	to	Recovery	(s)	 0.91	(0.68-1.48)	 0.64	(0.33-1.10)	 0.161	
Time	to	Maximum	Flux	(s)	 15.40	(3.58-116.90)	 24.15	(12.88-118.20)	 0.114	
Time	to	Half	Recovery	(s)	 22.03	(7.43-56.18)	 32.25	(19.20-121.53)	 0.021	
Percutaneous	
Angioplasty	
(n=7/6)	
Resting	Flux	(flux)	 16.20	(12.60-47.50)	 16.90	(8.70-23.30)	 0.893	
Biological	Zero	(flux)	 5.60	(4.20-9.10)	 5.10	(4.80-6.70)	 0.684	
Maximum	Flux	(flux)	 73.20	(22.30-97.30)	 38.35	(29.5-59.00)	 0.138	
Maximum	Flux/Biological	Zero		 10.69	(5.30-13.92)	 7.53	(6.14-11.56)	 0.225	
Maximum	Flux/Resting	Level		 2.23	(1.54-4.59)	 3.12	(1.47-4.35)	 0.686	
Time	to	Recovery	(s)	 1.75	(1.53-2.50)	 1.88	(1.25-2.30)	 0.500	
Time	to	Maximum	Flux	(s)	 70.68	(31.10-138.60)	 70.63	(60.08-243.90)	 0.500	
Time	to	Half	Recovery	(s)	 113.13	(53.18-139.78)	 90.81	(65.73-245.00)	 0.686	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Table	VIII:	Post	occlusive	reactive	hyperaemia,	baseline	results	compared	to	second	visit.	Healed	only	
	
Baseline	Value	
Median	(IQR)	
Second	Value	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/6)	
Resting	Flux	(flux)	 83.50	(48.10-151.50)	 77.00	(33.40-104.20)	 0.917	
Biological	Zero	(flux)	 5.00	(3.10-7.20)	 3.40	(2.70-7.80)	 0.173	
Maximum	Flux	(flux)	 171.50	(140.00-254.60)	 184.00	(168.20-197.60)	 0.753	
Maximum	Flux/Biological	Zero		 41.37	(21.21-58.72)	 40.95	(25.33-65.56)	 0.917	
Maximum	Flux/Resting	Level		 1.87	(1.68-2.91)	 2.66	(1.81-4.32)	 0.463	
Time	to	Recovery	(s)	 1.50	(1.25-1.73)	 1.25	(1.05-4.60)	 0.527	
Time	to	Maximum	Flux	(s)	 13.40	(6.33-73.85)	 19.19	(6.83-27.08)	 0.753	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 22.59	(12.55-29.20)	 0.917	
Percutaneous	
Angioplasty	
(n=6/6)	
Resting	Flux	(flux)	 66.40	(15.30-172.80)	 38.40	(29.70-59.00)	 0.249	
Biological	Zero	(flux)	 3.80	(3.20-4.20)	 4.30	(4.10-10.90)	 0.753	
Maximum	Flux	(flux)	 81.40	(74.50-168.30)	 102.90	(80.80-152.40)	 0.917	
Maximum	Flux/Biological	Zero		 20.01	(7.01-27.89)	 22.18	(13.99-27.92)	 0.600	
Maximum	Flux/Resting	Level		 1.25	(1.13-1.74)	 2.55	(2.08-4.76)	 0.249	
Time	to	Recovery	(s)	 3.23	(2.25-45.13)	 1.80	(0.58-2.10)	 0.028	
Time	to	Maximum	Flux	(s)	 210.50	(72.18-231.00)	 53.79	(27.38-177.83)	 0.116	
Time	to	Half	Recovery	(s)	 200.20	(80.03-222.50)	 74.01	(29.00-178.9)	 0.465	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 18.90	(11.80-22.9)	 18.50	(11.60-23.10)	 0.833	
Biological	Zero	(flux)	 4.90	(4.60-5.00)	 4.00	(3.40-4.70)	 0.249	
Maximum	Flux	(flux)	 45.80	(32.10-63.20)	 37.40	(35.70-46.10)	 0.916	
Maximum	Flux/Biological	Zero		 9.43	(6.98-9.66)	 9.97	(6.89-14.88)	 0.463	
Maximum	Flux/Resting	Level		 2.79	(2.49-2.92)	 2.50	(2.15-3.22)	 0.917	
Time	to	Recovery	(s)	 0.83	(0.48-1.15)	 0.89	(0.75-0.95)	 0.917	
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Time	to	Maximum	Flux	(s)	 5.23	(2.85-9.28)	 3.09	(2.15-5.28)	 0.600	
Time	to	Half	Recovery	(s)	 8.60	(5.13-14.48)	 5.79	(3.53-15.33)	 0.345	
Percutaneous	
Angioplasty	
(n=6/6)	
Resting	Flux	(flux)	 28.80	(21.90-43.30)	 13.40	(10.60-26.80)	 0.249	
Biological	Zero	(flux)	 5.50	(4.10-10.20)	 4.40	(3.10-5.40)	 0.173	
Maximum	Flux	(flux)	 65.60	(37.80-94.30)	 29.10	(22.40-53.80)	 0.345	
Maximum	Flux/Biological	Zero		 12.35	(8.04-15.21)	 9.88	(4.72-11.46)	 0.600	
Maximum	Flux/Resting	Level		 1.88	(1.59-2.22)	 1.94	(1.33-3.12)	 0.600	
Time	to	Recovery	(s)	 2.08	(1.60-2.68)	 1.54	(0.93-4.08)	 0.249	
Time	to	Maximum	Flux	(s)	 198.79	(69.18-287.33)	 142.33	(80.13-227.13)	 0.753	
Time	to	Half	Recovery	(s)	 119.83	(70.00-291.73)	 143.80	(80.35-228.68)	 0.893	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 65.70	(36.40-112.70)	 93.80	(24.40-183.50)	 0.917	
Biological	Zero	(flux)	 4.60	(3.10-10.20)	 4.20	(2.90-4.50)	 0.075	
Maximum	Flux	(flux)	 138.90	(120.00-303.20)	 213.90	(131.00-454.90)	 0.173	
Maximum	Flux/Biological	Zero		 18.02	(13.95-36.81)	 41.48	(11.16-156.87)	 0.046	
Maximum	Flux/Resting	Level		 1.75	(1.32-3.30)	 1.86	(1.73-6.03)	 0.116	
Time	to	Recovery	(s)	 1.64	(1.00-8.18)	 1.36	(1.33-1.40)	 0.249	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-262.10)	 15.53	(6.98-120.95)	 0.345	
Time	to	Half	Recovery	(s)	 53.20	(38.25-268.18)	 26.44	(18.28-121.83)	 0.173	
Percutaneous	
Angioplasty	
(n=4/5)	
Resting	Flux	(flux)	 41.50	(32.60-63.20)	 26.30	(21.90-54.30)	 0.273	
Biological	Zero	(flux)	 4.40	(3.40-5.90)	 4.80	(2.90-6.50)	 0.715	
Maximum	Flux	(flux)	 111.70	(83.80-132.20)	 80.40	(77.00-208.80)	 0.715	
Maximum	Flux/Biological	Zero		 19.83	(16.59-35.01)	 27.73	(22.59-43.50)	 1.000	
Maximum	Flux/Resting	Level		 2.39	(2.02-2.71)	 2.93	(2.58-3.85)	 0.068	
Time	to	Recovery	(s)	 2.03	(1.70-10.95)	 2.15	(1.98-2.98)	 1.000	
Time	to	Maximum	Flux	(s)	 34.38	(8.66-62.28)	 65.40	(30.03-69.55)	 0.465	
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Time	to	Half	Recovery	(s)	 55.79	(11.19-98.08)	 66.48	(34.68-126.33)	 1.000	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 8.70	(8.10-10.90)	 9.00	(8.60-17.50)	 0.686	
Biological	Zero	(flux)	 4.20	(3.10-4.70)	 3.90	(3.70-4.00)	 0.892	
Maximum	Flux	(flux)	 24.50	(12.10-39.90)	 27.10	(18.90-81.70)	 0.043	
Maximum	Flux/Biological	Zero		 5.31	(3.40-10.22)	 7.31	(4.73-20.95)	 0.138	
Maximum	Flux/Resting	Level		 1.91	(1.70-2.80)	 3.13	(2.92-3.94)	 0.500	
Time	to	Recovery	(s)	 0.74	(0.68-0.85)	 0.70	(0.58-0.93)	 0.715	
Time	to	Maximum	Flux	(s)	 10.20	(2.30-55.38)	 18.70	(18.15-102.18)	 0.500	
Time	to	Half	Recovery	(s)	 17.53	(5.85-23.05)	 22.35	(19.20-102.40)	 0.068	
Percutaneous	
Angioplasty	
(n=4/5)	
Resting	Flux	(flux)	 15.10	(13.30-20.40)	 13.70	(8.70-23.30)	 0.465	
Biological	Zero	(flux)	 5.30	(4.30-7.40)	 5.40	(4.80-6.70)	 0.713	
Maximum	Flux	(flux)	 71.10	(39.10-87.70)	 45.90	(30.80-59.00)	 0.273	
Maximum	Flux/Biological	Zero		 11.89	(7.30-13.51)	 8.49	(6.56-11.56)	 0.273	
Maximum	Flux/Resting	Level		 3.88	(2.15-5.29)	 4.30	(1.94-4.35)	 0.715	
Time	to	Recovery	(s)	 1.74	(1.13-7.86)	 1.50	(1.25-2.3)	 0.715	
Time	to	Maximum	Flux	(s)	 91.74	(58.41-125.70)	 76.18	(65.08-243.90)	 1.000	
Time	to	Half	Recovery	(s)	 94.58	(64.60-126.45)	 103.23	(78.40-245)	 0.715	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Table	IX:	Post	occlusive	reactive	hyperaemia,	baseline	results	compared	to	second	visit.	Unhealed	only	
	
Baseline	Value	
Median	(IQR)	
Second	Value	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=8/5)	
Resting	Flux	(flux)	 50.10	(13.10-67.40)	 104.8	(7.7-107.7)	 0.043	
Biological	Zero	(flux)	 4.70	(2.80-7.10)	 3.3	(2.7-3.7)	 0.686	
Maximum	Flux	(flux)	 149.40	(105.90-204.50)	 192.9	(75.4-277.8)	 0.686	
Maximum	Flux/Biological	Zero		 30.46	(18.60-56.96)	 58.46	(34.28-97.1)	 0.345	
Maximum	Flux/Resting	Level		 4.16	(2.24-11.82)	 2.58	(2.23-8.07)	 0.080	
Time	to	Recovery	(s)	 0.85	(0.68-2.25)	 1.03	(0.85-1.18)	 0.715	
Time	to	Maximum	Flux	(s)	 27.78	(3.44-83.36)	 8.5	(4.28-11.08)	 0.686	
Time	to	Half	Recovery	(s)	 36.75	(13.68-92.81)	 14.78	(13.83-36.13)	 0.893	
Percutaneous	
Angioplasty	
(n=3/2)	
Resting	Flux	(flux)	 84.00	(74.50-106.60)	 54.80	(16.40-93.10)	 0.180	
Biological	Zero	(flux)	 4.50	(2.90-4.70)	 5.40	(4.40-6.40)	 0.655	
Maximum	Flux	(flux)	 137.40	(68.60-193.50)	 76.90	(21.50-132.30)	 0.180	
Maximum	Flux/Biological	Zero		 41.18	(15.26-47.39)	 16.73	(3.37-30.08)	 0.180	
Maximum	Flux/Resting	Level		 1.64	(0.92-1.82)	 1.37	(1.31-1.42)	 0.655	
Time	to	Recovery	(s)	 3.58	(2.93-117.55)	 3.49	(3.33-3.65)	 0.655	
Time	to	Maximum	Flux	(s)	 288.78	(204.98-288.78)	 120.65	(8.80-232.50)	 0.655	
Time	to	Half	Recovery	(s)	 290.63	(204.98-295.23)	 124.30	(15.38-233.23)	 0.655	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=8/5)	
Resting	Flux	(flux)	 16.10	(8.30-22.00)	 16.2	(15.9-29.4)	 0.500	
Biological	Zero	(flux)	 3.80	(3.10-4.70)	 3.3	(2.8-4.5)	 1.000	
Maximum	Flux	(flux)	 45.40	(21.90-63.50)	 72.4	(48.8-87.3)	 0.686	
Maximum	Flux/Biological	Zero		 12.93	(6.07-23.75)	 21.46	(9.56-26.45)	 0.893	
Maximum	Flux/Resting	Level		 2.06	(1.64-6.05)	 2.6	(2.46-3.07)	 0.138	
Time	to	Recovery	(s)	 1.44	(0.84-2.50)	 1.03	(0.9-1.05)	 0.225	
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Time	to	Maximum	Flux	(s)	 11.25	(3.83-21.35)	 20.38	(9.78-209.2)	 0.043	
Time	to	Half	Recovery	(s)	 16.69	(11.93-27.03)	 39.65	(12.4-210.93)	 0.225	
Percutaneous	
Angioplasty	
(n=3/1)	
Resting	Flux	(flux)	 28.70	(22.60-37.40)	 31.80	 0.317	
Biological	Zero	(flux)	 5.80	(4.00-10.70)	 5.00	 0.317	
Maximum	Flux	(flux)	 49.00	(35.00-61.60)	 68.50	 0.317	
Maximum	Flux/Biological	Zero		 8.76	(4.58-10.62)	 13.71	 0.317	
Maximum	Flux/Resting	Level		 1.55	(1.31-2.15)	 2.16	 0.317	
Time	to	Recovery	(s)	 4.33	(3.08-5.93)	 3.40	 0.317	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-271.38)	 55.05	 0.317	
Time	to	Half	Recovery	(s)	 222.18	(94.63-272.33)	 60.43	 0.317	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=8/5)	
Resting	Flux	(flux)	 46.30	(17.30-75.10)	 36.70	(9.80-144.20)	 0.225	
Biological	Zero	(flux)	 3.60	(3.20-7.20)	 5.00	(3.10-6.30)	 0.893	
Maximum	Flux	(flux)	 95.20	(32.30-168.20)	 53.20	(33.00-269.60)	 0.043	
Maximum	Flux/Biological	Zero		 19.10	(5.05-28.47)	 10.64	(8.44-50.76)	 0.500	
Maximum	Flux/Resting	Level		 2.33	(1.66-2.68)	 1.87	(1.72-2.43)	 0.686	
Time	to	Recovery	(s)	 1.31	(0.95-27.29)	 1.48	(1.13-2.30)	 0.893	
Time	to	Maximum	Flux	(s)	 34.05	(10.68-123.23)	 11.83	(11.68-105.38)	 0.080	
Time	to	Half	Recovery	(s)	 66.96	(14.99-128.04)	 22.88	(16.63-108.43)	 0.080	
Percutaneous	
Angioplasty	
(n=3/2)	
Resting	Flux	(flux)	 21.90	(8.10-78.50)	 35.40	(20.60-50.10)	 0.655	
Biological	Zero	(flux)	 3.80	(3.10-5.50)	 4.00	(3.10-4.80)	 0.655	
Maximum	Flux	(flux)	 38.70	(17.00-155.30)	 90.00	(30.90-149.00)	 0.655	
Maximum	Flux/Biological	Zero		 7.04	(5.47-40.87)	 27.25	(6.43-48.06)	 0.180	
Maximum	Flux/Resting	Level		 1.98	(1.77-2.09)	 2.24	(1.50-2.97)	 0.655	
Time	to	Recovery	(s)	 2.55	(2.45-3.75)	 2.14	(1.90-2.38)	 0.180	
Time	to	Maximum	Flux	(s)	 127.43	(54.73-237.73)	 10.85	(6.53-15.18)	 0.180	
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Time	to	Half	Recovery	(s)	 133.98	(128.93-240.75)	 16.75	(15.53-17.98)	 0.180	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=8/5)	
Resting	Flux	(flux)	 9.30	(7.10-12.40)	 6.80	(5.40-12.60)	 0.715	
Biological	Zero	(flux)	 4.80	(2.90-7.00)	 3.50	(3.30-4.00)	 0.715	
Maximum	Flux	(flux)	 23.60	(15.30-34.60)	 21.30	(14.40-32.30)	 0.345	
Maximum	Flux/Biological	Zero		 4.01	(3.76-5.74)	 6.09	(6.00-8.07)	 0.500	
Maximum	Flux/Resting	Level		 2.27	(1.99-3.27)	 3.11	(2.65-3.67)	 0.345	
Time	to	Recovery	(s)	 1.21	(0.75-1.51)	 0.33	(0.30-1.10)	 0.068	
Time	to	Maximum	Flux	(s)	 15.56	(5.91-117.88)	 29.60	(12.88-234.58)	 0.138	
Time	to	Half	Recovery	(s)	 31.31	(14.40-141.03)	 34.90	(29.6-234.88)	 0.225	
Percutaneous	
Angioplasty	
(n=3/1)	
Resting	Flux	(flux)	 47.50	(11.30-86.60)	 20.10	 0.317	
Biological	Zero	(flux)	 6.40	(4.20-9.60)	 4.80	 0.317	
Maximum	Flux	(flux)	 73.20	(22.30-192.90)	 29.50	 0.317	
Maximum	Flux/Biological	Zero		 7.63	(5.30-30.15)	 6.14	 0.317	
Maximum	Flux/Resting	Level		 1.97	(1.54-2.23)	 1.47	 0.317	
Time	to	Recovery	(s)	 20	(1.53-2.50)	 2.25	 0.317	
Time	to	Maximum	Flux	(s)	 31.10	(13.23-273.9)	 60.08	 0.317	
Time	to	Half	Recovery	(s)	 120.08	(34.78-282.78)	 63.10	 0.317	
*Related	Samples	Wilcoxon	Signed	Rank	Test	
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Table	X:	Post	occlusive	reactive	hyperaemia,	healed	compared	to	unhealed.	Baseline	Visit	
	
Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/8)	
Resting	Flux	(flux)	 83.50	(48.10-151.50)	 50.10	(13.10-67.40)	 0.142	
Biological	Zero	(flux)	 5.00	(3.10-7.20)	 4.70	(2.80-7.10)	 0.662	
Maximum	Flux	(flux)	 171.50	(14.00-254.60)	 149.40	(105.90-204.50)	 0.491	
Maximum	Flux/Biological	Zero		 41.37	(21.21-58.72)	 30.46	(18.60-56.96)	 0.755	
Maximum	Flux/Resting	Level		 1.87	(1.68-2.91)	 4.16	(2.24-11.82)	 0.142	
Time	to	Recovery	(s)	 1.50	(1.25-1.73)	 0.85	(0.68-2.25)	 0.228	
Time	to	Maximum	Flux	(s)	 13.40	(6.33-73.85)	 27.78	(3.44-83.36)	 0.662	
Time	to	Half	Recovery	(s)	 20.58	(13.45-78.28)	 36.75	(13.68-92.81)	 0.95	
Percutaneous	
Angioplasty	
(n=6/3)	
Resting	Flux	(flux)	 66.40	(15.30-172.80)	 84.00	(74.50-106.60)	 0.548	
Biological	Zero	(flux)	 3.80	(3.20-4.20)	 4.50	(2.90-4.70)	 0.714	
Maximum	Flux	(flux)	 81.40	(74.50-168.30)	 137.40	(68.60-193.50)	 0.905	
Maximum	Flux/Biological	Zero		 20.01	(7.01-27.89)	 41.18	(15.26-47.39)	 0.584	
Maximum	Flux/Resting	Level		 1.25	(1.13-1.74)	 1.64	(0.92-1.82)	 1.000	
Time	to	Recovery	(s)	 3.23	(2.25-45.13)	 3.58	(2.93-117.55)	 0.548	
Time	to	Maximum	Flux	(s)	 210.50	(72.18-231.00)	 288.78	(204.98-288.78)	 0.381	
Time	to	Half	Recovery	(s)	 200.20	(80.03-222.50)	 290.63	(204.98-295.23)	 0.143	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/8)	
Resting	Flux	(flux)	 18.90	(11.80-22.90)	 16.10	(8.30-22.00)	 0.573	
Biological	Zero	(flux)	 4.90	(4.60-5.00)	 3.80	(3.10-4.70)	 0.142	
Maximum	Flux	(flux)	 45.80	(32.10-63.20)	 45.40	(21.90-63.50)	 0.852	
Maximum	Flux/Biological	Zero		 9.43	(6.98-9.66)	 12.93	(6.07-23.75)	 0.662	
Maximum	Flux/Resting	Level		 2.79	(2.49-2.92)	 2.06	(1.64-6.05)	 0.852	
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Time	to	Recovery	(s)	 0.83	(0.48-1.15)	 1.44	(0.84-2.50)	 0.181	
Time	to	Maximum	Flux	(s)	 5.23	(2.85-9.28)	 11.25	(3.83-21.35)	 0.282	
Time	to	Half	Recovery	(s)	 8.60	(5.13-14.48)	 16.69	(11.93-27.03)	 0.108	
Percutaneous	
Angioplasty	
(n=6/3)	
Resting	Flux	(flux)	 28.80	(21.90-43.30)	 28.70	(22.60-37.40)	 1.000	
Biological	Zero	(flux)	 5.50	(4.10-10.20)	 5.80	(4.00-10.70)	 1.000	
Maximum	Flux	(flux)	 65.60	(37.80-94.30)	 49.00	(35.00-61.60)	 0.714	
Maximum	Flux/Biological	Zero		 12.35	(8.04-15.21)	 8.76	(4.58-10.62)	 0.548	
Maximum	Flux/Resting	Level		 1.88	(1.59-2.22)	 1.55	(1.31-2.15)	 0.548	
Time	to	Recovery	(s)	 2.08	(1.60-2.68)	 4.33	(3.08-5.93)	 0.167	
Time	to	Maximum	Flux	(s)	 198.79	(69.18-287.33)	 220.28	(93.65-271.38)	 1.000	
Time	to	Half	Recovery	(s)	 119.83	(70.00-291.73)	 222.18	(94.63-272.33)	 1.000	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/8)	
Resting	Flux	(flux)	 65.70	(36.40-112.70)	 46.30	(17.30-75.10)	 0.282	
Biological	Zero	(flux)	 4.60	(3.10-10.20)	 3.60	(3.20-7.20)	 0.573	
Maximum	Flux	(flux)	 138.90	(12.00-303.20)	 95.20	(32.30-168.20)	 0.282	
Maximum	Flux/Biological	Zero		 18.02	(13.95-36.81)	 19.10	(5.05-28.47)	 0.755	
Maximum	Flux/Resting	Level		 1.75	(1.32-3.30)	 2.33	(1.66-2.68)	 1.000	
Time	to	Recovery	(s)	 1.64	(1.00-8.18)	 1.31	(0.95-27.29)	 1.000	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-262.10)	 34.05	(10.68-123.23)	 0.662	
Time	to	Half	Recovery	(s)	 53.20	(38.25-268.18)	 66.96	(14.99-128.04)	 0.345	
Percutaneous	
Angioplasty	
(n=4/3)	
Resting	Flux	(flux)	 41.50	(32.60-63.20)	 21.90	(8.10-78.50)	 0.400	
Biological	Zero	(flux)	 4.40	(3.40-5.90)	 3.80	(3.10-5.50)	 1.000	
Maximum	Flux	(flux)	 111.70	(83.80-132.20)	 38.70	(17.00-155.30)	 0.629	
Maximum	Flux/Biological	Zero		 19.83	(16.59-35.01)	 7.04	(5.47-40.87)	 0.400	
Maximum	Flux/Resting	Level		 2.39	(2.02-2.71)	 1.98	(1.77-2.09)	 0.229	
Time	to	Recovery	(s)	 2.03	(1.70-10.95)	 2.55	(2.45-3.75)	 0.400	
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Time	to	Maximum	Flux	(s)	 34.38	(8.66-62.28)	 127.43	(54.73-237.73)	 0.229	
Time	to	Half	Recovery	(s)	 55.79	(11.19-98.08)	 133.98	(128.93-240.75)	 0.057	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=6/8)	
Resting	Flux	(flux)	 8.70	(8.10-10.90)	 9.30	(7.10-12.40)	 1.000	
Biological	Zero	(flux)	 4.20	(3.10-4.70)	 4.80	(2.90-7.00)	 0.573	
Maximum	Flux	(flux)	 24.50	(12.10-39.90)	 23.60	(15.30-34.60)	 1.000	
Maximum	Flux/Biological	Zero		 5.31	(3.40-10.22)	 4.01	(3.76-5.74)	 0.852	
Maximum	Flux/Resting	Level		 1.91	(1.70-2.80)	 2.27	(1.99-3.27)	 0.573	
Time	to	Recovery	(s)	 0.74	(0.68-0.85)	 1.21	(0.75-1.51)	 0.228	
Time	to	Maximum	Flux	(s)	 10.20	(2.30-55.38)	 15.56	(5.91-117.88)	 0.491	
Time	to	Half	Recovery	(s)	 17.53	(5.85-23.05)	 31.31	(14.40-141.03)	 0.284	
Percutaneous	
Angioplasty	
(n=4/3)	
Resting	Flux	(flux)	 15.10	(13.30-20.40)	 47.50	(11.30-86.60)	 0.629	
Biological	Zero	(flux)	 5.30	(4.30-7.40)	 6.40	(4.20-9.60)	 0.629	
Maximum	Flux	(flux)	 71.10	(39.10-87.70)	 73.20	(22.30-192.90)	 0.857	
Maximum	Flux/Biological	Zero		 11.89	(7.30-13.51)	 7.63	(5.30-30.15)	 1.000	
Maximum	Flux/Resting	Level		 3.88	(2.15-5.29)	 1.97	(1.54-2.23)	 0.400	
Time	to	Recovery	(s)	 1.74	(1.13-7.86)	 2.00	(1.53-2.50)	 0.857	
Time	to	Maximum	Flux	(s)	 91.74	(58.41-125.70)	 31.10	(13.23-273.90)	 0.629	
Time	to	Half	Recovery	(s)	 94.58	(64.60-126.45)	 120.08	(34.78-282.78)	 0.857	
*Independent-Samples	Mann-Whitney	U	Test	
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Table	XI:	Post	occlusive	reactive	hyperaemia,	healed	compared	to	unhealed.	Second	Visit	
	
Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/5)	
Resting	Flux	(flux)	 77.00	(33.40-104.20)	 104.80	(7.70-107.70)	 1.000	
Biological	Zero	(flux)	 3.40	(2.70-7.80)	 3.30	(2.70-3.70)	 1.000	
Maximum	Flux	(flux)	 184.00	(168.20-197.60)	 192.90	(75.40-277.80)	 0.792	
Maximum	Flux/Biological	Zero		 40.95	(25.33-65.56)	 58.46	(34.28-97.10)	 0.537	
Maximum	Flux/Resting	Level		 2.66	(1.81-4.32)	 2.58	(2.23-8.07)	 0.429	
Time	to	Recovery	(s)	 1.25	(1.05-4.60)	 1.03	(0.85-1.18)	 0.177	
Time	to	Maximum	Flux	(s)	 19.19	(6.83-27.08)	 8.50	(4.28-11.08)	 0.429	
Time	to	Half	Recovery	(s)	 22.59	(12.55-29.20)	 14.78	(13.83-36.13)	 1.000	
Percutaneous	
Angioplasty	
(n=6/1)	
Resting	Flux	(flux)	 38.40	(29.70-59.00)	 54.80	(16.40-93.10)	 1.000	
Biological	Zero	(flux)	 4.30	(4.10-10.90)	 5.40	(4.40-6.40)	 0.643	
Maximum	Flux	(flux)	 102.90	(80.80-152.40)	 76.90	(21.50-132.30)	 0.643	
Maximum	Flux/Biological	Zero		 22.18	(13.99-27.92)	 16.73	(3.37-30.08)	 1.000	
Maximum	Flux/Resting	Level		 2.55	(2.08-4.76)	 1.37	(1.31-1.42)	 0.286	
Time	to	Recovery	(s)	 1.80	(0.58-2.10)	 3.49	(3.33-3.65)	 0.286	
Time	to	Maximum	Flux	(s)	 53.79	(27.38-177.83)	 120.65	(8.80-232.50)	 1.000	
Time	to	Half	Recovery	(s)	 74.01	(29.00-178.90)	 124.30	(15.38-233.23)	 1.000	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 18.50	(11.60-23.10)	 16.20	(15.90-29.40)	 1.000	
Biological	Zero	(flux)	 4.00	(3.40-4.70)	 3.30	(2.80-4.50)	 0.429	
Maximum	Flux	(flux)	 37.40	(35.70-46.10)	 72.40	(48.80-87.30)	 0.429	
Maximum	Flux/Biological	Zero		 9.97	(6.89-14.88)	 21.46	(9.56-26.45)	 0.662	
Maximum	Flux/Resting	Level		 2.50	(2.15-3.22)	 2.60	(2.46-3.07)	 0.792	
Time	to	Recovery	(s)	 0.89	(0.75-0.95)	 1.03	(0.90-1.05)	 0.247	
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Time	to	Maximum	Flux	(s)	 3.09	(2.15-5.28)	 20.38	(9.78-209.20)	 0.030	
Time	to	Half	Recovery	(s)	 5.79	(3.53-15.33)	 39.65	(12.40-210.93)	 0.052	
Percutaneous	
Angioplasty	
(n=6/1)	
Resting	Flux	(flux)	 13.40	(10.60-26.80)	 31.80	 0.286	
Biological	Zero	(flux)	 4.40	(3.10-5.40)	 5.00	 0.857	
Maximum	Flux	(flux)	 29.10	(22.40-53.80)	 68.50	 0.571	
Maximum	Flux/Biological	Zero		 9.88	(4.72-11.46)	 13.71	 0.571	
Maximum	Flux/Resting	Level		 1.94	(1.33-3.12)	 2.16	 0.857	
Time	to	Recovery	(s)	 1.54	(0.93-4.08)	 3.40	 0.857	
Time	to	Maximum	Flux	(s)	 142.33	(80.13-227.13)	 55.05	 0.571	
Time	to	Half	Recovery	(s)	 143.8	(80.35-228.68)	 60.43	 0.571	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 93.80	(24.40-183.50)	 36.70	(9.80-144.20)	 0.537	
Biological	Zero	(flux)	 4.20	(2.90-4.50)	 5.00	(3.10-6.30)	 0.662	
Maximum	Flux	(flux)	 213.90	(131.00-454.90)	 53.20	(33.00-269.60)	 0.329	
Maximum	Flux/Biological	Zero		 41.48	(11.16-156.87)	 10.64	(8.44-50.76)	 0.329	
Maximum	Flux/Resting	Level		 1.86	(1.73-6.03)	 1.87	(1.72-2.43)	 0.792	
Time	to	Recovery	(s)	 1.36	(1.33-1.40)	 1.48	(1.13-2.30)	 0.931	
Time	to	Maximum	Flux	(s)	 15.53	(6.98-120.95)	 11.83	(11.68-105.38)	 0.931	
Time	to	Half	Recovery	(s)	 26.44	(18.28-121.83)	 22.88	(16.63-108.43)	 1.000	
Percutaneous	
Angioplasty	
(n=5/2)	
Resting	Flux	(flux)	 26.30	(21.90-54.30)	 35.40	(20.60-50.10)	 1.000	
Biological	Zero	(flux)	 4.80	(2.90-6.50)	 4.00	(3.10-4.80)	 1.000	
Maximum	Flux	(flux)	 80.40	(77.00-208.80)	 90.00	(30.90-149.00)	 0.571	
Maximum	Flux/Biological	Zero		 27.73	(22.59-43.50)	 27.25	(6.43-48.06)	 1.000	
Maximum	Flux/Resting	Level		 2.93	(2.58-3.85)	 2.24	(1.50-2.97)	 1.000	
Time	to	Recovery	(s)	 2.15	(1.98-2.98)	 2.14	(1.90-2.38)	 1.000	
Time	to	Maximum	Flux	(s)	 65.40	(30.03-69.55)	 10.85	(6.53-15.18)	 0.095	
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Time	to	Half	Recovery	(s)	 66.48	(34.68-126.33)	 16.75	(15.53-17.98)	 0.095	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=5/5)	
Resting	Flux	(flux)	 9.00	(8.60-17.50)	 6.80	(5.40-12.60)	 0.310	
Biological	Zero	(flux)	 3.90	(3.70-4.00)	 3.50	(3.30-4.00)	 0.548	
Maximum	Flux	(flux)	 27.10	(18.90-81.70)	 21.30	(14.40-32.30)	 0.548	
Maximum	Flux/Biological	Zero		 7.31	(4.73-20.95)	 6.09	(6.00-8.07)	 0.841	
Maximum	Flux/Resting	Level		 3.13	(2.92-3.94)	 3.11	(2.65-3.67)	 0.841	
Time	to	Recovery	(s)	 0.70	(0.58-0.93)	 0.33	(0.30-1.10)	 0.548	
Time	to	Maximum	Flux	(s)	 18.70	(18.15-102.18)	 29.60	(12.88-234.58)	 0.690	
Time	to	Half	Recovery	(s)	 22.35	(19.20-102.40)	 34.90	(29.60-234.88)	 0.421	
Percutaneous	
Angioplasty	
(n=5/1)	
Resting	Flux	(flux)	 13.70	(8.70-23.30)	 20.10	 1.000	
Biological	Zero	(flux)	 5.40	(4.80-6.70)	 4.80	 0.667	
Maximum	Flux	(flux)	 45.90	(30.80-59.00)	 29.50	 0.667	
Maximum	Flux/Biological	Zero		 8.49	(6.56-11.56)	 6.14	 0.667	
Maximum	Flux/Resting	Level		 4.30	(1.94-4.35)	 1.47	 0.667	
Time	to	Recovery	(s)	 1.50	(1.25-2.30)	 2.25	 1.000	
Time	to	Maximum	Flux	(s)	 76.18	(65.08-243.9)	 60.08	 0.667	
Time	to	Half	Recovery	(s)	 103.23	(78.40-245.00)	 63.10	 0.333	
*Independent-Samples	Mann-Whitney	U	Test	
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Table	XII:	Post	occlusive	reactive	hyperaemia,	healed	compared	to	unhealed.	Last	Visit	
	
Healed	
Median	(IQR)	
Unhealed	
Median	(IQR)	
p-value*	
Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/5)	
Resting	Flux	(flux)	 59.80	(32.30-122.70)	 107.70	(104.80-138.90)	 0.537	
Biological	Zero	(flux)	 5.20	(2.60-7.30)	 3.40	(3.30-3.70)	 0.792	
Maximum	Flux	(flux)	 167.00	(128.00-190.90)	 192.90	(138.30-277.80)	 0.329	
Maximum	Flux/Biological	Zero		 35.19	(23.27-49.22)	 58.46	(37.69-97.10)	 0.329	
Maximum	Flux/Resting	Level		 3.00	(1.39-3.97)	 2.23	(1.84-2.58)	 0.537	
Time	to	Recovery	(s)	 1.50	(0.80-6.35)	 1.18	(1.03-1.38)	 1.000	
Time	to	Maximum	Flux	(s)	 64.43	(22.05-114.20)	 9.68	(8.50-154.38)	 0.792	
Time	to	Half	Recovery	(s)	 69.06	(28.53-121.43)	 36.13	(15.18-154.38)	 1.000	
Percutaneous	
Angioplasty	
(n=6/2)	
Resting	Flux	(flux)	 33.80	(29.70-56.00)	 69.30	(16.40-122.10)	 1.000	
Biological	Zero	(flux)	 5.30	(3.30-9.10)	 5.80	(5.10-6.40)	 1.000	
Maximum	Flux	(flux)	 80.40	(55.70-125.60)	 86.10	(21.50-150.60)	 1.000	
Maximum	Flux/Biological	Zero		 22.21	(6.12-25.12)	 16.45	(3.37-29.52)	 1.000	
Maximum	Flux/Resting	Level		 2.38	(1.56-2.79)	 1.27	(1.23-1.31)	 0.286	
Time	to	Recovery	(s)	 2.26	(1.68-4.88)	 8.35	(3.65-13.05)	 0.286	
Time	to	Maximum	Flux	(s)	 50.71	(27.38-105.18)	 141.08	(49.65-232.50)	 0.429	
Time	to	Half	Recovery	(s)	 67.24	(29.15-106.15)	 142.73	(52.23-233.23)	 0.429	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 11.20	(10.20-19.90)	 23.60	(16.20-29.40)	 0.177	
Biological	Zero	(flux)	 4.00	(3.40-4.60)	 3.30	(3.10-4.50)	 0.329	
Maximum	Flux	(flux)	 29.20	(20.10-37.40)	 72.40	(24.80-87.30)	 0.429	
Maximum	Flux/Biological	Zero		 6.61	(5.90-8.92)	 21.46	(6.82-26.45)	 0.247	
Maximum	Flux/Resting	Level		 2.19	(1.78-3.01)	 1.84	(1.68-2.46)	 0.792	
Time	to	Recovery	(s)	 0.86	(0.58-1.28)	 1.05	(0.90-1.58)	 0.247	
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Time	to	Maximum	Flux	(s)	 13.15	(5.68-13.60)	 20.38	(4.95-192.98)	 0.429	
Time	to	Half	Recovery	(s)	 15.80	(9.60-18.48)	 39.65	(12.40-193.23)	 0.247	
Percutaneous	
Angioplasty	
(n=6/1)	
Resting	Flux	(flux)	 24.80	(15.00-30.40)	 22.80	 1.000	
Biological	Zero	(flux)	 5.70	(4.60-6.50)	 4.60	 0.571	
Maximum	Flux	(flux)	 45.90	(32.50-60.40)	 30.50	 0.571	
Maximum	Flux/Biological	Zero		 8.18	(4.72-9.95)	 6.63	 1.000	
Maximum	Flux/Resting	Level		 1.88	(1.20-3.34)	 1.34	 1.000	
Time	to	Recovery	(s)	 2.13	(0.78-4.53)	 2.40	 0.857	
Time	to	Maximum	Flux	(s)	 175.76	(105.20-227.13)	 30.08	 0.571	
Time	to	Half	Recovery	(s)	 176.43	(106.03-228.68)	 43.38	 0.571	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 122.10	(51.00-184.50)	 109.30	(21.00-144.20)	 0.662	
Biological	Zero	(flux)	 5.60	(3.20-11.50)	 3.10	(2.60-6.90)	 0.537	
Maximum	Flux	(flux)	 221.50	(173.90-273.40)	 220.00	(84.80-269.60)	 0.662	
Maximum	Flux/Biological	Zero		 32.11	(22.57-85.43)	 42.39	(10.64-50.76)	 0.792	
Maximum	Flux/Resting	Level		 1.98	(1.21-9.29)	 2.01	(1.87-3.35)	 0.792	
Time	to	Recovery	(s)	 2.06	(1.40-6.48)	 1.48	(1.20-2.03)	 0.429	
Time	to	Maximum	Flux	(s)	 87.20	(18.83-291.13)	 11.83	(11.68-15.53)	 0.082	
Time	to	Half	Recovery	(s)	 92.98	(19.68-292.73)	 22.88	(16.63-23.70)	 0.247	
Percutaneous	
Angioplasty	
(n=5/2)	
Resting	Flux	(flux)	 50.30	(34.60-54.30)	 26.40	(20.60-32.10)	 0.190	
Biological	Zero	(flux)	 4.80	(3.20-6.50)	 4.20	(3.50-4.80)	 1.000	
Maximum	Flux	(flux)	 145.30	(83.90-208.80)	 54.70	(30.90-78.50)	 0.190	
Maximum	Flux/Biological	Zero		 36.49	(21.37-43.50)	 14.43	(6.43-22.43)	 0.381	
Maximum	Flux/Resting	Level		 2.27	(1.67-3.85)	 1.97	(1.50-2.44)	 1.000	
Time	to	Recovery	(s)	 2.38	(2.15-3.93)	 2.06	(1.75-2.38)	 0.571	
Time	to	Maximum	Flux	(s)	 69.55	(35.33-146.28)	 15.51	(15.18-15.85)	 0.095	
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Time	to	Half	Recovery	(s)	 126.33	(76.13-163.45)	 19.04	(17.98-20.10)	 0.095	
Non-study	
Dorsum	
Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 17.00	(9.60-20.70)	 8.00	(6.80-15.20)	 0.082	
Biological	Zero	(flux)	 4.90	(3.90-5.50)	 3.50	(2.50-3.80)	 0.030	
Maximum	Flux	(flux)	 34.00	(20.10-54.00)	 21.30	(18.60-32.30)	 0.662	
Maximum	Flux/Biological	Zero		 5.50	(4.26-10.81)	 7.42	(6.09-8.07)	 0.247	
Maximum	Flux/Resting	Level		 2.38	(1.22-3.35)	 3.11	(1.90-3.67)	 0.537	
Time	to	Recovery	(s)	 0.95	(0.55-1.43)	 1.10	(0.30-1.43)	 1.000	
Time	to	Maximum	Flux	(s)	 17.05	(12.13-142.95)	 13.90	(12.88-215.65)	 1.000	
Time	to	Half	Recovery	(s)	 24.73	(15.60-143.58)	 29.60	(17.85-216.83)	 1.000	
Percutaneous	
Angioplasty	
(n=5/1)	
Resting	Flux	(flux)	 15.90	(13.70-20.00)	 15.30	 1.000	
Biological	Zero	(flux)	 4.80	(4.70-5.90)	 3.30	 0.333	
Maximum	Flux	(flux)	 30.80	(29.20-55.60)	 17.90	 0.333	
Maximum	Flux/Biological	Zero		 5.39	(4.96-6.56)	 5.42	 1.000	
Maximum	Flux/Resting	Level		 2.01	(1.47-4.30)	 1.17	 0.333	
Time	to	Recovery	(s)	 3.23	(1.50-3.58)	 2.58	 1.000	
Time	to	Maximum	Flux	(s)	 161.88	(76.18-265.28)	 17.23	 0.333	
Time	to	Half	Recovery	(s)	 162.98	(78.40-266.98)	 21.45	 0.333	
*Independent-Samples	Mann-Whitney	U	Test	
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 COMPARISON	OF	DEMOGRAPHICS	OBSERVED	IN	THE	MATCHED	COHORTS	TO	THE	EXPECTED	
PROPORTIONS	BASED	ON	THE	RAW	DATASET	
Table	XIII:	Comparison	of	demographics	observed	in	the	matched	cohorts	to	the	expected	proportions	based	on	the	raw	dataset	
		
Diabetes	Mellitus	 No	Diabetes	Mellitus	
Observed	 Expected	 Residual	 X2	(df)	 p-value*	 Observed	 Expected	 Residual	 X2	(df)	 p-value*	
Sex																								Female	 43	 48.7	 -5.7	 0.963	
(1)	
0.326	
42	 56.8	 -14.8	 6.104	
(1)	
0.013	
Male	 110	 104.3	 5.7	 111	 96.2	 14.8	
Ethnicity																White	 149	 128.2	 20.8	
20.843	
(2)	
<0.001	
149	 144.8	 4.2	
2.407	
(2)	
0.300	Asian	 2	 15.1	 -13.1	 2	 3	 -1	
Black	 2	 9.7	 -7.7	 2	 5.2	 -3.2	
Smoking																Never	 17	 34.7	 -17.7	
11.907	
(2)	
0.003	
17	 26.3	 -9.3	
14.196	
(2)	
0.001	Ex-smoker	 104	 88.5	 15.5	 103	 79.8	 23.2	
	Still	Smoking	 32	 29.8	 2.2	 33	 47	 -14	
Hypertension													No	 25	 29.5	 -4.5	 27.776	
(1)	
0.356	
25	 56.5	 -31.5	 0.708	
(1)	
<0.001	
Yes	 128	 123.5	 4.5	 128	 96.5	 31.5	
High	Cholesterol							No	 60	 55.1	 4.9	 0.687	
(1)	
0.407	 59	 67.2	 -8.2	
1.789	
(1)	
0.181	
	Yes	 93	 97.9	 -4.9	 94	 85.8	 8.2	
Renal																				Normal	 148	 122.4	 25.6	 26.727	
(1)	
<0.001	
148	 142.5	 5.5	 3.059	
(1)	
0.080	
Failure	 5	 30.6	 -25.6	 5	 10.5	 -5.5	
Timing																		Elective	 108	 98.5	 9.5	 2.561	
(1)	
0.110	
137	 119.6	 17.4	 11.598	
(1)	
0.001	
	Emergency	 45	 54.5	 -9.5	 16	 33.4	 -17.4	
*Chi2	Goodness-of	Fit	Test,	df-degrees	of	freedom	
	
